var title_f21_28_21952="Approach to dx of Raynaud phenomenon";
var content_f21_28_21952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 607px\">",
"   <div class=\"ttl\">",
"    Diagnostic approach to the patient with suspected Raynaud phenomenon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 587px; height: 482px; background-image: url(data:image/gif;base64,R0lGODlhSwLiAcQAAP///wAAAIiIiLu7u0RERBERETMzMyIiIszMzO7u7lVVVZmZmd3d3WZmZqqqqnd3dx8fH7+/vz8/P+/v79/f3w8PD5+fn8/Pz29vb6+vr09PT39/f19fXy8vLwAAAAAAACH5BAAAAAAALAAAAABLAuIBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjS4BkJGSk5SVlpeYmZqbnJ2en6ChmI6kpVYBpnWoqaytSauub7CxtLU7s7ZpuLm8vS27vmPAwcTEw8Vex8jLtMqKAgRwzszUptMqB5EKDADQPgOr4FHeJwQCN+Ld0SzkONfV8IvvKAcLAAwEBwlA6VPtJebQzRPxz8bAeAgJHSxRb0QBB94aRLI3IBukbgeyGdhHABKBBAgMQFJg8YA4BiID/yggURIBgAAp7cGEZM9cPpSQHgBYEKnBvZQKBGSEuU8ET5oDCgQoYG8EOJEHEDCItLGkt4o0ARBI2WAqJJ83FiYc60fsiIYizP1rYABAAZ3ihDJIwFRoggQGBAhoKyKdOAXr6OkMcE5AgZeFD2/lpmAlggIDRvBMAHiEXLpN055ze25BgaIAwLlsPGKqg3TemAJwoDgaOAYFa5glSxvPbABo3UKMZhjSganc4q6r1wCsgK4KYC7wiyr3iAQSv76M/DoA9QD4NqMlsGBBSuy5yTkPCFwEdqerhCLoiDQ9Aa+Rst/DHpvG7dr45dxuiO+AOtMAPOBfAYWhIt4CdiVwwP9mGIGzz1+BSRbAPgb4ZF2A/l0ooFabkYaAdQfo5AB2lRE0XGZa6cRZN5+hJ0KFbAGQQADLTaiOWyiSRx9f7uTno0I2WKTSPt6wl9FOvhl4olYeJSDARHgFYBIqOKlUWkoHWOhbZJGYxKEIVer0pJTYVRnUkhLSmNRSKIIDiQEMrJnNAlEu6FpJXwL3WABgGfTjn4DcJ4NQSFw4gqFO9HMKoIzyIagLY0JWaGSHUproo0Bg2uimyXD6hKaehnoFqKLCQGqpqH5KQ0CnWJpEfS5ycWqqtCpxjXCaJaEoCogyOdIQsPY1qw/D1mosEQORw+oRu57QKwE+MfCQEMGGViz/D9ceqy2xJTywkmUGVPfVVtI9x95hC87HgGeQ6HWAUhsBkBxR8kJSAJ7zblTlsz596FJLDaxDwANCaZQAfBvxJEJx3UQS4VNSIgBxAS6NGdVLMYWmlGr5eJRNAYy9mcDEFb/p0kw0lpDttizngAtrAAQsrwC4auXaecKCli5wA1umj4J6xZuXXMISJLQAJT5rL4MihAgccJepBmYADigccwMfRvaPaPIqAE5k0D7mkreIYbSiZwkQEA1PkS24F4U0Xxh2AC7JTJjZJKzc8t72lTCjAwN7JrGSuZY3wgNLnbMzdgOIRAACyhYnSXF9phPdV2jxi5dO0PXE4QM+Hbje/0RWF7eAfzfGKpTlDRzl23Q7/YYzdgGlY87lfLJ+el8ZRrZ73nwHT8UuCjD12GFx8aUjNyV8iE/oOMvbgDfSIhgvQb/l3M31XQOQNQnQ3sPUZABUGNq7FZ8Y44w1MoAS1nTL+/AqFbIudt6+D5hY2ufYHjRo9otfZS70u0MJ74BQ2IVhKOQTcewpYOcwnLWk4yaR4MM3kNOGCOaVsnPVqV40QYBG+CUs7/gGLAZYx4Hk1MGlmC86KSSBm2ASp1UwbEx8gt3u1sSx/q0iIBys0cKgB5OT5U9lCEwiE/SWgmoZgS6u0kGzusBEJVrRPE5wYhEewCMeTFFWVwwjssQoG/8ympFbZ4xBFdPItzXSyo1sZBkcUTXHOB6rjqLCox3fKIo++vGPgAykIAeZiT0akhV6PKQiW5bIRTrSWI18pCRLFclJWnJTlbykJn+UyU16kjad/KQo4xHKUZpyGaU8pSp9kcpVurIIhIylLGdJy1C88pYG3FsrcRmqXTrCl7zEZBuD+UpgMsKYxPwTMhWxzGTmp5mIgKYzQTnMaXryAhqIwEsAEAENXKBW2NQmKrr5TWtaEgIBQKc6j6XOdKbTnJe0wCQscCx5SoKe8JzkBCoQiQpM4Fj77Oc/8zlJDEQCA9syKCQQStBJUiASFNjWQyER0YZOUgIBkEDLMKpRi07/MgMByEDLQCpSj16Ubx01qUpXylI11vKlMI2pLF0m05radBItbYI0DfGonQ4vp0usZlhi4VNXFnUQPSUqUJdwVEEk1RVNPWVUA+UypS71FVYY0wuW9SU0aPGpZegVVq9aKBQQqmnnECvsdDCjKK6Aq1y9QUAMpdaaycA6qIkQr6pqAgsaYYpqNUFgaxBXFUx1lMM4K26YpjK31uBDMYArY13mWBNoUQV5ZQFYnVKAvPx1NoNd1WRTQKqbmva0N41DYlG32OmEZCSXg43JXnK6jlwHNL76iEX6BMLDjMkALgFiJJjGrrvla2QzoVja7MWh2FqnAd8amLgCYFtrgYZs/+CajlWGwj0k9qgE0P0d4iAhwnPQBSIWMUBKHKAVi3QMZA2LWEm+RqMLzQtdGFwr72gyFZc4yGIni4nrFjDe+DmrB4e1jWrNOom0DmAv+PNe/Oz2LYYxzGd3ycuuiCbhukVDLdmDq4q2B7evaaUBDhrBXCmFV+w4r2YW5i3MZBaU6aDmN5jZ63ef8xAovoS9RvHP7uQylXPITG1IapsA7uct5mzGOhxmyWBcpRqYhU8BWKNYgFZyN0KximorKO0dF3wCxabLOgxIjgFkcsTzrTUpErwaQVCMiwvHjnfNBQtXG0ddBOCOzkMMUOK+RFewCQB01kodnKMnI6oFTsstNv9R01AEvB0bZXIY4dNdILPm1F2oSD7UjOukxJxK2blz0kEUfCARJ5BhZ9S9uzOrhKJpHd9izNIwK2vPbClCgdlf8tPvVr6FYaBtOHsdDjaI75IuE2D5bbGys/PmCmQCFkBSyVOxAYg9guIt4HjmGUCKD2RrP4FPRSkWgWr2chhPa+3DoebQ/bTXDygjm3zm65XUznKAaMw73LIesbopnctbQ5LMlt21g3Foj+jItoj6HZFb2fORZp0rvsDlUJTuxTQjjWYirJuhTwLicEP1u2gPXI1aF1g+sFinTuQ+sKX7e5be0GtGmyHHp+Gd6C/hsAF1qjfY7FWlLOn3fK9LMkH/PEdAIbdLKfSSucFrlWCpE+GybMB6GS3tgqTgtg9iPsO1GSxwNFRdsEaQFpDtoPYhbNYFBig72BFcguSsvQtjL3MAHjCjdp/h7N5lJF9bEfZug/kLebfs3tkA+EoLnuvWoDsJ7D6CDw1X0MV7wAWvPSHK+GbtdDnPvWL3q9eS1/R087yU2Jv4Sy9l8WMv7mFGR11uQN1KqEeA6g9wd1giPAZ2xRal6MI8MDAgG5P94l0HzwSsF1YHWne8DnBB+eYtRdA5Sc45lOJ5B0yFtYIWAE+WDJOY0UgkmUG/4b0vJbf4XcL+eZJOrt334r8rATzhbTb4nBm7f3+sskADwXcL/5SyAHrFBMp3Ag9wgEVTH6AWZszHA89nWQxYDg7mLOK2ENFXcNNXd4d3Dxw0IYizGUrhEtx3e5AAGh/Sb5+BQznhOglDFaEnCXTxfiOyEvLnfuY3EpZHFdgHCVUjgyhoI0fQeBwIAwM4fZTCHWNQYyeQgCo2WtK3dU3gfFIoQxpYgRCILR64dtrnFiJ4N0zCehOSHASXFqVXfn2VMi9CI2ZIAq33FA0zf34XescHX0sXDdVXPm7Ihrbye1gIFVIhg7jCQ/YADU9SfJdTE1zxE5EQGdLyIBtziOYQPVhBGOlyXi2BMVkRJjsBdXHzie0iQ5PoOsV3iYSDiuowYAXmEv9H2DcsYIgckg/mwlxzlTGqeBUWQWkcdIG9qF1J1xeTqBWNCA1TcVuaJXmGpw17YgDcN4Ii8FrO2Hkc9H4qZ2CnM1y35xPbKCPVqIMkMF4iQYc9SCDewx5DIhKdRTXdqHrXV1a59oQCRGymgSvmiDargwIxgmSvkTSR8QAqco8t6CVwyCC7U0C4MRiF4R8eAhk9UzQPWQICyT8SGWqpAReE82W9h0WQdwITuRhYCBpztZBugZE3UmXvRzQrZhjcsGLN8pE3AxvREGO/oIwCAX7FYIQcaQI3RntqoiSGQx8HaHP+sTyZExlaFpQyWQISBEVrhmo51HS40RTcwWePIw7/VumK6mIe8lEa5yEc5YErs5YNQDeFsKgCSllYiGOOKxY7YQmUk6CIeuZgF+aSuJCWESSUGhNnpGWTMzAis8UMOrlN8vgixdEW7GOP+1MQALIhy+Mh1uEAPGKOCxQb5gguh4FvFnJEkGkpWKYoWFaQLEKRovkkJ1kgNxKRA2eWM3ANlPkZEzhtF7g7lEk4+0YCCcJruelg6eYQ+7M8yrJtj+CXdASI6PEmrUYmQnQVwxgbRlKUeckAIjQTA+CEGsMmqUOKo4hzjiglm3lnnuhx4uBx2tlDJXAUInEjR5EN6vl0IsOayxeLwxhXIkdoR7SeqYgnz6GOvBYlUuJgH8RZ/9gJnOsgccPJhQcXjzyZSDPydTLgdV6gWAc6VEsgoTWgIGdIA1pXeGewgWQwmMMAhV4Qd1wQKZXVlx1JLfZyoo/gETvQdhPagUvAGkVBczXwgIW2BiAqVOZGeMR5BFIDYTbwD6FlBjuqSxEYeQi6BAuIVggDEkARX3SzOEt5O/FhHabHbWJwpI9HoT66pErwISPTIlMDETzyPWilLjjKYg/WRWFlnLjmpYj0o0eQFwzjkwuQZsqBkFS6puGmp532pgoqR0laChyqBEIhKevjh+qBKOGTiDhabb2Gk2EAoqh1qZgaUzSVqZwaSHT6RO13nXPCcFI6ODNRpUbGalA2Ef9G2qWEmgeDOahx+qoKlqDbEquqoAe46ga7Cqe2ege9yniuequ6igVFKhssCka0uqx2oEczwlo5SizJ+lZX6HvMqi3BCp9GwG5sCnDS2qrXOqvN6gQLYmFXiou7OIu/kRI6kaWlal8iQ18IMlutaA7L9Y5FOKzYWqwIOCEQSlckiZLEyBiOARlCKmGWAmVHAw7nAGx2s3bm0JvwSKxICqtNgDtsBnCns2q0ox1Umadq1h3g91yTkw6/UxGZBnQBsZbV+gOh1KkwG7OZCqz8qgTnZTQ/prEDkiMd4hiI0qgJ26YAtArAViIDtyzOM7FSkK3RRLMWuwSe4ZV+pqpHdIn/0Akm7CqlhxgJ3xNE/fBbugd1GxGxnqO0UcC0h5CtaEuYVFcFa1sIaluzb+S2jxS3T9u2P+VIdnsC5cSr4ppAdeu0JDABFgABGiCrJyASWnkDN/gF0GgZYviHebtIewsAFIAB/BQA2hSAIwCYkvBai2sDjfsDI9i4lDe6L/C4SycApvuBQvCygTuuAJABGBUJEGCcfTcCiqsDqEsEeygDqtswTPO7QQC7ekuztTsKJRABlWACzEsJztu8yyu9JPC8OBV4z4GvIjEv57C9VGN678GH3NsRGzEi6kVd+1BgBfJ54juKm8d9T0J+QUEVH7ISskcC98p7gkYASgE98otD/22BQ+eAOJmHQ7zXdx2hZferrUF1vLJLu5Jwu4ibu22YgYfxHQ5wf3IoEhnoHxKxAI07gjnYEWv3JNHAweBwGF8Iv4RRv/XCXvVbf85GNQryGdDIwfHrwpSXg9nAAAU2Yiacu0+iADKMdpOrSJV7uZm7uX7rN9qbete3ux+CmCmouFMcfo0rf5SHOA8AOD6ouLlbgmDoJC1sJZTnwpfDbdzHhw4AjXaXw2YMZiFINY/rxSJzfY2bxth7trGbqyVAuIY7wU+se1FsYBpcflZcfqVrJR2hF4tHwkoxAFcMxtdHwmMMxyvxhi4sAna4fjWcACOoIHSDyfWytbz1uJE8xf+5i7qd/Iqq4sB+zLeC7HeUfMEGBr7ckMhtschlO161ORNtUcveIxLTSMby6z3wUr/lyDT3agDsVWApQ8rNKKV087i/RRR4rBLLvMeAC8t0sLZTBQ6UirivTLmCe85h4LkZF8tL28ffLLepYrzmLLu1irdT8LZAQs/oHAO9ewKb/ALEGwjyjMT7/M6TJwluagL9bAIxjK8rYHcLPXdHfEiVq88v7AIRTQL/7AIBTVUTbUgVzc4Xrbsq0S7kmwDm6zjpe3kuPHbueHfRoRQO4ML3m424JwkN+x0IQHvhu6V0iy0yG9QyRYUGXc8bJAk6gcLt98EhTBgj/L1WMnZfWAL/Q/zCDY2HV/zBlVfImXF/+ScMPz11CAFaBT0H1Oe6uozFVqLFYMbFLX0Ya9wtxgXVK5HGLrh3ehoJ+Ee/k5DQVBTWMpoQZG3RIv27ab3IK9HITz3TUa3CkQu5OkHC/xx6V2x420eEfHg6ePihgF2o1DDYIl3YCM2HO63IhOG5OYR95vjW3hgJd5fAIsHYCrDNNt3C8HKCnuOTWtopHy2npETUZg3PxdnbPTrWwK0fwk1JnZ2iWSCidzWtYKpGZY3cv8rH0X2vl+kDsSGiUHghzn10Y3SWcBBO20ROhK3cxA3cXGQUWngDHlo0hnUdjwDdYi3dc9BO63TeJbC7OZDR/40w0BHIRcV3jNZFJnzyJtbyMfOiE1XSFT2BiPXVndtAiLgAMJQgO+95X9OBF0R8cS573G5gT5GAT+yM2uTF3zjg3ygQvBJ9z34JHfDScD7BMHfTAL9xjCZ2cgoTmtICOSrkJRBiAvU4DCECO7tiGlFGNZ4lsWjUmnQQUJDgT/tMwaTNu1bypS4e3SQwGYvGDTsXbv6TaEJCI+RADuKQG3iqKFD5nemAp3b2Ep11OIP24eIdBwoVAAxF2FTuvXfjvTOdEuHL59BAFCmNvj+Y01wbvz+426FdzoG9QZuBNsT4LV9uYz8UaqGZXYqGCka7qEIkIQyUsynm6UnuHRGStP9NHp9zMFEBUFF6/sQWzIdAeMjB3GIeTCNN7ciRreSMetpq6CjL7du0RmoiYKCwo3MZmCsn8R3S2b9mTiVAwUKfjrUntIOvZRJKMSe+chgvp16ey1ta/gLBylF3m720DMW27BJXPCMTcti+joN7t8V7B4PGfK+PPd0NXN9m1d6pANpzQFLlzsmDnLv8TeukfcWIzSS6PoYkPa8MMiLjXNTtHO5MOS284O9zkFJTPvCF7Iq4fPCmzbqYptqXLR3xC8Ab2ehOcKjwgPFKhM+CmuX6Xg0u36JCffOxVOfDLfOP3txnV/M1+dtOXt3dXN9V3VpNpEL8bgPfzdtDr+o0r/P/6M3zEWgYqtFs+14ETf/XUh/0Ld/1JIDiWdB6QxDXZlv0PS8UC5QuYOuVX+ENrVhc4mdDRHQxIyAzU7nsv3Jc9DXoDk31pgL2xiDeJk43Yp/iVz6kiweOJmD2OeD4RgDgXGcXBWDj5OdhuKn0OZsWI1Y6WTY23Ib39RDkRlNid8Pk6Z2MTx/1qy/w5x66UpCDjC+RmP34tR/5wV7cZjMm4oc6KGsZmk9rQJeVng9rJCD6QpQbf9YPLDsqIO71STCBKbD1P0D93Byjrk/S3DvMHpHLJe0AHBS+OPQALuyToJG/7JXIFEODLj0vvMdBAldg8wvvh0ZdSrESy8V5oKwS/28BAgkRBIcDPAFRBI0SFAiwHKQC4LmuB7v/A4NCYG9o3BVzggOuJkAEZAqCTmDACai5wiKnaAwCDIahgYj9loABNwyYKg2JnFsHZRzzemNyj+vvAQYxkJA8YGntZAEQCAA1ViUC1fmtCR4FDNRRVgJcYvokwOQYZIYVABwUJIRdlZKc4LwICATc4EDdqMrsvDgkqCaUIkCh1h4CFKD6EjKxzOU4BFzhJCgDo6Y4siDMJgckpBj6YocHbIsttEBdNQR08XXK533OA6rNnAPUTvPisjTIYo2EnBElZIwoUGZfoQY6GNQw0KYHGRtvCi3Y1HAex3jy6g0B+VDMGgO3hv9A+pFSD6eOezRyFBlEkChUOIbVZAdAFLhhWGqMCxALQC6dPp4BKOVgWDGGyJR9KwQOaQ4RhRy9eHFIW9IoPp9x/TZHKddn0hTwK4QspMu2PNzmkAl3Lt26oD7iPUIID1FwiwYA7ZFFHYkF7gozcqSEirgoFW21giGD3wEZJUgcvuKGcAsdDmziApcJ6IHIaPzI/UFz1M0oNVOtatVVRtNjtU7mgu3Pi9BySmt3TrbsnQ4WfHdIYwKFBB6uw0acAKvv4q9gZcGdNaontV0idLl3Dy++LXgkeY3sjTtgUYFDbhatxNHgSvxFQr0kCjOAkRk0D27o08ABY5jShzrQ7BT/BQ0MCACgJkXox18l5cUVCmuzvYbAKwTg4dNF0wRwSFoP5IaAQeBUZZABJ0ijwijCkGANKgm8QIIxhihRyIqt3eKcYxFJp5hV05xwXQJnzRCYYmyNh9p3TUIZ5VwUVthJaun1lUAW6b1HRUoCsFBCYpHsU0MDwMBjiXwNcCZmJvtoUeAMr5BEihWGoeXJgzjU0YBDTloppaDzlLLfoIEcyiRcVCbaaHiMenLeEFwuxJ4jtcDJyCGEFMlEfZJwAQefRfh5xm5vLqKnGwccIs1x+xTgkDKWPThHn38iGqiju/4gG6+K/vpHEBfoCuWbwf4KKaNXSqXYIoTVkClhCxh0/4CnS8I50DQJPKbArQxhpmemqgpGQg2vQrHfA0zoCWNppOK6naTI0lvvW/UKMoEFEGhQLBa2NIFtR8fam6iy83aET8HILruwwwzb2wcFGFRAQgT+wspFKgLHZOjDUh6MsTz8FODxx442fLLKg0LaXREZSCAVBPMuASYwlxJkGQ0NEABUzzDgQRqtOgBWGERbyXEYcT+rUEMBr64sLML0RF01sLlanXVdLdvVQ8xSgU2CDxGE3cM9B1gj4BNRAMCzJ7cQQIU6+x2ALavibtHFZwAwUIACA+owHyNyv1m31pFOfdfhh6e8uOMxRYwDzDLTzAQ/AtDAJxPHQlJHIwko7f8QwYRIhYc6sYBp7piec7xyyBM+7lKqUS5btu2345677rvz3rvvvwOve+Q5TFxxABfDXgW7TkAhBRWcO8L6gUmJbrLGOfT9N4Gdrl5EfFW/DmjseAMx+2I6fG/EibcUUpp548MfP9Y56Msvxviog3M/eHfuvQCPHaB6RCMNRLBSEHNdS01j0lr45ic/PZivEwRwSN9OQBwwve+BGtxglX5ArORx8GMNlBf22BYGYJgLAUNCBRtg0IXGIGAJLJAD6balIYtcpgUE2QHTfvY0cjmtRiKiQtHO8azSQAJExHkMwSTUPE904Q73CiEV4cc1H1yxio+yx7wm+IZ4seqEW3D/xAJWcZ+fJOBmJXSAFXjgCAERyGRxywfdHFEguhEuUwVY0mAMgIckXooJCqBGEw2yxz90QUAZ1CIjGfikRg5PZFQj2tPEALqNpGCPWBLDElqgJS1M0EQYYcALDNAFVMVJjtHzH7lw0D84YQlWZ0zifjJ3AHgU8kwGQEb7doM4SALTdY8MZrBGOEkdWItwY8HVHQ5ps7wtom+GuYIo0qQGVP5BlQqkJevUZKk4zG1Mb8qcAm6QLvRRUGPEUQ0x2/mwLE6xSU3UQ//m2ZJ5StCOJiMPF0UWTgCCYSMt5IK25JCWG7SwBgtIyyn3k6pCrtKV+uxml9YQJloQjlr6TBJR/2pQAzn+ST/rxKI7SxpJt9wDYBtb1D6HAB9HGKB192wpBL20USHgE6f9BGFdIjg+KSbOpEJl2TCxoIwuGA6lNFXfNmg6U5fQsqjimypdfLq4MJCgdSQcKlcNJtWarcJw/DCAzgLYQ6cFLYXkY8QrHMIZh7z0MAN6hXsoQieTFRFzG5Hhtl6qpxrKQaThrJEcbqjSDvLUgV0VDzwX61jFoVQRaItV3Z7oNpXOMZxJbcIhCknEOuXjk+LcTzmJUjI3iKqJh9zBgZaQxrr5dXRCCYNiMmGFsdCCGiQN6tUe2zXfAneLU5IsuDDHLsDwL6KJuWS4IMq3dNCJQTYV1y1dmf+RHlSXfLFcQHRTNcHYDkCUhaFEJpTWAlJOI01SkyRkgytV98IXcsNVXhPO8UQ4QG+bel3mWiGxl7u5CrxvMKecSnvOMeYAwJykgjTBK7hqknc9cvCBwtab2K3Gd1EZ3vBOI0vffOiPrMnVL0D764i9UGbBo+UbXdWEgIg0sYVGNBcnC3ED8Cb0HRH+0DsYukiqYpjDAxMykYPsksY6zqqM7XAggufkJ0M5ylK2XZGr3NshD1XJwmWvlbvsZaLO98u8vbKYy2zmrb33zB7hsprb7GbFYnl8LREhk99s5zuTmcm3CVg+swmlOb+zzngeNKF/6WElHHWllUjfeADtMGP/FjrSbkayoctkM7GqNS1UUNoCODM3F7jyEIRFEAoKgYAidqERPXtMXS3qQhYXYgBu01SjIC3pW5eZ0mdLW2X9owAonMB8gktJgRhwh9smBVtnTIbeUEEAPw7YtHs6ZBlpRMgB7CWWYGYzrrtdZV0T93JtuiW7FpE6MRF7P414gEPMG69OmgFsDEhJdglw3U1CBJfqFgC7USZobwO8yOD+MPNO0xfncQoFnuJlLZXh0AkHgQvXk6gsCDztS63CwG8CjMEPZeuAgzy+A1cCu/IHrs7I1UsIzMc7jnWARNRopAVlBWkWyGo1DTSKHj2WASTh8X+HPOjBHXknvhA1KVpj/6m0A7rQm75YotOTIFArGFan8wDd1prpTt+6SaF+649zPezE9LqkwS72szOS7JE2O9rbzkG1F5rtbp97/OBOaLnTPe+O0/WU++73vwMebFrXO+EXR+nCIxbxit/74tMctcBDPvKSnzzlcWfmwyse80tvPMguz3kNG/7zmxez5gtfenmK3lieT32cHcn6Jef69fJlnOy3/OXT6x33sKfiiw8bP+3Y3su6p/vwXdYdpEjjCmGxwzTsMgJfHh9Fy7cL8I0f+9pzm852QX7zg1B9t5SC1OGhSpO+j+brYx/I4Iv+HJLPEAEM6RxhEophOdQVX4gpDCeZQZhuEPOh0EghsP9R+5wAU4xCGdkIj3FIzD1ALfBbZzhgAJbAUJycCdREQtCG03Tf7t1e+l3Y+m0f2FyBA6YAM3VfMMgGnSyFULiDx+jEMYiFDniDIqjAbBRDTUydNyBFBEKFKlBHM6SBCrzGntUAMWxg8HVZ8bmdEp5fXXDfCNoXUMSATugET8AIL9yGQlRBiACA+5FfDOKAA5yIK0RBUyjNjQXGIeygPryAO6gh2CCIGOrIa5xFhhyh9ZGeB6rf47FfFzafA+ZACULB8sRG83lIKiBGDrwgF37hDH5DeBki/V3IQADHG+IBIFadFIxUcWQCO9AhwFyDr3Cg8OkhnPFhCLbfH55DzNn/X404QP11CNvgQAqwiw4gYHB8oQQKxVg1X4tgYCEcEmFxIT804HSUwi3oImiASynIwSggSYswI+qhXymumetlzfQNGhOGkDaeHTeCXtZcQ9mtHjVWY9Z4I+Kd4/hcgAZcTA9EgAZ8EDmyU+jJY+tVGQQEAD7qYz16Bz16GWFolRV9mQWAjQXw4zwOS6C5ky/44f7pQQHUoktxoTl+2QQYTwBUwAQc5G75QP1wgEK2E0POgyhgnRDAIEV+GQYUAgZsJEcSDwcYD/IsTDr2xVXwTUI8w7zBgHQoQHukhQmU4Pv95ADmDMAcY1bd5E6iCA7Mn7aolKZJRQLA4gWCQ2M4/+TPfRkFFAIFtOQiTU4hdID28UpT6CA4lKU54Mi/EICMwMYWUgFD5kahnMJFoAOCVN9H7dm/IAMKbotUuF8xlVnMSEBXZtDXSMUGGGYhbIAPJCYJLOYONGYAPOaYjQd6FQIligU3iEVYyOEOtSEXdmbzwaVRusYoaCb5GUVjCIVIOkVfUFOMsEb8BeToeVkGBEAGEGY8fSUJhCVIJspZQodYBGeQMGUnNl8mPqJOvEAUkaYKjcJwLqVrMsRb7uJh1cKf8GUzKqMfRqRXBWZuxhMOUABMWoxvHsoZTMMz3JBEgMN6Eucydt8x/guIXAF6klVzZggzombzwYhC3MeIwP9Ie24IA7zGye3IrtAkeG7QJ3ikedJLGEQkhDaKhI4dMFVe4JneEMRjwSSoD7TI/nyoiAlKiEJf2lmo1XQokaUoZSqohWnRih5T3tHkZGZfi1ZaFcFoe80dTbZMjqKdj47iyQApfPHo7NnoTJwoCOYeghoprzgaRzwphw0pHgoT4RVphy0HCRAABdaFYdVNlKLGfoDpXMBEeIwpP0ESILTPPjFawujIJdrYj+0ok2Jp81WE0nVE3/xJg5wpPYipEvapSwRqk+IoEnQBBjUJPuxSmfDNZt3oEtKppBiFNKwlDIzAEAKMA2jgFdzijfBRSZqGDKCaJwBFZriSljJXy5X/AhqM6jsEEKexVbg8RrtpAbmZixt0S+BgxBoEBq8ixrOFC2nc4myyaN0Zal8Qws4kUanuEGCxQia8wyrsA9apgRrhg9El3pw6Co3ylFF4YlSOAhGWYV/+0L/wUbxYgrrJSrN5whsNCCGsB9oIw0ZFiBdpzN74XtvQB4F1QzohwKzdEkyIChAITnuoyb0622cxgOesRROaKA8k0ubAjR25axytEW01AVKpV1rsqXJM3KO23ZRC1qTaQoFi6q+Ngk6cYRp0563UEHNgk574CRYIkMvK27GcWwJBUWC8A8Be16ikgnohmrlwiRjIm3+JwSaUAgGUqD0WKg+oVX7FbCee/8jPIoKmEpfgnBy6iixwdS2w6MSdmiwMaAkoFqJuDQSDTAff+A0WeAu8MBsPOFQquZYa3ce3fOybJNy6jImrYOtPWNR12UoPDOwaKVwy4Ezc5gDSLmx0ftEb+ByhUpGaqpfUzm02PZiOJYE1xBRxUQ+jIqSMMp4iSgXTJghoiMMI3AACMmOWOtPalgRBCMC3FNHmXK64GMRatk1hwG3t8s/KnciJRRdEpOcCuAuuvsL+VQsTQEsP+C7juku1yEDJfOPDxkXlGkpUPZQmsIBCccIDSOuHFVCFhae20h5cXKf8tGl4kK8fiGGYWW+TrG+MEt/odkRj6G78zO9ckAyeYv9lIxWfNIjfB4as/R5pPwIwimbotkruAWfr5CqwlUZqjS4MVvnvOMavynztY11psdaFo+XUDnTuoGjZNibpKW7dBHAlAnunB4PMBVMvCUfui55wlaZwAHCATJavoPTohAqGtWyL0lhmYEFr+8wqnNSCTgphqE4CULyQqTVEFiRx7s5BzOlPZXjCKwgth1rohf6d2HEACUCABWjkA3fe4HXHewyINTTUtOIWxoqL0fVNDLlP3cZUvaJr3nQhKixbqiyBQ8lrTIHJHz2Br7Ur6DqoAwPXBUhFBWDACncwBX+wYNRqG7vbjvHsQmnBzO5DQK3JD7wsJ5mJaI0LJwuAn/z/SSOMm7hkjlh2pdjsANmEzdiUDS3PcizXMi7fsg7IsuDpsi/zci3jI9gs5ow2cJNUVNB6QrBBnALF8btpQd1+KdweGFNuMbO10bhIMy3Ia6+dSi0pRwjzygbjGTnXCyMXgiNDsgELSjJX12FYpuaqB6wxx+xQ8bdEUO3OHHoGRCJQcYBiWnOB87hwcW6aM72EcT6S8Q6jsDsZwAWPZHYNwUM/GngedLBMAA7rsBnb8KRp6fhc9KQVmQojqT8qspweZEi7MkqeNEq39IapNEc7cEy/9DjvCrfuYaLs7wKJs5Sk24LW9LdNMAE/zE4LilGzc1BnWCQTdaOBCBpAQlrE/1DOeFqBrKqoOvEjtBXLdYZgSfVYIUBVk5aNrJBJK/VSD3VOO7W6JsaBWdZ0kQtbI+wjKGwOHAjGujXbuE26LQFfiFFSn7V7MbVai8e3qHIttjJypZvNlo5KnBh0FULj4kArcxSv8rSsxUsmEWsiB7bXprUpIjPcNkJeOw+ttVLbrCvzadN/tUrSFgFpQ65p2xbgMJ+x9XRBEyZNz+RnG1mUGLb+RAFYs9zc0G7NRRDjpphkz2dw58xwv4khVR1czfBKb6Ru43ai4DRoyw9FBwt3K+krt5luW7c4GnR4A/ZJj3cHqpl4B3Z6k+J6nzf8DKpgW7R5m7UV/ak9QPT5LP9QdyA1mraTFwv4gBP4hQK4NcrPxilhCc/Ffx9ZSbk3BqNxeGR3b0OJYSlAtU0rqWLGDkUGFgsNpz21qLKAxpwV0AARDAgRPTdADfEMcPuDs/LYFVuGFnsaDFFpMEX4NE54jhM2+2JddVVXgLxrgUjB/t2Ngss1Ga1CZhXORBVOHslxDHjX2igdpwxyWxuyPqgBsXGpw+r4AWfRYGu3eKCXKcEJ1orL9taBa4WOuNgsX4jBK40WRWGXVGiyRFG2HVQtJ6uyVNguR33JKPt4mor5gf+vJHdHtSpEbd2unFDP9CzE3cKtMzW5cnETK6HWu1HDaONT5i5UNxfyNwt6w8b/7WpVb5gf6ZjzNv1KiY+hQPhO7YNIXYkdhjp8cs51D8VB+isxkbEBRFSbGh107zsANHALUOYAZJgUVvimeg2HnVVsZ6E3tTS68Hjs9HxHDZpwRAOCObT3VJiQCJI4zhfaBSCq3oP7W4+PhwAbgbYL6Udft6p3B7kHBPyYe12kwJdT+4+LRzHvMtQGfE3vuL/PQy3sEi/khqbCQCTWCJMnoA40hiOkQE82rFWOgCM8XwqsQAu8QAzURCkMCAMOiQncX1aNwIRZpR0M6Iiku9N+N8FDuHjEXwG8IsAUoU7IJdmiOA0eAnQ0xlr8pR/6UQ1eBwOow5kcYA0iBTkEw84z/4E7LMDQI9PZUgdtsvtJvdN+21nBl7lbNIgKFEXKRqJzosLK8kaRhAg2yiYiMqSR1CHZXwFSIIVSGKDynUPbh8ZrmuWyjQer3/dMcv0RwDtUbbbWg/tcPMADzEHS50Yoln2B7oRx5MjPCwU2RoOYUMYs6oNZlGy4giJJOP0q3H2pLUlyVP2zXgFr/j2iR7CQDr5Iu9PpOUBjOERusG7kSwYwCow4HBI2psWODIRiwP3nK4MQggvjq0gBjive04KOUCAsXv3LH7MGO0qNSNwctBH24y6qlrUSdYGuS3HLlUlEVDFBDLAsJKBwSzWsJpEWszjiGzqvpG+UsKURSD4Eq//7+R4KCAgHA5THApwiWQaDmCSGMARJCQQCIBRAsVsUEqIBoMYbJQoLgeE2w0lXJUQAAWgQrEZp1gAg7HRJgKIBYBSw3rb7DY+3A/K6/Y7Py+n6PvwREEhw4+cnEPBglxDgU+j4WMgHKQlZ6UdpideAhiNA4HCQxdkysFkigAYIlGNUwxDAAutZgjSbstAQGDgqZVqyEHp0EnxaEBgqxgoAnKIbgJJpiRlNXY0zbZ2tvc0djd333Z0Z3k1VshRlzgqTcLBTBesC8BC62kNEQEtnq/IkpZCv0wh4WAByKfHKwTxkY4wwOyPloLg65CZadFPxosaNHCNJ6zgOZJhAjR7/DClBgKSylAEG1diV41grY0x4BKwV8IQZXSgKdMHB0sehAAawDL3C8gBDZcwYGNDFwJbIa1OnZqxa1RghrNyuUuTqEWwyR/KoOQi40cDPql7BUmvrtoTWPg4CKLijFdC7uN4+8sUDl1vdrZfW/j1sJzDiS4vlzOX2uHElxRglx6FsObPmHJurYa6WgKWOlDtSIhBCUoGuREd3PFU9mmgCK3cRiN4ampHWQzsABboL7DcPXQcUomYEwLYgFmz9dqb6PLp0KZ+nQ68KaFRdA68GMWI+91CiA7CeDqgRKtcC2inWtFG9Y7eO7TisgFHfqeWiAswPDFkQAC8iVXdddAR2/2XYI1JhtNaCdiBh3RsHTjdhJQiQxwgW5KmmUC7CzQWbLg48hYB98+hAm4ltkPiDDbzlFogARwXywFm63KeLAlY4AwZWE1bYEZDWlBUHhHI46AWRNh2J1hFCgvXkZlE+kt1wARADwBKwGEPCIbyQaKJe7PnHhhQpKSTfXnUdoKJcLrSpJQP+McfVj9ZNOU6CjiBJXYNNPoinVRE+EmgeIRJAgpY77MjIDkOx5gwCYBJ1ogDsKRfIVnISleZRBhiHoQ5DPVWULqtgaledzhkIUg1PsWllUaxogdIDDdwVxgO1KCUbrbk6CJsPRAWCwiwD0ISCGAS4k88AoabxVICDcv82LWOHLdFItZLZSWGrV5ih47e0uvAKA+W6YgUDuzKwxALllrugOmSIsOQqQoTGXb07IAGRGmV2q60ehSqISMDbrvrcwHBAKAIzwqwkgK0oRYwGTiYkS/GSOPhCyjKheFJuCwyMBTIsTjbD06AKI7aywS4XSNad3pZgQANWFJSPPM66t0wBPp3MDwo7G9WkvA59nI89Q5CctKN0QCTFKtK1/BfVLxvM7dTeBpLvqFiUZUCTB9y0T07QhH3Kn0ExhfQRyIbxziwADgstVAicpPXVX+nNdzZZs9qRkXIsoefgP2O3F+B9S7h4m4vHPJnMgXv1QI96VP64OFbHNU1dZMD/EZkXLGJl4uiZ5/F3wqevPiTr1L13TByhI+a463ek3tnmtk+rO5ReYPuUQnXdBV+ID8BY3E4IbPeUGDEC8FqMKT2x33AK7JeSe5giGhF5xoChWonRXpEAbMkfyq5oTj+vMsK5704Nn4kVzjn8mByiAP4ADL9TfDbs5IB2DCF8dclHStx1Jei5AD1ZeEb18PfAVPknAQDiBXlKRKnwPQUaAHwFluBTpVMUjDx0ytskJPecsaCOfnv60xsExwoY8qV3qpJCqBiRAP7Bp0U3mEvwCJgqDlVvUmDQSwSvh5zhMYprOKieicI3N9kYwxlECNUDLkQSBIQoEAqJEO6kJB0V/1ZFfhRhoe92RwkG9o8+O+QSAAVYvivoMAABRA4RK7UfItilevybkxt8lgBXKQ8HG1QNB60glIKVIDteCtgXNUPDncimBjVogi6ahawo4iJlyxKE90iwwGG5ZyhsglG2vOCU3xjrbSIgzxOQkMpAnGcfvPIHbPwBkkg2BweqScT+EpiSAzxlfcdjyaeUN8c6+uCOejlRS/aYxFShClcl8ByplDdFacVRJbdEBPqsFIh/mZBQKNyIE6BAAzJYQSGzsNfSEveFMOQDQEZwRwzlQQCbuecBCqgBYd6DlnYGYQgraBe/AhLKJLCLCeeEHjw1oktBwW+ilYkcwDjioV1AyP9hJYvFyOI2xaVAKBkJFUUUE6iKh16sE4gyWQ6iYjYk6OSeGjtBRqWVS/tRdKevs+g4NdJQfRDEDE3jwdISkZCFwO1kSy3pJu4mzuTAQiIlAAhLf+Aogsb0abVJaNCCKlHbRZSnZzzhRTkSogUYyUNjcxsjUDC3BSRFpHwg6SxLYIqjNOAl0nJQLPOHybfWVK10wKJ5LHYLST5jQDol604fmZmxxgFqIlELRSUbpMUoKQ9kdGyS3AfGvxizhJ69CGY5EsnjbGEOZoRDZyvhMG1B1jKnLW390AiSRSikfBy8Rmvf8FpIxLZasz2YbW1bW4jm9nO8VIk8bhlIFzzDa+D/bBaGMLYsEXAtWh1KmRti+4qjhSFaaPDVCUxZQ7P+9GXh00ztdilWkch1F1VkjgsaOoMaLEpcW5BHO1HgAB8QoGsjeMUOfIVXy3kBvPJgBgG6igDzEvafYSXnWZdIxzuYbiOza25ULSEeajiumW6gzzaSa1qsyMBWvHDBTffKB4c5i6MtdcZH09axWfQgdt8lRng9ttQc4MJsJ5IafC08zvdKpsNV/ZY1QhwNJTMWt4FbrQxkNBBSgBVCNyNql61aE6DEDaFGKJlC6CHVtQx3sctaal2iEopjHVIWeMusTxUnVQUzTzYbHIkW5UgUAxRRF71piTHusmfnqZMliNrz/xOMd5TzOdlNwpGkMdhJ6BMR4NBLTIBvUpWfYygze1jA4vemoAPsZWhHYJjUMu1CxwTW4C4+21t8O8KAEOFqbc/liZGo6yG0OSt2TMuxAY/RNimcVEZcQ0amN2UAJvAVDfmrMOSS7AwbFHAkAihgd5B5oxCfqZnGWF5LRoLAUEywgtsmDQ9RnY/2toE8LwgiHUNMQnJfIcQmBq5+kKO/CzruRQCXJqVcrUAuBi8XRqj1Hhp7XClYNg9iNByFlXtn1dWHUjjgXzPJkwuFABFXHDrRA5pJomTuB8OfSpW+b2AjJsp7kc5wwA45tEU6onzfBYMRc/cnmidEE4k+GHiqh/+eZwVi8NVswF8BFGxr16G4WhU3rnrx7DiPz4vHIxdhIsZNhpTbW5ntYY7W/UcCYwzgiZM+RLzvXbAzNRIHO0fA3KuZQByo3T58TBUgBZkfAfS9q62mIyKVjoPryuWUjKNyxFlX3MZQAsMOOHuWjPGOrtO8UZVSusqRM03LP2pUGZy0DBgRvNw8PcMzQkDdT6+DG3VRhMMSug/4Z02Oi1DwSDeR57KHeJoTw+GXgfjjTxd5zXq2HS7NzLbtQGLAGP/4j0s+y3i6CJL0VjJP4VkdACmw6WskVAogrSNk2IequyG4WQrKO+zpI9BCkvpknfpEIqmTkR3g4n5Avx7U7wj/mLMMLnRk14Zn9Cd+yCcSM/UDIsc10VVJV7ILTPQKD4ghIxAtiYAejAAbD/Bj+uVrb/NpdpcPI+gGlUMn5FEagnADR2FAnoCBMDFgMCEplZYY8hdZXvRb/Wd/G9GD3YB/HCQG+JVO70AGDVBgRJIQEKIAteETlJQC80QHpmAKY+FOunVVGQYHCdAA3wMNQ7h/V7ZOSzJgJNAva0AAzSILUHeDGfc+k3NJK9QxYqYMkXBXt9MFm4UHAGhtqxOEeucAL2Yk/kVmqEJYKxUGh7hUSHAsIZMMIfNS2tUA+JAEAcJ/OAAgNyAGvoAKNBZkNyRXO/AuqmEA21d8bhhaHOEK/4Uxh0mygwvTFnqYfipVgH64gCigfzyAS0ylDLbgYmCwCBMGLmk2UvtSVwawa76kNFvBUE1SE0ZmBu9wL3DDDu7wZS9YVbzwiM1HL7eDg7TlLczhCYcwMixoShn1CtGCMehISh8mBKcABqH0Kl8DDEh4DBEGFfjEgq6SId/FE8pyABmFAvZ0LhJYAB24DLogIKiTgBZBfoSQVoNYZmR2LBK4AKcXgwVTjExVF10QVxXJBFoiG54gkk9wN4ShXVfSBcnAaDfAVthYN4FwY/DiXW14dRqnis7wAgdQZmGYX/8zh/MiYA2RHPtETVLQLj+AAqFUEHcBaomXCGVxXz6ZTv9GkE9vMBZl2AtgQJCwAIVtBSDKBpTg0JC7w37QR4teAI3vsZB+841WtxGriGOicAqpwHlS2QqwYFcJSRzA9QnBUFL0Ig9cqJB16GKcgAoQwjFekJUgFTtdqS51ZYzLMD7mZ5NS51hqMHvikAv50gajdX9vKXnheFVJEAPwJ1VJpQxoRlIKAVVTUGdpcCVGeIc1wxT/Y5taOJWnmU54hQZUlSsTI5tnhgxoQI4bKVOJ8GZhcWsIuDjWdxg0JJcaMxL6MW0NFA8ysVQeEhWFWW1e0IWEEEpcA0pGEEsBiZ0/1pKKaZx/EldZiWxOMiyRKZy1cAzNF36O55x8A51Vwzr/S3CJGjFxcAl52rBhbjBzdiBl+1lRN/mGDNqcmBk1oEaKb1BybnCgsGNuRwkHpTNpEDoHoql8ICqhEdoiV8BqFqqFK/KhCNqicrCgJNoCInp9MmqL+tkiB6kAp7ZNxeEpS+QasLZYNdgSZoiiqRIcupcc3lN6COBz60MG3/RpwIEhHJo5/TlDiFE9VeF/eWIJfIhkJeomQ3EI4ENHHgRAEWFH5FNrEyRI4ZMisjFvR2qmrodTwzEezQcf/WYi+FGgqDh/G1cw/HMRIbalfXAU5fcIMCSLdvilaRmmf6p3NqAUJpJNmVJyuUZFLFJulJJ9cYRB+aNISAl6TYpFGZJz/w6QkojwpDMyqgoIqDkoqIBmpdxgqMjRB/SABSPzim7AqL26B8CKlZBqgJLqJoTAdr1lSP3DQyTCQG5qqnbBd23wd01KdwFyd4cHZb/EJkoqpsX6oFLlSvyzPexScESXEhQ0RXexH6+SdjnSaYxAagw0az/AeAWwmdjJZjAoAt+TABU4SZSAjg2GDOTlJN1nFPdYh5t3Bfa0BGdhsIpVlc8AksmCIZ3EH1YCKz1loo9hItsEet9zN5xiA+MDK0TKPXCKpBiiZ1zTpN/Uet30AJ4CKplmrOCailJ1Bs90F+tmieeafeFEKeJRPQAiNvfVc+eqQIEoD8QnMm/QAGCglf/VuBdLiAny8GMOpoaRaZX6hAX8tLA5MHvMoLVOAmckIAb6JRcDFRpSWE+WYpSfhaM2yjs0Gp1qej1VynJHtKX8JhulOmgicqu3lypOx4Z6t307BkxjhhI2IxqK6FuyKV7bSJ8m5QyhoCSSGAM+UYpLVS6+kLZ8AIl6OZlwc1JYQi0mSrftE6vguHGIJhx+dA44BEG4aiJEe65uB0CNNHgmQCyL5wX0YJ4EACDEGWSzoAa4AIwUe7VdxGZLUZC++ZqRS63FEm3CCS9h6A5GsozJUIzTG6Jzu7rlhLOBCg8kJ02icRe+kRJEh4lThAb7YQyDcHqrF0DR0rsnMnyMp6//DVCOV7IU4HQXFUkekItXMjkq0OuVfJBXhUkkJXkDi/AOlFu/2ysJFbuIkglOAvKDXTG+smW3/jkRhxqAPwcJZ9kqsemDZfkcXYqoBMifIZylI4yrjwB+mYDCHWEAvpRT4msRi5WQPChUhSBGOVy3rUugH/wyHXxiAwINYdkHEOLCemDErOugOavES8zCQPjEdOCw+NqvctqSF8iPazCNTkBJ08U1WJAMLnizzHmAWYw1W9wV2QZkzEC17PCT+tC1iXUCattltCIGB1HFXiTDtyXHWuzD99fFlzcAnWsL+cSJMDbEefWXTCVjDOGJN3rF5pvIc7zImtPIutgIyMtQ/9qbTjfAnpcXBVz2LVY1yK8Mw3qDpZyTbbeMy7msy7vMy73sy78MzMEszMNMzMXsDHR8YqMswbQHai2Jkas8Dyfxa2u8nVwzy1dTy5+szfXHF8dCCIVMhwiYzdtMzsgsoDwMzr8UoJ41zuXszpz8zklsLfFMz+xcz/JMlvesz5dVB4R6EU5rB7yBajx8fO28zwdtyF7gOe/gzxYB0HUg0PlB0JYQQYlAwtogZRd9meWL0B2NzbCTdw09EQ99JD+3rU/2quIQo/McqR7t0orcRD4TPL8kaPrhaDdwHLAraC1X04q2A98E0EeRCJ/mNEFAEq9KpCjKaOZaAKTmTH63Bv9UBEhuVAChkKRH2a5XwtTpmtMnanhLba+admjJMT7/YtAvjdYjmh+iCrvrOx/nRhq3iwieQxTt9gxo2lzxcUr643UjoaookkAn3Wcm8B8/m0gK0G9hDWW1phcAYimU4qdZghxGG7RXMLSIoCI+iwaMTQblNthy28lpLdo/dUNDwD/icXZ+23K48nlCYUVh3VyzV3KAMLNvfRcnHUWlwiOD96SKrUi1ZgVjQ1DZxsNO9LelPKhEYSIsF9Z1l9uEcdajLd3xhwNqtKepQhpnJ9c1Amqtra0F47R8jad+zRuCdNKE9AyyK9mES01r4tuc4HAsQXhuwLe2e9lXlHfq3dz/YTdpn526LT3dAS6rTeZLa0LX0mJ5x4EGhNrakvQUiRDUq+FM9kAGvvHgE0qD6jt4NBvWsIcteOdkScpc8qsfh6rgTfbVObLfQTqyMMGxAC7gMV6jHa3RqHXIMo7jK+zRNa7joZ3jP96HQN46SCzkRf7DRt7ERI7kS+6W1cInYDrFV3rjTE7lcLwRIDvRL+wGUF42ExXdVQ7mDwcSgqbKh8tZBMjlPPXlYc7m4csRVvBP6Z0SealHyi0MurAkGDyD0iJhFrPnaHAcxJrQPt7mhZ6fqoi6OYArVGgz/PUDGtjlV/hgUhVhW0WGW0sAWQ7TMG7onS59HZEurkgL/AEL/5kcMjgxujcmZH3e5ZT7yC3xYSCs5J5O627OEYJGAo+8sAMGYUSFVcOhL0YVGjvwZvQiZ34uinralrJO6LXu7C++Ef9bAFH5Ex1Je7IyN+SR52+jPmngStLW6sn+vxv70bP+7LXeg8HVjau75ue+5Panma5FEsJ6XO3u7kbOxPRs7/cu5Pkez/vO7z/+g0oCpvNT71Me8FQeSVjOIGYi6MHa8GEr5eae8GweSWR+BIdL8A9/GXrSqBPf7BVf6DQE515AXb3GPr9QmLGE8mTgAlC8CQM7SwiLXi4D8CIv4NKJuoGcMzuJtiqViQrQI/eVsXYF82iAl1CYT/5EywiP8/9FTvL4mcmzwglitACVOVOHKZwvz8BIn4d3aAoptekc/fQjX1n58sjXuA6obEPKCQtNmGZUe0/mkpvOC/ajEOqgHPJlX+WRJO2QYucuUMGJQ0pTRR70Bnv2pI9PV14y6VQw5uJ6z+l8b/FXk/dZwoAHT/GUj+8Gw1dGKAjUd/Ocj9b+/s6jT/oubfrujPqp39GrLwWbwrg22vquf9ALbzyXo4bUyVqi7/S2P90X7w+6biiEf830V/vAf89RH+fAMOdOUudFoUm05K9pTE9lnLB27sbDxmYGG+iDPvnKD/Wtkuigxug8n8Gm2Q5FSApK3+hYoAVj+F/7I2CYrulxzNL/4q/wIHH5IAAAwSAOBRMwy2G2hAAMASAQItHM4jjsQKPBcg1rhFQgqYIBUoyBIUBA8KrWKzar3XKxtG73Cx6Ty+YzOq1es9vuNzwu987JBgNDZujxCAYFAEIAlcIN045NU8HCT89PkCDh1CBAIcBiFZMTj0JD3SddmxgoaanpKWqq6urc6CoDQVLBA5+IA4mIQJIB1SGNbhJgI8mjJzAvUNLBzcCBMoDmkjIVK5xr2nW19jZ3t/c3ajZ4YnUneLib+Pk6e7v7+6l6N0OBw2psAB58nTxZ/z7AgAIHuvtH8GA7g2EQMmzo8CE/iBLXKeRScSLGjBrhXdzoUVS6jyJH/5L0dq2BkgUlV5rpmMUly5gyZ15xFSsGrAQ0d1aBWZMn0KBCR6VoUUWBkiMJAhSIVYAKi10AogYA9KDqLKEcQ2rt6nXkqFuAsCAVsLRAjaqCDOgMlC/ZgqtJaH2lyLUu3rwNRwkyykOAs7lnAYjVRTetkgAPrsbQC86nFciOJ1M2ZTMAzkloDQ8Wu7bt2iqMK3eTzMM06dSq15xMWWmX4s5VpwbeQxXz6NWsUI/Q7fs3KN7AC94dbvz4GeHIHxdf7vx5ZOgTeSuXbl1r9eurqGvvbjy793jNw5OnDL588PHo139N7P49/Pjy59Ovb/8+/vz69/Onr549gAEKuN2ABf8aeOAn5yG4IIPkKdgghBE696CEFVq4GoUXarghXhly+CGIO3kYIoklanSBBhH0FoEGF5j4Iox4QRDAjDXGeCOOQFngngU5+vhjSRNUoEQFEwB5JJIZYaAEBkk6+SRDFChBAZRVWrmPBAFIcCWXXYKTQQAZeDkmmaxsWSaaaaq5JpvY9PcmnPm1OWd4IxJIJ57W2anKnnn6SVKf6Pw56HcfBUooohIdalmijaq2Jy6MOjrpZK4sUEASU8QR6RnA5JOHp2OdRimpeY2ylD0JKKCSNSWgAZgIBtACKwMHNCbCoqXqys6pmFkBzAFUeIrAMb1EEYAnDBxLAhL5JDDDDJf/6iTAHn+1kICtNRhlzqi7eguUpfg0kAACTwHwgAKCuBoJEIYwo4IltTQRgAMzNHaASvhW4akn2gaCSbffCiyTOAnIukBi+PpVRDPQ4KSCvj0ggE8AjIhhgwN+5dJCA9XyG93AIa80ygCaGixAudS4tS4llkTDgAKAqNsxAEtZzEMCBRhw68axGqNxTyILDVYVMCsx1sfDFuvwvAwg4EwUPmDqzM08PFBAW9aKUKsAsIYyNNgZ5aoFE6yFffZ069ySNTZou+3Q2Om9PTdBcSdIN94B2R1R3n0T59HefgseNOCDG25SnIkrDt/hjTv+OOSRSz455ZVbfjnmmWu+OeedDHv+Oeihiz466aSFAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients who present with a complaint of cold sensitivity of the digits of the hands or feet and who have color changes of the skin (pallor and/or cyanosis) can be considered to have Raynaud phenomenon (RP). While patients with RP may present with asymmetry or a dominant more sensitive digit(s), patients with primary or secondary usually have involvement of all digits (relative sparing of the thumb) in a symmetrical fashion. Patients with primary RP meet diagnostic criteria including the absence of tissue ulceration, negative symptoms or physical signs of a secondary disease, normal nail fold capillaries, and negative presence of autoantibodies. Patients with secondary RP have a history of exposure to causative or aggravation factor(s) or symptoms or signs of a secondary disease process. Patients presenting with persistent asymmetrical or single digit ischemia with signs of vascular compromise mimic true RP because of associated vasospasm of involved digital vessels. In these cases, larger vessel occlusive disease or embolic disease should be considered.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Fredrick M Wigley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21952=[""].join("\n");
var outline_f21_28_21952=null;
var title_f21_28_21953="Patient information: Gilbertâ€™s syndrome (The Basics)";
var content_f21_28_21953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/17/34066\">",
"         Patient information: Jaundice in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/62/22498\">",
"         Patient information: Jaundice in babies (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/16/3328\">",
"         Patient information: Gilbert's syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/45/16083\">",
"         Patient information: Jaundice in newborn infants (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Gilbert&rsquo;s syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/gilberts-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9274291\">",
"      <span class=\"h1\">",
"       What is Gilbert&rsquo;s syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Gilbert&rsquo;s syndrome is a condition that causes a substance called &ldquo;bilirubin&rdquo; to build up in the blood.",
"     </p>",
"     <p>",
"      Gilbert&rsquo;s syndrome is caused by an abnormal gene that runs in families. People who have Gilbert&rsquo;s syndrome were born with it. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9274306\">",
"      <span class=\"h1\">",
"       What are the symptoms of Gilbert&rsquo;s syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Often, Gilbert&rsquo;s syndrome does not cause any symptoms. If it does, the most common symptom is jaundice. Jaundice makes the skin or whites of the eyes look yellow. &nbsp;",
"     </p>",
"     <p>",
"      Jaundice is common in newborn babies. Babies with Gilbert&rsquo;s syndrome might have jaundice longer or worse than other babies, but doctors can treat it. In people with Gilbert&rsquo;s syndrome, jaundice can be triggered by a fever, physical effort such as hard exercise, stress, or not eating.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9274321\">",
"      <span class=\"h1\">",
"       Is there a test for Gilbert&rsquo;s syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can do different blood tests to see if you have Gilbert&rsquo;s syndrome. If the doctor or nurse is not sure whether you have Gilbert&rsquo;s syndrome, he or she can order a test to check whether you have the gene that causes Gilbert&rsquo;s syndrome. But the gene test is not usually needed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9274336\">",
"      <span class=\"h1\">",
"       How is Gilbert&rsquo;s syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Gilbert&rsquo;s syndrome does not need treatment. The jaundice goes away on its own, and does not usually cause health problems.",
"     </p>",
"     <p>",
"      If you have Gilbert&rsquo;s syndrome, tell all your doctors and nurses that you have it. Also tell them about all the medicines you take, including over-the-counter and herbal medicines. Your healthcare team needs to know about your condition when deciding on medicines for you, because people with Gilbert&rsquo;s syndrome can have worse side effects from certain medicines than other people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9274350\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/17/34066?source=see_link\">",
"       Patient information: Jaundice in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=see_link\">",
"       Patient information: Jaundice in babies (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/16/3328?source=see_link\">",
"       Patient information: Gilbert's syndrome (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=see_link\">",
"       Patient information: Jaundice in newborn infants (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/28/21953?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17219 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21953=[""].join("\n");
var outline_f21_28_21953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9274291\">",
"      What is Gilbert&rsquo;s syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9274306\">",
"      What are the symptoms of Gilbert&rsquo;s syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9274321\">",
"      Is there a test for Gilbert&rsquo;s syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9274336\">",
"      How is Gilbert&rsquo;s syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9274350\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/16/3328?source=related_link\">",
"      Patient information: Gilbert's syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/17/34066?source=related_link\">",
"      Patient information: Jaundice in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=related_link\">",
"      Patient information: Jaundice in babies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=related_link\">",
"      Patient information: Jaundice in newborn infants (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_28_21954="Parasternal long axis echo close up aortic valve vegetation";
var content_f21_28_21954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/79209/laxzaven_conv.mp4?title=Parasternal+long+axis+echo+close+up+aortic+valve+vegetation\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parasternal long axis echocardiogram with close up view showing aortic valve vegetation in patient with endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parasternal long axis view from 2-D echocardiogram with close-up of aortic valve shows large vegetations of both leaflets as a result of bacterial endocarditis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21954=[""].join("\n");
var outline_f21_28_21954=null;
var title_f21_28_21955="Male cystectomy PI";
var content_f21_28_21955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51018&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Surgery to treat bladder cancer in men (cystectomy)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 652px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Some people with bladder cancer must have surgery to remove the bladder and nearby organs. In men, the surgeon removes the bladder, the prostate gland, and the seminal vesicles (shown inside the dotted line). The prostate gland and the seminal vesicles each make some of the fluid that makes up semen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21955=[""].join("\n");
var outline_f21_28_21955=null;
var title_f21_28_21956="P6 acupressure point";
var content_f21_28_21956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    P6 acupressure point",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 376px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF4AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3EcH8aeM+ppOjGnDHXvTIHrn1PNOJwMk1CJMkKgyakVDkGRs+w6UALuJOEyc96cqE8u2fSnAADjAFKf1oGA9ulOGfWmg08dOtAwGeOaM8n+VB7mjvxxQIXPHXig5zQB6c06gYAe5oz7mgD8qO3WmAuc96U5yDR+dAxn3pAOB96DmkFOXmgABoGetHHrSZ5/xoAXmjJ9aQgde9GPXigBwPAHU+9Oxn1pqYPanfTigBp+p60xs4qVvX/JqM96AKzg4PWqk68Hmr7jPWq8q9aTEYt0hweuawtQhJz1/OunuI+D0rLuocg0MDzbxHZM8bMM5Fedaikkcv3mH48V7jqFiHDblzn1ridc0BWZ3UZPpUSRrTZ5lMZOgY/wDfRpq6hqEaeWt7cBOwLkgfnXSz6Twf3fArLuNOZAeDx3qJI6E+xzFx4t1LQ5hHqFtFqNo+THK37uQexYcce4p8njfR7qMh4LyFsdDhh9Mg/wBK0NS02DULJ7acEK3IYclD2NeWajZTafeS21yu2RDj2I7Ee1ChGQOtUp9dDpdR8VQksLC3kPo0zY/Qf41v/De9k1HTdUtp3d5o5VuFyx6Nwce2QOPevMq6/wCGFytv4hlR3CCW2dRnoSMN/Q05QSi7Cp1pSqLmOu1GGZAxjjQsOh/yat6G7rYIskssMhcsQg6jtzWjqVoFg80yKFIztx2pmmYjAAJAI3A+1c078p6dKKc00alqqlUP226Vu/z/ANK6rw7PscBrydtowBtyayNK3zbVAU8ZIOOea6rSYwdh8pUYDPAxx9a45XZ6kEkrGrFGws7iV2YgKTyfap/DcRWBN4JBUcVn+NL5dI8KXc2cKNkQP+07BR/Ot3w5Ik9pFtOcgcVjzNPU551bJmX4vtXn0y+uY5Zle3AZFQ4DAfeBH+eleI3N1eahcO1y80SMchEPJXsPWvoTxFAH0PUUHR4Zecf7Jrw23TyrfMY25wfMf7xH0rWc1FJo53eas3oVoo9hcorl1AJYg5I/z6VZyEgSSSSSPBzyx5HpUmJDtLTNlsZIHr296SRHDrtMi5J28gsT7DtWDm2UopbEFxcyRwu4Zo+u3fkED6ViyzS3BYiZ0j7yA4Nbbad5pczF2JOSG7f4077JCPkVd+CPl6A/gK0jUjAznTcinBqcKxJGzzgqoUDaW34GM8dSetWXuWKBo1nbPGC23HvjsP8A69WiiWwEs8scCoMqeP1qCS5kkCyWlu8pOf3jDYP17VPMpO6RSTirNjf9OZVzKlsvcISzY+p4BocJ5oMk0zMOPmkPP4f/AFqRUdt0l3MPmHKQfKv4v/hUIGw+Xa27O7DLFeBg9yxoXl/XzHtuWI5nRMQAxrjILE5/Lr+Zqo8uZCGkklOCCo5x+FSPauFZri48tMfMIxtA/HvTI2RkUWdviI/8t5shfr6mqT6ktO1mIHu5GPl4t4wOCXDP+Q4FMS5jjbary3UxPLbi2Pq3QU75CwBZrt8Y8tQFTPsP8TS3DDb5N3IFJHy29sMkn3x/Wq/r+uorWHPPKIi0jiScDmOLJ2ge5qoWnlAaaQxoeFjQkMf8+1TLbTnci/6LCmcKh3P+OeBQhhSZhApkm24eRuo9i3QfQU3Ky0J5b7kR+0OMbvs5zgDPzkeuP8ad+8Rf3ZeRh0eR8gH1z0oWQO21GkkbBBK/cH1PemSusa4fzJpCeI1Gf8/Wi7CysNi82adGjeR2BHz5IQH+ZP50VYGRIGun8uI4GwdQfc/4UVcbsho+rN3zYUFj7U9UY43tn2FKqgHjIp9e0eGAGMAdB2p4OBim57cU4DkUgAHOKdgCkBpc+lAC0ucjikAzinY4wcUxigHrS4757Ug4pfSkADnqcUvUUnIxTu9ABxu9KTvS4o70AKKBS/h1o70ALQKTrSigYpx3/EUnX0FKOvWkbk/SgQA8dKPrSd+nHtTgOKAFB9euKUZ465puMcdPanAc89aAHAU1hk8CnD0pevSgCBhxUTpVph+dRsvPNAGdLED24qjND7YradM9AKqyRAigDnbi3JB4rIu7Hfnj8K6+W34qjPbZosNaHBXmlKzE7cGuf1HSAASF/IV6ZcWmRgisi8sQc8cVLRrGdjx3UdNZGJC7TXG+LdCOp2u+Jf8ATIgTH/tj+7/hXuOqaSsmeO1cjqelBH4GAOai1ndF8yloz5uYFSQwIIOCDVrSr19N1K3vIwGaJw20/wAQ7j8RkV2PxD8Nm3ZtUtE/dscTqOx/v49D39/rXBir3Ri04s9/hlt9U8OWt5bN+4eIkZOMY6g+hGKp6SxuY7MwqWWXGMqSMZ9uorz3wNq9ykyaLNcg6beNsaJlLfM3GFI+6T+VesaPZpDfyeWvyQIscYBwEJ64/wAa4qvu6M9rDTVSPMtzpdM8Oa6IZpwLO4jUFkSMFHA/kTW/4OuU1KCL5Q0ZOeR6dc1o+FzKtszuTkDgk9asaHbJa3OooiBQXySPVgCT7da552smdiqSinGXyPJP2lte+yWei6LA2Gln+3SgHB2p8qfgSWP/AAGvQvhzqgn0e0mLcbAc18y/FvXv+Ei8f6ndISYIX+zQ4P8ABHxkfU5P416j8PNfe30i1hdSqxoACTkkepp4mg1Si+v+ZwYebq1px6HueqTxSaTcMrAhoplb24rxG1jcW6AEFyBwCOBXcLrKvoerxF8Ex+YrD1+7/WuDnuEhVdxVeAPmHP5DmuOd2lFHY4qm2mWAkYwry845Vfm/DNRySoXJiQKGxnC/zqrDNcXpJtoQYs/KZPlB46gdT+NK2nkgfbpmk4/1cZwo/Ad6z5UviYua690ZLdo7+Shd5c8pCQx/E9BUm2+KqdsFonU7jucjrRC1pbuYYIz5n92FNzD/AHm6LUjrdXBUOyQQ9NsQLMfqx/pmm2lstPMFd7v7ivNbWcUqvIvmMTuHmEuW+g61YZLqRowu2JWHIfnA7fKOM/jUai2tBsgXc5zk8sc+9IZGji33kv2cEHduPP0GO/0ou3/X6BsiVbO1jZzd3E0zZ+SMHcCfoOKS6aRwxLJCpAO9iCTxzx2/GprJYpYWeKMrkgYddrNjqSOtVNQuYRDGY4kCIcB5xsX8B1NWk5Mm6RAqB3L26mZhwZZThB/jUDqkku6WWa9fOAI8rGD/AJ9amZkaIPds+ScBXyq/UDrSPIRDhV+z2/RXYAD8B3q1f+v6/ITt/X9fmCo+A80gijQcpFwCPc5p0c8TPmyjIHOZGG0Y9Mn+lQwQlxwGdDyZJcDj2WpXMAkTzleSbHyIp3N+CjpRZbCRKwMaElzcSuNhVgBGO4x3zVGfAPl3hErdfJTp9No61o/ZmMQeZ1hTlvLQAsoPqegqEMsalbCIAHq7A/mT1NLmHy9RgjlaLbKVtohwqr976egqErJBJstIgn96Vjz/AIn9KCzCZABNcztnA4CoPfsP51JPFGxU3D78j/VDlSf6/jT2/r+vxDdFe3w9wvlOZnDZZ8jHXpmip2W4aVEYpCobhQOR+XA+lFWrMh3R9XA8ninYz1pO/wBaXt7+1e6fPDhQeD1pvWnj6UhgOeuc04U0Z70+gBaVcdqaDjnOKAfbNAx+etFJg8dvxpegHrTAWndPc03P5U7HakADpxS+tJ2paAFFHH4UCjOB2FMBaB7U3d83elpALS/0pKKBijgcD8aXHH69KbSj8RmgQo70oHYZ5FIMkY4/Ol7gUwHfU/nSZGcdu9MyWxzUi9OaQARn6+tG0dKWloAjKccVG6Zqx+dJii4yjJFkdKrSw5NabJntUbxg5oAxJoMZ4rOubYc4FdFLFmqNxDjOelAXORvbYDJxxXOapZB88YIrur2Dg1gXsAGf84qGguedX+mIytHNGJImUq6NyGU9QfavCPGfhmTw/rPlHcbCcloJPb+6T6jp+tfTGpxei5/rXG+JNEh8QWEmn3XG47opccxv2P09faktDW3MrHivhueG01/SX6qt1GxPYfMM171o8CwXF7G+ci6YDntxivEhpNxpt7cWF7Cba5t22SDvnsQfQjmvStF8TW7wxRag7JcKADLglZCP4jjlT6+tcdfc9TAvkTUj2nRJFW3xu5I5zjpWT408Qw+HPDWv6nuAkRCIQf4pSAqD8z+hrk7XxXbWsLCO7hZj0EALsfxPSuE+JmpS+ItEkiDsBbuJo4lBOcZBLH1wTXPFe0lGJ0YiSjByTPIYGxON/O7IOfevXvCl9anwzYu5K3EaGFwnzFtpwD7cY6142Dg5r1H4W3Fs9tqMVzGjPHsnjLYC46HOffFduLdqfN2PJwU3GrZdTropdSu7eSO2dLO2mADSfedgD09Bz/8ArpbXTLaJWJDzOT85LkB/rTnmluZCsSlkwcscpGo+vVvwoe1jMf76YyKMfJyFHqcD29a8iU33tc9e3M7vVk015tAFtEJudoWIYVfxPU/SmLBNMW+1spwMiGIEAeueef0pq3ccp8rT42l2gksvyoo/3un4DNRSRgJjUrnzM8rbW4Kg+n+038qlRt/Wo7p/1oOiuI0jEVogbBwRCAQOP4j0FOmiZXD310ypkbYYerf7x6mrM64tbYqy2EKIfOiYAk88Yx0GOoOeapxPg/8AEvgDLJktcSEgD8ep/Cl5r+vmO/Rj3mkWMCNEsoRwCQNx+i9vxqG3XfIht4XmZcBp5Dk9+c/0FTPDFHOv2tmnm6gYPzf8BHP4nFF5PKLbc8iWUZPJcDI+gHGfzoXZdf69RvTVk8btawSebcAeacsxGAPYdc1RnlknuA8QSG3VcK8inI9SAep9zUkUSjDRb9xxi4nyzufYdcflTWghgmDTb7i6PIUncfoF6CqjZO73Id2vIjiVHmMkcTon3TPcEkt/ug/4AUSx28LhrgvPP2B55+nQU6b7RKcysLePHKkZYj69vwpkRiJb7BBvxw0x4Ufif6Vfz/r1F/X9IdIklw4ad/IhGeB1cf73p9KYHEXyaZaxlpDywOAPdmqS5aBWRbjbcTH7qKDz/j+NDJLt/eulvCeSoODR0/r+mO3b+v8AIikwQWnJuZgeI4z8gP0/xp7GTyzNqDCKM4xEg/Qnv+FJFJvDJYIqhfvS7cL9c1E1vbW8gnupmkmHSRjnafRf/rD8aNNn/X+Qa7jQZHHlwIbSAjcHC4Zvov8AU01pobYDG4MwwGOWc+wFS5lueUIgiHJduXYe1QYhjLNCAzZy0rHv65/wqkuhN+qJsSu6STOLWIbSFBzIR7ntRVe3Bfypcb5A2DLM3yAE9QKKtJmcnfU+tx1NGKQ5zzjFOFe4eALTvamdDSg4xSGONLTevTj6U4djQAClGMUlLmgB1LjOKQH3NKvtTAVf50tJ7mng8UDE6etGT2I4oNGDj+VIAJpcGlxxQKAEoHIpRRjigBQM0djS4o/nQAUoHU5xSfQU4ZxjmgBO2CM84pwJz7etNHLDqacOO2B7GgA5HP404fnScDvQefagBQQelLTfYDApR9aAFFFBIFRs5bhDz0pAPOOATzSFc0InzZP86lHuBTAqunrVSePIPFabDg+tVZkzzQBgXMXByKwdQg64FdbcxE5FZN3B8p9aQHCajb5U7utY1pZF7gMenQYrs7+0LseKpQ2giPzD5jU2NYs474leCX1/Rhq2lxbtZsY/njUc3MA5K/7y9R+I9K8csrqDyAYEecnBwvTPua+s9LV0ZHTIZTnNeU/FPwXF4ZvT4i0m3jj0e7kzcoB8trMx646BGPT0PHcVlXhePMlqjroT15Wzzyysbm5K/aJfKiOT5aDHH863RZWcFnJCyoiNGVy2Rj8/eqEFxLIUFnGxGM+YwwuPXJq7BbQRky3sn2iQdmztU+vvXlzlLroegox6aniGt232TVJ4gMKGyB7Gui+HVzHD4gsxcFPKfdCd/QEjIP5gUvxOsxBrizxj93Ou5cDAx1/rXO6TcNb3KyJ96NhIPqDmvXmvaw9V+Z4SvSnr0f5HunmO7M1pG1y33d6/Ki8dSx5P4VBdRxRlRfyPPJkEWkCcfio5P1OKuNNPc2yyyXC2trKqyIISN5BAPLdB+FQwGUB47HybWA/emcZLn2HVj7mvCTt/X6/5HvvX+v0/zJJBMMG5KafaEDbGjAyn/wBlQfTJpqyGDI0208sNzJcSZLY7deWPtUgW2tUVZpJbq5djsL/NI30HQCpLmOVV3XU/2Zeu0ncx/wA+lRe+/wDX6sq33/18kVUEaSGS5d5pT0V1z+Sg4/MmpbqO6kjUz3C2EGPvnmX8OwotllEgFlAYlfh7m5PzH6L1pJ0hgfdIftV5wBg72X/gI4FPr/X/AAyH0CFNgEdnA0KseZJvmkk98dfzqKeSzinVQGubwchP9Y6/0XipZLWefeL2ZbS3zzHESXYf7TUsDxJEYtIhQRI3zY4GfUt/hk0vPf8Arqw8tv67Efk3ci772VbS3IztU7pCPTNSII4YiLGAAjjfKecfWobhYLdjJfzNK3aNVIGfZRyfqaljE81thUS2tlJYEqN5OPXr+FHTy/D/AIIktfP8f+AVJdsWJLuVpGJ+WJBkE+mOp/SlCzz7jck20AGQMZk/Lov6mi3uLeKWWKyDTTfxSn5j+JpPLJLNOyuVIJXnaD7k/wBau9v6/QVhEl2BlsoEyeWdm2qP+BdT+FMmVFiD3nly7cEO67Uz688mnedPdIFgRShOPMYERjHv1NPKxxyDmS6nUclvup/QCnsG43zpbkL5LIsZGAxXj8B3qEBI3YoHuJuhfPC/j2+gp8zvcSMrFpM/8sYlwGHu3p+VRRjy5CjnzZBytrb8IP8AeY9T+QqktCW/6/r/AIcaSZS0aL5xTrj5UH496aihl3lhdMDxjAjQe3rVhg8wMThZmPPkRnCr9T3phgVZk3nzfLx+4QbYo/qe/wCdUmhNdhkeJ2WVcbI3GXkO1VI9M8HFFNmkkaVSm27YONgZQsajPG0d6K0inYym2nofWWcHing1EDycU8fyr2jwh+fxpVHqabSjrSAU/WnA0yigY8EZp1Mz6U5elAC96cvBpKcvTn1oAXGVpV6470nQj27U4deKAFAp2KaOtLQMKXr9KSloAP50Dp70H2pcE0AH86UD14oA6E07px1oAaBTs4HpRjnOaB6cUAHfqaUDB7/hQPzowO9ABxjvS0EetIzBRz1oAXPFMeQD7vJpAWkOMfKevtTkQLz1PrigBAHbkkjPtUgAA46mjnNKO3SgAFPHemA4p6mgBSPyqF0yKsKM0pTIoAzZo8dqybuPriuglTOazrmEdxQBzk9v1qstpliSO9bU0POe1RCLPagpMjs4NoGRWn9kt72zns7+3jubK5QxzQyLlXU9QRTbeH1FaEKgDAoKbPmr4geGr7wh4hXT8GbTbkGSxu5OhTuh/wBpeBjuMGsKPy4jhw9zcA5EcYJI/Dt+lfVHifw7ZeKvD9xpGpblSQbopk4eCQdHU9v6jIr5tvtKvtB1O60d7Fba6tGxLK+dso7SKerAjn9D0ry8XQUPeitP6/A9PC13UXLLdHB/FSxnn0K1v5o1Vo5TGQDkgHpn9a8ut22yr78V7r4msobrw/qdo9w095JD5wBOPucnavbgn16V4NyD7iurCS5qK8tDhxcOWq/PU9r8F3lrN4fsGkBmvYswBSS7Lg8bV6DjHNb8sTthrmVLOM9I0wzn8eg/CuJ+FN080epWUbpGXVJ956gDggDv1FdlLLYWrq7ebPdD5VGCzN+A6V5eIjy1XFf1/kephZc1KMn/AFYtWpOx/sca2gJ2/aHXdI/uM9ar3HkWUhY5luj8u5zvlbnPHZRn/wDVVqKK6vTuvSbO3H3Y42xI4927fSoreOCBSmmW4ZySC+ev1brXNonr/Xqzotp/X5CQw3E5eS8Jiib+HflyP9o9voMU241GC2zDZL5kuOVQAZ+p6Cm3caZI1G4ZVX7yKcfy5p9oWu1Zba1+y20f/LR125PsP607K3M9vw/4IJv5/iM8tI4/P1QgFsEICCo/2cdz7mkaae+BaENawKcl5R8xHt6U8/ZYrgiKN7icnOX5/H0AqTyp5ZP9JuMJ/wA8YuB+J/wouuv9fIaj/X/BM9RbxXBisfMvrxuHc5bH+83QD2/SnzWUs7hryfeinmOA4Hbgn/8AVVlru2XNrYJvkj5KxnCL/vGqk8IkO+9uBIvZFyqA+mOrGq1vfb8ybK1t/wAhN6keVYRIRztAO2NPx6mopYoRn7QTcvkFVA+QH2Hc+5pbqR1gwAtpF/tgbiPYUiqIod+RCjHcZJfvsKuN7CbuNlmkkZQzFSeFii5cj8OlTrEYo0jlcxr1WKI8n/eNMAZFLQBbWFjkuR+8k98H+v5UsoESOWLWsDHG9jukkPsP8/Sm+yBb3Yl0ZGGx2kSIAbYITh2/HsKjljYOEaRY0I5gt1y/4tUsW2ANujaNWH8TZlc+p/u1SvJLifi3eOEE/MAvUf73rRFa2CW1x0k0XzRFvLXGBDEcE4/vN/Ske4MiBTwg42AYA/z71hENDOFkDQyNncQeSPUGpY5XhZVZvMQg4LHqT6V0exS21OZVXfVGtD99SNo56+lFVLa5hkuEHVi2Mde9FJR7jc0z646k8U8e9IevpQDXsngj8/Wl3c/40wHn159aXt1IpjHg85znNHfntTQcDgU7POPSkA4HPTpTgc00fpSqfSgY+nL1ptOX3oAeMdq57xV4x0jwxKlvfvJPfOu8W0ABZV7FieFB/Ot9JVWRdwBA+Y/Qc18n32rTavqd3qt2S895M0zZPQE/KPoFwB9Kwr1HHSJ04Wgq07S2R9HaT458O6kij7cLKY/8s7obf/Hhx+tdPH+9iEkJWWJujxsGU/iK+VIbghRtKg+prT0zVtQs3VtOurmFiesUhTn6Cs44iS3R2Ty5P4GfTGRnHeivGNN+I3iGzOy6e3v0HUXMeGH0Zcfrmuw0b4kabdkLqlpLp7n/AJaRnzo/xxyPyNaRrxe+hyzwdWGtr+h3IFLUNjc22oQibT7mG6i/vQuGx9R1FTHI6gj61snfVHK9NB3elximZPHpThk+tMA+tL+npSbWP8J/KlKsOSCKLAHp79aDhRk8CmGQdBz70gUtnPXP50AKzErhe/FKsQzlufbrT1AAwOlOoASgUY9KdSAQ0g60poAoAOpqRF/WlRemetPGAcdKYCgUo6ijrx2FKO9IZHIvHHNUrlM1fboTVaUdqYjKmj5quIxu5rQlXv2qAjHQcUAOiXAA5q1EKrR8DFWou1A0Woh2rlfiV4NTxbpaPbyvb6paAmKWMAmRP4ozn17Hsfxrq4+manXjnmpklJNMqMnF8yPkvTkj+0+VDb+TBI5triS8G2ZhyrKR1znPWvnzWrRrHV7y1kBDRSspB+tfbPxs8E3E5PiXQpktjGM6kgTJZAOJV9x39ue3Pyf8XrVIfGEt1CSYbyNLhW9cgZ/XNc2HpujOUG731X5ffsdOJmqsY1F6P+vvK3w7uvJ8RWKGUxLMTbvIOqhhx+uK9cSW3gm8rTraS4lUEME9fVmPA/zxXgemzNFOHQ4ZCJF+oOa+gLe4lu7SGayXybSdBKJD8obI59zzn0/GuXHx95SN8vldOAyeGZ/3mo3HkRcARRP1PoT3+gqyTO4ZLeNbWDj5mHX6Coo4YLe4VmDXN5j5HkG5gP8AZXoo9+KleC4uH3XTrGnJ2h+fxx/T9a852fp/X3nprT1Kjm1gkbYjXV2MDAGSfc9hSyR3N6A15cmGDoIIPvN9TVtmghiKxBQR2QY/Tr+NU3S4dHaXNrGfvbeWI927U731/P8AQLW0/r5k32i3tGFtAgL4yIIzlj/vN0FVblZHjeTUZo7a3UY8lDhfxbqaSF1QeVpluip1aZ+EHqSepNRRxxz3AkgzdNGf+PiYfu4/XaOn+etVGKWv/D/8D8yHJvT+v+CP8/8Adj7JDtt8Z81xsUn/AGVPX6mo7RfN3zrIEjxj7S6jc3+6D0FWGLSXAW2WW4nAy8shxGn4/wCFN2rIwkIe9w3Mr8RRnvg9M/maf9f1/XyBPuMYFY1dEJOCfOuO3uRUJiVSZlfMig5u7ocAd9o6flU7N5srfIbhBg+ZIuIVHb/ePsP0qvPLCZ2lG66mX7ryjCKfZelNJp2B2Y/zI4ttzk9MC7mTLEdyqVQXUkLEQNI7DrNJjcc/y/Ci6t47pzJceYXfoyNg1k3sRtZtjbn3KNjnn8x61vTpxlo9zCrUnHVbGvJIoJy6+YOowSTQGwABwTzyOay/MEOWJL9FB689T/8Aqqwtwu3DMqIcAHOSTVOnbYUat9yxKkZQrIm/P8OM/lVabT2PzQylW5ARxn9auI5c5jUc9WPf8KXOMksS3v8ApUqTjsU4xluZMDEzjJVZFk2t83Qj+f0opZQqayuYWxgE4P8AFnk0V0rVXORuzsfYOeT+tLu5phPNAOOtekeUSU4H3zUYIz61IDx7ikMUde9O7U0ZOMmnjP1NMBRz15p6nHQU36U7Pr2pAOHpSk4U0mR+FJIeOtIZSuJgkgz908GvlK/tGsNSurAjD287xfUA9fyr6i1DOG56d68O+KGltBraatGp8q4wkuP4ZB0P4j+VYVo3VzpwdTkqWfU52BgMRgjcw6Vrxu1vH8gBYDIrnrOQGb5jnaRj2FaU84HBbGdo+nNcrep71NXRvWFqZcZJkkzub61ofZdig4AJPb2rH0+6ZHAQgHPIFa1tcGYgDpyck9aB8rvdl6CMwskkUjRy9niYq35itqLxHrkCKINZufQLIA/8wawhKTIFHABBqT74YHOQMVO2xlKlGXxI2pPGPiNQQdV6HGRbx/4Vm3PjPxAzHzNauQueBGqLn8hWY6M6sozt9c1kXS+UBkcdj6VV2+pCw9NfZX3I6b/hI9cJAOq3+fTzzVyHxBrca+Y2q3g4/ilLfoa5DTrgSg4bI7sOa1wkYHDMzZ5PcUkmJ0obW/A7TTPHWowFBewwX8Z/i2+W4/EcfpXX6T4q0fUiqLcG0nP/ACyucLn6N0NeTRyjawb5VGDmoY5w7kRDIHHI4/Kto1ZROWrhYPbQ9+KuBnHynoRyKbn8/evF9P1jUbDAsL+eEf3EbK/keK6aw8d38WF1C3t7te7LmN/8P0rZVl1Rxyw8ltqeh54p1c3YeM9FusCaWWyc9p0+X/voZFdDbSx3UfmWk0Vwn96Jw38q0U4y2Zi4Sjuh+KcBSdODxThy1WSPBwBSjn0pBwKdQAdM+lOGcHNAH1paQxj9Kgk71M3Iz2qF/agRUlxg5qswq1KDk1Wbj60AC9RVmPjHFV1qxF2poZcjxU6/Wq6HvVhaAHdcggFTwQehHpXx1+1X4Lh8M3GkT6dGqaZOJFgRR/qsNuKfQb+Pb6V9i149+1Zo39q/CWa6Vcyabcxz5xztb5D+rg/hVQSbsxNtI+H7c4mQk8Hg17Z4Ga51Pwja7Z/IFo7W5lHLYHPGeBwRXh6nAPqDmvUPhVdXUzX+nW8qRrIq3W4jLLj5Tt7Z5FcONjenddDqwUuWrbvoegs0FjCsMR2l/wCNjukc+oHU1Er3F0csXtweMYDSsP5L+p+lJFNbWUrJZRveXrDDy/ef8W6D86USSOW+0ATSlseXEcqox/Ea8fl6/n/ke0pdBPOSKRo7CMPKPvux4HuxP/66gjQTMwBfUJM5Mh4hT2x3qRI0cmO6jLk/dtIOij/aI4H40+R/LCwyoqAH5LW2/kR3/lT223Fe+rK8sSS3casJdRdW2iBDtgiI7sRx+FOkKSOkcztdT4+S3gXbFF+PQ/U0+USPi3lWSEg4FrCw3Y/2z2pssnlx4kUiLHywx8Lj1Zvr6U9X/X9fh94W/r+v68gYidmWRzcFfvxRHbEP95+/+eKp3uqR28KQvIJmhXCQx8QxjPQZ60l0ovYUS4LfZ0+5EnygfQf41Vl03/n1kCqxyVlO8Mfb0NaQhH7X9f1/TIm5/ZX9f1/ww+TUWupd1xNlm4UE8CnBnAGwBcjGO59qw5MKcsMSRkggEgg+grUtjJJEjMQATywPQegraVNRV0YwquTsyU8EB8DPvzTpoIpoCkwGw8/MeQfX/wCtSKOD5IHHVjyf/rU1huC55b1HJ/CoNvUy7y3a1MKxSeZHIcAuMHIqOONvtJaJgwA2jAwM1a1lcLbEKrASEYP8P1qgFUyJllJzgk8jHYZFdEHzR1OOouWdkakJJAWM9uAo/XNTHO3CjnPzHNQ2wIUBuvUjGBUibixHVffp+HrWDOmOqKWoAb4HwN5cIDg8jOelFJcTCa9C7T5MfGc4LP7D2orphdRSOOq/e0PrncA2OD+NJnnn6Uw/ePpTlA/iNekeWOU+nT2qXGOAaYOvt6U7OfpSYx+cU4Hk0g6c04H0xSAcp9TzTvpTPzpRmmA4nsKOo5pCfXrThQBn3sfBPGCK4vxBp8d1BLDMm+JxtZfau/mTctYOpWu5Txx9KloD5z1TS59Fv5YpMvE/Mb4+8P8AGqzz+ZJH82TkZHrivWvE2jJdREFAzDpXlWp6RLbXR8nIXJyh/pXLKlrdHrYbGK1pGlp9xiRSSB6gVoW1wPlIcZB/OuRW6ltXCyAqw6E8A1ag1KNTksR2IHesXFo9KFWMkdtDdjdtHYk5I7VO0+XKRyH+8Tj8gDXLWmpwsTkgH1FWrG7EkkhDAgt6/hUWsaJp7HSLKFj2ByAB/Dziue1uflgGXJ5IAwcVpPfEpsUky7c/QeprKv8AM5U4EnGN3rVJmbjbUm0WZBFGAMKO1dNaX1sseIF3t3LHj/69cdBMY0WJfmUkA9uK6HT2BZSCADwTirXYxaL8gLNukO9jzgcAVHHFI24x8Z4wTxT5ZtoOBnb909zSWymddznjPQdjQhNOxYt9+SANzD0p6oXdtxPX8qURN5fy5H09ParKQiMAmRskZOaZElYj8sEHI5HbPU0sIa2kEkLSQzDo0TFT+YpzEHBTBU9yelDygIQvLHjJ7GixDibVh4x16zwHnivIhxsuEyf++hzXUaX490+fauqW8lhIf41PmR/pyK8ztWufJH2hhIwbqFxVpVSXCs4DfSnGco7GM6FN6W+49zgljnhSa3lSaFxlZI23KfxqTOO9eM6Nql74fuQ9jJmMn54W5jk+o7H3FeoeH9ctNcgLW2Y7hADJbsfmX3HqPeuinVUtHucdWi4arVGtntSgYpoPBp2a2MRrVDIPxNTGo5B70hFSUVWccn+lW5arOOaAGDqKni6DFQjr71LHzx2poaLsVWF/ziqsZzirKdBSAfWN4z0ga/4O1vSCATeWckSZ/v7TtP54NbNLGcSKaafK7iaufl7NGY7h0IIIJGD2rpvAF0sOv2AlWR4pH+zukb7WYN0GfTOKt/GjRf8AhH/ih4isAmyNLt3jX0RzvX/x1hXLWErwzF4iRIjCRCPUHIpVoX5ojhLlakfQTqY0EN26W0OSot7fqe+N3Un6VEnmLBHEcafbHmKJeZXHXgdv1NLblLu2jv7RRGJo1f7XcjLNlcnYPxPPAoM6RhRbKRu+/dSnLNjrgen5CvnbPb+v6+9n0Ka3GlZETyvNaxgc7toO+aT/AD+NQTT29guEf7Mz4JjjO+4f/eY8L+OfpTprhYnc27KsjZ3OTukP/AvT2FUPIWRsvbwhe7YGT9fWtIx6y/r+v6sS2+hCb5+Wt40t4mbcwHzl/XcTy2fSnfbgQJAQMnAwT/LtUd9aIscssUrq6rkY5U47Y/SqUbpgDdtjCcgAcHH610xjCSujncpQepsKQJMkh26f7R9OP8adGzFgSAuOp3DcR6ZqrbyD5Wjw3y7WAHQ+lSEEty3A7evtWTjY3jK5jyfLd3cIGMsWBcYYfSrWnuJNwkaUSgYweOBUd6oGp/MwVZ1ByF6Y9fU0tltWaQn5uMAnqR/hXQ9Y3OVe7OxoDey4OxVxg4/Sn8KCFUEjg9/zqMug3Apk/wB33pFDHK8D6d65rHUmijrcyFbaEB2GS7bV/LFVAzyynb8mRggY6e4pNRY/2lLuzlECqNvWpdNVFjkZvkkU4PbP0rpUbQOST5qhfGVGDktjoO1Q3VwYoWYsfNf5EVRnH1p3Jz5a4BP51Uv32zx4ZWMXRSeNx6/p3rKKvLU2lJqOhBbIyXEETB8nBPGQTnqaKtafbbTE+0ZLAlv8KK0c9TJQ01PrXHJo7+v1pOS340uMV6p5A4c9ealXp9KjHFOBycYpASZHbFPH6dqiHXFSL055pAO6YNLnFJ2pepouAvanD+dMHFOB56UwHdTVa6g35qxS5HfpQBzGoacGBGK4nX/D6Tq2Vw394CvVZkD/AHBnNZ0+mq2cjrUtXGnY+fNU0S7iYxlPMj7ZXNY0mmxBj51sVPtkYr6IudGjwQEAFYd94bhlOXiU+9S4G8arR4Q+lxg/uLmeLPbhx+Rp1lBcWOdt4sirkjem3Hsa9O1bwpAqs0alW9BXG6hoFyTJhCqqMg9sfWocDaOJknuR6BqDYYXBAuHOWwcjHbmta7VVTcvGc5xXE3cE9pKfJDOyjdkcACltNa1om1jvNPCrO22Ni235fUg1zSp21R6dKs5K0jeWB1m3LISvbPWtrTZWCDGPmxxVdYy4XOMqMjH86sJjhgOCcECkmbNGxb5dBvHJ7VaUbG+9g+3pVG1n3x7W4YH73cVdUiQZc/MB196PQl76mgkmYyArcd++acgFwpHt1PWqNucfKu44OcVowuJPlU4bvxmqWpnKy2HwoicAEcYNRMnOOwHU9x6VOclw2/jGDmmwp87NJxk9DVIxYsbgLsVMnr9KY9q2d7NjHpVnH9wDjjrTxllJwcdMVRCj3M9tzEDHHv2qa0mkglVoZWhuIzmORDhlP9fpVow4j6lQeciq80WSAhBC8nJrNjtoegaH4xgn2Qa0Utbk8LcD/VSfX+6f0rrh90NwVPIIOQR9a8WU7kxJjBHfvV/TdU1DTCv9mXjonQwyfPFj/dPT8MVca7jo9TnlhebWOh6yMDJyTk9+1RufWuRsvHEZGNUsHiI4Mlsd6/ip5H4ZrYtta02/wLS/gZ26I52P+RreNWMupyzozhui7IevP41A+DT5dy9VOP0qHcK0MhakT2qNfWpYVLMFUEmmhlmLoPWrCe2a5a48U2UErxxPEcMVDO338dSAO1OtPFsEvDmIOT9wAg/nWbqxTsaeym1ex1fYUpqK2mS4gjmiJMcgyD/Spe9WnfUzPjn9szRvsfxB07VkQiPUbJdzeskZKn/x0pXg0DYljY9PumvsH9svR/tnw90nVUUmTT77y2OOiSKc/wDjyoPxr45X/VnnocirnrZ+X/AJR7f4PjuG8C6VqNyqz2vny2CyFtwgdDuCEdmKsCPar7yvIzbgSQvGRxn2rW/ZZFj4n0Pxj4L1hs21wsWo26qPmjb7jyKexBEVUNX0y+8Pa1eaNrQUXNp0MYwJ4z92QZ7H+eR1Bry61Cyc13/r+u56eFxHMuR7kU1qggR5pAbpzkQr/AncsegPtUDkAsqE7M8KOQB9aes2WARSpPUAc4psoUt+6IAH4DP+NcuvU7UQSxCeF4sEE/Lz09c1ko0hSSJ2XzUb5cJj8h3rYY7cKADnkgc/nWXqaLDcpK25llJ5Xsa1pPWxlWjpzdiSynmDSI/7t2BBZAF4q8oQbT07c/561kM4jwDlgxLFQccdv8/Wr0bDHyAYYZBHOKc11Ipy6FbWCpubXaowCykg4P51WidvOfkoU5GRkkVevLfzrNxjA++GbjOOwrJDFkhmi2qRyVDd/SrhZxsZ1FadzaR0WNj0ZuuB+tSMpADOSqHt6/Wqkb4UMx3OyjHGAD7U5nZELSEZz93cMk+hJrJq7OlSsjO1PYb0OjKuIxuYnFPtY1YK/GOw3EioUeS7m8x0QruycDPI6D8KvSFIYHkfZkZ2LnAJ9MitZe7FR6nPFc0nPoNub1LYBFdVnbu38I96jghVSrgDOOSOQffNV0Kzt58rx5XGQF25+vtVj7Uu12JxGn3m9fYUnHlVluUpczu9iaW4W2aIdZmPAPRR64orIRzeXW7A3lwD8+QF9AKKuMIpakSlKT93Y+yu5xSg9MGmn7xpevtXos8ocfrSjBpAKev4cUAOFSDp6Uz6dacMDr0pAP7Ype9MzSk0AOpR0phYL1/Kmlix2jAoAkeTaPU+lKcscY4IpiJtGeSakzyKAHKAAMDijAIpu4AVDeXUNnbtPdSxwQL1kkbao/E0XGOeJfyqnPbmTiJCx9hXH658SbSFWTRrU3soz++mykQ+g6t+lcDqGs6z4gZm1PUJ2hJyIIm8qIf8BXr+OaylWS0Wp1U8JUnrsjtPE+uaXpkrwmT7bfDI+zQMDtP+23RfpyfauG1C6vdRxJdFYo8ZW3i4RT7/AN4/WobS0jjkKqoCgcdq0p1BtSuADjFc06rkd9DCxhra7OX0Hyplme4XdIW53DNP8U2s01vBdwpuNu2WUf3cc4qWaD7DeRSbdscqhXPYOOMn8Ksrc+RdGKXJjcblPY1DkdkY6WG6c63FpDJbuDhf0pk5a1kBIyjelWUsUtpRParhD95V/nVl0S5t8FcgjikXayI7aVZYQVwCR27VcgmzLg8+vuaxFMtvN5bYPHBHerySblyCfX/69Naks3Y5OFIPzdfrVm1nYScgLkAHjisSCcqQB6d60oX4Cj72Mg+1O9jNxNlF4DnBbPPH61YC/NxgAdfes+3uRkBSVUjBGetX4sEBlJPPftVJmTVmTiHJ4IK9Tu9KkbPm7S+fYUQlT1+9nueAKHYZAjHzdRgVSM2iG6JVNqgkZ6ntUATtnPsOBV+8wyZPloCM7Qcmqi5GCMY7DHNSXHYNnYjoAaQ7lIOeO4qW3DDO45PUk+lPcA8Dpk1IJW1Ioyc4Y5P6UPGkufMjVhnuOKjRtu70+nWnFwuQPlXqPSlyjciWG6urHH2G6nhHdQ2V/wC+TxVv/hLtUtQTLDa3kY67gY2P4jj9KyGcEdR15qu6LIecHHIwaqN1szGcIT3R01r8RtKLbb60vLU92TEq/wBD+lVfG3jKwvvDy2XhvUlmuL1zFMy5R4ogMt15GeB+deb+KYBaoZAF8snBIPSsHw1f7dUWWM8x9ffg8VftJ23CjhYOadjt/DX+mASMAqqcBR+ldcbGMxbjkHbwa5DwgUijNuzYZWOAfTOa9DwBYq+Rg8c1NOGh2VaijKxH8PdcltvEZ0O5lLQ3MTPAGOdsqcnHsy8/8B969MIIzkrx/tCvnbxVEC1/PCT5gUMjDqpUdq87m1ea905VRmUscuQeWHoaqNR000tTirYT2kuaLtc+i/jhBY658JfFlh9stmmjsmuwiSqWBhIl6Z77MfjXwLYWc17JLHbqGZInlYFgPlUFmPvgAnFe3eGlSLUWik4imVo5AP4kYYYH8DXkXiTTLnwt4ovdPErrJbSFVkU4LIw4P4qR+db0qzn7rWxzYnCOglK90z174CWWp+Df2idP8P3Twec8E1tcmF96SRmAzLhvTKofwr6O+LPgt/FWirPp8YXXbAF7ViMeev8AFCx9D1Hoce9fF/gXWLqT4j+Grw3EsNyk1vZ+dE5Rtu0RDkc/dwPpX09FfeI7ad0j1zUVAbHzyh8f99A1FSqoSaaumZ4ejOa5ouzR47bSFhl1aKRcq8bfeBBwQR2INSMykqrDYPTJOa7/AFPwzHqmpTX96rS3s7eZJIjCMufXC4GePSs658G2obcomTtjzSTjvXE0m9D04qVtTjGmGwrw3pgcD/Cq7RxyRtC7HDDB7kfia7AeDUMZVGnUDqoYc1CfBgfOy5nVsYzwSP0pbBZnAK4DGF2Y7Ny7+ox7elX7WddgKY3Dq2cj2rpJPAR3ITd3Lqo5yoHPrS/8IiysD585A5woA/IYrScosxhSmmclqMx+WIud0n32xyq+n41Vs41P7wlI0BKlRznFdkPB1u8rs8t2Gbrubt6cCnR+ErWM4RJMD+IyE4o5klZDdKbldnMrIAmANiAcsR0rMmk+0SKU+UD7q4z/AMCrvj4btAGDRZHcMxxTofDdtHu/0eMqOjBO31pRkk7lSpSkcXGViUB5FVR14H+c1Skl+1XIwkqoBjBHT8vXrXoiaJbxsMRK23tg/r2q1Hp8agbVCnPAK0c6i7jdBtWPPIYWcg+U7EDG3ae1V57S/urldtuUVc4EjAfia9QOnARqxUnPGUbmlSxXJ24HHRlxQp26DdG6seeWelXcZijVYwM5A3cZ/CivSYdMPVidxYHaT/L2opqfkJ00tj27HJqRR15pDjJxS16h4guKUe9NzSg8jPApAOzx704U0Ee1NMqjIUFiOwpATA4HYUxpOyAE00rKw+ZCqep4rB1rxXo2klobi73TjrDbje/4noPxNJyUdWOMXJ2irnQKuSS55p4k4wBn6V5nd/EiZx/xK9KjAPSS5csfxUYA/OsO88ZeI7xmX+0jbpjlbZFjA9s4z+tZutE6o4Oq99D2sCQjOw49SMVQ1DWdN04H+0NSs7cgZKvMNx/DrXhl1qGoXKEXd3d3APZ5WYH8M1jFWWVpCiggjAH86j299kbLAP7TPUNd+JaM7QaBalj0NzdLgD3VOv54+lcRqGo3WpXHnahdSXMx6GRshfoOg/CqEcYVNzEF27+9TJEBgnOT1rGdRvVndQwkIbIfDFuYBiSMfWrUEaxM3y8N6+tQxRhRwMrjk5q5AyFSgBLEd+1QdXLbQswY8mReNyn9BTpgrohxyG7U1CI1AkwQ3APrVm5TdEXXAKrkAc5pMwacZXM94VuIpY2G5S2celZ2o2EkJiYZdY8gfT0rRtZtrOHOCTnJP6VaMZk+XIyfu55zU2NkzHtDuT5GIx2b+VSCQox/dle5HUfUVYu7J1dnXHy4/GmIMyqJuvvTQcy3I3hEq4KjPr0xUMS7A0b5B9auPE+8qCNg647Ukqo65JIlHfNPzFcSMKrbWGV7E9quGQmMAnBHoKzXkYD7o9yO3vT0mcLtOSo65pozsbFpMCN2Q2OAO9W7eeRZsoPlJ5Wsa1A270IO77vP9K0oJcAAtkdRx+lO4cqZuRSNIOPlI9BnH41YjwsS7sDHUnkisyK4Axhm24yAeKsrOARjOW6HFUmZuKL0MRIw+5kXPJGA1NeMhskg89KmguBlQHK4GDu5qF5TMRHGuUHVh0+lJscEho+fkgDBqWOPcvSmREvIsa8L1wPSrZVR93oT09BU36A0VPJ52g/N0z7Vj65dLYICxAXrljXQRje7ZzkVw3xQBjtIo+hlcR8+5pkW5mokFrqP2yWNrgvHpwO5yn3pSDwo9v8ACu50zXmIRLOxgSEEfeXk1524222m2oHyuzMSMcbcAD6V33h2EK0O4YGBwKcLs2qUIRXvIfrR03xHHNpup2aW1xKpEN1H2btn/wCvXg3hpJrbXNQs7xdk9vMYZF9x/TvXumqRqkju/wAqo27ce3NeTeIrdLb4iyyrkrdwRzE+rDKn+VU7q6YU6ai7w2Ou01H4Zep5HHQ+tdCDqcsCRyXjbOyhQAaxdOuFEYXIwMdulbMFyzj7uBjoDWTsbNvsRT2hdGWQ7mZSCf6V4xZ20lpfXdq6kCN3QEjGcHivcw2xhv69h6V5d4yhaDxNO8CcMgbjoatWtYiV73M2zi8u+iY4AJHTtWT+0Hopjl0TXI1+W4hNrMQP405Un3Kn/wAdq0b4QvH5kbkqw6cVs/EJ7jxN8O74eUo+xBbyNV7BeG/8dJrSElGSMsRCVWk0ump4Rpl01jf2t6n34JUmX6qwP9K+4LiJJJ2lQZjkxIoPcMMj9DXwsh/dke+Pzr7O+Ht62s+APDd4rbmaxjic+rR/uz/6DTxK1TPNwT1cTWEYLEbeh4GaZJBxk4I75GKvPHziPAcdaY0bjG7P4965z0PMzzZg4wm3HQ+1QNZLE4cqXIOMjtWsybQEPGexPWmMoB6HI5GPWkkNMy5bRWAdeDUPkIVw+8npnHU1rKhABwB9e9Qyxu3z7B6dMUNXBdjNayBJJXI6HjmopLFFwxDL6nrWt5bY2gj8aYNzfKuSfaiwzLGnRunCnjoc4yKgFh5bEKo24z61siMqm3JHoDyKY0JLchSOuR1Bo5RXMjyYyMmM7hxtxR5Dcr5K9eCBWvJFv4Jw+OpHakSEiPBJK9dvoaXKPQyDbRBxgI2eTzyPwqU2u8fKEZugB7/Wr5UEgoyb1+8CORUTqykbQWB5DCmoiKkNsgPAw4PIB6e1FaCRcq7ZYnGc9aKqMdCGegk8k9qF3N91SfpXk+t/FC6mlePQrNIEBI8+5+d/qF6D9a4vV9Z1vUpVXUdSupwckKHKqf8AgIwK65V0tjzqeCqy1eh7hq3izQtJkaK81GHz16ww5lcfUL0/GucvPifpybvsWn3c5H8UzrEp/LJryq2t9g4Cg55zwatxxoSdxBGecCsnWkzqhgILfU6+5+JerT8WlnYWwPc7pG/p/KsW+8X+ILnIk1WeMEHCwgRj/wAdGazigOdhAAOM+tNmEJZAckr82efyqed9WbxwsI7RRVvby5lIa4mnuWABJllZs/nRCDvDEKMfNgUt4u+NnUBVTpzmo4ctKC2FqL6aG8aaSNJJPlwRjP6VICzbsZOeMDj9ahiAkGc4JH51oQqcDjaO+R0qW2aKKSIlU+UXwOBwPSsVJC05OM5/GtfUJTHBIB7d6wIZ1V9g+YnvQncJ6GpEMEFiQ2cgGr6P5gII5PQ1RgUkfNnjvWhA6KGLenYUjSKVrk3lICvzHIPfvUxUKQw4OfTFMjG51XqcAgnirMbbT8o3D+dBW2qEn2NGAVyc5yOpNSxxuVUqfl9M9alRRLGQwUHPA9KsRxFW4yf5ZouYydtTLubJmkBDAHrkHrUS3D20iCcdP4sZBFapRvOwwHIpzINhjkwysMcrSvoZ3IkmimVSAADSyxQmP5j8rcY9KoT2YVle2aQD0X+lNkW7R/kJdfQjvQkhejLAt4dxyTggYJqJk8mTavzsORxUJmkSVfMR1PTBp6SKHLb/AGwRVJ9g5WJOgly3JJ9KqtyuMnI46dKuiZQWDHA6gnvVeRgORwntRcag9iGGQxtkD8PWr8UofcTx7H1qkQrggk+1TQQux6Nz3PQ0cxoodWa0Up2jB/A1bguEZ9gzI4HIA6f0rJhgYN8z5A/hGQPxrUt9yqAoUAf3e9Cdg5Ua1ujTAeccL1wD1+tXjJwFwAO/PGKy7ecIATkCrSss3QMR+WapO6M+Rp3JLYfO0pJGBgYq6MBcAYXoTUYyeNoGKcCWPocdc0NXJu1qxwTaC/J9SK83+KNx5moaVbZJzLvb8B/9avTLd0ERDH5jwa8j+ID+Z43tUzkJGWI9sYppNImFpTRYgbDRMQCUPB9B3r0LQry3YRb5oQoHOXAPSuH022E6gqSNtdLp8ESR5AJdeOR2oUnF6G9SMZk2tXkU8M0UTK+48lTnvXmHjFyvjTTiRybPGf8AgdelT26ksUUBeprz/wAdxD/hL9DlQfIbeVefUEH+tJy5m7l00oxsi/YzmWV8MBGDj5j1Nb8EwZEH2tEBHOZOn4Cua0Tym3pIAxZuN3SupsbJ1U7LO3dR/EW61kk7lzaSsJHJCnzRNNKSeXVCR+ZrmvFiqNRs5GU7ZY3jJPHIIIrttsgBMtyiqcfuocAfhXN+OYt1hY3OCojuAv4MCKpKxLaaPPNYtzFIcqTj/Oa7HwX5Fzava3IBt7iJ4JB14ZcH+dYmrRGRjHGA5VQwx2HcVb0DzoGiiVFz97ketU31FBdDxe28NXVl4ybQtVjjguEYqyzBircZUjaQTkYI5r6S+ASyRfCfSA0gfzJ7hlGP9WPMI2/mCfxrgPi1pE41PQvEtkqeZbOlrdyvkRr8w2Mx9OSCfpXp/wANdMvPDWk3egak8LT2N9MVMOduxyGGMgEdc8+taVqsZRiup5McPKjXlG2ljr3Q7gW7c8DmkZmTAIGxunrT5mAI4J6dKQgEEkYI5xnpWV0dS2EdFdFJwWHTPakaHYC2MNjOev6UuAHXdkDPIzT3Y9mYYPpQtCbMiGMAOMgc1XY5btt9PSrYB4AIG70HSkdVRsjnPt0oQ7IprDgndgq3enNCcbsEAenFWhGgYHI3ZOO1KANjB88cnjoaVwbM9l2nGevQkcCmlMPjZkEdulXJIwwG3nPPWmPGeo4OMnNUJyKLpskwAcHk5PSnCNxxgcjrVlOMflmnDCHB78nNMTmVmhBBDKAe9Q+WNu5MYHFXWXJ5yR2zTSm3DKRnnrQUmVPJAZWwN3HfrRVuKPJBfBIPUCimgcjxZbdg7c/xGnSJtuRnAAU4p5lCOTKBnce/vTbq7QGIgHAPJ7YPah3udbsWYowIs8ZxVlYt0e0ZHHPoazBehEwzqufXvTX1S2Tl7hBnrlsYpWYN2NcQ4+8AAfekliXCMgGRkYJrHPiO2BCpIZSO0al/5VBJrsh+WLTLgsx43kL+eTRZkuaRpah5ZQbehI5JpluqAbywz6HtWO8eqXZwq29sB03HcatwaVdsMT6g2euI0x/jTasSp3NuKZcfMy5HA+lWXnh2hTKucdM1groKs+XnumzzkyEfypx0GzBzIsjD3lbJP51DszRN9CbV7hWj2rMijHJB5NcjDqkMF59mmyXZsoRzurfvNB07PyWgP1Zj/Wsu20SCDUGuI7OOEou1DyTk9etVDlsRPnbRuafqQOY956fMCOtX4WZzkNgds8is2xtldySOR3xnNaQt2QjHI/nUuxvT0WpPHPIpVW+Rv4eevtV+3ui+MEYx0z3qpDEGUBjyeMdafLC4IKYOBn/GpLdmacErK4JYDJ7VpxzZ+8Qrda5+3dT8rKTg85rUUqEXGRjvT3MZLuWUc+YN5LIePpUk2GBwPyqONw8YG0fTtTgroAXOc980O3UxcddCuPlfAyD6VNHOwznbkdferDpHk4AyTnJP8qpywEElGxjpk0bgrPcXcJHb5fmHI9qtLbq4BdV4655qmQ8YJwSeDx6VdS52/KcEH26U7DbaKv2KIyFtigemOD+FNFrGOka59xwavTOnloBwPfuKjRwznI3D0pWQ1JlIwIoO1UTHHFQqU3DgjGc84xWk6biOF2Y6VVYLkYxyeAKNi4siUyRsBuXnkgjnmrtqZfM2BCAeOWqONDE+7OT93JqyXUMp5GBycUWZSkX7aD+JhtPY561fiwAApDDviqEMnylg2fQ1OGA5yDn0qkiG7miJk+UnaPSgqPMUoM1UEoIwNp9fWpYH+cKxz709iORlpSroflxjODivF/EMnn/EG8BORFGFH4kV7NG33gD1rxjUP3njzWGGPldFGPzpt2iyKUf3h0GmOYsZbGa6K3nJRSWUDGcc8VzMqkQL5QLYYfmetbOl3Uaod5mXC4+VTyfSs72Z1SV1c3E2zxuPMUnGcg9a8/8AiEm280Vj98SSrx6YFdwtxG42os7rngsv9a5D4hxn+0NCbB2mSQHPrtFFxx93QXR41VwXAJPJFddbwwmJf3Ube5UGua0wKNvUHNdXaZ2DJA6Z69KpIxqSJljVAAAAO2AB/KsjxnZ/bPCepqgy8cYmQejId39K3SAmCE+bGcnmmSxCeKWB1O2VGQ575GDVW1JjI89slXULZX5WQpxhsA8dKns9KBmUO8pVcZBJ6enSqnhSBzZQL5hWSPMZI/2Tj+ldrBbz4PERbHduv61C7M1k1F6ENzp1rd6dcWN5BHJY3EZjdO7A/wBR1zT9HE0VzH9ourm7ncbJLi5YNJKcAAsQAOAAPwq+LcBN7qm4DnYuAP1zUb4zvXGUIORSceorprzNYF2O5j8p96nVgxx27mqyuuQSMg808SE8EdeDiixyuYMQm3OcZwe+2nB8tgk8e9MkIY9CAOx704geWCCRnn0xVWF7REu8FRg4/wA9KYS27Bbp0pisAVK7twBzmnnGOMk57CjYjmvsSRsSuDkjPNBXglRwMDFM2qCQAwx/OpgQDlgAO1LYLshGUzuXntRsDtuyST+NOlIJXH1+lJEOmVBIPr0plcuhGFw+ACfx4pfvjbgZXt6fjT2Q5Yjr7dKawb5QF5PGPSi4uVEJQg7geTxtpByxBXj0I704hscnjvQFJbKkjPvVENCKctzwR6UVKFJGM96KehJ88TW19PK7S3CIAT9xCaf/AGQ0oKzXdy3bGdtbpjAkLLx8xIyKcyAuS5Ab88mlc71HuY0fh23Jw4dz23yNn8anGi2Fs2428WT1O3dj861VRwM5JGKdIibCzgtg89qLk8q2KFtGqW4MaDABOOmKiWJ2mUyHk9eKv+YBb7FHLZ6jAqDzSs8YB3AUrlKnrqWoVKgDAU/XNXooxwpPvzVKF8/O5XPoB0q7bkMysQcH2/zxUPU0UbMmeMjA38CpfIjMTFuTjI9aRQztgt09OM0F8qw5B6DvUl2IntcoHj5b6/pWPdEPKS/ynd0rds7hUQB2U44x6fWsHVmDXDlfu5496paikNiTa5MZ4HPHeraStwrjK+nSsmObEoXP1P8AntWpA4faTxx0xVNWGncuRbd2EyGHI9jU0ed3zsQQe44qJIyRnOeetTqgBH3jz+FTcbJio3A7Sfp3qxbA5QOcewqG3VpDjIVSeueat7THwFzjgUiJMtwthQAoPPepvPRspIBjpxUFrMpVtyjPuOakISSPJQc980WMm9SKbKhgThF6NVdyVXG5sHpxUzyfIQScDj6ioPMO8lxhegxRawtWSQTNgggjA6elRBiCcE8HOPSpwoMhaPjjAHrVS4kMbjceec09gSfQleU4zjP4UxZzn5EJz61Gswk4QNkd+uaaW8x9p5Hc/wBKRpFWJ5Ll3QgE46Fl/lTQ7JwOmehGKlji5VEyFPU+lKqbXyOM8D3p21HcZJLtYMOWBqWGboGbPPr3psgxtwM/MeakRVZAF6+nrT3CPmXoZSGyBz6Z4qxHMABx74z0rMt4jyAxVs8fSriklgpGSvc96afcfKi+GBAIqSKT+I8P9apLJlfnJHYccVYRo2UYYZz2PSqC10StNtcPuAB4ORXlUGJfFOszcYNzjj2Fej3c4WNgW+UjqK8p0yYi4vnkYbnu5McehpP4TPkcZXOutW8xSmQuTnOOnNdHpvmxYbymYHIypHIPsa5vTNu4ZHJNdXZj5GcAsMYyP1qUtbjlLSxaWWSXdmJo07F2H8hXG/Edj5eiuSAVvCh/FDXZDuOMnvXG/FEFNGs5OcpfRsfoQR/WmlqC0QmnO25CDg/zrrdPB2D19Aa4fTptioW9M59K6WwuWGHySGHsP504mVTVnRkoIsKcd8E//XzTS2ZVOTjPHNZf2mYBSPnQepz/ACq7FcrMo7Edvem3oCVjz3Q98Gq6ja5AMN5KuDzwWJH86761P7vDEFsckfyri9YjNj46uG4Ed5Ekw+o+Vv5D86620mPkk5O0D73OKlbs1qO6TLmGKnAfI9elQkc8jGeoqMvEW2h03c5BwTj86RiQ/wApwF9u1N2SJjc1LRt8ERBG7G38uKmyQRgdTjiqWmNuWVSeM598GraqC38QHp61O6MJaNodKMngk44OaaNpVkBOeSD607ymDZBXb1B7Usce1lIbdkZPHeqWxk9RVG3r1I71KoyOjH68UyPGWOfx9KfGSxJ60gURp75UYycnPSk2bc8k5OAfSnSKI8sMA+vSkLEuA33c8elA7MI5F2YdtvOMk96kJXqWwSPWqNwiyrtJAIOelTrxtAOeMcDmhg0Sgg7grkkfhik5C5Ibcev+FRAso+vGaUnBBPJ9KLBqxrNu5yPpTSSCOCPTmnMwIPv+GKXO7nsPamLYQEhxjjn8jRSPlnGT34zRVIGeOlQZ3UNzuOeanZ9oCqy7R3qg1wqytgYXcee9Kky4yDgE4NSdvMaC5IDbycfrTiDIh3bQc8VRS7UMBt4HcUx9TgjGW4b6dKVib9S4jr5W1SMgkfSqE5VbqN1cbSckelV5NXhMhZWVSev0+lUbvUECA+ahCnPNUkJysdFhDggkDrx3q3A6jBAGBzzXHjxJp8G3deQA46FqSbxJb8mJLibOMCOMnJ/Gk4NoSqW6ncLdr2AA6nJqvJc7g5PP41zVtPqt6m6KxSGPpumkyfyFTR2N7P8A6698sekKBf1OalxRSqPoX5pJArHaoJ5znFc7qU00W6QTKdv8Lkc1rNoUMgzI08vs0h5qneeGbd1wtshPX5upq04rcJe0ktBNLu4rm3ilRSFbPJrqLBoiAHOPb0rjLPT5LDMCYWIcqmPu+w9q3bCOfALHHoTxSlYundaM6mFkz8igLj6VODE+AW2468daxbZ5A5XcrYHftTlnYyYTczd8Vmb8pqyBI2YxM2egGetWGuXkVQR0NZsYnCKT8uTye4p484MMPnt9RSJsi7LIFIbHzjgA1HG0pwN2Vz0qq8skg28k+tSRMwB4YM3qKETZLQsZYE8E0ofgZY+4PrUYkRDhy2fp0qKSUAg44HOaq1yWyWa5ER2jPHTmqzSNIw3YJ9T2pruXwWHFNUYOG5x6UhFiKNwp5wzHHvVqJPlO04HuOapw7txYA8VcRiDgfL3PpQOw4FkQAZ54x6U+NvmJP3sDj8KWHJO7qv8AOnsmcMARjtTQ/IiikG35s+uRVtSAB+Q4qtbruT5QSOdwParSqCgByBjnHFGw2TIhHzdsdRSXDEAsBwOopqkYUA9PfrUcjBiyknkY46U0xpEa3Qx8zHB96dDfgNyc8cDGcVi3TmNyq569KrPcNkYyDnPFKTOmnFG7dXQZW2nBJ7cjFeYadNuM7dR9pkxx711F3qPlQyMxIAU9eMVwXh+7803ABwftLd/XmnG7RjiNGkenaOSFQ7uR3rq9NYCX5uZDjaCOMdxxXF6XIVVd3UfrXaaOf9H3PuKZ+7xgVSOSTNUqCpOFAJ4CDj61y/xJt/O8I3bDloGjl/AOM10hkU4AO0DoCazfE8LXXh3U4CAS9tJtx6gZFUtwTOEeUW1qJCflUDnNbHh4y3jq0IC8dSMn61xOryNJp2m4YhZggYdK9C0VZEtYRbrGrN/fB7d81D0sNtbmu0sVqoV0eUnliSR/XioftBEu5VcLwMcflVV7a7L7JRahxuJXByBnGSc1YhhkIzM0O3sQ2Bj6etDehaS3M7xooZ9Iu4+GSRojkdmGf5imvdBlihZ+B91QcZP1rR1uPz/Dz5IZoXR159CP8a5nSfLn8WmKclkTaeew9AKlvS4Rtt2OmWRjHlPsiY6/u9360/ziETy/LdcdEXaar6pPGkL4iuQxcjAj4x9aign/ANHRI4LhmGRkptyKHsOKvqbekzBr35RjchBHoRzW2m0IcZB5+hrldHkb7fCxTYNxXBPrXUI46AcLwQR60omNVWkSA4YrsPOCRTiQAoJIIOCM9RVdnJbOcg9PYUqyDHzY4zxiqMmiTzPmOQcHp708ZUBjxn9arnLqV3+wPSp1fgDoR6+1Owm7BICMgoPXPU1GSGzg4A46ZzSAtzzkcmnsMqoz0GTQFxjDPBxnHIxSqBjjPHpSsAwAJ57+/wBKhQ8kdvrTBDmbPenNnbkHqaRpFDBsDGajclsACgCQ4PP5gUgYhTtJ65xTW4I7UxycEArzQIlU4IJ6j1oqFW+bA7GimhM+S7vxzOJZFgtVAyQC7k/pTbfX/El6MW0SRrnO7y8D8zW/Z6JZRzu3kRjDfexzW9DbxrHkKvocDtWrnFbIcKFWWs5fcc5a2Or3w/e3joh9WJ/QYrSh8Heau641C6bP91sf410tpGqELjnvitKOEOeCfy61m6j6aGqoR66nKQ+BtNA+d7tznJzOQP0qaPwZogb95a7xn+ORj/M11iQsidASB6dKay4ySBkjkjjFL2ku5Xso7JIxIdH0uyb/AEaxt4wBwVjAJ/rULQMZwVQIinHFbEgC3EasBwM81UupQFyDk5yaV7lqktCyhZFUL0A5B9Ks28fmc9APU1UtW8xM4ywq1bSFAFAPJ5xUs0jFLYt7BH0xkYpSVdgCBk9zUTsSwB/MdadIymMDI4FJFWsiheWOJPMAGwEc56VXdwhCs2D0OKuT3DBCuQcc7SOvFZMs6zEmRdrDt05qkiW1cvQurspDZI71at5PlBAHr1rng7BtsYxk5rUtoZZFHmSbVxwF70milK6NuK4A4dxt9B6UTSZceXkr3BOKqQW0cYwGJH51P8iDkEntmpYKOpIvmMhHCeu2pomeI8biR0PekhjErHLFcdhTwxEhAOV6daRatsRSSja2Tznv1qugYk5zjsOtSOgWUcHcR+FSKuASSBimrg0iIdcbafgjk8ZHGalGMbhkjHPrTJkMjADoozxVIyY6MZOVbJzxU8eNoUqd3U1FETGq8dTgsRVuH94N+eSce9MLk/kt5Z2HII6DqKkiYr8o7eoohPIOce9SsEy6kj14pEp9yqEBkLtlcnIHY1LKdoLA4IOTj0oOFGGJBHrVeS4VDnhl6c/rQXe4v2ghjxkr0PrUcj8tk9ccE9DVSSYeZwxVTxzUEswjOT82OooGnYTUDgiT+EVnPMJEypGe1SXN9E+fm+UdhXF69rq6eSIXWTJ4XuKFByehUsQqcbsm8V3/AJEJjDjJ61y/g+UyXF4Cf+Wyt+YrJ1TVJb+QtJuz7Ve8IhoLickEbypANdHs+WJ5ssX7Wqux6xpM54U4+grrLC+IRB5mOQPlwf8AGuAsLgRyJEuJJD74FdbpBcNG8koRc4LKoO38KyZ0JJ6HTLMVIDAkdt3NTyP5iSI+3DqVx9QRWcTkMjX0xYgkjaqg/hUsQjVNwdwRgfN0+tJsaSW55k9sbzw9bR8efbOY8jnBUkf0rsvCs01/YfZrqV4pNu07e4rnIFa28Qa1aOu0Gfzkxg5DDPH45rf0wIJQGLq4+ZXibBpNAzWW3W2n3NcTN82xkdA4I7VJbpErbY7ONtvVipOfwqYTag8g8mSymQDO+VCrZ644701WvVkLTT20ZZssIlyR+JosUrhrsKR6fMBGUzGWZVPb8K4q5D2fiG3uIQxSRApbrn64rstUkW20nUJUDSssLHe3OeK563jN3bxzWyl12gmM9QcdR/hSktLDjpqdNdzJLCpaV4mlxglTtz65/rVOLzI7eCO9uY0VWOQW5+o9RUC6nbSQra3TujhQuyUEA80+3msoHDWiwI4wMj52P0oWqCMWiaFwbpDCGCBwQzDGee2a6bzPlyoGc9K5qIsXZ2/hOfoa0YbrzDk4GeT2pLcir0NNnBC55C856fhUZkU/ewcjrVXzmcEMByPWo5Z2VBjoeKpGdjSSRQBkc9u9SpIcEA59vWs+CTI5/ECpC+GyuBRci2paDKxPPP8ASntJjI6DNUDJ/EPz9aeZDggEY+tMOVEwcYOSxGajDtliDwfWmiRQmeTUe4kBsYFCGWGwy57g/nSbiE4OSaiGVIIxTgyseoAHpQJkhcj5XO0jjNJIMevJqrNIiv8Ae6DniniXcBg9vzoB9yyCS4wAM470VCD8ykMQwPaimkiGeFxxpvZjySTkdqu4jMTbB8wB4FZEd2sc7tICVyQCDjvVtL2KRyFIBPGenFNpnZzI3bcrgZHTkEd6vRFQwbzNxA6ehrnbXUMgKSNw+U45GaspeJuIVwoxj6VNu43NdDbaberFeCc/jTJZSqhSVJI5rFk1OCJyZJlXJyAxANLDfPcn/QrS5uP+ucLN+oFNJEc1tWaNyQVz/EF6j2qjdTq0XQk+lDRauyEtpN8qn1hIz+dU5VuwNv2K7QHqDGelNRI9rHoyza3BjUY9Oa0IrjaoOBzzya54NeICGtpNuepGKgmu50P3AGHbdmm4Nh9Ygup0zXHz8tg+g5/Oqsty0YJMmCecA9654TX9wSsKM30FVZLa6mmKSzjcOqRnP5mmqT6mbxSekdWaN/fRAfPPz3yxrnbzUURiba6cN/dDZzW1aeG45j+/3NxkjOa17bQba3C+XAi89QO1F4xHarU8jlbDXbmLBvoXMWf9Yinj3Ndfp2qxvGrRPvQ9GXpTpNKVo+FB7D2rJFhLp7s8CjaxJYDofU/Wpcoy2N4QnH4tTrLW6U7eoOOT3rQjZHGMk4HT1rA0eRXUNnOehrYjeMYJHIySKzN0X45N0XCDPT3oQY52k+4HeqwmVQccE9KnWUAA5z7570rD2GHIILHBz9anIGADyvU0gZXI3Yww5NNiY/d5+UU9iW7iiPC4JwCM/wD66dt4bp7Y70SZTBccZ7U/eHUEAcelNGTdhY8ODxweox0qUIVQt0APPqKqw3GxnIOUJ6GknusMTnKn/apsVuxZV2jHzOSD0p0d1ubg4OMVlzXQJJB6c1Va4O5uT70bhe25qS3RJKn5ufXFV5HSQMpYJnt1xWc8+FB3gAjqBmqUtyGmEcbNJM3RIxlm9sCmoidVRLszhANku4g9D3rG1DU47dW88gHrxya108P6pLH5s6G1T+FCcyH3PpWVe+HmALTglvU8nNawpdzirY5bROJ1fVLq9DeQnkRc/Nn5mrC+yySMQAW9Sa7q90vGQF69hVRLBUBY8dvrXQo20Rwucp6yObg0zacuOa1NOiMVyCgAJOBV+RVReAKhtyftS9iOelTP4S6LtNG7YSmG8aMFTK3A3dMV2Gk/aQioFiccjG4riuMjiU3kUmGJyOVGSa7S0aKaSN/KmZl++iofmH+NcktD16dzatILwJg/Y4gT80mdxH61fi2LBzfCQP8A8s+MfWsqCG1ZmzFcABWOJWCID/WtWxFiB5VnGHY9ZFX5R+NSynrqcVr/APo3jSOXnbc2q84wCVJFb1vHFOoKrhs5Knv75rF8fEL4l0Zc/L5MnzfitX9GlJY7wMEUCa0udLCFZQFdSoHSWMNj8etSPEow2bdkH8SDFQ2EkLFWlbBJ2Ac9f61JNGVjJRFjlAJaNpCRj6dqOg4lbVFWbS76INuDQOPT+E1zXhaXFpbMTjKDDdq6UZkRoidqsrDGOORXH+FcrYxq4xtUofwOKnc1aO6XFyh8+OOXIwS8W7B+o6VG8MYUKqxkDAwi7f1ptiMFSu5vXqKsybAWKAO8Z4B296p6mUXZ2ICAFWLAUEHhR0rHtbtlXLPhuR1/SugmdVVVRBuGCQT0ryHV/ESab4h1G1YhTFOwwx9eRjPsaUI3uKrJJXZ6EdRYNw2cjirEdwsuSxPrmvNV8TQyMCsitz0Yj+laEPiBWxubGfeqcWjLmT2Z6BHdhMrzgdwetTG63BQ7hfcGuMh1uHqr9uOQKkGqxsQwfIpWHozrlvQoJYgbe9OF4OVyCfauXj1BfL4Ydc8c1JBfplhlc9fSmFkdMlw+7qNman+0YViq7h2Ge1cuLze/yuMY6f571YFwcIfMB9eaVwaOgS6Vhk4HYUrTKFwprEN0uVIPzA4IxzT4rtcnYrZ96L2JaNEN5nEhDEcdetWEAO0sOhwPasc3Jdg2cdiKlju1A2hvmHWhu6E0zVaQJMqkc9etFZnnZkUK2eQSBRVIho+Z7ia+id3mux949gMHNQw3upyn91IAg6u6/wAqtXEFvFO0s7s/zHlumfYUj+fOo2ARxYzufuPYVrzHJr3GS6veQAkzAOP9nH5Cov7V1a4HyzmFOpbHzH/CpzBGmX2jAH+skNQyM0nMGfUMRxQmugNy6s9W+A2tWkl5caFqsVu1/KTPZXMkatI5A+eLceenI/GvaZkVVADnB5xnFfHtml3DeRXVjJL9tgkEkUicbGByDmvc0+Iyz2MDPpdzLfNGDMnmBYg/fB5OPw71tGSsZOnObvFHcXUcDHADO56YyawtVi0+FCb24gts8fPJtY/h1rjL7xFrGooweYWMB4EVr8pP1bqazdPsYuWOGcnLO3JzUOquhvDAzesnY6Sebw+Hwsk1wewjjYg/icVUa7sl4tdJ+jzvjP4D/Go4IFVuRkj09anKEryAfTFZurJnTHBQW93/AF8jM1Ca5ukCzOEhOB5MK7F/Huar2tqkW5QoXPPFak8KK8ZI6ZxmoJVG9HUcZGSKjmvudcKKirRVi7Yx7Fzng9j3q3GgJ45z+lQRYEKLnFWUXB68fzrNq5rF2LGz5VXt6dapXVrkuyBl7cVdhnIGNqlSO/alkJcEEqoPv1osWp2OZWGW1mYRjcvX0P5VYS52uPvYPJrSuUAbaDgdazmkcEh40JHJHSmiHJdC5HciQnPQe9SrcDYCPXAHesV5xGF2ADJ5AOaBKTuK5GKfKw9omdQt2hVQ2Mg9aqyXCpLxxxjINYUdwQuSc846dKJrpnjKqTkYxRYi6Oga8LIqORx0JqGS+CZCNx6isLzSYwxLDPXNTWkNxdyeXawyzt6RIW/lVJGcqiWpo/bQp6jNRm8GdvHA59K0rHwNrt0QzQJaqR96dwMf8BGTXT6d8ObaPBvr6SZj1WFNg/M5q40mzlli4xPPpb49SwHbI7mr+k6VrWqY+wWE8if89pB5af8AfR/pXruleGtL08g2enQK46SSDe35mtloSw+clvatI0O5zVMY3sjzCz8AnIbWL8yHr5NoNoHsXPJ/ACun0zRLLTYtlnaxW6kclR8x+rHk1uzKsXJwKqSPxkn9K1UIrY451JT3Zl3sa8qoNYGo2ilCGHUd+a3764VSStcr4n1iHTbAzzhndzsiiXq7fXsPWq0RMItuyOW1ZY0ZgBk9s1zdwTk8HGeRVm4vNT1J2LSwW6E/diTcf++jWdq2nTwwGWO9mduu7dkE/Ss/aK+h2/VpxV2Ur6ZIVLMeRwAKzNLvDNqijoNjEVj31/cPc+XdfOc4DKMcVPYSCC/iYd22HJ9ab1RnH3ZI9IsgxCFMlgQeTXYWV0kNqVmG7PyghiDXD6XccqADnHWuusCE2ssfzHGSD1HtXHLuerTd9GakMUEy+YlqhZWwwlclsfSttJgkax+T5YAGCBwazgquFjljxLJySCQTgdDVk/NFJ5LYiPByclcd6zZ0LXc5D4ikf2vob8HIlB+ny1b0t8oM4GO9UfHsOLnQpHYsA8ke76rn+lWtPH7tQDwOn0qlrYm1tDp7Zsywq0mFbnO3IK+9STbYoiJvKZ5OCyE8f5GKi02eJMEjIb5SQuefU+3Y1ZkdwgBGI1G0ovQjtQKJXlWQSxs0nKdAP4q5HQCymaMjgTSAjPT5jXVESKy7c+WDlWPPHpXJ6Q3+m36bsYuZPp949fzqDbodjZhY0yp2Y43Dt/n0q44b5gAxxgZC/wBayreUoNhVVyMgnkGtRJCEJfbsBwdvUfjT6GWz1EdgzkAEMDya8a+Idh/xVd/KUJacJLnGMAqBz+VezyFkWQKV8vGCD+hrhPF+mvNrkEpLHdDt46Ag9T+dEJcr1M8SuanoeSnSGkmG2M5+u3j1qKXT3gB2SMGHXaxAH1rvdRjtrLEe4Fn5wo+Z/p6D3Nc3dQNdKxk2xRDIA9T7etbxqcx5jio+pyrX1/DIwtriQ4/vDP8APtVhPEOqQEhvKlbp0IrUnsFAURjYvq33m+tZc9uVUiNMsDgmrvF7mfNJapl+38Z3MJxLbkMO0bZrVg8aQFF8wtGGOPnU81xpi2kiPDOeWfHSpY7cZCKplcnPJ/pTcUVGtUXU9DtvE9tJhknUnt83GK0YNeGQVkBHXA715imnJkyXLBsnA47+mO9TCylUF2ke3jXptYhj9fSs3GJ0RrT7HrCazG4BEoTHBOec1bi1RQOJBnr1rxtLu6Rw3mlYeil/vP8ASrsWqXca7po9i+u7tScS1XuevJqLY+9wOpzViC6GFBPHUjNeUWniIB8yOVI659K2rbX0kOFmic55w/IpOBaqJnoy3WXTjjOOtFcVZ6wDIoYkgEck+9FKwnI4M24WeSWQqZCxJLEZAzUKyNLJtjTdgfNIw+Uf41ZntVlkZp2yCx+XoDzUMtwqER26F2BwFU4GKrdnPayGQWiM3mXRMsg5AP3RVq3gF1IIwfkHXA4qq6HINzIOAR5Y6f8A1zWppDNFId8flhuV3HBP+FPfculFcyTNiz09IFAwFHv6/Sr0EJDLjBYc9MYFRx3Ck4fAHrVy3kQsBnI9RSZ6kYotQwAxK23I5p1rEYyysMEE1PaTqY9hZcDpgdqiZ9lw4HU+vSosUkkXVAIXaPm6biaCAp3BsnPpVUSLxk54zxSyXGE6hQPXiixEncmuIw0R3Dc45A681nySeTAUKMHUnt1qxHdPK5S2jkmY8EIC38qtpoes3QAh0y5CkclxsH61SXYynUUV7zMyC5WQKWOMD0q2s+Mjccn0rUsvAerMw897S2U9mcu35D/Gui0/4fWyDN7fXEx7pCojX6Z5NV7OT6HPLFwi97nHm4VV6jp34pY3kmfEYaRiMYRSfp0r1Cz8M6TbYEOmwsR/FL85/WtiK0Ma7Y1SNR2QAD9KtUH3MJY/sjyD+xdXvP8AVaZcHPd12j9af/whOvyyhxFFH6rJMOn4Zr2IWxP3iT9aUWi/jVqgu5jLGze1jyN/h9rDBSJLIt3Hmnj9KfH4A1jjc1iMDgmU8fpXrgtl9KetuuOlP2MSfrdQ8ng+Gt47Zn1K0gHpHG0n+Faln8ONPiYG7v7qbp8sSiMf1NeiPGVwFUc1JDAvVsZ9KpUooh4io+pytl4N0e3O5NOjdv705Mn6HiuitrMQxCOJFjQfwxqFH6VoBQOgp3A4FWopbGTk3vqVktR1bFTrCo7U+lzTJFVQOgpsvTpTgainZVXnjNAGPft82SeBWNNPuk5PB6fSrupFpJCA2B1xWRcnZGQvHvS0EkZOs6j5TbVG4968+8R3rXuqReYMpEmEB6ZPJNdZq4Hm4IwDXGXJzetkAMOB3xWdR6WO7CRXPcnygjCt94jOAOQPWpRE1zaSoUZmQbhu78cYqrEHllO05k6ZJ5x3+lX7AeXcGePcIz8h3Vz3sei1zLU8u8VacVBl2Mp6muXmujFdRsVOY9uMHrivY/GtpCbVphkuQSRXimpf8fUn4VvB30POxEeV3PXNImICMPvnkmu40XY5h8zkKcgHoD6/0rgdGOIYyo5wP5Cu50JkEi/Lls54B9a5po7qTudTbPKmBNIZF6YI7+v4UshYlWAAkIwyjgGmZXLKcEsMjB5PrUjbXC9eM5Oe9ZM6loct8QvlsdEO4Ei8I6f7Bp2msWg4+ox3qj8RJT9r0KIYMZmkkIHHAXH9av6XtMUe0fL25/zmrtoiHLdG/ZqWA2MyAA/MuOlXJ224dkCsf4/7xqtDLtQLgEkYxjgVIiBtxJIB64yePQUnoENdRH/dbCM5JDba5G1ATXNUUf8APyxP48/1rsWjGUVDygGOO3pXLSkL4o1SIjBfZIB9V/8ArVF77mptwxgAFvm5+UfWr1sPlIAwoz8w7H+tUrdxHgAnPbvir0bqyIN6kqepOc49qfQi92W4yw35jC8dx94VzHjUTW+lJcWqjIkEZLc7VPpXTyMAFB3FunI6VW1uy+36Ld2pO1pUO0qeVOMjFSrX1KqR5otI8akRxJOWJll6k9enqf6VVniCgS3cm18YVT2+gq5JLDBABEN2wbdoJwD6lu5zWFcTkTHGZrjaTgdFHv6V0RbZ4ktNwmzICzt5MPp0ZvqazLiXcoJfZD0Cr1aoru+LvhyrOenoBVR7hIvmnYsTwAfWrUTK5dgiaZwiDZEOTjktWkiwiMxWqqzrwcnK/ie9Z1mTKu528uMHkA4J/GtGzmRpFEIEVuB948fkKUtjSBKsSoyZIluiOAB93/Cie3aa48pENxOPmK5/dr7ntV61hLoxTEEBHMmPmf39hVmJywNtpceNrYeY9z9e5rJytsdCiZcljHZoJrtxNcMeOMDPsPT3qrdWjznfcDbGvIXPH1NbE0lpZuXkmE90P4QdxBqvJ9ovnDCJYk9DyfrjpmknJ6l+zb0RiPayXL/uIysPQvj7/wDh9arS28cS7IIvNYdSo4FdhFpzuxMzs3Hf/Ctay09U4SMceg5quaxvHBtnnduLm3ljcyTq+4ELz60V7DaacSyAwBwSAdwFFP2nkN4FraR5NcBpJpDdny49xG1OpP8AOpY42WIkH7Oh/j4z/wDWokJFyxgiM77j82flHP6U14oxJvvZBJITxEOg/CmcSFhB2sLJfvHDSyHcc+1NCrFIcM9zdHoRzj+gqdwdpMuIoX74wagZ/LGLbbEh4Mhxk+woQbGhFfTwJi6KZBxtXkipo9VVPmMUgB7etY5niGdm7PTJbLGmzS7cBQPUqTVWvuWsRKOzOmGvxxowkEg2jqB1rv7PwHrF/Z2t5FfaYLe4jWWKQSO2VI9Avv0rxYyAp85+bHYcCvZ/2fPFCSiXwlfSfP8ANcacW/N4v/Zh+NXCkpbini6iWjN+y+HSrtOoarJIB1W3iCfqc10Fh4R0a0UeXYJMw/juGMh/Xiup8oDoMUoUDtWqpxXQ5J4ipPeRQitPKTbAiRIBwqKFH6U9LYyNls/U1oBelLt5HFXsYMrx2qA9OanESDoKeKUnAOe1IVxAB2FL+FM3k42g4p/PfNACjqKUA55oxx0pRxTHYUDvj8aPrSZ46GlxxzQAfrTwKB+FL35oAX8KX1zSdOtGfamA6imk45JpuS5IGQKAJC2Acf8A6qhkUtlm59OKmUY6cn1NMm+7QBz2pnDYHesK7OfTNberHnvWDc8njpUgjm9bbYTtAzjua4m8IXUHB4OB713GvgLCzDHSuJvCpvg2DtKj/wDXWdV6HbhH7xNp6+c7BR+8xwe2O5rbsLVYkQjcc8KRzj61jWUgjZiBhgMA46CujsFDy7ssGUAZ64Hp9a5ZHqR1MDx1bldKJX5mGckV4JqQIunyMc19HeLYh/ZMmFAAGcGvnzXYc6gFXq7YAreizgxsex6Jo+Hjix12A/oK7jQTuxgfMR+VcXpiKroMnjjJNdlpEmEOQwXp+NZTNqVzq4ZS04aToQFPuPrVnA3E8gk8DrWRbXAyEyXGM/U1NqmoCy0t5xjzfuxqerOelY9TtOO8UMb7xQwVg0VrH5KnPG4nLf0rY0xvLjRSMYGfoazrayKRKHOZeWdu5Y8k1sQR7VUKMcc/mOf0q7mT3NmDMioOqN19auKPJLKuWjJJGcD86y42KICWOf4SCf8APtV2AMsQzgkjLE5OD/XFTI0itB6OUJwMEngDr+Fcl4qtpbXWU1iBjlIljnTrlMn5vqCa61XQyqWx9TVTUYUummIC+XsMTDsRjtUrQuRWs7kSwq4wAwGGA7/5FatvIzRlSBwGODg4IrmtLDpGiDPA+YA1qxlxKjbQ4fcOTikmHLqbJPyjbk45z0FPaZjtZQMD0qrbTMwKNkDbkbvSrESfKVIGCPXvTWpbVkeG+ODPa+JdSsYyLe3STf5jd1YbvlH41x11OHJS1BWPuc8mvRfjTbfZtSsb9ziOaIwsf9ten5g/pXk88rzZI/dxAcY9K66equeBiI8tRoknn2DbEufUnoPrVKOb9+Gkbe5OAF5/CoJ5t3yxjCjv61f0e0kYGbAUdmb09q1tZXZzr3nZGpDltolUM3aJRwPqa27VUgjWS52vIfuRDqPSqOnQtI5MHKDq57mtq2W3sUa5uGLbB8zNzjPb/AVhNnXTj1LMxVbd7jVJFitwR+7Xqx9B6n9KzGvLnVG8m2X7LZ9BGh+ZvqaoXc9xrF6JWjIgUYjjHOPU/Wus8PaadylVBx0xUcvLq9zspQ5mR6Roiqo3x4J7V0NtpGAJFUADt6Vuadpg4ZmwwPT/ABro7azRYgjDryGB4HtUOVzvUIwRxsNjwpPp3FamnWQGCVLnHAUZya1LqyVGJUEEc+wqfT3jVHCSKkoHBI6ijdjnO0bohFnIrrvwBkfKCemaKoXuuR2k4junUSZ4VTkt9BRSdjJzfc8cHnyvIDtt7fccFeCearSXVvbDZAilsc7jyfqasXUYmmf7QzYB4jXgde9MjtIBkmNN49smtFbqeW72sjPmummlw252PUBSR9BSFJJGVHgkCddqLnbWxHkHag24HanrFlCM8d9vQf8A16rnt0J9nfdmGI5HO4QNheFUDpUqwXRAItyV6kNxW7gKADxjpkY+tJnJGxSD0wOfxodTyK9iu5jPb3SqC8YLZOFzz+NTae+pWFzBe2EYgvLaRZYnXqGBzWmPvE8yN69gPrTxl+nIPA29vxpe1aE6K7n1B4S16DxV4astZt1ETTDbcQ94Zh95f6j2IrWwBXgPwg8UL4d8TGwvZQNK1MiNz/DHL/A/t6H6+1fQbo0blWHI4NdkZKa5jjqQ5HYjA7072waD1NKTjPOfemZDC3OBzTQGLHJ4pxHOaWgAUYHH4UuffFNLZ4B5poHPzdqQEhODgUAZpOgzUTSEnAB5pjJS4Bx1PSmqW39MsO3bFNRMgbuKnwKAHD8Pxp/Q8VGDzS5waYD+3akLYwACWo7e1BAJz37UANVSxy2cVKoxwOntSe9KKBjqinxtp+fzqOb7vPpSYjndVBJyTxWBdSKjYPLegre1Vs9M8HnjpXPyJltzcnoAewpMEc5rsTSjJbaMZxXI3hxOi9igxiu41z/VgA84PWuGvPvoSWxg4P41nU2OrDaSC1l8uQEFs5yR6V0umPuUIGKgHO4cksewrllJbavGBya6HSJwAAWIB5OR0rlketTY3xhJjS5V3YGevWvDbmI3PiaCNckK4dh6Ac/0r13x1dCHTmYtnrxXmui25EpupM+ZM2ST2X0rWnornLiFzSsdTZJhgGBI6j/CuossrlXJ6dvSsGxBBGM5HfNdLaoZOQNu4c5NRI1o6su2j8qFPQ5ApZGGoX2/Obe3+WPPdu5qlMxQ+VGSoIy7+i+1W0KpEigALjoKzSOpvsI4Ug4GfSpInBLgLux+OTUMkmHHfjkUR/IBkjHXPpTM0rloS4AO7BAwOcDPc1tJMEt0VMgYGMd/esAFFZCF5HB/xrZiOYCXJztyu7mpZ0JaCTO/kjaflz35yaWN0WExNywXBI6UiuJFB52DjHrUJO1htAz1x6npUsJLoVrSP5icjPy5wOlWSREysDtZZDgEHGD3p8MTYQ8lgQ3A7Y7etI7eXLHI43qMnYp4HoRQkJbmlosnmxvjavlEY3Hr1zUs7nzOMMD97tis3QguHMrIQpKnzB35PWtB3Em9QBnAI9Aaa2NGtTkfizp4v/At8wQNJZFLtB9Dhv8Ax0mvm65naTjop5AFfXZiWWMi6UOkqGKVT0Kngj8q+U/GGjSeHvE2o6VLnNtMVUnunVT+KkGujDO90ePmNOzU16GfYwCecKx4HJrqLa3zt+0HEQ4EQ6fj61maLCBGTx5h546+1dTpVkk+Zrk42fdQ/wA61nI46Ub7FvT7eSdIorddikgFzwce1Z2qtHdaoLO1Ie1tSQzdd8nc/QdK19Z1BtL0tpLZVWWU+TEehzjkgewqj4Vs8SRlhnIOc96xX8zOyMbuxreHtPUt8yncDwBxmvQtEsfLg85F5TGV6ZFZGi2RWYHlhjjjtXcaVEsWFkx5bfK+P51lKWp6MfdRDcRCKNblQWiYgNnse1bFom+23Lz0wD/jVCOZbaWfTrsblcr5bHoyZqQpLp6Awhp7Qn/gSVlfU0ab0JL/ABIrH+LGCp7elcD4j1Xy7prewJlu1Hz4YBYh/tH19q6DxBqUdvpstzGzHd8qEDPzH0FecOqxxFSjRo3zmMfec98mk5GU5OKsQwqFuN0b+bduwWS4b7qrnoKKbsXdE10cIGGy3Tncc+lFUjibMh+Z32fKSxPHX/61IFPl4T5mzyB61UNxIJ5d2dpYnC89/Wm/bZ2XhThckdua6eVmHOuprssa2SlynnRy4KDqVI/oaZ5iqwAB9wv9TWPHNIqoCcZJwTxzVuG5LFV8vbk4yT1pOBUaiL4UK5APUnGTk07LMMJxx0qqjlAryg4Zshep/wDrCrMUm5uNpwORnIFQ00aJpjvKG0AgEkD5eeaeUYNucnYO2KnWA7f3hA3cntzSNglQoyejEn7tRcbTRFIBIpX+Bgcsa+hPhP4oPiXwyILqXfqunARTk9ZI/wCCT39D7ivn/duQAESFepA4FHhnxRdeFPG9lqdoWkSLMd3F0EsLfeX69x7gV0YeVpW6HPXjeJ9Zd+PXpRnr/KmwTwXlrBd2UgltbhBNDIOjKRkGgn611nAB6d6jbO4Ac5qSmk96BDRhc9+aUuB/hUbtgccc9aailuSP1pAPyZF4NSBR1PWgDGaWmNDuOtANIOPoaY7YOF6Hv6UXGSFgD70K3y5IwKiyRkHlu1OUM3OKYiQP8444qYVGqAcg/nT8jGQaAH/jSd6Sms2OFHOKBjiwXr3qtMWkHIwOlSBecvSzfd/lQIwNSHJx+tYUwyeOhFb+pLnmsSYc1LEjB1tMwnPUcZFcHfZOzA+UMQfrXoerpmBu3Brz69A2e248ZqKnwnVhviKyDncvOfU1qaXKpYryeev6Vk5Xkc4B/CpreUpJ+6wuO/8AdH+NcsketBlL4gzCWWCzX5lGWJznj6Vh2CZI+TsAK19TjEku4kE+rc8fWqcCBMDgE1a2MJ73NWzQg8niulhysK4Az1A/rWHaR5RSMHuTWoOVVU6sefpUSNaaJxFub94ox13evuaTJEYxkgndnOOP/r0qS4jBdhgEg1JdABdqnPGSB0yeg/CoOjoVWZvMYsQCOOPWrUTLLjDDB456YqpG6mRh0K1Yhbyh2wW4IoZMdx3mgSRgkZO4jvn3rWtWQWzSOhfA28+prIZCxVjjAIUD0960rbPlMGYY2ZJPfPp61D30OqKVtS5ZfvIyUwMDcc9GGahb5iVICkDOf5UyGQRhNpPGQA386A5YkcFjxjPWi1lcmW5ct3KMXGRtGSucbue360yaMFioKowIIU/UHFRRYUcY+Yfz71OCNiliqks2WYdPwpsztZ6C6cP30xBJyzHDgcCpuGDBeVGBUcEe1SWUjcByeqkdaktvm45Kk4I9c0lojS/UurGzIS38PU+teRfH/wANvNHZeJLaPLKq292AOw+45/8AQT/wGvXhhY8Dr2/DrTbqzh1CwktLqMS28yFJFPcHrVQlyNSOWtTVSLiz5f06KOFASN8p+6gPLexrqtLtp5zGLxV2lspCnAz6Z71Um0abQNdvNJlUyS27AmV+B5R5Vifp+tX0Et0rLbMUtFGGkHytJ649BXTN9jzKUHe3Y57XLl9R1QzYxBEfLiXHbPX6muz0C1BtkbuB1FcvqtktvIrQN+7P8OemK6/w4/7iMEjKjketRPbQ7aMPe1Ov0REfcF4ZeQSe/pXSWR+TKkbXXDZ9RWFpMYVsBTk4xzWxD+6kY8qpJLD0rnkd0kXfsaalJ5UxKSjDpIOqtj+VPupZYrdoJgRdRjkZ4cZ6irOngRqCSSFB2t3Ht71zPi/VEt7Tz5LhUZW8tT169QPWp8xX77HJa9qMd7qDR6cfMSNfnc/6uN/X3NYchRAy27+dMSN8p6A+1STDzIFjmY29ozY2Kcbvx70yRHMZBAgtcYSJPvN7moerucspOTK8Q8uZRGrXN2x+aZ+FXn17/QUURErtQYjiDdPx/WitEZS0OTnsZRPIIyXXcSzZxu56VMLWWQ480Lx0Hb0FXX5lbOeSSPbmpIE2q2ODjGRXS5M5o04mTd28luoLsWHqPWo1ff5Zw2McKfX3rfjijVP3i/QtzWNd2/kznaCwPKds/wD1qcZc2hM4cuqJVVM8sWYnsv51p2UkYV1EbKwOVU4OB7ntWSZP4H2hmb5toJ59BV+0VkIR4gMnPBwDSktNS4S1L4IYjcxlJPGOgNDKx+8cDPQdP0pyuoDgYUAdODz7VGJFK/uo8noWJ5rn1NwuJPKjZm+VAM4xk1zkZDTmR2faxyMLkmtG9mEzFGZ3WP7+zj8M+lVMqIi6xjHQc8iuimrI5ar5np0Pav2evFjGKTwpqU2TlptPLEcd3i/9mH417Qepr4306Se1mgvLB/Jubd1mil6FWByK+rvB3iKDxV4cttVgwsjfu7iIH/Vyj7w+ncexrphNS06o56sLJSNgnHpSDoetB6E0mefrVmJEU+ffn8KeMjvSt15puTngcetAh+e3egtiomkA4GCaCBu3Ekg9qAJN3GSQF96TopIB61Hgu3bHpVhAQM5pgIkfIyfwqYcfSmilz1oGP69P5UdDUbOqnHU0K525PHsKAJc9cmjhgDxx0qHdvBGenanxgjOTx2FAEn4cUyUcZpwHqaST7tAGJqQ4PH41hSjnt+NdDqK/Ie1c/JnNJiMrUQDCcnOOxrzvUVIWTkD5vSvS7pd0ZzXnOrAL9pHGQ2Rjmonsb0HaRhxZIxnGKuRAlVRBhT19zVWILuxjk8HNX7Jlz0z7E1zM9Wm9ChfI33T0xkZqCBR8uASe4rT1SPBLsv3u2Ov/ANaqETKD/tE80LYU1qativRQR07dSavyB4iC2COBkcfhVKxVVdfmH97ntV+7UvFxwcdR6etS9zSLKTSupAX95zyD2xW8sSPpplfJk4Xj9a59VLAKrALjvz+Jrc05gluoEhILbtvbHepe5v0KzcStjGff0pFxjcwzxzUvlDG4n5jzuoMTI7DJxj09qQouxGHw+MccAZ9O+a0bfasaxgFieQOoFZtvCZDhgT6nHetMW5jQBAcnpjIBpG8WRsXMhBcE9Cc8fSrUeGBUsQw6EfxGm+UUUnbz0JPU4pzYztHzY/i75pEyZFk8k4I54q/ArSxnkHaOn48VmzSkFeMLuycdT/kVoaZLhSm4KwO4A8ZHr9afkZSk0i4AfKLFfujgZzRaj5EODgEk4PU0y8k8pVjXKkDIB4xTbQnyeWII7dyai3Rlp3VzQaRSVCjqMEHnFWovkixjIHHvisyEMx+YlCvB9/rV5eQMnJ6898079CJdjj/ijoIv9PTUokMtxZDLKv8Ay1j7g+pHUfjXll3qyKqRxKUDDOWUjHtX0I2zynQ5AORXFaroltHOsrwq8YyHBHAJ7/StIztozJwueaLDJOqyLyF5z611Oj2mIQ8YAIIyO3401tNitdTdIObVx93PCk+hrodKgPlKUGCpxjpQ5aGkI2dzX0xQI0VsAk8OD1rUhIaZlIHQE4PHTFZtohQAlSoVskD0rZtoi2yTGcDDNjAIOetZN3N7FtgILYbeGDcg/wAq828Wut1rWxIi7Q5Klj8qk8k49a7/AFm7SO2+bgKOSTzgV5dPM13NNK+MuxYhR+nvUS02Mp7alYhY8GdRczqMK7fdX6CqkzySMWkPXuT/AJ/KrbOQAo4UDqRxVXUJoLC0lublsBMHk4z7Uoo53YjSM+apkLEBgRx1orlYvGMc9/ErwmOLzBzn3orf2M1ujldeF9GamyUSyHy2UFj2PrU0ccgyfLfGcEEHFFFaMqI4xyEozKx2k8lTWdq8EpaIhTxwTg8/hRRShuKq/dYKCYv9WwcnsvOKuWkLwI21HJZuPk5C/jRRVz0Ipu+pI8cj4DK+O+OcVV1BpYohEgILDHAxxRRUwV2XVdo3RSS3dbXasTe5OQasQWsuVV1Yjqq7egoopybM4JFiYi2gOVZpCOF25JNdL8IfFk3hvxWftYcaLqREN1uBxCw+5IPoTg+x9qKK0o+7Zin7z5XsfS7KQxxyOxHT60zDdwaKK6WcAvOeh5qOVXKELnOewoopiIwrDnb+NSrGxIzketFFDAmVcDoacARmiihjFwe+aaWOOB+NFFIBBu/iB3dKREZmOQee9FFUBKqbc4FSKDzwaKKQDsHoRQVJHT9KKKYGZfISp4NczcBg7DBB9xRRUsRyXjHxVp3hy1c3O64vWXMVnCfmb3Y/wr7/AJV5P4a13UNd1rWG1IbTJErxQoCEjAboPz696KKib0sa0laSZsJC5Y4R/wAqnt1mDkBCPqp4oornZ6kC5doxt2JDs+DkkcmsdUYbcKeOBxRRSQ5s2IImZkUqVYDNW5vMWAnBBAJOFNFFS1qVB6FeyUzuQ4ZVB4XbWstvLCmFDNntjgUUVL3OhSYRByuzBHTnbTiW3KQjHI5yOtFFD0IiPtVK3CjacA88e1a4h3uh+YYzwATRRUmyeiI5klDpwT8uCAOg9qimXLDCsvc8df8A61FFFtxSZFLHuGdrAngcd/enDdGilVPmqMEgdfrRRTsTbQWV5JiGlU7gMcCtS2Vlt18sEFhjO2iipmOLsh8MbBjhS7Hnmp4o5Y+ucDgcdBRRSS6kTbuTRjGSVbJ9qyNcie2W3vSGaMN5ci88hulFFUlcSk7nPXGnbJy0cTtE3Uen0q/pkeFCsWIGOTRRUPa50I3reJ9jNtGenTg1qwRskRO0gHpkdP8A61FFNqzJbOT8YTFrdYgr/M+MY5IHWuPljdwSA0cQOMheT7Ciisp6szqPWwx0bYVRCR6lf0ri/iKlw+lQbY38sTc9STxRRWuH0mjlxD9xnn0EUgnjzG/3h/CfWiiivUPIP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressure or massage at the P6 acupressure point is reported in some studies to relieve motion sickness. The point is found three of the patient's fingerbreadths proximal to the proximal wrist fold, between the palmaris longus and flexor carpi radialis tendons, shown in this picture by the tip of the pen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Judith A Smith, Pharm D, BCOP, FCCP, FISOPP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21956=[""].join("\n");
var outline_f21_28_21956=null;
var title_f21_28_21957="Aldesleukin: Patient drug information";
var content_f21_28_21957=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aldesleukin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/33/30231?source=see_link\">",
"     see \"Aldesleukin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39350?source=see_link\">",
"     see \"Aldesleukin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12806506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Proleukin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Proleukin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3860402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have any heart or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700665",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad low blood pressure and harm to your organs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad nervous system problems including great sleepiness, seizures, weakness, or numbness or tingling of the feet or hands. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have happened in patients who take this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691921",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat kidney cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aldesleukin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems with this drug in the past: Bleeding from the stomach or bowel, coma, dialysis, a fast heartbeat, heart disease, hole in the GI (gastrointestinal) tract, lung disease, organ transplant, or seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697834",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an immune or inflammatory disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having an x-ray with dye, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loss of eyesight. This can be long-lasting.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count. This drug may need to be stopped.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11039 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.96.59.103-A977B79397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21957=[""].join("\n");
var outline_f21_28_21957=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12806506\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131251\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026716\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026718\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026717\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026722\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026723\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026725\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026720\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026727\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/33/30231?source=related_link\">",
"      Aldesleukin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39350?source=related_link\">",
"      Aldesleukin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_28_21958="Appendiceal carcinoid tumor";
var content_f21_28_21958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50408%7EGAST%2F80087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50408%7EGAST%2F80087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Appendiceal carcinoid tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Carcinoid tumor in the appendix.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Appendiceal carcinoid tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathologic specimen of a carcinoid tumor of the distal appendix (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen E Goldfinger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21958=[""].join("\n");
var outline_f21_28_21958=null;
var title_f21_28_21959="Follic lymphoma nodal areas";
var content_f21_28_21959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F63663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F63663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Follicular lymphoma lymph node locations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 572px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAI8Ai8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuD+J/xDsvB1g8MLJcazKuYbfOQuf439B7dT+tTKSirsqMXJ2R1Ova9pfh+zNzrF9BaRdvMblvZR1J+leRa5+0BYQytHomj3F2B/wAtJ5BED+ABNeGa5q2oa7qct9q91JcXLnJdz09gOgHsKqpsAwK4Z4qT+HQ7IYaK+LU9Vu/j34nlyLTStKgz03B3I/8AHhTLL46eLrd917p+mXUfdRG8Z/Pcf5V5lvjj/jCn8KimuXORvDJWXt59zX2EOx9FeGvj1oV9MsOvWdzpEh/5ak+dF+JAyPyr1fSdUsNXtFutLvILu3bpJDIHH6V8Ju6uckD860fDPiHUfCmsQ6lo1w8UqsC8W47JlzyjjuD/APqreGKa+Iwnhk/hPueivPvBfxW0HxPeR2QE1heyYEcdxjEh9FYHGfY4zXoIOa7ITjNXi7nLKDi7SQUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHK/ErxXF4Q8Lz3/wArXj/ubWM/xyEcZ9hyT9K+Srq5uL65uNQvZHub2eQku3JZj3r1n9pjUmk17SNNB+S3gacj/adsfyX9a5r4RabDe6lLdSjebMDYCON7d/wFeZiZ3m10R6OGglG/VnLab4P1zUYlmhsJ9jttUuu3J9ee3vWxB8NvEM1y1vFZMNpw00jBI/wPU/gK+g7KEYBPNaKrxXOrs2bsfPE3wk16JQym2lPcI3I/76xmmRfCHxHcqx/0ODA4EknLflnFfRgX2oK1VieY+b4vg34meYLO9hCmeX80tj8AK6q1+FNjpml3KzSNd38sTKszjCxkjqq9vrXsL1Tu498ZqZNjjY+UA81nNJZ3cbQ3lu20noVYV9X/AAh8UP4p8HwXFy+6+t2+z3B7swHDfiCPxzXhXxs0YQS2mrwqAWbyJiO/GVJ/Iit/9mHVHTV9U00t+7uIBOo/2kbH8m/SujDS5Z+pliI3j6H0bRRRXpnnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXNN420fzZ4401ifyZpIHe30a8mTejlHAdIirYZSMgkZFH/AAmml/8APr4g/wDBBf8A/wAZoA6Wiua/4TTS/wDn18Qf+CC//wDjNH/CaaX/AM+viD/wQX//AMZoA6Wiua/4TTS/+fXxB/4IL/8A+M0f8Jppf/Pr4g/8EF//APGaAOlormv+E00v/n18Qf8Aggv/AP4zR/wmml/8+viD/wAEF/8A/GaAOlormv8AhNNL/wCfXxB/4IL/AP8AjNH/AAmml/8APr4g/wDBBf8A/wAZoA6Wiua/4TTS/wDn18Qf+CC//wDjNH/CaaX/AM+viD/wQX//AMZoA6WiqOi6raa1pyX2nvI9uzvH+8ieJgyOUdWRwGUhlYEEDpV6gAooooAKKKKACiiigAooooAKKKKACiiigAooooA+V/2g0mPxKmEgYK8ERjJ6Fdvb8d1dT8I7BLTwpBIMF7iR5GP44H8qb+1FbiO70K8QYkMU0RPqAVIH/jxrb8B24t/C2jxj/n3Qn6kZ/rXkYhWm15nqUHeKZ2tvhYwBVhXFUGnSMAEgemTiq7avaLL5ZuYBIP4fMGfyzWKlYtxubQehmrPhu0lAKMCPUHNSNMB1NVzk8hM7VDL9w1nvrmnLcGBr22Ew6oZVBH4ZqY3kUi/JIjD1VgalspI8++LiBvBmpZQPtCsM9juHNcl+zcXPj6EKpKrBLuI7AjjP4ivRfG9j/aXh7UbZD80kLAfUDI/lXnn7NkMj+PlkRTtjtZRIR2BxjP41rQ+JepNb4X6H1QKKKK9g8oKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5r4e/8gG6/7C2p/wDpfPWj4p1q38OeHNR1i8V3gsoWmZE+82BwB7k4FZ3w9/5AN1/2FtT/APS+etrVtOtdX0y60/UIRNZ3UbQyxn+JSMH6fWgDjLDxlq+n6FJr3jTTtP07R2t0nia0uXnlVnZQkTIUGWO4cqSOKdD8VPDstmk4XUPNa8+wG2W1aSYTbC4G1N2cqOCM02L4X6YdFuNJv9X17UdPkhWGKG7uwwtgrKymPCjBBVcE54GOmasWPw6062k06STUdSuZLG9W+iaQwrlwjIAQkajbhj0AOe9AE9p8QdEubuGzUXkd9JfLp/2WWArKshj8zLKeQu3nJrO0f4lWVzomizNDdalqWowSXK2+mWjsfKRypfaxyq5wOTknpWx/wg+k/wDCf/8ACX/6R/ankeTs3jys42+Ztxnft+XOcY7d6yrL4YaXp1jpMOlanrFhc6bbSWcd5bzRiaSF33lHyhUjdyMKCKALc3xF0a38TWeh3UV/b3V3IkUMksIVHdlDKOu4ZzjJXGeM1c+GniG48V+BtK1u8hihuLtGZ44s7Vw7Lxkk9qxV+Fejrr0eqrf6t5iahHqfktLGyNOi7dzEoXII6jd3OMV1HhDw9aeFfDdlomnSTyWtopVHnYFyCxbkgAdSe1AGxRRRQAUUUUAc18Pf+QDdf9hbU/8A0vnrpa5r4e/8gG6/7C2p/wDpfPXS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHivxdnfxVpt9bw6ZHLa6bcFUuBPiXcpAkITGCnUdc8Zrbs4lMMccLeSmwKhQD5RjjFcx4lsINNvfFSXTussc7TQyKfmCyruUL7ZLAj610OiuZdPsZO7Qo35qK8au25u569GKUVYyte0TQY2eTUG1S+njQuUE8kjKByWwOn14FcNDpmgarrt7p1vpmuR3ttt82PzgSgZN4bByWBU54zXtDI+xmUD512uMZDj0I71haX4ftdKvJrjTLTyJ5eGkBJOPQE9OgqE0h2bM/wlZw6RCbO3llkjk/eIzn9K19Vuza2ckzZyo4+tTS2gS5gfH7wPkn1z1qp41j2aZlRwHXP0zUvVlrscBP4X01mFxJY6ldySOA6W8gVN7cgFjjn2zR4Yi8J6rpyXdlZ36QHnzzI4A5I5I4HIPXHSvQDbC+0gWssYmtJVBMZ/PI9DUujaVb6NprWun24ggbl1H8X19vaq5laxNne5Qs4BCBFFPcTRHAUTNvx+PWsz4XvbeFbm9v/wCy2Wx1K98g3hkAMS7yqYTGSm48nPfpxW6JQJjwAFBP5VxXhi0XU7XQYLZ3+1XN6sNwGJP7sHzSR7ALxV0G1JNCrJOLTPoqiiivZPHCiiigAooooAKKKKACiiigAooooAKKKKACiiue1/WdStNc07S9G06zvLi6t7i5Zrq8a3VFiaFSAVikJJMw7DoaAOhormvtnjH/AKAXh/8A8HU3/wAiUfbPGP8A0AvD/wD4Opv/AJEoA6Wiua+2eMf+gF4f/wDB1N/8iUfbPGP/AEAvD/8A4Opv/kSgDpaK5r7Z4x/6AXh//wAHU3/yJR9s8Y/9ALw//wCDqb/5EoA6Wiua+2eMf+gF4f8A/B1N/wDIlH2zxj/0AvD/AP4Opv8A5EoA6Wiua+2eMf8AoBeH/wDwdTf/ACJR9s8Y/wDQC8P/APg6m/8AkSgDpaK5r7Z4x/6AXh//AMHU3/yJRp2tax/wkltpOtaVp9r9ptJ7qKW0v3uP9U8KlWDQx4z5wIIJ6GgDpaKKKACiiigDmvh7/wAgG6/7C2p/+l89P+I00tv8PfFE1vI8U0el3TpIjFWVhExBBHQg96Z8Pf8AkA3X/YW1P/0vnrpaAPOJjqfh+6T7ZfpomkX9wF8xrn7QLXbEx/1ko2oZGA4wVG3j5n4h07xZqsur6JHqF2kf22OBRa2oi8wswbMkkT/vAhG1gUOFGdwODXdXGu6db6kbGW4xcqAXAjZljzkje4G1CcHAYjNVR4u0L7JLdPqMcUERj3PMrR8OSEYbgMqxBAYZBwcGgDzqw8TavbeG9Bh/tyIvJBMbm+vJokMVwgjAt3d1YA/MzFWw5A4Iwa17/W9audO125lvLVYLIWqiCCM4Z5I4XYiTcCVy5xwOOue3ax+ItKlsluobyN4nlEK9QTIV3BMHodvPPaorTxPplybVFmbzp4Y5tqI0ixh13KHdQVUkdMkZ7ZoA4268W6nCNSlivYpbyJNRM2nmNc2KwiTyZDj5vm2p94kNvBXArvdBF5/ZcDajdJdXMih2dIvKUZGcBcngfU1nT+LLARIbUSyyG6t7d4pI3gdBM+xX2uoJXrg4wdpweK6GgAooooAKKKKAOa+Hv/IBuv8AsLan/wCl89dLXn3g/wAI+G9U06+vNT8PaPeXcmralvnuLKOR2xezgZZlJOAAPoK3P+EB8Hf9Cn4f/wDBbD/8TQB0tFc1/wAID4O/6FPw/wD+C2H/AOJo/wCEB8Hf9Cn4f/8ABbD/APE0AdLRXNf8ID4O/wChT8P/APgth/8AiaP+EB8Hf9Cn4f8A/BbD/wDE0AdLRXNf8ID4O/6FPw//AOC2H/4mj/hAfB3/AEKfh/8A8FsP/wATQB0tFc1/wgPg7/oU/D//AILYf/iaP+EB8Hf9Cn4f/wDBbD/8TQB0tFc1/wAID4O/6FPw/wD+C2H/AOJo/wCEB8Hf9Cn4f/8ABbD/APE0AdLRXNf8ID4O/wChT8P/APgth/8AiaP+EB8Hf9Cn4f8A/BbD/wDE0AdLRXNf8ID4O/6FPw//AOC2H/4mj/hAfB3/AEKfh/8A8FsP/wATQB5r+0Bcw6RqdheSIW+125jCL/G0bgjP0Eh5rI+G3jW21c2ukyQtb3cMIVCW3LKFGDjgYOOcfrXSfF74UWWp6Nb3Pg/R9Ns9Qs2ZmhtbeOAzowGRlQMsMDGfVvWvP/hV4Mv7PxA+paon2ZrB2h8hvv8AmFO47Da1cmIp01FyluYxxGM+tRp017nXTp11PdYFBUU+RMCo7ZxtFPmbIrz9LHtu9zNmdPt8ER5dtzAew6n9R+dM8R2ovNKmiH3mQgH0Paquo2N7PdNc6dPDGxj8r96pOMHORjr16ew5rOe31yaQW/8AaNurp95/JJ3D6Z4/M1Jp5lzwbK1xpyBx8yfKfqK3LwBYjWRots2mB45HDyMxdmAwCT6Creo3GYjg0rqwWbZ5f428a2+hX8lnHA1zcsh3APtCZHGTg898Vf8AgXcQar4hs5IARJaQTNKh/h+WNFP45auR+JHhG/u9VfVdPTz1naONogfn38IoUd88dOa9P/Z78Gaj4csdSv8AWbdra4vCkccUgw6ouSSR2yT09q9KhTpuKlHc8GeIxv1uVOov3ettOnTU9fooorsNQooooAKKKKACiiigAooooAKKKKACiiigArmr/wD5KToX/YJ1D/0dZV0tc1f/APJSdC/7BOof+jrKgC1421w+GvCWrayIPPayt3mWLONxA4BPYZxn2rjovE2veGvCZ8T+LNQsNSsri2ilitLC1MTpLIyBEVy5DJ8/LHB+tejXkMFxaTw3iRyW0kbJKkgBVkIwQwPGMZrktM+HHg62sruCz0qKS0u4vJkR7iSZCm4NtUMxCgMAflxggelAGNb/ABV860tj/wAI7ftfz6h/ZyW0ciYdjGXVkd9qlTjHOMGr1p8R4pvEMOgz6Tcwa21+to9o0qsY4zD5pmyOCoHHHetmz8DeH7RrRo7Sd3tbgXcLzXk8zJIFKg5dySACRg8c9Ku/8Izo/wDwlP8Awkn2FP7a+z/ZvtO5s+XnONudue2cZxxnFAHDeF/iNdanpGgQabpt1rWsX9lLfuJJIrbZCkpj3McbclsAAD64q3P8T4rbxhaaHcaU4S4u47E3EVwshimdNwV1AwpzkY3Z4zitl/h34XbTdPsF01o7fT0eK2MV1NHJGjHLL5iuHKknoSRSL8PPCsWrQ36ab5d1HcpeRhbmVUEyLgOIw+3djqcc980AHwk1u+8R/DvRdW1aRZb65jdpXVAoJEjAcDgcAV11Z/h/RrDw/o9tpekQfZ7C2BWKLez7QSSeWJJ5J6mrqzRtM8SyIZUALoGG5Qc4JHbOD+VAD6KKKACuav8A/kpOhf8AYJ1D/wBHWVdLXNX/APyUnQv+wTqH/o6yoA6WiiigAooooA5r4e/8gG6/7C2p/wDpfPXS1w+gXmsaHa3llJ4U1i6/4mN7Ok1vNZ7JElupZUI3zq33XHBAOa0/+Ej1T/oS/EH/AH+sP/kmgAuvDU0t5rIjv0TTtYO68gaAtJnyVhPlybgFyqL1VuQT3rN0/wACm2hhR7mwDxTWsglt7ExSSCGTfhyZDnOOwABJOOcDS/4SPVP+hL8Qf9/rD/5Jo/4SPVP+hL8Qf9/rD/5JoAS58JxzeKZtX+1MsckJ/wBF2AqLgp5fn5znd5XyY9KqaR4QvdItJrOw1kRW1zDEk7C2PnCRLdIN8b78JlY0OCrYIPPNXP8AhI9U/wChL8Qf9/rD/wCSaP8AhI9U/wChL8Qf9/rD/wCSaAMfTPh+1pcyTyX1oJHawZvs1kYg5tpZJNzZkYsz+ZgsTxt79K72ua/4SPVP+hL8Qf8Af6w/+SaP+Ej1T/oS/EH/AH+sP/kmgDpaK5r/AISPVP8AoS/EH/f6w/8Akmj/AISPVP8AoS/EH/f6w/8AkmgDpaK5r/hI9U/6EvxB/wB/rD/5Jo/4SPVP+hL8Qf8Af6w/+SaAD4e/8gG6/wCwtqf/AKXz10tc/wCBLW7tPD7LqFpJZ3E19e3PkSMjMiy3UsiBijMudrrnBNdBQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeTfFK+bwdf3usLF5lvqMK7R2FymFGfZkI/74Nes1ieM/Dtr4p8OXek3nCzLlH7xuPusPof0yKzqQU1Zj55RT5HrZnzJovxX1+31aOXUZormxLjzIBEq7V77SBnI9ya+grmURQs7K7AdQi7j+VeG+F/AOnx6w51G9aaewnKXFlsA2urY5bPzIcdcCvcIJ0mQFTzXnYl020oIrKqWKpxk8U7321uYE2uXk0hi07TygH8Vy4Q/gvX86r/aNYEhfyIY2/iaSRcH8gf6VualavOPkRXPbdVK20qdpN00KhR6tmsL+R7anFLYjsr2/unCXGnrgf8t4pcp+teR/FnxRqsHiWbTLO7mtba2VOYXKFyyhskjnvjHtXukhaKA7iMAV5p450PRdUYXuqCdJl/do1uwEkvouCCDWlGcYzvJHm5lQrYmg40HZ3+9djI+FOv6xrWpWVpNpl9rC6dN9td7doVcgAhAxkdAcOQeueK93/wCEj1T/AKEvxB/3+sP/AJJrmvgT4dt9I8LSahFEEl1GQtgncVjQlVBPc/eJ+telV6lOKSvFbnBTjUhCMKru0c1/wkeqf9CX4g/7/WH/AMk0f8JHqn/Ql+IP+/1h/wDJNdLRWhZzX/CR6p/0JfiD/v8AWH/yTR/wkeqf9CX4g/7/AFh/8k10tFAHNf8ACR6p/wBCX4g/7/WH/wAk0f8ACR6p/wBCX4g/7/WH/wAk10tFAHNf8JHqn/Ql+IP+/wBYf/JNH/CR6p/0JfiD/v8AWH/yTXS0UAc1/wAJHqn/AEJfiD/v9Yf/ACTR/wAJHqn/AEJfiD/v9Yf/ACTXS0UAc1/wkeqf9CX4g/7/AFh/8k0f8JHqn/Ql+IP+/wBYf/JNdLRQBzX/AAkeqf8AQl+IP+/1h/8AJNH/AAkeqf8AQl+IP+/1h/8AJNdLRQBzX/CR6p/0JfiD/v8AWH/yTWZa6ldah8SdI+16LqGl+XpN/t+1vA3mZms87fKkfpgZzjqMZ5x3Fc1f/wDJSdC/7BOof+jrKgCX4iW8138P/E1vaxSTXE2mXUccUalmdjEwCgDkkk4AFc7ceG9SstSsfst29omp6iovF0iDyY4YUtJ8E53YLOIwX4/gAwQDXZ69qcWjaNealOjyRWsRlZUxuIHpmq2peIrHTdRe1v3MCpbrctM/3ADIIwPXJYigDkvD/wDwkLeJJheXl1DP5t0hjms55IGjy3kHdkRYACH5SGbJDc5xH8RZ/EUFk6Wf2t9QgsJriC50+1uWjmnBJWLyo3IBwF5lZlOeFPIHWt4q0dbdJTdP87vEIhBIZt6DLL5W3eCByRjpz05qQ+JdH861jW+jf7SsbxvGGePEn+rJcDau/OFyRu7ZoA56G/1geJbOxePUdo1qYyv9nfyfshtJTH+827dvmeX3zuwDzWL5HieHw/o93bvqV1rUtldSv9pjUmGbyfkUAqAhzwAep655r0PSta07VpLmPTbuO5a2bZN5fOxskYJ9cqePaqi+KtHaKaRbtmjjO0OIZCJTu24jO394d3HybueKAOUub65sJY5NI/4SSawewvIyLi1uZJPtZ8gwnDrvAwJefuAkjI6VVvP7WiuZ5pLTUf8AS7bTop7mNJ90RCTl2Kw4kfDbFKqQQXBJAzXZy+LdCiW1MupRIbnd5SEMHYq21htxkFW4IIyD1xU1z4h0+E2ipcRyvc+S0aqwGUlcIj89iTx3PagDk/B6a/e3ulf2vdarFBb2sjODEYlmdbhlTzNwLZMYU4zkg5Oeteh1ix+J9KljmeCaaZIjjdFbSuH+bb+7wp8wZ4yuaLHxFa3+rWtnZfvYri1luRNkjaY5FjZCpGQQWIIOCCpBFAG1XNX/APyUnQv+wTqH/o6yrpa5q/8A+Sk6F/2CdQ/9HWVAHS0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHyd8efMtfiDqVvH8sDlZeOMlo0JB/LP41D8JfEFxY309pPdFbMx7kEjHar5GAD0GRn8q9I8XabY674t15L+3SeNbmONc5BBWJAcEcjrXn3xCktvCjW+laJaRQGaLzpXI35BJAHzZz0PXNcMpqpeilqc1XDTwtdY+pP3FbTrta3b8T2O114JjzQKnn8SRBcLjNeF+ANR1DU55rJLmVXjj81cAMu3IBG08DqOmK6LxC+paZo9zeTzylYgOERY8kkAZIGepFckqc4S5Lns0cXRr0frC+HX8Ds9b8SJFEEbLzv8AcgT7zf4D3NfPGq6je32pS3V5LJ9o3nuRs56D0xWppPiq9tL4STlZYHbMilRuI9d3Un6k16dqfhXSprn7TcWMbzZyWBIBPuAcGuiH+yv31e549e2dU19Wlbleqem+z0v2O0+EX/CVX3w70ia11jRYYdsiLHNpUsrgLIw5YXCgk4z90dfxrsfsfjH/AKDvh/8A8Es3/wAl1z/weu0it9U0jhTbzC4iUcfu5B29gwb869FrupyU4qSOl05U/ck7tdTmvsfjH/oO+H//AASzf/JdH2Pxj/0HfD//AIJZv/kuuloqxHNfY/GP/Qd8P/8Aglm/+S6PsfjH/oO+H/8AwSzf/JddLRQBzX2Pxj/0HfD/AP4JZv8A5Lo+x+Mf+g74f/8ABLN/8l10tFAHNfY/GP8A0HfD/wD4JZv/AJLo+x+Mf+g74f8A/BLN/wDJddLRQBzX2Pxj/wBB3w//AOCWb/5Lo+x+Mf8AoO+H/wDwSzf/ACXXS0UAc19j8Y/9B3w//wCCWb/5Lo+x+Mf+g74f/wDBLN/8l10tFAHNfY/GP/Qd8P8A/glm/wDkuj7H4x/6Dvh//wAEs3/yXXS0UAc19j8Y/wDQd8P/APglm/8Akusy1h1iH4k6R/bV9p93nSb/AMr7JZPb7f31nndulk3Z4xjGMHrnjuK5q/8A+Sk6F/2CdQ/9HWVAGtr2mR6zol9ps7vHHdQtCXTquRjI9x1rlPEnhjWL20u7p7u2vNVcWsMIitjDFGiXKyMxVpCWPGfvDhcDk87HxGmlt/h74omt5Himj0u6dJEYqysImIII6EHvXGag3iTRdXtJpfOunsbS9hsLZZmf7aI4i6O4B5dv3a885RiPvUAbU/hjWYNdsr+yvLV7ya6nury6e2PlIWgjiQLF5ob7sSD7x5BJ602y+HVvp9zbvaz2s0SR26yC9tPOctCAodGDqFJCg8hgCMgdqyrDxXqUkMaz65YNYzXMEUuoRTRSPZho5mbeAgRAWjiRd4JBkOc4FUNG8QS6ZpIb7XM0ZgmxdKyDDNqDoJCW/dquDksVIA7HpQB6f4d0v+xtLWz87zsTTS79u3/WStJjGT03Y/CuafwRcSeH7DR5tTt5LTTDGbENZnIEYKqJv3n7wbCV42Hv1rG0nxJrWqR29oupwo2b8Nd2wSbzBCYjGQxQKf8AWckIAR0A610d9r15/wAIDpurq0dvNdR2bTz7crbpKyCSTB4woZjk8DGTwDQBY0HwuNL1G1u/NtQYbeeAxWtsYY2MkiPuALsQfk5yTknPHSqGneBI7G2eJL9nxfW9xCWiH7m3gk3xWwwfurlgD/tdKo6ZrmsajqunWFnqcL2kkt3i/wDIVzdxReTtZcEKDmRlLAYO0kAZGJ/HmoXWmeJdPubH/WJpF8cldyoPtFiGkK99qlmx7UATr4P1BfD9loq6xAbGx8tLdHs2IeNOAk+JR5g246bckAnPSrHhTwgNAuLWUXUUggjvIxHFb+Un7+58/wCUbjtC/dA/HjpWHN4p1W2sZJ9PuotXtE1H7DBd7UIuPMtwYzlMKcXDJGSoAwT3U1Sn8Xa8bcCeSGziS9/s64ujsiWOSOHdIwd1ZVDSHaCwI+XA5YGgD1Wuav8A/kpOhf8AYJ1D/wBHWVZvhfVta1bXY4bi/sfs1vptrdTC1j8xbiSSS5QlZM8LiJTwD7HHXSv/APkpOhf9gnUP/R1lQB0tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFBIAyeBQAVk+J9bt9A0mW8uPnf7sMIPzTSH7qL7k/kMmuK8ZfFvRNGufsGn3MFzek7TKdxgh92KglvoPxIqlpdsdXki1a6vf7TnkXKXJxsVT2jUcKP19TXNXxCprQ2oU41ZNcy03XX7ivoWnTkGW7YSXUztNO46NIxy2PbsPYVD418CWfiyKBpJ3tL2AFUmVd4K+jLkZ/Mda7GCFYlAUU6YYwy15kZSi+ZPU7q1KnXh7KavE43wP4J0/wAHLM/ntd3k4CtM6bQF64VcnH5npW5rdlp+qaZcWV2oaCdNrAcH6j3B5rRZVnXDVVl0+NRncaUpyk+ZvUKWHpUqfsoq0ex5RZfCvTrfUllur17y0Vtwt3hC7vZjk5H4Cuqfwb4dcHboWlD6Wcf+FdE0IL4HQVchtMrmnKtOe7FQwlDDJqlGyf8AXU8//wCEX0XSdUtdQbw7pl3bQEi4tjZRvviPUhSOWXqPoR3r1LTPCXgPVLNLvTvDnhu5t3+7JHp8JH0+7wfasa7tiOR1FcZ4p11fBu3VbKWS21GZtojjGUucdRInQj/a+8M8GujDYiUXyPW5GLpwUHVbskerf8ID4O/6FPw//wCC2H/4mj/hAfB3/Qp+H/8AwWw//E1y3w0+LVj4xvxpl1aHTtSK7o18zek2ByFOAQepx6d69Or1Dy6VWFWPNB3RzX/CA+Dv+hT8P/8Agth/+Jo/4QHwd/0Kfh//AMFsP/xNdLRQaHNf8ID4O/6FPw//AOC2H/4mj/hAfB3/AEKfh/8A8FsP/wATXS0UAc1/wgPg7/oU/D//AILYf/iaP+EB8Hf9Cn4f/wDBbD/8TXS0UAc1/wAID4O/6FPw/wD+C2H/AOJo/wCEB8Hf9Cn4f/8ABbD/APE10tFAHNf8ID4O/wChT8P/APgth/8AiaP+EB8Hf9Cn4f8A/BbD/wDE10tFAHNf8ID4O/6FPw//AOC2H/4mj/hAfB3/AEKfh/8A8FsP/wATXS0UAc1/wgPg7/oU/D//AILYf/iazLXQNH0P4k6R/Yuk6fp3naTf+b9ktkh34ms8btoGcZOM+pruK5q//wCSk6F/2CdQ/wDR1lQB0tZlxrunW+pGxluMXKgFwI2ZY85I3uBtQnBwGIzWnXNXXhqaW81kR36Jp2sHdeQNAWkz5Kwny5NwC5VF6q3IJ70AWB4u0L7JLdPqMcUERj3PMrR8OSEYbgMqxBAYZBwcGp4/EWlS2S3UN5G8TyiFeoJkK7gmD0O3nntXPaf4FNtDCj3NgHimtZBLb2JikkEMm/DkyHOcdgACScc4Gjc+E45vFM2r/amWOSE/6LsBUXBTy/PznO7yvkx6UAW7TxPplybVFmbzp4Y5tqI0ixh13KHdQVUkdMkZ7ZqGfxZYCJDaiWWQ3VvbvFJG8DoJn2K+11BK9cHGDtODxWfpHhC90i0ms7DWRFbXMMSTsLY+cJEt0g3xvvwmVjQ4Ktgg881T0z4ftaXMk8l9aCR2sGb7NZGIObaWSTc2ZGLM/mYLE8be/SgDvaKKKACiiigArmr/AP5KToX/AGCdQ/8AR1lXS1zV/wD8lJ0L/sE6h/6OsqAOlooooAKKKKACiuH0Cz1jXLW8vZPFesWv/ExvYEht4bPZGkV1LEgG+Bm+6g5JJzWn/wAI5qn/AEOniD/vzYf/ACNQB0tFc1/wjmqf9Dp4g/782H/yNR/wjmqf9Dp4g/782H/yNQB0tFc1/wAI5qn/AEOniD/vzYf/ACNR/wAI5qn/AEOniD/vzYf/ACNQB0tFc1/wjmqf9Dp4g/782H/yNR/wjmqf9Dp4g/782H/yNQB0tFc1/wAI5qn/AEOniD/vzYf/ACNR/wAI5qn/AEOniD/vzYf/ACNQB0tFc1/wjmqf9Dp4g/782H/yNR/wjmqf9Dp4g/782H/yNQB0tFc/4Euru78Ps2oXcl5cQ317befIqKzrFdSxoWCKq52oucAV0FABRRRQAUUUUAFFFFABRRRQAUUUUAFFcv4m8TtY3g0zSIY7rVCu997Yit1PRnI5yeyjk+w5rBltdfvAWn8Q3ilhyttHHEo+nBP65rCpiIQdtzaFCU1fY7HX9f07QoFfUJwsj8RQIN0sp9FQcn+VcLqV1qfiYkalustMP3dPjf5pB/02cdf9wcepNUV0S702aSdIPtcr/fnZy0zfVm5P0p0erRxOFnWSFx2kUrXDWxU56R0R3UcNGGr1Z4N8QdHvNL8VXy3NuyQzTM9uwX5GQn5QvbgYGO2K9p+DOmX2meDFXUUeN5Z3mijcYKIQoGR2yQT+NdNb6rGyjkEeoq0l9E3epnieeChY8/DZSsPiJV1K976ev5lulXDAqe9QLcI3Q04sCMggVgmenYz3na2uvLf7p6GpJ7jKgZqS4jS9jZG++OQ1Z0On3TShZTtjB5Oeo9qRenUu6egm3P8Awg4q+MdBVaVxBGscQ2oBTEu40X5jzRsKzZadAw5Fed/FXwhceIrC2fTin2u1ZisbHAdWxkZ7H5R1ruG1KMDpVaXUoeSWUfU1UZuElKO5lXw8cRTdKpszxjwn8MdXF6bvV559OWMfu1t3jaTd6g4YD69c4xivS7O/17TrjZq/inX30zACXNtBZu8I/wCmitbszD/aB+o71pNqsJO1CXPogJ/lTo4r25bMFqYl/vy/L+nWtvrNTm5jKhgKOHpeyj/wTotP0u51G2W4sPHutXMDDIeJLBh+ltVn/hHNU/6HTxB/35sP/kauSi8IWCyvcSKy3TnLSwO0Jz/wAirEV7q/hyZZLa6udUsAf3tnct5koXuYnPJI/utnPqK64YyL0krGcsK/su50v/COap/0OniD/vzYf/I1H/COap/0OniD/vzYf/I1bGj6nZ6xYR3mnTrNbv0YdQe4I6gjuDzV2uxO5yvQ5r/hHNU/6HTxB/35sP8A5Go/4RzVP+h08Qf9+bD/AORq6WigRzX/AAjmqf8AQ6eIP+/Nh/8AI1H/AAjmqf8AQ6eIP+/Nh/8AI1dLRQBzX/COap/0OniD/vzYf/I1H/COap/0OniD/vzYf/I1dLRQBzX/AAjmqf8AQ6eIP+/Nh/8AI1H/AAjmqf8AQ6eIP+/Nh/8AI1dLRQBzX/COap/0OniD/vzYf/I1Zlrpt1p/xJ0j7XrWoap5mk3+37WkC+Xiazzt8qNOuRnOegxjnPcVzV//AMlJ0L/sE6h/6OsqANHxQpfw5qaLfHTi9u6i7AP7glSN/BB468EfUda8+0jxDFpTObUaYlotxZrdahZXzXFmY3Z1OS+BHJnbnk5DJknivVaKAPM28YTXEWnNPrtrpdpdz6qv2zbGcrBcmOELvyD8uM8EnnGDyHQeJ9bk0+/1HUpfsUdnYWkstpDbqZEmmiBbLucKqMc8jAAJORXoM1jbTahbXskebq3R44n3H5VfbuGOhztXr6VZoA8s0vxdf3DPa3+tWtpZR6hJbNq8ckUqkC2hlRPMKLHuYysM7AMJgcndVe88Q3Fhfa9FaaoIZ7i/8yK7d44oJNmn2R2lnR+WL5CKMnDcjBNet0UAee2vinWLi60W02xrPrdvaXltIsRKRJtDXSn6ADBJ6zKO3Nbw14iuLmayt7/V49KjECSwI4Um+dp5VZcyZJwEQbUIYF85wQK9LooA8i1Xxbcav4UubV7qB7g6DcT3iRYDw3CvGu04+6Rub5TzV688ZX0fiW4htLuNoN15A1rO8fmxNDE7K4jVNyqTHwXc7lYEKMg16fRQBk+FXvptBtLjVLqO5ubiNZi0cPlKu5QdoGTwOepqhf8A/JSdC/7BOof+jrKulrmr/wD5KToX/YJ1D/0dZUAdLRRRQAUUUUAc18Pf+QDdf9hbU/8A0vnqx48vbjTfA3iK+spDFdW2nXE0MgAJR1iYqefQgVX+Hv8AyAbr/sLan/6Xz10F1bw3dtLb3UUc1vMhjkikUMrqRgqQeCCOMGgDwHQPG/ja417wLZ6o0ttayTLb3czRADUTIpkVlOOgj8vOMfMx9K1tO+Mmqz2N3q02gRtpIt7mWJY3KyRPFnCSE9cgHO0fL717A+ladJ9i8ywtG+wkG1zCp+zkDA8vj5eOOMcVXTw3oaX898mjaat7OGWW4FqgkkDDDBmxk57560AeL3XjLXY9R16bU72KbZHpLJDpt06QxmaUhtpyTnBGfXFdLL8T72Px9HpUdvZXWkvqMmmtMm9HjlRSSCzHBII5wuB/eNd7beE/DlrFJFbaBpEMUhQukdlGqsUO5cgLzg8j0PSpW8NaE2pnUm0XTDqLOJDdG1j80sBgNvxnOOM5oA8W1n4seJp/C/iB4o7HSNWtLRbyOLyneRIzMqblZg0Uo+bG4YHPA9N/WfHmq6Hqmus0Frd3lvDpyiNLuQ2xaeVkJXj5frjJr0m08MaBZ291BZ6HpcEF2NtxHFaRqsw9HAGG/GhPDOgpEYk0TS1jKxqUFpGARGcoMY6KeR6HpQM87ufiRrVlbarZX9vpUeu2mqR6fEsQlkin3xeYAo4O7H94qPfsYvB/jfUvFHinwbPNmzjurXUVubWGQmJ5IpFQN79yOuM9TXpl54e0W9W4W90fTrhbmRZZxLbI4ldRhWbI+YgcAnkU6y0LSLB7d7HSrC2e3DiFobdEMYc5cLgcbjycde9AjSooooA5r4e/8gG6/wCwtqf/AKXz10tc18Pf+QDdf9hbU/8A0vnrpaACiiigAooooAKKKKACiiigBsjrGjPIwVFGWZjgADua8/1XxPea87W/h6RrXTc7X1DHzzeohB6D/bP4DvVbxRqreJdRm063Y/2LbSbJyp/4+5QeUz/zzU9fU8dBWhZ24VFAAAAwAB0rz8RiXfkgd1DDpLnmQaRpttp0Rjt49u47nYkszt3ZmPJPua0wSOhpyQ8UMmK47M6W0w8zP3hmmSxwyrh0Vh6MM0tJSuIoPotgzFhbIp9Uyv8AKhdLtk+6G/Fiav8A40UirsqCxiHQsPxp4tEHdj+NWKq3+o2WnRrJqN5bWkbHAaeVYwT6ZJoSuJzsrtk6Rqn3RinA5qOOeKeBJreVJYnGVdGDKw9iOtCNRsC1Vx7orjDAGoTZwE/cFQ/2vpv277F/aFn9tzj7P5y+Zn/dzmr1NruKM09mVzZ25GGjBHvQlhZqc/Zos+u0VYooQ7jkEUYwiBfoMUpc9hTQKkVc9KYiM5PWoZog4q+I+OajeLHShxYKRzcllcWV81/o1wbK9b/Wcbop/aRO/wDvDBHrXS+H/F0V5cx6fq8P9n6m/CKW3RT/APXN+/8AunB+tVpIww5rJ1awhurZobmISRNzg9j2IPYj1FaUq8qWnQmpSjV33PSKK4bwh4guLa8i0bWZmm8zIsrx+suOfLf/AGwOh/iHv17mvVp1FUjzRPOqU3TfKwoooqyAooooAKKKKACsjW/Dun61c21xe/bEuLZJI4pbW9ntWCuVLKTE6kgmNDg5+6K16KAOa/4QvS/+frxB/wCD+/8A/j1H/CF6X/z9eIP/AAf3/wD8erpaKAOa/wCEL0v/AJ+vEH/g/v8A/wCPUf8ACF6X/wA/XiD/AMH9/wD/AB6ulooA5r/hC9L/AOfrxB/4P7//AOPUf8IXpf8Az9eIP/B/f/8Ax6ulooA5r/hC9L/5+vEH/g/v/wD49R/whel/8/XiD/wf3/8A8erpaKAOa/4QvS/+frxB/wCD+/8A/j1H/CF6X/z9eIP/AAf3/wD8erpaKAOa/wCEL0v/AJ+vEH/g/v8A/wCPVZ0nwtpml6kNQtzqEt2sLwLJd6jcXW1GKswUSuwGSiZI5+UVuUUAFFFFABRRRQBzXw9/5AN1/wBhbU//AEvnp/xGmlt/h74omt5Himj0u6dJEYqysImIII6EHvTPh7/yAbr/ALC2p/8ApfPWtr+pxaLoOparcI8kNjbSXLomNzKiliBnvgUAcJqEupeHEYS3Z0qLUblUtka+DxwbI2LF5pkYJvIGFVW+7xyzYZpXizWL2yfULm4WO2tNAtdTnhtrUSSSyyfaQ2wsRgfulOCPxAznpLbxtp0+padZiOZGu7V7qR5NqrbBc5STnhso4OM42HPar0firR3tnnW6fajIvlmCQSMXzs2x7dzBsHBAOcHGcGgDztfEupXRiWbxBFFaWuqwBtQgnilTypLeQ7ZHVEjIDgDpjJAySAa2bzxDqcNheXd3qa28UmqzadblEjhSAI8mGllkDqAQmM7epUAEnNdBo3jCz1G0Fw0MsSGOSXaFLvtSZovuAbySVzjb3xVo+K9GEcLfanJlLgRrBIZF2MFcugXcgUkAlgAMjPWgDjvD/iy91I2K6trNtpa/Zi8cqqhW+lFxLEyguOQFjQkKFJMoIwBiqNlres6Jo/mWMrXvnx6rNHbPEGETRXWFYbRubh2JGTnAxjv3Vr4t0+6uJ4IVm8yC/wD7PcSLsHmZIyCeGHB6c+1TWfinR7xJWtLszCOLzvkhkO9M43J8vzjPHy5weOtAHEf8JZfDTlik1yzYzXYjgvoby3KoPKLFJpfKMakkcAIWIwMdTWp8PNUudZ1mW/vSnn3GgaZLIEyE3mS83EDtnFdDD4ls7nUNOtrMNKLt5o2ZlaNoWjUEqyMAwPI4IHrW7QAUUUUAefeD7nxJHp18umaTo9xaDVtS2SXGqSQu3+nT5yi27gc5H3jxzx0G59s8Y/8AQC8P/wDg6m/+RKPh7/yAbr/sLan/AOl89dLQBzX2zxj/ANALw/8A+Dqb/wCRKPtnjH/oBeH/APwdTf8AyJXS0UAc19s8Y/8AQC8P/wDg6m/+RKPtnjH/AKAXh/8A8HU3/wAiV0tFAHNfbPGP/QC8P/8Ag6m/+RKPtnjH/oBeH/8AwdTf/IldLRQBzX2zxj/0AvD/AP4Opv8A5ErD8Za94v0zQpW/sjRIJrhhbQyRavK7K78AhTbKDjk9e1eg1wHxOlL6joFoD8u+a5Yf7qBR+slZVp8kHI1ow55qJyOiJ4gtbaGC30jR/LiUKudUl/P/AI9+tdBFceKQONG0T/wbS/8AyNVrSV+UGtdTgV5EGt7HpTTva5i/bPFQH/IG0P8A8G8v/wAjVE974pP/ADBtE/8ABtL/API1brMTTapz8iFHzME3fik/8wbRP/BtL/8AI1J9q8Uf9AfRf/BtL/8AI1b9FTzLsO3mYH2rxR/0B9F/8G0v/wAjUfavFH/QH0X/AMG0v/yNW/RRddh28zA+1eKP+gPov/g2l/8AkaqHh555PFmq/wBv21nBqW2P7IsdwZv3G35ghZEON+7OB3APQE9d3qC+0yy1KJY9Rs7a7jU5CzxLIAfoRVRkuxnUg3ZroYWg/Z/7a1v+zNv9nZi/1ePL+0fN5u3HHTys47575q3rbXQ0fUPsGftn2eTyMdd+07f1xVUS3V+72ug+RYaXasYTciIMXYHBWJfugA5BY55yAOM1XntNZsz5tnqTagV5a3vI403j0V41XafqCP50SXvXM6crU3FJta6rz7a30BD4cPgr5vI/sryuem/fj8/Nz/wLd71u6F9q/sTT/wC0M/bfs8fn56+ZtG79c1R0a30jUhHq8Gn2ou2J3SvAomRwcMrHGQwIIPNblKT6FUobS02tp/X3dgoooqDcXNKGwabRTuBMJeafvBFVqUMRVKRPKOfGagmTchqTNBqXqUtDmdUs/tUDwFjG5IaOQdY3ByrD3BxXeeENXbWtBt7qZQl0uYbhB/DKpww+mRkexFcrfoA2ak8B3P2XxNqVgeI7yFbxB/tqdj/mNhrowc+WfL3M8VDmhzdj0CiiivVPMCiiigAooooAKyNb8RafotzbW979se4uUkkiitbKe6YqhUMxESMQAZEGTj7wrXrmr/8A5KToX/YJ1D/0dZUAH/CaaX/z6+IP/BBf/wDxmj/hNNL/AOfXxB/4IL//AOM10NzPHbW8s9w4jhiQu7noqgZJ/KvOfAvxRXxDpuuXWoaPc2UmnRx3awRHzpJrWRdySKMDJwCSBn8+KAOl/wCE00v/AJ9fEH/ggv8A/wCM0f8ACaaX/wA+viD/AMEF/wD/ABmsmb4i6ZeQWU+iXCzWk2qWunG5eFmilaXkrGQR8wBGSeAetZnhv4i6hqmpeGreeztlTVJdUjl8sMWUWrAJt56nPP6UAdT/AMJppf8Az6+IP/BBf/8Axmj/AITTS/8An18Qf+CC/wD/AIzWHB8W/Db2+rSzi+tm0yBbieKWEb/LZwgICsf4iAQcEZ6Vbu/iXoNkt19uTUrRoLYXfl3Nm8UkkZl8oFUYBiS5AxjPzD1oA0f+E00v/n18Qf8Aggv/AP4zR/wmml/8+viD/wAEF/8A/Ga6RG3IrYK5GcHqKWgDmv8AhNNL/wCfXxB/4IL/AP8AjNH/AAmml/8APr4g/wDBBf8A/wAZrpaKAOa/4TTS/wDn18Qf+CC//wDjNWdJ8U6ZqmpDT7cahFdtC86x3enXFruRSqsVMqKDgumQOfmFblc1f/8AJSdC/wCwTqH/AKOsqAOlooooAKKKKAOa+Hv/ACAbr/sLan/6Xz1p+J9L/tzw3q2k+d5H2+0ltfN27tm9Cu7GRnGc4yKzPh7/AMgG6/7C2p/+l89b95cwWVpPdXcqQ20EbSyyOcKiKMliewABNAHM6z4G0zUZZ/LH2WK6F0LtYh80zTxeWzAk/Kcc9MZ56k5qWfgme2eC5ju9Ni1C2njninh04oG2xyxkSr5p35Wd8YKgE5A7V1tzqNnbStFcXMUcioJSrNghc7d30zxTrK9t75JHtZBIscrwuQCMOjFWHPoQRQBxg8BTi1CLrG2by2VmFuQj7rozkMocEoclCoYZHftUB+HUi2H2e31CztJDNNMtxa2LQyW/mFSRAVlGzG3odynC5Bxz6FRQBy3/AAisv2uRvt6fZTqi6mkf2c71bHzIW3YIJ6HaMe9UH8CSf2XYWsOrNFJaWAsRIsJAk/exSEsA4O0+VtZQQSrH5hXcUUAcd4e8FDSNQhuhdW37u6mufJtrTyY/3kSR7VXccAbM985/GuxoooAKKKKAPPvB9z4kj06+XTNJ0e4tBq2pbJLjVJIXb/Tp85RbdwOcj7x4546Dc+2eMf8AoBeH/wDwdTf/ACJR8Pf+QDdf9hbU/wD0vnrpaAOa+2eMf+gF4f8A/B1N/wDIlH2zxj/0AvD/AP4Opv8A5ErpaKAOa+2eMf8AoBeH/wDwdTf/ACJR9s8Y/wDQC8P/APg6m/8AkSulooA5r7Z4x/6AXh//AMHU3/yJR9s8Y/8AQC8P/wDg6m/+RK6WigDmvtnjH/oBeH//AAdTf/Ilef8AjW88Sy+LrZbjStHSWGxJCJqkrrh5OuTbjn5OmPxr2WvL/F5Mnj66H9yygH5vIa5sW7UmdOEV6qKmn3PicR/LpGjH66rKP/berv2vxT/0B9E/8G0v/wAjVp2AxEKt15akrbHdJO+5zz3vidAS2j6IB/2Fpf8A5GpI7/xPIMro+iH/ALi0v/yNVrxPqEGmaTcXd25SCFdzEdfoPc9K848NfFizk1NLS+spLe2lk2rceYG25PG5ccD1OTWkYSndxjsc1bFUaElGrOzex6B9q8Uf9AfRf/BtL/8AI1H2rxR/0B9F/wDBtL/8jVv0VHMux0W8zA+1eKP+gPov/g2l/wDkaj7V4o/6A+i/+DaX/wCRq36KLrsFvMwRdeKSeNH0T/wbS/8AyNUGt6p4qsNB1G8OkaMgt7aSXcuqSsRtUnIBtxk8dMj6iuqjWnX1pHe6fc2k2fKniaJ8ejAg/wA61hbsZVE3FpPUx9Es5dP0GytLiGGGWCIRskMpkXI77iqk56kkDkn60x2/eVFoN89zpgtrshdRssW90nfeBw3+6www9j7Gi4dY90kjKqKCzMxwAB3JrGp8TNKDi4JrYg0MeR4j1m3TAikjgvMDsz70b8/JB/GugrnPCRa7kvtWZSqXjKsGRgmFAQpx7ku30YV0dOW5FH4b+b/MKKKKk1ClUZoAzUqLiqSE3YYy4FQSyiPqcValNeJfED4nXFprV3pmlW0DRW7mGWWbcSzA/NtAIxg5HerjSlUdonPiMXSwseeq9D2VG3DNOrhvCXxA0/V9IS4ktdSWdWKSpb6fcXCKw7B0jI6EH15ra/4SzTv+ffWv/BLef/Gql05J2aNoVYVIqcXozR1Bcisu1k+yeK/D1z0DTyWrfSSM4/8AHlWobzxVp7D/AI99a/HRrwf+0qw9U8T2K/YZlg1YGC+t5ctpV0vAkGeTH6E8d+lFNSjUTsXJpwaue6UVzX/CaaX/AM+viD/wQX//AMZo/wCE00v/AJ9fEH/ggv8A/wCM17Z5B0tFc1/wmml/8+viD/wQX/8A8Zo/4TTS/wDn18Qf+CC//wDjNAHS0VzX/CaaX/z6+IP/AAQX/wD8Zo/4TTS/+fXxB/4IL/8A+M0AdLXNX/8AyUnQv+wTqH/o6yo/4TTS/wDn18Qf+CC//wDjNZtrrVrrHxJ0j7JFqEflaTf7vtdhPa5zNZ42+ai7unOM44z1FAHR+KNFi8ReH7/SLm4ube3vYjDJJbMFkCnqASCORkHjoTXLxfC3QbHUJb3QZr/RJpbFrB/sEqqGjJBz86thhgYI6V2Gs6hDpOkXuo3OfItIXnfHUhQSQPfivP8Aw94u1Wy8NalLrAkur/TZIZ50nt3t5JIZgCVjRlUlhJ5qIMfP5ajOTkAGlZfDHRLGztbKyuNRh0+11G31O3tBMrRxSxdl3KW2seWGevTGafa/DTRbf+zgJ791sft2xWlUbxd/60MQoPH8OCMd81la34o1C50iC4ikFsbvTWvUFtLuCD7RCqgsOrbXwSDjORz1pt14v1LTNO1NrMi9urW41G5kgkjLnyIpiFG8ugRe2fmPopxQAsXwZ0FNOu7N9S1iSK409NMJaSEFIUkEi7cRgZyOpznnPPNafjjwP/wlHjLwlqcothZaRLJNcbmbzJT8rRoBjBXeoJye3HWnz+K9UU67eRWVodK0ieJJcu5maMwwTSMFAx8qSuepztAwOp6Hwzqj6zp8l9sRbWSeQWrKc+ZCp2rJ/wACwWH+yVoA1qKKKACiiigArmr/AP5KToX/AGCdQ/8AR1lXS1zV/wD8lJ0L/sE6h/6OsqAOlooooAKKKKAOa+Hv/IBuv+wtqf8A6Xz1Z8dWNzqngjxDYWMfm3d1p1xBDHuC7naNlUZOAMkjrxVb4e/8gG6/7C2p/wDpfPXSMwRSzEBQMkk4AFAHn+v+F9SXUL6XSmvLgS6ekKSTXe5g4nVioLHI+UE+lY/iLwzrtzYXttFpjSB5dRntpYDbmWOWSUtE26VsIpGDlBvGOq9/V4pElQPE6uh/iU5FOoA5fwxotxb67rep6nHL9omuIxbs05ZfK+y26thAxVf3iSZ4BOM9MV1FFFABRRRQAUUxpo1mSJpEErglELDcwGMkDvjI/On0AFFFFAHn3g/xPYadp19a3FvrDyx6tqWWt9Iu50Ob6c8PHEynr2JweOorc/4TTS/+fXxB/wCCC/8A/jNHw9/5AN1/2FtT/wDS+euloA5r/hNNL/59fEH/AIIL/wD+M0f8Jppf/Pr4g/8ABBf/APxmulooA5r/AITTS/8An18Qf+CC/wD/AIzR/wAJppf/AD6+IP8AwQX/AP8AGa6WigDmv+E00v8A59fEH/ggv/8A4zR/wmml/wDPr4g/8EF//wDGa6WigDmv+E00v/n18Qf+CC//APjNebX3ivT9R8WapfxQasbfEdtGRpV0S3l53EgR8fMxGDz8tereL9UOjeGr++j5mSPbCPWRvlQf99EV5/4btBa2UNuDuMa4LH+Ju5/E5NcONqJJQ7nbg4O7mFp4q09VwbfWfw0a8P8A7SqyfFmnf8++t/8AglvP/jVa1uhU1ZPSuBcvY6ne559421PT9f8AD15pwj1mNplG1jo15gMCGGf3XTIFeJ6T4euZtajtdQttRt7cENI4065YlM4JVRHnnpyBX05enJrm9cDWstvqUYJNsSJQOrRN978sA/ga1p4h004x6nFisrpYucalTdfivM1E8W6cVH+j61/4Jrz/AONU7/hLNO/599a/8Et5/wDGqu6beJIi4YEEZUjoRTb3VPs1wyOFRBjDt3z3+lZKUTucZXsVP+Es07/n21v/AMEt5/8AGqcPFmnf8+2t/wDglvP/AI1VrT9Wju5EQYJYkAr047/T3rVU1ScexLTRiJ4t04H/AI9tc/8ABJe//Gqr6f4h1HxFNeNoKx2lnav5Qk1CxnDTuOG2g7NoBBU/eIIOQOK6cMK5o2uraXcXS6SLK4s7iV5xHcyPG0LuctgqrblLEtjjqea0Ukloc9VSbV9vL+vyK4gi17fcXUUlhrFlIbaWW2kIZSAGwGx8yEMrAMD97pmqN/pVvFBNda1f3t/a2yGZo5ygTCjOSiKobp0Oa19PtW020uZL24SS4nka4uZsbU3YA4yeFCqoGT0FZr6vpGqwvYvM5ivEaFWeGSNJQwIIR2UKxxnoTUNtvTYFCCh79uZ9+va62ZNbXHiIWf21ILArt8z7BtfzduM7fM3Y3+23Ge/eujsLqK+sbe7tyWhnjWVCe6sMj9DXN2sPiE2ZsVnsAu3y/t+5/NC4xu8rGN/vuxnt2rpLC1isbG3tLcFYYI1iQHsqjA/QUpWsVS5ubrbz7/18uxPSikoqTclTFOLgCsK/1cWk0iOAgRgMnuD3+lLpWqm/lKKh2gEl8YH+TTUg5epqyNwTXiHjr4dzX3ieS50q5hUXrvM8c2RsbqxBAOQSf1r2W8mCKRmuZspPtt3NfDmI/uofdQeW/E/ypwqypu8THEYKli4KFVFr4f8Ah6Lw1oCWMcnmyM5llkxjc5wOB6YAH4V01ULFiFxV7PFS5OTuzSFKNKKhBWSKl8eK5/xIjHQrx4xlolE4HrsYPj/x2t+5Uufaq8yLs2OMqwKkeoNTezubLax6DbTpc20U8R3RyoHU+oIyKkrmPhvcNN4StYJCWlsmezfP/TNio/8AHQprp692MuZJnjSjytoKKKKokKKKKACuav8A/kpOhf8AYJ1D/wBHWVdLWRrfh3T9auba4vftiXFskkcUtrez2rBXKllJidSQTGhwc/dFAGlc28N1C0NzFHNE2MpIoZTg5HB9wDUU+nWVxcpc3FnbS3EZUpK8Ssy7SSuCRkYJOPTJrE/4QvS/+frxB/4P7/8A+PUf8IXpf/P14g/8H9//APHqANb+xtL2lf7NssNuyPIXncwdu3dgGPqRnrUd34f0a9AF5pGn3ADO4EtsjYZzlzyOrHknv3rN/wCEL0v/AJ+vEH/g/v8A/wCPUf8ACF6X/wA/XiD/AMH9/wD/AB6gDWu9Ktp9Pv7SFfsgvUKyy2yqj5KBN2cEFgqqASDwoHQVatLaGztIba1jWK3hRY40XoqgYAH0Arn/APhC9L/5+vEH/g/v/wD49R/whel/8/XiD/wf3/8A8eoA6Wiua/4QvS/+frxB/wCD+/8A/j1H/CF6X/z9eIP/AAf3/wD8eoA6Wiua/wCEL0v/AJ+vEH/g/v8A/wCPUf8ACF6X/wA/XiD/AMH9/wD/AB6gDpa5q/8A+Sk6F/2CdQ/9HWVH/CF6X/z9eIP/AAf3/wD8eqzpPhbTNL1IahbnUJbtYXgWS71G4utqMVZgoldgMlEyRz8ooA3KKKKACiiigDmvh7/yAbr/ALC2p/8ApfPUvxEt5rv4f+Jre1ikmuJtMuo44o1LM7GJgFAHJJJwAKx9AvNY0O1vLKTwprF1/wATG9nSa3ms9kiS3UsqEb51b7rjggHNaf8Awkeqf9CX4g/7/WH/AMk0AcldWGt6R/bkVpbeVcXE9rI02m2jxwPajCuUVSWEo5DANvKhSvI4W1tNQGs6Je3M+r3KRWuoQRTJa3EZRmkt2iRwwL7cI43vwdgyTwT1n/CR6p/0JfiD/v8AWH/yTR/wkeqf9CX4g/7/AFh/8k0AcnJFrlrommm9uvEU00+ltOGhR2kW/Kx7UcIvyqOcBxszu3dq0Xl1X7Zq51I6uuqon+graRym1K/Z1J5UeWT5nmff+bIAHGM7f/CR6p/0JfiD/v8AWH/yTR/wkeqf9CX4g/7/AFh/8k0Acpq03iDR9BuhFNrt5d3WgzPAwt2mdb7aMDCJhDkjAIA6+laWrDWEm8UXZOrTRJfQ21rbRM6IsDQ22+VBGvmPhjJnaSflYDBya2f+Ej1T/oS/EH/f6w/+SaP+Ej1T/oS/EH/f6w/+SaAOc8IR6tLrmkyail7NFbHUYknnt5Yj5bNAY8+YS4z82NxJO3rxXpFc1/wkeqf9CX4g/wC/1h/8k0f8JHqn/Ql+IP8Av9Yf/JNAHS0VzX/CR6p/0JfiD/v9Yf8AyTR/wkeqf9CX4g/7/WH/AMk0AYfg+58SR6dfLpmk6PcWg1bUtklxqkkLt/p0+cotu4HOR948c8dBufbPGP8A0AvD/wD4Opv/AJEqXwJa3dp4fZdQtJLO4mvr258iRkZkWW6lkQMUZlztdc4JroKAOa+2eMf+gF4f/wDB1N/8iUfbPGP/AEAvD/8A4Opv/kSulooA5r7Z4x/6AXh//wAHU3/yJR9s8Y/9ALw//wCDqb/5ErpaKAOa+2eMf+gF4f8A/B1N/wDIlH2zxj/0AvD/AP4Opv8A5ErpaKAPJPiLqfiae40rTbnSdGjJkN4Vi1WVwwj4AbNuuPmYEdfu9qr6XN4lVQU0jRz9dUlH/tvV7xPMbzx1qTZytpDDar9SDI3/AKEv5Vr6au2MV4+InzVXpserRhy0lruZwufFP/QG0T/wbS//ACNQbrxT/wBAfRP/AAbS/wDyNXTRJkVHKuDU6WvYOu5x93c+Jh97SNGH01WX/wCR6z57rxFjLaVo+O//ABM5On/gPXW6gcCua8Q3Jt9EvpV+/wCUVX/eb5R+prJtN2sbRTte5xmh65rtlaRlrDTzayMWiZr11EKk5CnEJ+X0PauuXVdduIlW40XRJl6jfqUh/L/R6raVYL9kjVRwihMHuAMVVuLqGwvRYaOk13fH/l1jb93H7sT936Cqum9EUqblpc6C0vtejXFtoehRg/3dUkH/ALbU+XWtfhOJtP8AD8Z9H1mQfzt6yIvDOp33z6vqciqf+XazOxB7Fupq9b+DNIj+/YRyn+9KzOT+Zp8y6r+vvE6cVvIc3ibVgcfZ/DWf+w4//wAj1ImreIZ1zDp2gyA9CmsSN/K3qQeFNGIx/ZVpj/cqGTwJospyLVrdv70MjKR+tHNHt/X3i5Yd3+BmeJG8T3mkTxHRtMdQUd449RkZpFVwzIAYBncAV69+/Sn3+rW2t+HHsIWt5dYul2Ja20jSGCTPyu2VVlC8NllXpitA+FJrJC9h4h1O3VRwsjCVR+BqAr4qtQsi6tazQH+Ka1A/PFUpIxqYfnb5Zbqzuv67+Z1cSGM1ZVs1zDQeL5FUpf6MqnnKwsc/nQLPxeTzqmlKMdrcmo5fM25b9UdQTimlxXMeX4yhX/XaNd47FWQmoJfEOp2P/Ia0C5ijHWa0YTJ+VFn0BU77M6mbyZB+8jR8dNwBqtJcpEu2NVUegGKo6dqtlq8Jk0+5SXH3lBwy/VTyKo6rEsqlJHfYeqKcZ+uKhsahrZmZrWtC9vIdPty3kSyiK4nU8DOfkHucYJ7ZrctY1AVI1CooCgDoB6Vx2rRLawb4VC+TtlUDttIP9K7SBgcMv3WGR9KHsirWNS2THSroHFVbPkVfiXIqoq5jJldl5qjqQwoIrUlXBrP1Ifus0SVhwd2S/DiUpqOv2mePNiulH++m0/rHXcV514JfZ40nXtPp+fqUk/8As69Fr1sK70kebiVaqwoooroMAooooAK4zxPpGm618QPD9vrGn2eoW66ZqEixXUCyqGEtmAwDAjOCRn3NdnXNX/8AyUnQv+wTqH/o6yoAoa/4U8FaLoOparceENCkhsbaS5dE02DcyopYgZXrgVw+neIPhhqN54XtLTwdpT3GvBiif2Zb5tsMVxJxwdyuBjP3TXrXifS/7c8N6tpPneR9vtJbXzdu7ZvQruxkZxnOMiuItfhNpljqOgX+nzrb3enzxXF04iJ+2MkXljjd8nduM8sfrQA2EfCaa5u4E0/wnvtUeWUtYRKgVDhyGKbWAPB2k4pq/wDCqG0577+yPDi26yLD82korM7DKqqGPcxIBPAPANUNP+DUWnxSW0Gp2ktmsc8VuLnThLLGsmcqzmTaw57KpOBzSx/BwrpMcDeIJmuoL0Xlt+5draD5NhjETSs20g8/vByBjA4oGW7yb4RWdja3lxYeFFtrqJpoHGnRN5iKdrEAJngggjqMH0NRW1z8KrjxLJoseg+HvOWzW+FwdOg8ho2Qvw+OyDcSQBjvV/SfhmLC5t5v7RgHl6dd2BjgsvLQmd95cDecY9CST1zVaz+FP2eNLdtaL2Uuhrol5GLXDSqquFkRt/yHLA4IbpjvQAts3wluLK6vI9O8Ki2tjGJnfTokCeYcITuQfK3Zuh9aS0i+Gtzc3bR6F4ROmW9kt6b0W0GNhdlJK7OBlTznk8VVg+ELLpc1nNrFqzubYCePTirlYZVkAcmU7iduONoGc47Vu+LPh1B4l1PXLm61CSKLU9PgsvLjiGYmil81XyThvmx8uOg680AP8P6B8O/ENtJPo/h3w9cRRv5bn+y40KtgHBDID0IP41qf8ID4O/6FPw//AOC2H/4mr/h6z1WzgmGt6rDqVw7gq8VoLdUXAGNu5iTnJyT36CtagRzX/CA+Dv8AoU/D/wD4LYf/AImsy10DR9D+JOkf2LpOn6d52k3/AJv2S2SHfiazxu2gZxk4z6mu4rmr/wD5KToX/YJ1D/0dZUAdLRRRQAUUUUAcZpFz4q1qG7u7XVNDtbdb67to4pNKllYLDcSRAlxcqCSEycKOtXWtfF6qWbXvDyqBkk6LMAB/4F0vw9/5AN1/2FtT/wDS+epfiJbzXfw/8TW9rFJNcTaZdRxxRqWZ2MTAKAOSSTgAUAVoYvFc+fJ8ReG5MddmjynH5XdNmXxTBNDFP4k8NRyzsViR9IlBkIGSFBu+TjnivFfDxv8Awn8O43todR0m/kvNMguWTQ2spmUlg6Bm3faG+9zjqenzV1ehL4quNU0QTrrh0ltbuxDLewH7THaeQQrSErlBvztLYPTtigZ6L9j8Y/8AQd8P/wDglm/+S6PsfjH/AKDvh/8A8Es3/wAl15J4H0rxLZaJ4Y0O3m8UaYTqd3HqTi3wsMZ81kKM0ZXa2VO7kbm4Oa3t3jKHx2kIfXZJE1iONcx5sG0vyxudmxt83OT13bsYGKAO3vF8UWVs9xeeJPDVvboMvLLpEqKvbkm7wKLpfFFoivdeJPDUCO4jVpNIlUFicBRm76k9q8j8WW/iTVfBHiK01WDxbc+I5TKHtY7ZnsCgnBjEWFwfkCkbSWznPHNaniLSfEi6nq2lu+uavptvrGj3NnNcxGQ4LMZyrKoBVSFzjhfagD077H4x/wCg74f/APBLN/8AJdH2Pxj/ANB3w/8A+CWb/wCS6810a68dR+NbiTUjrLMk92Gs1t3NrPDsbyRHLt8pOi4bO7J+YGufs9R+IKaN4ha1TxNvk0iKe3Se1naSK689QyIzrlm2E52gA9QMDNAHtX2Pxj/0HfD/AP4JZv8A5Lo+x+Mf+g74f/8ABLN/8l1saNYyadYrbzX93qEgZmM90U3tk5x8iqMDoAB0q7QIw/Bmo3mqaGZ9TNu13Hd3dq7W8bRo3k3EkQYKWYjIQHG48mtyua+Hv/IBuv8AsLan/wCl89dLQAUUUUAFFFFABRRRQB49bSfadX1q4/56ajMAfUKQg/8AQa6ix+4K5PQjmKZj1a7uD/5GeursPu14Mneo35ntWtBI1YR8tQTnmrMf3Kp3RxmtZaIxjuY+oyZJFcr4ofMFlbf89rgMw/2UBY/qFroL190uBXOagVufEwgBB+yWoJX3kbr+Sj8651vc6raWItUv57a0tbTT8DUL07I/9gfxOfpXR+GtGtdJtRHbjc7cyyty0jepNc34fUXviLUr6TmODFnB6DHLEfj/ADrtLVSAB2qttCqmi5TSRFA4p+0elRxZA5qWmc7EAFL0oooEVrmMz7Iz9zOW96zb3xDpFvJNbzTsVi+SZo4JJI4j6O6qVX8SK2GYKa5Hw5rem6PokGnapcJa6hbLsmhkzvmfPLovV9xy3y561UY3Ma1RwaV0vN/8Ov6R1FiFW3Xy3V4iN0bKcgqemD6VZrjfD3hO2/smJrs6vbSSPJIsCardRiFGdmRNqyADapUYA7Vp/wDCJ6d/z863/wCDq8/+O02op2uXGUpRUrbm/SHgVg/8Inp3/PxrX/g6vP8A47TW8J6f/wA/Gt/+Dq8/+O0rR7lalfxB4esb6b7Vb7rLUV5W5t/lbP8AtAdawbbU7q2vF07Xwq3Tf6m4XhJx/Rvar9/pPh60ult7nV76G5b7sUmvXKufoDLmszWvCOm3kDwtNqhYco76lcybG7EBpCKHbqbU6nN7u9vPYk1NBIhBGcgg/StPw5OZtDs2Y/OieU31U7T/ACrh9K0qG4tp4b2bU/ttq5im/wCJlc/N6N/rO4q74V0e1nS/jlk1VAk3mRbdTuVDRkkZwJOfmRuanlVnrt/XcufMnY9S09srWrDXC6X4a09zg3Gs/hrF2P5S1sReE9OP/Lzrf/g7vP8A47Vw5e5zVLnRziszUBmE1Tl8I6bj/j51z/wd3v8A8drPvPCuniM4uNa/HWbw/wDtWnNRFTbLXhxvK8caWe0ttcR/j8jf0NemV4rpfhmwbxZokRn1fbI8wJGr3YYfuieGEmR07HmvRf8AhC9L/wCfrxB/4P7/AP8Aj1ehg7ez0OTF/wATU6Wiua/4QvS/+frxB/4P7/8A+PUf8IXpf/P14g/8H9//APHq6jlOlormv+EL0v8A5+vEH/g/v/8A49R/whel/wDP14g/8H9//wDHqAOlrmr/AP5KToX/AGCdQ/8AR1lR/wAIXpf/AD9eIP8Awf3/AP8AHqzbXRbXR/iTpH2SXUJPN0m/3fa7+e6xiazxt81229ecYzxnoKAOm8Q6omi6LeajJE0wgTcI0OC7dFUHtkkDPvWbdaze6HZvd+JBYrbnYkYtHbcZWbAj+cAHr98lR1JAHI2NWsLbVNNurG+Tfa3EZjkUMVO0jsRyD7jpWANAtdZsnjm1++1NI3RopPMgJt5EbcGGyMAt2+cNkZBHJyAUbrx7AfLmskja1Fhe3M3mn5o5LeSBNhKFgR++bkZzgEHFad54z0qw1mbTtRZrV44pJvMkaMqyxpvc7VYuAFBOWUA44zUF74R0+822t9qV3LcPZXVsuTCjtFK8JdgqoB8pjjAIGBu5ySKSbwHptxNN9oub2W0lluZms2Mfl7rhXWXkJvORI2MsccAYAxQBvaRqLajC0jWN5Z9Cq3SKpZSMgjDH8jgjuBV+qGkWUlgjQzand37gLhrox7lXoPuKvXnk5J9auTzRwRNJPIkca9XdgAPxNAD6Ka7qgy7KoPTJx2z/ACBoikSaJJYXWSN1DK6nIYHoQe4oAdRRRQAVzV//AMlJ0L/sE6h/6Osq6Wuav/8AkpOhf9gnUP8A0dZUAdLRRRQAUUUUAc18Pf8AkA3X/YW1P/0vnrpGYIpZiAoGSScACub+Hv8AyAbr/sLan/6Xz1L8RLea7+H/AImt7WKSa4m0y6jjijUszsYmAUAckknAAoA1J4dP1WJUuI7S9jjkWVVdVkCOpyrDOcEHkGre4btuRuxnHfFeaXs8OnW2nLbXGqR29zqUcNz5OlSWcrp5Ux2qEjV2yQOVBIx1FZ2p2Ot3+lFLuDUpEWBXR/KbzzEmoBowxA3GTyFUlfvZB4zQB67RXnd5FrTjWrqzu9b+zQyWcdtCUYM1sVhM7qrLvaTaZOvIYdAc1Ekmom8jS7Ovjwz9ouPJeOO4+1YEcHliTA87ZvN1gnrtjzkdQD0aKaOVpBFIjmNtjhWB2tgHB9Dgg496IJo7iCOa3kSWGRQ6SIwZWUjIII6gjvXnml2Oo2uvtewDVFWfXNsiybwj25sxl2T7v31X58cEYz1FYnhmHxHa2fhu2uX1DT0t9P01II1s7iRcCNBMkgT5VYkMp80fKMEY5NAHsNFeRS3nid5NVks49Xt2m0y8cwGC4cwXKyxCILJJlGYq0mBGoUgfxYBHqmnWpsrOOBrm4uSuczXDBnbJJ5IAHfsOlAFmiiigDmvh7/yAbr/sLan/AOl89dLXNfD3/kA3X/YW1P8A9L566WgAooooAKKKKACiimTypBBJLKQqRqXYnsAMmgDx3Qv+PDf63E5/8jPXU6acgVzXhyNj4dsHYENInmnP+2S39a6XTlwma8Bv32e2/hRsK2ErPvW+VqmLkCqF2+QaucrozhHUykQy3QHvXPz2fk2Np4mxgX17cQM3rFjEX4Zi/wDH62dYney0m8niGZvLKRD1dvlUfmRXR+L9DS2+F0unxIGOn2sci+5iwxP47T+daYalzxk/IVerySj6nCeBoM+GrZz9+ZnmJ9SzGut08n7j1kaKsSQxxW6qkKqPLUdAvaugihxhiOa593c6Kjuy0BgcUtIvSlqjAKMc0GnqOKaArTcVHatl2FS3fCk+lcpaanqeo3dydKeyt7aGRog9zG0hlZThsBWXaAcjPPQ8Urag5WWiuzsKKxtG1k3sUiXMQgvIJjBNGrblD4BBU9wVZSPrWzR5AtUpdwooNMZuKAOM0L+zv+EVcXv2f7Rg/wBp+ftz52fn8zPvnGe2McYrA0a314aNC0Oo2CQEt5Kz2EjSCLcdmT5w/h29v8a7zUNI0+7uBdXVhaTXK/dlkhVnH0JGao3y9qqc+3Uzw9Fxav0VvU871eHW9O1I3pvtPbzoWWQrYSbcoNy5HndT0zmuq1Pw94i0IeHQ2p6Vma1Nkf8AiWyDawHmgN+/+Zs7+Rjvxzxbjsvt+q6Vp7DIurtC4/6Zx/vG/wDQQPxrvPiXbNL4Unuo1Jl0+RL1QPRDlv8AxzdXTQg50pMeIqKNWKOA0+38SK/y6tpA+umSH/24rcjt/FPGNZ0T/wAFMv8A8k060Cl9ynKMNyn1BrWt2yoB6iuSM2jWcUzLe38VY/5DOh/+CiX/AOSao3lr4n2fNrGike2lSj/25rqCc1Vvf9UauU2yIxVzjtOtvEY8VaJt1XSBKZJQjHTJCqnymzkfaOePcf0r0X7H4x/6Dvh//wAEs3/yXXHCX7Pr2gXDHCrfLGT6b0ZB+pFerV34J3p/M5MYrTXoc19j8Y/9B3w//wCCWb/5Lo+x+Mf+g74f/wDBLN/8l10tFdhyHNfY/GP/AEHfD/8A4JZv/kuj7H4x/wCg74f/APBLN/8AJddLRQBzX2Pxj/0HfD//AIJZv/kusy1h1iH4k6R/bV9p93nSb/yvslk9vt/fWed26WTdnjGMYweueO4rmr//AJKToX/YJ1D/ANHWVAGl4ntYr7w5qdpcfafJnt3if7Ku6XaykHaMHJ56YOfQ9K86mvL6wtJ2Eckdo9zp8Bv7bSZbG5lQzFXiMZG58KeGVR98gDINerswRSzEBQMkk4AFQultfRIXWG4jVxIhIDgMpyGHuCMg9jQB5beR+JN0N3psOoPJFZanHaSzxsZlha6tCgbfz5hjWQoG+YhRnkGtHS4NWuZdOtHvdWk06W/k80iG5tnii+zEhDJL+8K+YAd2erbQeMD0iigDym1k8RFLaW+h1RYn0/S0v5YoGFwQHu/NClRvLf6rcF+YBiRgnNdP4ntnvPh5dQaeuozM4URiZHNwR5o6hxuyB/eGcDmusimjmDGGRJArFGKsDhgcEH3B4p9AHndxbarHqItFjv7iyt9bkWF5laYi3bSnbO9skr57sobPU7c9qyNMk163k8OQw22qWjWq6dbvGYbh0mhMcYlY4Iij2lnUhgXymflGDXrdFAHOeBLe/TRFuNXub6a9nZi6XWB5QDsAFXAwMY68niujoooAK5q//wCSk6F/2CdQ/wDR1lXS1zV//wAlJ0L/ALBOof8Ao6yoA6WiiigAooooA4fQLzWNDtbyyk8Kaxdf8TG9nSa3ms9kiS3UsqEb51b7rjggHNaf/CR6p/0JfiD/AL/WH/yTVHSLnxVrUN3d2uqaHa26313bRxSaVLKwWG4kiBLi5UEkJk4UdasXieKrK0nurvxF4chtoEaWWR9GmCoqjJYn7XwAATQAs2t307RNN4G1yRon8yMvJYEo2CNw/wBJ4OCRn3NS/wDCR6p/0JfiD/v9Yf8AyTWToOsat4hEx0Pxn4S1DyceYLfS5HKZ6ZAu+M8/lWt9j8Y/9B3w/wD+CWb/AOS6AD/hI9U/6EvxB/3+sP8A5Jo/4SPVP+hL8Qf9/rD/AOSaPsfjH/oO+H//AASzf/JdH2Pxj/0HfD//AIJZv/kugA/4SPVP+hL8Qf8Af6w/+SaP+Ej1T/oS/EH/AH+sP/kmj7H4x/6Dvh//AMEs3/yXR9j8Y/8AQd8P/wDglm/+S6AD/hI9U/6EvxB/3+sP/kmj/hI9U/6EvxB/3+sP/kms2DUdduTp/wBk8VeGrlNQ3/ZpLfRppY5NgJbDrdFRjB6ntjrWl9j8Y/8AQd8P/wDglm/+S6AD/hI9U/6EvxB/3+sP/kmj/hI9U/6EvxB/3+sP/kmj7H4x/wCg74f/APBLN/8AJdH2Pxj/ANB3w/8A+CWb/wCS6AMjwtpni+DTJit3pelpPfXlylneac1xNEstzLIoeSO6CEkODwOM45xmtf7H4x/6Dvh//wAEs3/yXVnwZqN5qmhmfUzbtdx3d3au1vG0aN5NxJEGClmIyEBxuPJrcoA5r7H4x/6Dvh//AMEs3/yXR9j8Y/8AQd8P/wDglm/+S66WigDmvsfjH/oO+H//AASzf/JdH2Pxj/0HfD//AIJZv/kuulooA5r7H4x/6Dvh/wD8Es3/AMl1zfj/AP4Su28OyW0ut6I7ag62SpFpMqOd/DEE3Jxhdx6dq9JrznxTc/2l41WBTmDSoce3nyjJ/JAP++6xr1PZwbNqEOeaRh/YfEcduiJqujBFAVQNLl4A6f8ALxVy0tPE/ljbrGij66VL/wDJNbE6fu1FTRukMS+YcA8V46k7nptKxiyWvijvrGi/+CmX/wCSa8d+JnijxJaeIJtKl1NY0tgh32MT23mFlDZOXY98dccdK9/3xuwAdST0Ga5fxh4E0fxPMlxfLNFcou3zoGCsy+hyCD+Vb0akYyvNaHnZjQrVqHJQlZ+vQ4v4P61f+KdU0/SdTdpxa3K3TTPyXRFLBT64cLz719GXcCXVrNbyjMcqMjD2Iwa8o8C6HY+GfF+lWunRFYpbe5Rmc5Zm/dtuJ+i4r1yvQoOMk5RWjZzxp1aUIwqu8kjxnwtvWxtY5P8AWwgwP/vISh/9Brs4vuCuXgj8jxBrsI4EeoSMB7OFf/2Y108P3BXkyXLJo9lvmimSUUUUiQp7SJFE8srBI0UszE4AA6k00VleNP8AkStf/wCwfcf+i2q4K7sZ1ZckHLsULrxRZvGjyW97b2s4xDdTwlIpCRwOeVzxjcADniuR0yTUbOaf+zhazW8ztKEnkZDGzHLYIU5BJJxx1PNdv47RW8H64pUFRYzkDHTEbYrkNI61lWlytNdf+Ad2X0faqam9Y2aa03vdemn9WuUJ9L0lLhrvxBaadeXEkglubm4t0YAcDA3AkKAAAM9q3rXTvB088CSeELO1juW2W81xpUaJKSMjHGVzg4DBSfyrG1oB7mzVgGU31sCD0I89OK7rxcM6ZBx01Cy/9KoqqhNyV292Z5nBUJKFNJKMb+ur3+78SH/hC/C//Qt6L/4ARf8AxNNbwX4X/wChb0X/AMAYv/ia6Giq55dzDlXY5pvBfhgjjw5oo/7cYv8A4msrUPCHhyNht8P6QPpZR/8AxNd1isjVkGc0nKXcuCV9jE8E+C/Dl94ovDP4e0iS2tLRF8trKMqZJGJyRtxkKn613cnw/wDBzxsh8KaCAwIyunwgj6HbWZ8NFH27xE/8X2iJPwEKkfzNd1XrYZfukebiH+8dj56t9M8H6HpI/t/S9Fie2lktGeSyRmkaNiucBSSSACfrW74e0jwNrtsZ9L0bQrmNThsWEYKn3BXI/EV5l8XtPvZ9avNVjjkfT2u7hMqMiNxKwJPpkAflWx8AdMvk1K/1F45I9PeDygWGBI+4EEeuAD+dck6SUHNSOZZhUeNWGdP3fx239D07/hC/C3/QtaJ/4ARf/E1Bd+DfDCx/L4c0UH2sYv8A4mtx7+2QlWmXcOCByabNIJrfeFZQezDBrlcpdz2VFX2OJ1nwVoUulXK2mhaVHcGMmNls4wdw5Hb1GK77QfCXgvV9GstQh8KeH9lzEsmP7Oh4JHI+72OR+FUSn+j59Ks/Da6+zz6pornCwyfa7cf9M5CSwH0cN/30K6cHUfNyvqY4umnHmXQ1P+EB8Hf9Cn4f/wDBbD/8TR/wgPg7/oU/D/8A4LYf/ia6WivTPOOa/wCEB8Hf9Cn4f/8ABbD/APE0f8ID4O/6FPw//wCC2H/4mulooA5r/hAfB3/Qp+H/APwWw/8AxNZlroGj6H8SdI/sXSdP07ztJv8AzfslskO/E1njdtAzjJxn1NdxXNX/APyUnQv+wTqH/o6yoAl+IlvNd/D/AMTW9rFJNcTaZdRxxRqWZ2MTAKAOSSTgAVzd3od3o16lzM8yaffXAN7DodvLH5YSJhGQse5zlsbmXB4QH5Qc+iUUAeXTad4j1nStUg1KbVFYeHYhFAuEWe4f7UrBzt5k2iHcoIAJGR0qHV7nVkttPXRYtdjNvbwPDJLBdu07GUiRGT5VXaB1lBypG0d69XooA5/wXbzW9lqS3EUkTPqd5IodSpKtMxVhnsQcg966CiigAooooAKKKKACuav/APkpOhf9gnUP/R1lXS1zV/8A8lJ0L/sE6h/6OsqAOlooooAKKKKAOa+Hv/IBuv8AsLan/wCl89WfHVjc6p4I8Q2FjH5t3dadcQQx7gu52jZVGTgDJI68VW+Hv/IBuv8AsLan/wCl89a2v6nFoug6lqtwjyQ2NtJcuiY3MqKWIGe+BQB5HbfDjW9O8Dy3Y2al4ln0mz077FJtijhij2FowVcB3GD8xYA49Dg0vD/gTxQLSysL621GDTB4gNy8f29I3SzMG08xScDf/Cp+nrXq8Pim3El3BqFpe2t3bNGrwrCbhiHVmVl8rdkYVvTG3nggmf8A4SjRDcQQLqMDzT263USJlmeJgxDgDqp2Nz7e4oA8p1rwd4oPxIsr/TdMkisbTU7Mx3UF2mHskVFcSF5PMLbRgqAAeT8xOT0/jzw34kn8NyW1re3HiNpryFpILlLeFoYRu3mLaI1ZuV4kJHHr17vStWs9VWY2ckhaFgkkcsTxSISARlHAYZBBGRzUT67p8eo/YZp3in5AMsTpGxCliFkICMQoJIBJwCexoA8Xs/BPiyLw7o9tqemXeo2dpPfq2mHUI0cCTH2eTcHCkL83GcrnIHaui8L+BdYl1+0bxhJd3dtb6NbQebHfuiPdKz78qjgsQpHLDB69a71PFmhtYz3jajHFbQGPzJJlaMKJG2xt8wHyseA3Q84PFVIfG2lXMl9HbGZ2tHhVmZCisJfL2lWbj/lqvBweuAaAPNPAXgnxNosHg61XT5tOfTpb8X8/2xJY3LwMsUoQOcruKjbgEEEkDqep+FGgX+isqavoVxbaktsY7vVJNRE63sm8HcF3E88nLBSOgzmu4sdasL+9mtLOdpZYtwYiN9hKnawD42sQTggE4PBrRoAKKKKAOa+Hv/IBuv8AsLan/wCl89dLXn3g/wAT2GnadfWtxb6w8serallrfSLudDm+nPDxxMp69icHjqK3P+E00v8A59fEH/ggv/8A4zQB0tFc1/wmml/8+viD/wAEF/8A/GaP+E00v/n18Qf+CC//APjNAHS0VzX/AAmml/8APr4g/wDBBf8A/wAZo/4TTS/+fXxB/wCCC/8A/jNAG/eXEdnaT3M7bYYUaRz6KBk15b4WWW4ia8uRi4vZGu5fYucgfgu0fhVz4i+MtPn8MS2UNvraveSx25MmjXkfylgXALRDJ2huBzWZpnibT41ybbWfw0e8P8oq8/GtyaijuwiUYuTOsdN1KFG3BGRWIvivTj/y7a3/AOCW8/8AjVI3ivTh/wAu2t/+CW8/+NVx8kux0c67mysEKvuWJAw7gUSyBVNYjeLNOA/49ta/8Et5/wDGqx9Z8Y2MNhdSxw6sHSJmUtpV0o3Y4yTGAOcdaHGXYaa7nU+DbdtT8UXGpgf6Jp8bWkTf35WIMhHsoAX6k+ld/XDeF/EelaR4d0+wFnr4aGFQ/wDxIb45fGWOfJ7sSa1P+E00v/n18Qf+CC//APjNexRp+zgonmVZ88mzkJsN4u8REdPtiD8fJjroIP8AViuAtfEti2savOYNWPnahKwxpV0TgYUZHl8H5eh5FdFH4r04KB9n1r/wS3n/AMaryakZOpJ2PSTShFXOhorA/wCEs07/AJ99a/8ABLef/GqP+Es07/n31r/wS3n/AMaqeSXYOZdzoBWT40P/ABRev/8AYPuP/RbVV/4SzTv+fbW//BLef/Gqy/FXiWyuvC+sW8NtrHmzWc0abtIu0GShAyxjAA56kgCrhGSktDKu06ctejNrxzz4Q13/AK8Lj/0W1cfpfFdB4l1my1DwFrF3A8yQzWksMXnwSQtI7IQoVXUE5LDBAwa5/TwNmc1zYlP3b+f6Hr5TZyq+kf8A24rat/x92H/X9a/+j0rufF3/ACC4P+v+y/8ASqKuF1ZlS5sZHIVEvbZmY9ABOhJPsBXceLmA061Qn5n1CzCjuSLiNjj8AT9AarD7L1/yOfOf4j/wL85GyTQDUZNIWqjnsTnpWbqq5jq+GylUb45jNJjjuS/Dg7dZ8Qxev2aX80K/+yV3lee+BDt8YakvZ7GFvykkH9a9Cr18K70kebiVaqzzS6hbRfFV/ZyjEF67X1s3Y7seYv1Dc/Rq1o3DAEVN8T4B/wAI4t+B+90+4jnDdwu4K/4bWNZWnTZJQnOK4MTDkqadTtoS9pTv2NPaM5wM/SmTrlDU0fNOlT5axtdF3syii5iIrIjuDpfibSr/ADiPzfskx/2JMAE/RwpreVcAiue8RW32mxu4BwzxsFPo2Mg/nilGXJJS7FW5049z1Sis/wAO339p6Dp97nJnt0kP1KjP65rQr3U76njtWdgooopiCuav/wDkpOhf9gnUP/R1lXS1zV//AMlJ0L/sE6h/6OsqAOlooooAKKKKACiiigAooooAKKKKACuav/8AkpOhf9gnUP8A0dZV0tc1f/8AJSdC/wCwTqH/AKOsqAOlooooAKKKKAOa+Hv/ACAbr/sLan/6Xz1p+J9L/tzw3q2k+d5H2+0ltfN27tm9Cu7GRnGc4yKzPh7/AMgG6/7C2p/+l89dLQBy2r+DrWeC2i0pbOyijmaaaCS282G5JQr+8QMu4jjBJIGOh4xV0rwQ+naVdWcOqyRvNpFvpSzQxeW0RiM5Ei4bv5/QYxt688dnRQByGheCLKzOof2pb6Vex3ckcvkJYCOJGRSu4KzPliCcknPJ9aqah4AGo62by9v4pYTcTynNsftGyW3lhMXnb+EHm5ACj7ozk813VFAHHnwfc3Cl9R1SOa5D2ASSK1MaiO1uBOAV3nLMcgtkAcYXggz6n4VmvLvVWS/SO21Ca2uXjNuWdJIWi6NuA2lYsYxkE5z2rqaKAMPw5o93oqta/boZ9MQyGCL7OVlXc5YBpN5DYyR90ds5PXcoooAKKKKAOa+Hv/IBuv8AsLan/wCl89dLXNfD3/kA3X/YW1P/ANL566WgAooooAKKKKAOC+JEnm6x4fsweFaa6Yf7qhB+shqazQLCtZ3ix/P8f7eot9PRfoXkYn9EFbFuvyqK8jEPmqs9SiuWkizEmRUc4wasqMLVWY5NTJWQou7Kly+2M1y+oIdQu9P0/qL28ijYf7Cne/8A46hrf1B8KRVXwfa/bPGwkIzHp1qXJ/6aSnA/8dVvzqaMeeokazlyU2z0qiiivbPHPJtF/wCPvUCep1G6/wDRzV1C/drmbRDDrmtW54Meoytj2fDj/wBCrpY+VFeHPSb9T2E7xQ6iilqRCqKRhnII4NPBp2MiqsK5xWu+H9P0+wnurS0ijeNSIlySkRPGUTO1Tz1AFcJb35tZvKkllMijc4SNpNo9SFBx+NejeNbgEQWKH5mPmOPQdq4jTb200n7Zb6jIltO08koeU7RKrHKlSeuBhcDn5awmuebvrY9TDf7Lh4qNo8zvd7afdq/U0NN+z395Z7zFc2s7BSCAyOp4II7jtXbWvh7TLK5SeC1/ex/6syO0nlZGPkDEhOM/dx1ryvT7G6e7lvYdS1Cxt5bozRRpHDwvHzYeMkZIJwfUZ716W2hagef+Er1sj/rlZ/8AyPV0o8t4pmOPftlTqzjrbf57rr5ms9RseKxZND1Af8zVrX/fqz/+MVWl0e//AOhp1k/9srT/AOMVdl3ONN9jp4zlKqXZ/dNWTDomoFf+Rp1kf9srP/4xUNxod+YznxRrJ/7ZWn/xijlXcaeuxueBFL+L79x92OwiU/VpHP8ASvQ68r+Hvh3UblNVv4/FOtQCS5+zq0cVmfMWMYyd0B/iLjjFdf8A8I5qn/Q6eIP+/Nh/8jV62Hjy00jzMRLmqNmvr1gNU0S/sGxi5geL6FlIBry3w7dtNZWU78O0ahx6MOGH5g13f/COap/0OniD/vzYf/I1eXTeH77T9e1bTx4i1VRDP50ZEdr8ySjfu/1PXdvHGBx0FYY2F4qXY3wU7Nx7notu2cVbYZSuMsdH1B4wR4q1ofSKz/8AjFaS6DqJT/kbdc/79WX/AMj1yQStubzunsbDDBrI1FcODUD6DqIP/I2a3/36s/8A5HqhqGg6gFyfFGst9YrT/wCMVEoruXCWux1/wwmLeF/szfes7qe3/AOSv/jrCutryj4f6NqL3uvWsfirWrcRzxzfu4rM798Y5O6A8/LjjA4rsv8AhHNU/wCh08Qf9+bD/wCRq9ei700zzaytNnS0VzX/AAjmqf8AQ6eIP+/Nh/8AI1H/AAjmqf8AQ6eIP+/Nh/8AI1amR0tc1f8A/JSdC/7BOof+jrKj/hHNU/6HTxB/35sP/kasy10260/4k6R9r1rUNU8zSb/b9rSBfLxNZ52+VGnXIznPQYxzkA6nX9Ti0XQdS1W4R5IbG2kuXRMbmVFLEDPfArFtvG2nT6lp1mI5ka7tXupHk2qtsFzlJOeGyjg4zjYc9q1/E+l/254b1bSfO8j7faS2vm7d2zehXdjIzjOcZFYus+BtM1GWfyx9liuhdC7WIfNM08XlswJPynHPTGeepOQC+PFmitAZRdP99UWL7PJ5rllLLtj272BVWIIBBCsegNTDxJpJure3F3+8nEZU+W+0FxlFZsYVm7KxBPYVzg8CyfYpYml0U3DPEwmXTHQ/IJACSs4YN+8OGVlxlhj5jRYeABZ6jBcm9gvjvtpZ5NQtTNM8kKRoHR942kiJD8wYhhnOaANW98baHbabqN6lw9wljay3jrFE2ZI4/v8AlkgK5BwDg4BIzirn/CTaT58EJuiHm2hd0TgKWbagc4whY8KGxuPTNYc3gNJ9KjsJdQbyxpV/pbMsWCRdNGxccnBXy8Y5zntjlZfBUs+tNqd1c6bcTztDJcCWwZhvjwA0X735OFX72/BGfagDWi8WaRcXcVvaXkM7NcNbSFXAETrHK5BJ7gQvkDkdenNXtI1iy1eN5NPleRFAO5onQMD0ZdwG5TjhhkH1rBn8FR3Okafp094xhtru7uXKx7TIs8dyhUc/KQLnOefu9Bnjb0Gz1CytVg1G+t7sRoqRtFbGEgAYy3ztknjpge1AGnRRRQAVzV//AMlJ0L/sE6h/6Osq6Wuav/8AkpOhf9gnUP8A0dZUAdLRRRQAUUUUAc18Pf8AkA3X/YW1P/0vnrpa5r4e/wDIBuv+wtqf/pfPVrxta3l74S1W200O11JAyoiNtZ/VAexYZAPHXtQBqW15bXRkFrcQzGM7XEbhtp9DjoanrhNTntZLBDoGk6hZ+W0Md1JBpstvMlt5g3pH8gY/RMkDJHOKzmi128WOIS60litnqctuwMkcrFZIPswkOA27Bk2q3zMB8wPzUAemUV5s0fiBZTAsurmK5j0qWWQ7yyySTSi6CnHyAIsZKrgJnOBmopYPE1pbNJpcmqS33n6lbQrcs7xiNUlNsWDcfeWPDnls4JOaAPTqCQASTgDqTXm6f2rPOIdNk18aRJcWas90sqXAJ837Ry4DBMeTyOAS20jtvaUNR/4QfUorpbqS7je/hhEylpHjWaVYevLZQJgnO4EHnNAHSpcwSSMiTRs6kKyhgSCRuAPvjn6VLXldpBrFrf29zHpl3K/26KV0EWzcF0iReGIwn70Km7jDHHtUOnXHiDddI51o6Q32GWYrb3SzRqxnE6xmXMrEbYNxTGFYlVB5IB61RVLRfL/syDyGvGiwdpvA4lxk/e3gN/31zjGau0Ac18Pf+QDdf9hbU/8A0vnrpa8+8H23iSTTr5tM1bR7e0OralsjuNLkmdf9Onzl1uEB5yfujjjnqdz7H4x/6Dvh/wD8Es3/AMl0AdLRXNfY/GP/AEHfD/8A4JZv/kuj7H4x/wCg74f/APBLN/8AJdAHS0VzX2Pxj/0HfD//AIJZv/kuj7H4x/6Dvh//AMEs3/yXQByt2wuPHWuyjkJJDAP+Axgn9XNdLbLwK830eHxFc6jqVzHqukhpr6YljpkhDFW2ZA+0cD5eBz9TXVwWfirHGs6GP+4RL/8AJNeQ0pVG79T1G3GCVuh0shwtUZmwCayZbbxV31rQ/wDwUS//ACTVG6t/FAU51jRT9NKl/wDkmlUt3FD0Ld225wCeK2fhjb50W41Rhh9SuGmXPXyh8kf/AI6uf+BV51q9v4lljS0TVdKaa9kW0j2adIpy/BIPnnGFyenavSrLSfFllZwWtvrfh9YYI1jRf7Fm4UDA/wCXut8FT1cyMXP3VA6uiua+x+Mf+g74f/8ABLN/8l0fY/GP/Qd8P/8Aglm/+S69E885/wAW2x03xil0eLfVI1XPpPGMY/FMf981oW7ZQVzXjm08SXetaXYXeraLKyxS3KtHpUqBCCqg4Nycnk46Y561DZp4nU7G1fRww6Z0uU5/8mK8nERiqj1PTotumro7CiueW28UEZ/tnRP/AAUy/wDyTS/ZvFH/AEGNE/8ABTL/APJNY2Xcu77HRKabcXcVnayzzsFijUsxJrnvsvij/oMaJ/4KZf8A5JrifH1zrkggsb3VNLlsUuEN00enyRqOuA+Z2yuduenXnpindLqNRlK7S0W5ei1WDWL+e5S6gmkJyyxyBtg7Dip5blAcA1iajFHdX+l22nKhv2mQQ7MZ8vPz5x/Dt3Z7dK72LwrZi22zSyvORy6nAB9hXJyOSvE95YunSfJVeqtt2/S3+TOO1PULWEIkrsZWGRHGjSMR67VBOPeu88O6rBq2i29zbyrJgeW+OqsvBBHUH2PrXm07JoGv6jBqrLD5zI0U7nCMgUDG48DnJx/tVreArxW1rUmiBFrdLH5bEECR03bmA9CCBnvtrSCUdTixdV10lFp2b06pK+r12dk9lute/dXD1UB3NT52yaWBM81TONaIsRcLiqWsTPBaN5K7p2+WNfVj0q+CEQk9e1VpEHmCR+Wxx7U72JRsfC9mHg+3tpdvn2ks1vKR3ZZGyfxyD+NdZXF/D2Ty7/xBaHoLiO6Ue0kYB/VDXaV7VGXNTTPJrLlm0Fee/EW1+za9pWpKMR3KNYyn/a5eP+Tj8a9CrC8caW+r+GL23gGbpFE1ufSVDuX8yMfjRWhzwcR0Z8k1I5PSpcHaTW/A2VrjdIvFuIbe6i4SZA4Hpnt/SuptJMgV40HZnq1Y9SxKKpXi7ojV5+RVaYZjNORESh4HfyvGmpQ9p7GKT8Ud1/8AZxXoVeZ6G5g8faW3ae3uLc/htcf+gmvTK9TCO9JHDilaowooorpOYK57X9G1K71zTtU0bUbOzuLW3uLZlurNrhXWVoWJAWWMggwjueproaKAOa+x+Mf+g74f/wDBLN/8l0fY/GP/AEHfD/8A4JZv/kuulooA5r7H4x/6Dvh//wAEs3/yXR9j8Y/9B3w//wCCWb/5LrpaKAOa+x+Mf+g74f8A/BLN/wDJdH2Pxj/0HfD/AP4JZv8A5LrpaKAOa+x+Mf8AoO+H/wDwSzf/ACXR9j8Y/wDQd8P/APglm/8AkuulooA5r7H4x/6Dvh//AMEs3/yXR9j8Y/8AQd8P/wDglm/+S66WigDmvsfjH/oO+H//AASzf/JdGnaLrH/CSW2ra1qun3X2a0ntYorSwe3/ANa8LFmLTSZx5IAAA6mulooAKKKKACiiigDmvh7/AMgG6/7C2p/+l89dLXNfD3/kA3X/AGFtT/8AS+ervjPUp9H8H67qdoENzZWE9zEHGV3JGzDI9MgUAbFFcc/iS60PSp9S8QRXZsYpEWaZrZYjAhyN+1XYsM7QccjOcHmoZ/GV7Z311JqGlfZ9NttJXUplMgNxGSZfkwPlJOxRgHgk8kUAdvRXExeOJnjRP7FuHvJLqO1jjjchHLxu4IeRU6eWwYY47ZyM2IvGLf2hHFc6eLe1e7msPPe4HyzRwvM2RjATbG3zZ6jpjmgDrqK4BfHE98RBBbi1uI7vT9zLveOWC4mKZVnRCfuOMgEdMMecaHj7xBdaMksVi4SY6VeXiMUDANE8Cjqf+mp4wc+2OQDr6K4jUvGzadBeuLeO7kt7m4TyAzLIY4gpJVURy33hyQqjIyRWto/iGXWb6T+zrHfp0TJHLcSTBHDtGsnypg5ADqCdw5JwDjNAHQ0UUUAc18Pf+QDdf9hbU/8A0vnrpa8+8H+LvDel6dfWep+IdHs7uPVtS3wXF7HG65vZyMqzAjIIP0Nbn/CfeDv+hs8P/wDgyh/+KoA6Wiua/wCE+8Hf9DZ4f/8ABlD/APFUf8J94O/6Gzw//wCDKH/4qgDpajuJVggllf7salj9AM1z3/CfeDv+hs8P/wDgyh/+KrG8Z/EDwsvhTVhZ+JtEnuXtnjjSK/iZizDaMANnvSbsrjSu7GD4IUnSbJ3+9Inmt9WJY/zrtoD8tee6H4p8MWsMcR8Q6MqxoEGb2IdBj+9W9H428LAc+JtE/wDA+L/4qvGgpXvY9Wo1tc6KY9ayb2TtVGbxt4WwceJdEP0v4v8A4qsPUvG3huOKWVde0qTYpbYl5GxbA6AA9aU4yfQdNrudF4QtP7S8XyXLDNvpUW1fQzyDn/vlP/Q69GrzrwN4p8JaT4ct47rxV4fF7OTc3P8AxMYf9a/JH3u3C/8AAa6D/hPvB3/Q2eH/APwZQ/8AxVerQp+zgonm1p882zpaK5r/AIT7wd/0Nnh//wAGUP8A8VR/wn3g7/obPD//AIMof/iq2MjE8QyiXxzcAf8ALvYxR/izu38gKbNHgqwrl28Y+HbjxHrd4+v6QFluRHGTex4ZERVBHzcgndzWqPGHhZosN4k0XP8A1/Rf/FV41dSlUbserSajBK5tROQuak35Fc3H4x8MqSD4j0bH/X9F/wDFU5vGXhnp/wAJHo3/AIHRf/FVnyy7F80e5q6tqIsLGSUY8z7qD1Y1w0jbYWMnzM+S2ec5rPvNfuvEjm60mWxNhCxESkly/uzKcKSMcYOM1peFP+JxMly8ZWKLl0bs4JG38CD+Vc1WMnKx7OBnTp0uaStdX9V5ff17nS+EtEtNHtTNFawQ3U4y5jjCkDsOK3y9U/MoMtbJ2Vjyp+9JytYx/F9sJLZLtR88Rw3+6f8A69c0JzE0Nwn3o2DV21yBPDJE4yjqVNeaGK8utQvLNLhraO1by2KKpd2wD/ECAMEdu9YVINyuj1sHilGl7OSu72S9bvrbsz0uEiZVdeVYAj6VcUbRXL+Bb2eWG60+9YSTWQQrKBjfG+7bkeoKMPyrpWbJwK32R5Mviats2vuHrmV8dhTLvirMKlFJqrdUdBLcPCs3keNQpOFvLFl+rRuCP0c16FXl0cv2XX9BuuyXnkt9JFZP5la9Rr1cFK9O3Y87GRtUuFFFFdZynkd3Z/2P4k1PTQNsJf7Zbf8AXOQkkD/dfcPxFbWnS5UDPSrXxQsvLtbLW4x81g+yfHeCQgN/3ydrfgayrFikgFeNiafs6nkz16E/aUvNG+G4pj8g0kZytOrO4Wsc5ct9m8R6DcDjZqCxk+0isn82Fep15L4xLQ2Etwg+e2ZLpf8Atm4f+QNesRSLLEkkZyjgMp9Qa78C/daOTGLVMdRRRXccYVxnifSNN1r4geH7fWNPs9Qt10zUJFiuoFlUMJbMBgGBGcEjPua7Ouav/wDkpOhf9gnUP/R1lQBV1Twf4K03T57yfwhozxQqXZYNJjlcj2VUJP4Csfw/afDPXdGTVbTw9oENhIzLHLd6VFbiTaAWZd6Dcoz94ccH0Nd1rSXcmk3cenJA948ZWNZ3KRknj5mAJA+gNeWeGfhlqsNj4GsvEcWiXVp4flu/PiDvMs6SxnYQrxgbg5OQeAFBBJ4AB1k3hr4dwQ280+i+E44rgZhd7W3Cy8Z+Ukc/hUp8JeAhHK58P+FwkSqzsbK3wgb7pPy8A9vWvGtf8Da34Y0e1s006PWrqTRb3TFigtZ547dpbiSRJI3EZVX2yBTv2fd4JArpNX+GXiq60fVrPTp9Hjh1rStPtbkXbyCSGW2QDC7VIIPPP6UDO2h8P+AXkvVn8L+H7QWsxgZ7iwtkVyFDEqcdMeuDweKfN4f+HEFpBdz6R4QjtZziKZ7a2CSf7rEYP4Vz938NL298QSXV4dMuLCTxF/azwy7n3Q+R5e0qUwW3c46Y71lXvwr1/wDsSLTLObR/sS3d/Kbcu8YWOZgY9riMsNuOUGAfU0AdfbaF4BufEtxocPhTQ2u4bWO8ZhpkHlmN2Krg45PBrY/4QHwd/wBCn4f/APBbD/8AE1z/AMOvBGp+G9XtrvUJ7SSOLQ7XTCIXZj5kTMSRlR8uCMHr7CvRaBHNf8ID4O/6FPw//wCC2H/4mj/hAfB3/Qp+H/8AwWw//E10tFAHNf8ACA+Dv+hT8P8A/gth/wDiazLXQNH0P4k6R/Yuk6fp3naTf+b9ktkh34ms8btoGcZOM+pruK5q/wD+Sk6F/wBgnUP/AEdZUAdLRRRQAUUUUAc18Pf+QDdf9hbU/wD0vnrc1Oxt9U0270++j820u4Xgmj3FdyMCrDIwRkE8jmsNvBOj+bPJG+sQedNJO6W+s3kKb3cu5CJKFXLMTgADJo/4QvS/+frxB/4P7/8A+PUAXB4a0wrGsyXVykcqzKl3eTTrvUEA4dyDjOcdMgHqARHH4T0VEhQWjGOK2NmI2mkZGgOf3bqWw6jccBsgZ4xVf/hC9L/5+vEH/g/v/wD49R/whel/8/XiD/wf3/8A8eoAu23hvTbcwFUupTBKs0RuLyaYo6qygje5wMO3HTn1pZvDekzjE1msi/aZLsq7MQZZI3ickZwQUkcYPHPTOKo/8IXpf/P14g/8H9//APHqP+EL0v8A5+vEH/g/v/8A49QBNa+EdGtpC6W87yE253zXc0rfuHZ4uXcnCs7HHfPOau6toenau+7Ubfzm+zy2md7L+6kKF14I6mNOeoxxjJzmf8IXpf8Az9eIP/B/f/8Ax6j/AIQvS/8An68Qf+D+/wD/AI9QBPeeEdFu5JHltZVeVpTI0VzLGX8zbvVirDKnavynjjpU9p4c0yzvVurWGaGUBQVS5lWN9qBFLJu2sQoAywJ+Uc8CqP8Awhel/wDP14g/8H9//wDHqP8AhC9L/wCfrxB/4P7/AP8Aj1AHS0VzX/CF6X/z9eIP/B/f/wDx6j/hC9L/AOfrxB/4P7//AOPUAHw9/wCQDdf9hbU//S+eulqjoulWmi6cljp6SJbq7yfvJXlYs7l3ZnclmJZmJJJ61eoAKKKKACuH+Jc/nNo+lKcme4+0yj/pnEM8/wDAyldxXlkl4Na8TX2qBgbVcWdoexjQks49mfP4KK5sVU5Kb8zow0Oad+xq6ZCUTce9aKnFVonQIACKl3jbnNeUtD0JasgvJOKw7a0/trxTp+nEZt4T9tuvTah+RT9Xx+CmtG8mUKzEgAdSa0vhpZk6ZcaxMpE2pyeYmeqwLxGPxGW/4FW2Gh7SprsiK0/Z0/U7GiiivYPKCqesX8el6TeX83+rtoWlI9cDOKuVyPxNmzodtYDrf3cUDD/YB3t+iEfjUzlyxcioR5pKJzHh23kh0+3FxzcODLL/AL7ks36k10cfCis+0Xc+a0gOK8Ja6nry7HM+I/FWhaJdLb6lqMUFyQD5YVnIB9QoOPxq1/atu2kPfW0qTQlN0bIchuw5+tfPvxN0vULHxnqb30UhW5uGlhkIJDoTlQD3wMDHtXdeD7G+0zwVaW1+jxSXNw9wkTjBWLCgZHbJyfxrfEUo06XtE9TzcqxtXGY54acLRX6d/UbHbahp9kLa1+yyQDiJ5GYMi9gVAIbHTqK9D8KaQNJ0O3tyS8rZllcjlnY5JP4mua0yIXurQQn/AFanc30Fd9vrjpScrtn0ePhGlywi3t9y7L7uvkMMQ703yh6VLnIpQRWx512Q7AO1cH4q02a28QteWM6wNcopkV496ORxnGQc/jXoJYAdq5vxioa0hmHWN8H6H/8AVWdRtRujqwajOsoz6/L8UZXgyI2V9erLKZri4VXeQgLnbwAB2AzTb74leHtM1V7Od7qZ0bZJLDGGjQ9xkkE49gadoJK6zZyMflc7D+IryTWfAPiKx1eS0j0y7ulLkRzxRlkcZ4JYcD8cVvgoxq39o9jzuI6tbAuH1WN0993/AFfufS1pcwXtlDc2kiy28yB0dejA9DUFwMg1y/hHwjqmleG7Gzl8SapbyRoS0MCWrIhJLEAtCxOM9yavT6FqA/5mnWT/ANsrP/4xSlFJ6MqjOTinJWY3XQw0m5kj/wBZBidPqjBx/KvV7aZLi3imiOY5EDqfUEZFePPoV62UfxNrBVhtP7q05B/7YVv+AtI1S88L2n/FX65E1uXtTGkVkVTy2KADdbk9AOpNdeBdrxuZYxXSlY9Gormv+Ec1T/odPEH/AH5sP/kaj/hHNU/6HTxB/wB+bD/5Gr0TgN+9tor2zntblA8EyNG6nupGCK8m0YTWbz6ZdsWutPkNszHq6jlH/FSpruv+Ec1T/odPEH/fmw/+Rq4Tx14Zv9L1ey1MeJdYkW8ItZ5XitAwYAmPpABg/MM4zyOa5MXT54X7HVhKnLPl7nU277lFT1ydpouoMqkeKdZAPpFaf/GKuf2FqP8A0Net/wDfqz/+R681Jdztk/Iua1As0LK4yjAqw9QeDW98ObxrvwlZxzNm4s91nL/vRnb+oCn8a4270W8ClX8V6yfYxWf/AMYqp4YsL6w8SNZf8JXrFvb6mN6SJHZ/NcKMFTugIGUAxgD7p6104WShUtfcyxEXOne2x7HRXNf8I5qn/Q6eIP8AvzYf/I1H/COap/0OniD/AL82H/yNXqHmnS1zV/8A8lJ0L/sE6h/6OsqP+Ec1T/odPEH/AH5sP/kasy10260/4k6R9r1rUNU8zSb/AG/a0gXy8TWedvlRp1yM5z0GMc5AOw1K8i0+wuLy4DmGBDI/lqWbaOuAOTVWDXdNltbOd7uK3F2FaFLhhE77vugK2Dk9hT9ft7i70S/trNYmuJoHiQSuUXLAjkgEgc+hrj7zwdqN5pt0kv2BLqXQ4dNQiRmCSozkndsB28qc4zkdOBQB2h1OwF69mb21F2i7mg81d6jGclc5AxS3OoW1uis8gbLRLhPmP7xwiHA7Enr04PpXnJ0e+uvEK6Utuxto7zULqS/MMqnFxHIACWQI20yqo2u2Qg4GDi7B4T1qbLXv9nQuI9GiVYZ3kBFndtNISTGuCythRjr1I60AdvHqlhJPNDHfWrzQrvljWZS0a+rDPA9zVU+IdMZLF7W6iu4ry5+yRyWzrIvmbGfBIPop/SuXTwfqlvaQfYLmyt7yKHU0EuCw33EoeM4K8gADOe/Y03SvB+qQ6ul7cNbxj+0IbxkN7LcthIJIj87oCSSynGAABjjAyAegUUUUAFFFFABXNX//ACUnQv8AsE6h/wCjrKulrmr/AP5KToX/AGCdQ/8AR1lQB0tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFQX15b2FnNd3syQW0Kl5JHOAoFSuyxozuwVFGSxOAB615pf3r+MNTSYZ/sK2fNqhHFy4/5bMP7o/hHf73pWVaqqUbs1pUnUdhdS1bU/FTNFb+fp2jMMBV+Se4U92P8Cn+6OT3x0rQstPgtYUjRFAVQqgDAUDoAKu28AUYUcd/eo79xBGTnmvJqSlP3pHowSj7sBvlp0AAqpeRSqMxHj0pun3BllYelaLDIINZ7l/Czj9RJvGtrB8r9suI7ViOyucMf++c169BGkMKRxKEjRQqqowAB0FeQeKSbEi9i+/aSx3Y/4AwJ/TNewowdFZTlWGQa9DAW5X3OTHXvHsLRRRXecIVwfjt/P8T6PbjpbwTXBHu21F/m1d5Xnetv5/jrUSelvbQQj6ku5/mK5sW7UmdGFV6iLVnHhc1apkQwoqXHFeUkd7eo2uM8RS+drM392FAg/mf512u2vnDxj421L/hItQj0+VYIEndD8isXwcc5B9O1P2E63uxGsyoZcnWr37K2+v3dD1Hw3CYjcXZHDN5YP6n+ldNDNvHHNcr8OtW/t3wSkzxhJ4Znhlx0Zhhsj8GFaehzFbu5tHOQhDof9k/4EGs1TdP3Xujoni4Yx+3hs9vQ3gx9KXJpqSK0pjB+cAMR7H/9VMuZREPmOBkDP1OKZkNmfy0LMQAKzNRgN9plzj7oQsPw5qLxDKVtFjz/AKyREP0LDNbWnR+ZbbWHDKQfxFJq6NIT9nJSXQ4qCTy0glH/ACzdW/I16QCCMjoea+T7/wATatPdvKl5cQqCdsSOVUDsMdD+Ne9eDPFeqap4X067k8NarcO8e1pYZLVUcqSpIDTKR09B7cVssHOirye5ySz3D5lUcKSa5b79UdsarXFZLa7qP/Qqa3/39s//AJIqCbXNQ7+FdaH/AG1s/wD4/UuLLjJGgy5Nanw5fZJr1p/zzvfNA9pI1P8AMGuR/tu/z/yK+s/9/bT/AOP1Z8Ha9qFv4k1kJ4W1qVpoLdzGktmGXG9cnM4HPsT07VvhE1UM8S70z1eiua/4SPVP+hL8Qf8Af6w/+SaP+Ej1T/oS/EH/AH+sP/kmvWPMOlrn/H9l9v8ABurRD/WJA00Z9HT51I/FRUX/AAkeqf8AQl+IP+/1h/8AJNZHi3xZqdp4Z1OVvCOtwnyGRZJZbIqrMNqkhbgnGSOgNTK1ncqN+ZWMfR7qW6ihaHkMisT2GRmuiQELycmuN0DUb2z06GCPwvrLiNFTcJbPnAx/z3rUGu6j/wBCprf/AH9s/wD5IrxFBnrTmmzcaCNiSyAn3qhqWjwXsBjIKHIZWQ7SrDkMCOhB71kxeJb4TvG3hfWSc9PNtM/+j6vDXtQZePCetn/trZf/ACRTULicrFvSfFF5ok8dn4lfzrJiEi1HGCh7CYDjH+2OPXHWvQAQQCDkHvXld7qN7dQvHL4Q1plYEENJZEEeh/0iq/hTxfqfh6SPRtR8O6zJaSSCPTyZrXeuf+WTMZ9uB/CSc9uwrvw9Z/BM461JNc0D1yuav/8AkpOhf9gnUP8A0dZUf8JHqn/Ql+IP+/1h/wDJNZlrqV1qHxJ0j7XouoaX5ek3+37W8DeZmazzt8qR+mBnOOoxnnHach3FFc78Rppbf4e+KJreR4po9LunSRGKsrCJiCCOhB71zeuXOpeGYLCCM22nRXk0nnXYuyUTagKL5k6sqlju6jkLgcmgD0aivMp/EevPbyTrqNoj20Gmswto1kgme4lMchDHkpgZXBHbkipJfEV/b382nahra2Npb3NzEdUmiiDMyJA8cbZATJEsh4AJEWBgnNAHpNFebQ+J9bksNQ1HUZfsUVpYWsstpDbqZElmiBbLucKqMcnIwACTkVB4e1u81bXdKjvLuG6+x6zPbJPBKsiyodPEoyyqisQZCOFA479SAeoUUUUAFFFFABXNX/8AyUnQv+wTqH/o6yrpa5q//wCSk6F/2CdQ/wDR1lQB0tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVheNdWfRvD889tg3kpW3tlPeVzhfy6n2BpNpK7Gk27I5nxXqEniLU5tFtGI0q2bbeupx9ok6+SD/dH8Xr931rSs4Y4IwqgAAY4GKzNFtINJ0yKAPnYPmdjyzHksfckk/jWXe+JEOtQ6dZ4klILygH/AFaAdT7kkcV41Sq6kuZnqwpcseVHVzXSRIcEVzmq34ckA5xUdw15cttjjOD3Jqex0chxJdHJHOO1ZSk5G0YqGrLOhwMkHmScM/OK1KgeeOLCrlj6LSxySPyU2j3oWhDu9TlPHLY0y+z/AM8HA/EYH869asI2isbeN/vJGqn6gCvLdXhGpa1pmn43C5vI1cf7CfvH/RcfjXrNehgY6ORyY2XwxCiiiu84QrzFnMvijxBMe94sY+iRIP55r06vLdP+e91eT+/qVx+j7f6Vx41+4vU68GvfZvxH5RVhBmqkHQVcjrzonZIjvX8mznk/uRs36V4Nr/gi31G7F3BctbyTEeYuzcC3qORivdNbDNpF4q53GMgVxEFjK17ZKy4XzFJ/OpqVJ05Jwdjrw+Dw2LoSjiY8yvf7l5a9Tc0Lw/aeHPDyadYhiiZZ3f7zuerH/PYVjWDf8T6TnpCM/wDfRrs7gbon9xXB2zeX4mmH/TJM/wDfTU5Ntts5qMYwioRVkjobdwPETJ62ynH0cj+tJ4qYx2oI4+eP/wBDWoUb/iqIDj71o/6On+NSeLv+PVPeaEf+RFpFdTL8TtiG2Pfz4/8A0Kup0n/j2Q98VyfiT/j2gPpNH/6GK6vR/wDjzSiOwTPJNY8EaTda9eyyLNGfOYmONgFPPpj+WK9Z8HRRxeG7KGFAkcSmNVHYAmsW+05m1i5dV+V23fmK6Lw1A1vpxiYYw5I/GinOpKVpO6R0YjD4WnS56MFGUrN29C3IOaqzjircw5qrP0pyOOJRz81TeEjt8c3Y7PpqH8pW/wAarucNUnhh9vj5Fx/rNMfn6Sr/AI1phX+9QYhfu2ehUUUV7R5AVy3xOBPgbUyOiCOQ/RZFY/oDXU1T1iyTUtJvbGT7lzC8R9twI/rUyV00VF2kmcVorboW+taPeuZ8F3bS6fEs3EuwK4PZ1+Vh+YNdC02w/OrAevUV4S00PXluUtUtWZhNCPnHUDvUdnqJTh+1aqOrDKkEe1VrmxhnJJXDeoot1Q01a0i3BdJMvBqnrGnW+pWslvcIGjcYPt7g9j71SktJrX5opCV96p6B4kjvZJ7a5xFdW8hjlTPKkHGfofWnzN7i5baxOk8Fa1c/aJNC1mQyX8Cb4J263UPTJ/214Dfge9TeIxqFp4u0fVLLSLzVLeGxvLaVbWSFWRpJLZlJEsiAjET9Ce1c/wCIlkFvDqWnYa/09/tEWD94D7yH2Zcj8a9B029h1LT7a9tW3QXEayofYjIr1cNV9pGz3R52Ip8jutmYf/CR6p/0JfiD/v8AWH/yTR/wkeqf9CX4g/7/AFh/8k10tFdJznNf8JHqn/Ql+IP+/wBYf/JNH/CR6p/0JfiD/v8AWH/yTXS0UAc1/wAJHqn/AEJfiD/v9Yf/ACTR/wAJHqn/AEJfiD/v9Yf/ACTXS0UAc1/wkeqf9CX4g/7/AFh/8k0f8JHqn/Ql+IP+/wBYf/JNdLRQBzX/AAkeqf8AQl+IP+/1h/8AJNH/AAkeqf8AQl+IP+/1h/8AJNdLRQBzX/CR6p/0JfiD/v8AWH/yTVaxfU9U8b6ff3Gg6hplpa6ddwNJdy27bnkktmUKIpXPSJ8k4HSuuooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArz7xbMdU8Z2tkpzBpkXnSDt50nC/iEDH/AIFXoNeea14b12HW7+60kWt1BeyeafNmMTxnaFwflIK8cY5rnxKk4WijfDOKneTsYviNWub+2tNNlkjv7uRLZHjPQE5YkdDtXcc9qdcafZ6b4uurKwhEdvZW0MK5OWZm3OzMTyWOVyT6V2HhLwp/ZNw2o6pOl1qbIUBQYjgQ9VQHnnux5OO1cNJb3Oqvd+JbV/393cOUjY4V7dTsjHscLuB/2vSuKdL2VL3t2dkKqqVdNkddAQIQTj3ppD3HUlI/bqa5rSdfimcwuSkgYoY5PlO4dQOzY9ia6OK8idRzg+hrl9Tdq2qJ4okjGFXFJO4SNmPGBUUt4iDgjNYmt6qlvatJOcJ0RB96RuyqO5J4ov0QKLerLngq2N/4yuLsjMWnQbAf+mspyfyRf/Hq9Irn/A2jyaPoEaXYH264Y3NzjtI38P8AwEYX8K6CvZoU/ZwUTy68/aTbCiiitjEK8p0VspeHub+6P/kZ69WryfRxt+2r/dv7of8AkZq4cd8KO3BfEzooOgq7EMiqFueBWjB0rhgdMxXUMpVhkGqb28ayBgvI6VeaoJRzVTQoSa2IXGUP0rzyT934qkB6NEpH4M3+NehnoRXA+KIDZ6rDechBmNz6A4wfzH61maxNW1bzPEcZTBMdo3JPdnH/AMQaf4oLraxmYj5Z4WOO48xayvtBhuIL23UyMilHjBwWU88e4Iz+dTy3E2qvBJcQPbwQnzCr9Xcfdx3wOvI649KnzKsV/ETborZO5niH/j4rsNIBFoua4e6cXGq2cAOcSGZvYKMD9SK72xXbbqPamthTLUcal9xAJq2qhRxxVaHrVqtobGEmV5xzVSbpVyeqU54rOZcDOm4apfC/zePIv9jTJP1lT/CoJz81WfBg3+Nrxv8Annp0a/8AfUrH/wBlq8L/ABUGJ/hM9Aooor2jyAooooA8nmhOkeL9Vs+iNL9rh90l5P5OHFdNGwdARUXxL05xBa63bIWkscrcKoyWgb7x/wCAkBvpurN0nVIJbdGWRWRhkOpyD+NeNiIezqPsz1aMvaU0+qNN4FJ3RnY/qKI5GDbJRhux7Gg3MWM7xiq895Ftx1Hr6VjoaJNlm6IWBifSuXsNEj1e58R28S7NRSKK9s5l4ZZGVkIz3VjGuQeOadfa/FLcC0s83FywOAOEGMZy3TjI4GTVzw1FJoPinT5riXzDq6vbXLnoJAC8WB2GA6ge4rbD29ok9mRVTUG1uR+D57a40/cgYSzDL7zliehB9MHIxXQfDmY2o1PQ5D/x4zebAD/zwkywx9G3j8BUHiLwdcrqE2o+HZIkkmbzJrSYlUd+7owB2se4wQevFWPCOharb6zJqusmCJ/s/wBmSGFy5I3BtztgdMcADua6aFGpSq7aGFarCpTvfU7KiiivQOAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/H+oS2Xh2SG0bF7futlbn0d+C3/AV3N+FcNqtzPoGhPA6xNbWcGInQ7dwUYUEHoScDjP4Vv8Aji7aTxdpMEMD3C6fDJdzqh5Xf+7Qgdz9/j0rkdbuxq3iPR9MRHKTXCz3AZSNqJllU57krnHoK8zFy5p8vY9HCx5Ycxu2Gm2Nv4dt7O7ENzsTc5IBDyH5mYfUk1j+HtIjvzqF1DPcWsCzeRAIZSF+QYZsHIOWJHT+GtDxXLZ6Fpd1qEUKRuiFsLwGb+EY6dSKXSdPudM8OWUT3YKLEpZPLwdzct82fUntXJ3Z0rsYTLcSeLLHSodTvCjQvNOcpkAcLj5eOa1zpMC+JdDtIi008l2kkksrFm2xgyHk9B8o6etZWhWEV3r0OoXLyRm9tJbhGVyhEfmhIx/3yu7/AIFXT+FoEl8fQiEs8dnZSuWY5OXZVXJ9SFf8q2pw/eRizOpP3JNHpVFFFeweSFFFFABXlGncT6mPTUbof+RWr1evKol8vV9djH8Ooyn/AL6Ct/WuLHfAvU7MF8TNu3PArSg6Vl2pyBWnB0rz6e511CYjmoJhVioZxWsloZx3Kj8CsjWbaO6gZJFDKRggjqK15OlULn7hFc7N4nES6Nc2hJtLrMQ6JKu7H45B/PNV9NbU79ZArW6KkjRkkM33TjPUV1NxyhFc94GLNp10XGGa5dxn0bDD9DQndXNLampo2jiC4aWV2llbG52GOB0AHYV2MAwgrMslyRWqgwoprUzmTRdasjpVWP71Wh0raGxjIhm6VQuOlaE9UJ+hrOoXAzJvvVoeAF3eI9el/uxW0X6O3/swrPl+9Wt8OE3TeIZ/716sQ/4BEn9Sa1wS/eixbtSO0ooor2DyQooooAhvIFurSe3f7ssbRn6EYrxrwzo0V5p0QaSS2uYh5UphbaSyHacjoTlfSva68ptbRF8Ra9ZXDyQtHevKhR9p2vhx+HzH8q4cdH3UztwcrNo5/wANxT6hdX9lc6ldLcWl1JA20qMqD8p+73FXL/S4bDxDDHdGS5t7qHchnkZ9rofmHJ7hgfwqvHYjTtbvbyIuYpdRezlLMSSxiSWMknv98fiKu+MIri30ODVHuhKllOk+zysHYx2sM5PZv0rgcbO3c7VK6TLniuK2h0aC+tjHGbCRZRggZQ/K6/kc/UUt/DqepaQXtWijktmW5tmPzO8kZ3KOOFBxjucHtVywsrDUrGQNbxO8sZRnIycMMZGenB7Vz/gbWp101baSKSS5gPlPGFJLFSQGHsdp59QaSdrSQNXvE9e0TUYtX0iz1C3/ANVcxLKo7jI6H3HSr1cb8MZmTTL/AEyZPKnsbuT93nO2OQ+YmD6YYj8DXZV7kJc0Uzx5x5ZNBRRRVEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeWatqsGleJ/E8moyrDcM0TRBzjdCIgFK+vzF+nesmw069Gs2e8iDUDA+ozh1ztMp8uOM+m2ND+JNew3NlaXUsUlzawTSRHdG0kYYofUE9K4Hxa8mjeMJtQmgne1vLSOJJY4mkCyIz5U7QcZDAj15rgr0HFSmtbndRrczjDaxyPjKOXUo5LSfazQRCV1Ukq0jyLFEv5sx/4DW14pnvTpMkBg8iaXEEKhw253IRcY9zVu08NajeeFr/UPs7LqtzdQ3cNtL8reXCwKRtnoSNx56FhmrOhabqOueI7W91GwuLHT7FvNVLhQrSzYwoAz91ck57nGKx+ryfLGxr7eK5pX2I9c0y0tvFlhZyJ/o1vowji+Yr9yQA9PYj860PhlCHn12/Ufu5LhbaP/AHYl5/8AHmb8q6LxD4dsNeWD7aJllgJMU0EhjdM9QCOxwOParulada6Tp8NlYRCK3iGFXJPfJJJ5JJJJNdsaNqrqHJKsnS5OpboooroOcKKKKACvML1fL8WeIk/6eIpP++oU/wAK9PrzbXU8rxzqw7S21tKP/H1/9lFcmNX7o6sG/wB4XLM8CtKCsuyPStOGvMgd1Qsk4FRSnIqRulRt0rZmSKsnSs264BrSk6Gsy7PBrnkdEDF1WTydNu5v+ecLv+SmoLG1/s+/uLTGNlvaNj38hVP6qafrqGXSZ4R96cpAP+BuF/rWv4siEHjeYLwstjC4H+67r/hVxjejKXmgcv3sV6k+m8mtUdKydN61qiojsKe5JH1qwDVZOtWMcVtExkRzGqVx92rcpqncnCGomXAzH5kx71vfDJc6Fdz/APPxf3Dj3AcqP/Qa58kCTceg5rqPhtGY/A+klussZmP/AANi/wD7NXRgF77ZnjXaCR0tFFFeqeYFFFFABXmvjK3jg8cxPOp+z39ouSGK5aNiDyOejr+VelVl6/oVlrtvFFfK+6J98UsTlHjbGMhh6jg1lXp+0g4o1o1PZzUmeeR6aJ/CvjIWSf8AHtfi5g5J+eKKJiMnr0I/GqerzXF94O1CO3thPbNbGQPvAwAN2MdT0r1TR9IstI04WNjFtt8sWDEsXJ6lieST6mvN30fW9EW+0ax06a7gkDx2U648sIwIUOSflK5wfUAYrjr0JJRa1sddGtFuSfqU/D8c0dxNZWcyKYH/AHbyZOYmUPGcDr8rDuOlVFt5dJnursNvGm3bRXThcZgmxKkhHYK7OD7N7V0mu6LP4dn0m+topJ4I7OOyumiQsQY1wjkDnBG4E9vlrV8ARSXl1repz27x2t40UUQljK+YqIQW2nnBLEc9cVMaD9o4NaMqVb3FNdCp4Lu0vfG2ozWLB7c2ES3DIcqJQ7bBkcZ2k/hivQKhtLS3s4RFZ28UEQOdkSBVz9BU1d9KHs4qJw1J88uYKKKK0MwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8+8Yr5fje3btPpxX6lJQf8A2evQa4f4gJs13w7PjhjcW5P+8gYf+gVz4pXpM3wztURUsj81a0PWsm0GHrVi615ED0qhaP3aY3Sn5+WmHpW7MEVZehrIvT1rXm71kXo61zzOmmZxXzdT0WDGfN1CEkeyZc/+g1q+Po9ni/TJe0tlMn/fLof/AGY1T0hPN8Y6CnUI08x/CMqP/Q61/iRGRqOgT9hJPEf+BR5/9krrpx/2WTOecv8AaYoo6eea1V6VkWB5rXTpXJE6Km5InWrP8FVl+9Vj+GtoGEiCTrVK7+6auP1qleH5TWcjSBhaxL9n0u+m6GOCRv8Ax016R4dtvsfh/TLbGPJtoo/yUCvMtfQzaXLAOtw8cA/4G6r/AFr10AAADgCu3L1pJnNjn8KCiiivROAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuQ+JSbdM0y6x/x7ahCxPoGzGf8A0OuvrnviBbNdeC9XSMZkSAzJ/vJ84/VaipHmg0XTdppnOWp/eEVqRHpWLYyrKUlTlZFDj6EZrZi6CvDievMtjpSE8Uq8rTW6VsYIrS96yr2tWXoayrvlqwmdFMXwpGJPG8J/54afI34tIg/9lNa3xLXGm6ZN/wA8r+PJ9mVl/wDZhVPwOm/xVq0n/PK0gj/76aRv6CtX4jpnwjdyd4Him/75kUn9M16dKN8M15M4asrYhP0OasutbEf3ax7bh61oT8teXA76hMvWrOfkqsvWp/4a2iYSIX61QvDxV5+tULys5GkNzLKGfWdDtxz5l+jkeyBn/wDZRXqVecaBH9o8caco6W1rPcH6kqg/m1ej16eBjanc4cY71LBRRRXYcgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFYfjPxNY+EtBm1XUt5iQhEjT70jnoo/X8AaCZSUU5S2RuUV5N4G+NOn+Jdeh0q802TTpbhtlvIZhKrt2U/KME9B15r1mgilWhWXNTd0FFcnonje11G1tp7ixvbNbqxj1C3BQTGWFyoGFj3Nuy6cY/i4zg4syeL9MS6th5qiyls7q7e5fKCEW8kSOrKRkHMvIOCNpBFBqdHRWMviXTGtZJ45LiRY5vIeOO0leVX27sGMLvHy/NnGMEHoapf8JnpS6ubR5cWzWlrdxXahnjdZ3lRckDCjMY+ZiAd4FAHTUVzkXi/TVgmkvnNsY7m4g2hWkO2FyjSHaDtQcEseBkZNa2o6pZabax3N5OscMjBEYAtvY9AoGSSewHWgC7RWHJ4s0SO2guHvlEUyswPlv8iq212kGMxhW4JfAB4ODTL3xTY2+vafpMW+ae5umtpHVWCQlYJJjl8bScRgbc5G4GgDforCTxbojwPKl7lVKYAhfdKHOEMa7cyBiDgoCDg4rXsrqK9tY7i3YtFIMqWUqfxBAIPsaAJqKKKACiiigAooooAKKKKACiiigApk0azRPFIMo6lWHqDT6KAPJfDO6LT7e3kz5lqz2r59Y2Kf0FdRH0FYV1F9i8W65a9FaZLxB7SL83/jyNW5GcoDXhTjyzaPYUuaCkWo24pzdKgQ1LnirT0M2itL0NZc/Mlak3Q1msMyVjI3gXvh+h/tvxJJ/t28Y/CPP/s1b/i+D7V4V1eHqWtJcfXacfrWP8O1z/b039/UWT/vmOMf411dzEJ7aWJukiFT+IxXs0F+6S8jyqz/AHrZ5lpsnmwQSf30VvzGa24D8tcz4dYnSbLP3liVT9Rx/SuktjxXiR0Z689iyvWpmPy1Cp5pzNkVsjBjDVC8PNXzWfeH5uaiRpDcm8Axed4h1y8IyIUhtFPuAXb/ANDWu6rlfhpFjwyLth819cS3R+hYhf8Ax1Vrqq9qhHlppHlV5c1RsKKKK1MgooooAKKKKACiiigAooooAKKKzdZ1/R9D8n+2tW0/TvOz5X2u5SHfjGdu4jOMjOPUUAaVFc1/wn3g7/obPD//AIMof/iqP+E+8Hf9DZ4f/wDBlD/8VQB0tFc1/wAJ94O/6Gzw/wD+DKH/AOKo/wCE+8Hf9DZ4f/8ABlD/APFUAdLRXNf8J94O/wChs8P/APgyh/8AiqP+E+8Hf9DZ4f8A/BlD/wDFUAdLRXNf8J94O/6Gzw//AODKH/4qj/hPvB3/AENnh/8A8GUP/wAVQB0tFc1/wn3g7/obPD//AIMof/iqP+E+8Hf9DZ4f/wDBlD/8VQB0tFc1/wAJ94O/6Gzw/wD+DKH/AOKq9pHifQdauWt9H1vS9QuFQyNFa3ccrBQQCxCknGSBn3FAGvRRRQAUUUUAFcX8WvCMvjPwi+n2kqR3cMy3MG84VmUMNpPbIY/jiu0qvf3lvp9pLdXs8cFtENzySNhVH1oIqQjODjLZnzv8Nfg/4itfF1hqGvwR2NpYzrcD98kjSshyoAUnAyBnOOK+kKxtM8S6XqV2trbzypcupeOO4tpYGkUdSgkVdw9xmtmgxwtCnRi1TdzirTwDa2HhGx0jT5YILuCK2jnu/s/F2IgMiRQwYo2D8u7v35zlal8P7m28O3cWnTwTXQs9Rhit4bcQRlrqWKQBQXwoXysYzznqMc9bonizSNatdMudPuGki1EO1uWjZSQgy2QRleMHnqCCKvx6vpslo91HqFm9sjFWmWdSikdQWzgEUHScze+DLq9nku7vU7Wa7muBLPG9kxtZUWLYqGLzMnHLZLEZJ46YqW3w/nt7MWKatD9hl0210y6Q2Z3yJC8rZRvMwm4TEchsY4rura4hureOe1ljmgkG5JI2DKw9QRwRVddW05zcBNQtGNsoecCZT5S+rc/KOD1oA5G7+H6S3bXSXVrLM8lyWS8szNEUmlMmNokU5UnGc4IJyOmOj1HRReWulQLMsQsLiKcbY+G2AjaBn5Qc++KefEGml9PEF1HcRX0jxxTQOrx5RGdssDjGFP41Kda0sW09z/aVl9ngbZNL56bY29GOcA8jg0AcvJ4GmWC+itdVWIagt3DdF7beTFPcSzYT5xtdfOddx3A9Svapn8FM13An9oL/AGVFfT3y2/kHzcywSxOvm7+mZmYfLkYxz1ran8S6TBfWltNewILqA3EMzSKInUMq4DZ5JLjAHWnr4g00C9a5uo7SO0ufskkly6xqZNitgEnnhh+tAHL2nw/+zacbXzdIkKxxxJK+mtvKocguRMCW4BymzB5x2rrPD2nSaTo1rYzXct5JCuDPKSWbknuScDOBkk4AySeauzzxQRGWeVI4hgF3YAcnA5PuRVRtZ0xbGK9bUbIWcrbY5zOvluc4wGzgnIIoAv0Vlav4g03Sp7S3u7mMXN1LHDFArr5jF3Chtuc7cnk1ZGqaeZLqMX1qXtBm4XzlzCMZy4z8v40AXKKgsru2vrZLiyuIbm3f7ssLh1btwRwanoAKKKKACiiigAooooAKKKKAPP8Ax1D5Hi3S7kdLu1lt2+qEOv6F6tWjboFNSfExAtpo11jmHUYwT/surIf/AEIVDY/6n6V5OLjarfuenh3ekixT93FMorC5oMm+6aogZkq9IPlqoCFkBPrUSLiafw2XOhXU3/Pa/uX/APIhX/2WurrmPhrj/hDLE/xF5i3+95r5/Wunr3aStBeh5FXWbPJdMTyGurf/AJ43U8f4CRsfpXQWvQVjSYXxDraL90XrH8Sqk/qTWvaHivDmrVGvM9i94J+Rco/GgUUzMD0rA8S3BttKvZl+8kLFfrjj9a3n6VzPiEfaFgtf+fi7t4fwaVc/pmla7SKjomz0rRbMafo9jZqMC3gSL8lAq7RRXvnjbhRRRQAUUUUAFFFFABRRRQAUUUUAFc1f/wDJSdC/7BOof+jrKulrmr//AJKToX/YJ1D/ANHWVAG3q2oW+laXeajeuUtbSF7iZgpYqiKWY4HJ4BrB8NeO9A8RGdbC6kjeGBbp0u4Htz5DDKyjeBlD/eHH5itHxhpk2teEdb0u1aNLi+sZ7aNpCQoZ42UFiATjJ7A152PhCq+BXsRfNN4hlsrS2kuLmRpYAICjeQowCISykdM4wTnGKAPTk1bTpLNLtNQtGtXO1JhMpRjzwGzgng/lWVqXjDSrK80u2WRrttShuZ7Z7Yq6OsChn+bOM84Hv6V5f4j8Ea3Z2unyrp9jdXd94qt799PtVdrO2RYHTLNsyFJA3NsA5HFXYPhZrEcdi/2nTFlA1iSeGNnWKF7yNVSOL5fuKRznB9AaAPSNP8WaPe6pbaYl2I9Uns0vltJBhxE/TJGV3f7IJPfpzV2LWtKlt7meLU7F4LY4nkWdCsR9GOcL+NeZQ/DDUEvdMk3aUAPDCaFdTjd50EyoV8+H5PmPIXkqcD8KzdK+FfiHT9F1C3tpNGgv5bKGzScTPIkwjkVvmRosR8A4bDkE8dKAPUb3xZpNs+kCO4W7TVLr7Hby2rLInmbS3JB6YU+tb1eN+GfhhrWmXNjLNNpyRw6//azRx3EsmI/I8sqGZAWfd64BH5V7JQAUUUUAFc1f/wDJSdC/7BOof+jrKulrmr//AJKToX/YJ1D/ANHWVAHS0UUUAFFFFABXOeNUYQaVeNBJcWljfJc3MUalmMYR1DbRydjsj4HPyV0dFBMo8yscXq+s6b4jm0qz0G5h1C7jvoLky27b1tURw0hdhwpKBk2nk7+nWu0oooFGLTbZ5dB8OdRj0/SbNL63hiTRGsLwxliVufswgE0fHOQBnOOI0961z4U1C81KO+vItMtiJ7ItbW7s8Wy3807hlF+Y+YABjACLzXdUUFnO+H/Dv2K0VbyWXzYr68uYxb3MqR7JbmSVAyggNhWUEEEA5AyOvH6H4Z1640S0kijtdLuLa1uoINzN5kplnRz5gMf7sYjPTfy4b+HB9SooA8zbwdqlvb6hcyeSS13c3ohS6luX2vp4gCh3UMzFwTjpg8elSaf4a16Swt7uNbOwnNpY2zWkdw6eZFF5hO6Xy90bfvBjapI2kZ+bK+kUUAeZQeCdZtrFYI49KmL2upWjie6lcRrc3JlUgmMmTC4BBK5PfvUs3gXUo70XUFxHc7J5tsT3UkBkjkhgTc0ioxDgwnjaQQ55FekUUAczqPh17jwdpejQJBGLWWwLRySNInlwTxOy7iMt8sZAJHJxnGTWYfC+pW2qPf20em3ZM96RbXMjLHsuDGdxIRvmHlkEYwQ7c813NFAHnVj4K1TT47azjms7q3S50+4e6nkZZgLaOJGQKEIIPlFgdw5kbjvUFr4Bu4rR7W6ht73y4pIoZ31KaMyBpUkyUEZEbEorEgt8y9OTj0yigDG8J2OoafpJh1e4Se6M0j7lIbCliVBYIm8gfxbRn36nZoooAKKKKACiiigAooooAKKKKAOV+JyZ8G3cneGSGYf8BlQ1l6Y+YW56Gt34hR+Z4I1selq7fkM/0rltIctHx/Eua8zHaTTPRwmtNrzNWGZZc47HFS1iaHJ++nVj82+vmXXdX1LUNcnvdQnmF6JD/EQYiD91fTHSsqFF1r62scuZ49YDlvG9z6ykIC81lao+yDcp6GsvwXqN5qHgLTbzUWY3ckTbmbqwDEKx+oAP41ZlLS6Orsck96wqKzcT0cPNVIRqLZ2f3nS/DCTd4bmT/nle3CD/AL+E/wBa66uM+Fn/ACBdRHpqM3/stdnXt0dacfQ8ytpUl6nkzt/xU2tKe965/wDHVrWt7hY3WPq7dBWNe/u/GOsIf+fon80U1Yj+TxBFuPBTivEqfxJep7EFenH0LWveJ9H8PLF/bN/HbNJyqbWdiPXaoJx71b07UrPV7BbzS7mO4t26Oh7+hHUH2NeEfG7TL+HxfNfzRyNY3CRiGXGVXCgFc9jkE4963PhDoWrQaJqN5NqupaXazuphjiSH95gHLYkjbjkAEYzg9eK65UIqkp31PCo5hVqY2WHcNFf19e2p67a3a3Ucm3qjbTWPKPO8R6JF66gjf98qzf0rH0DRr+S1uJh4l1eMO5+7Fac/nAaNP0W/l8WaLF/wkurhmmlYSCO03JiJjkfuMe3IPWsKSTqR16ns1Hywloe20VzX/COap/0OniD/AL82H/yNR/wjmqf9Dp4g/wC/Nh/8jV7Z4x0tFc1/wjmqf9Dp4g/782H/AMjUf8I5qn/Q6eIP+/Nh/wDI1AHS0VzX/COap/0OniD/AL82H/yNR/wjmqf9Dp4g/wC/Nh/8jUAdLRXNf8I5qn/Q6eIP+/Nh/wDI1H/COap/0OniD/vzYf8AyNQB0tFc1/wjmqf9Dp4g/wC/Nh/8jUf8I5qn/Q6eIP8AvzYf/I1AHS0VzX/COap/0OniD/vzYf8AyNR/wjmqf9Dp4g/782H/AMjUAdLXNX//ACUnQv8AsE6h/wCjrKj/AIRzVP8AodPEH/fmw/8Akasy10260/4k6R9r1rUNU8zSb/b9rSBfLxNZ52+VGnXIznPQYxzkA7K8uYLK0nuruVIbaCNpZZHOFRFGSxPYAAmodM1Ox1SN5NOuoblY22P5bA7GwDgjscEHnsaz/HVjc6p4I8Q2FjH5t3dadcQQx7gu52jZVGTgDJI68Vgaz4XmjvoL+WO519ZZgb62YxIZEWN1iwpKIQrMThj1bOcqooA7us5dc0wrKxvoEWIyh2kbYF8pgshJOOFYgE9ORXmLaRqs2pS6VLbT3Wqw6NpxhuvPUrp8vn3X7wszBiwCgblDFthB4PNzWfCetXtpqdutruing1jahmUK8ktzBJBkZ6lUfBPTvjNAHqdV9QvbfTrGe8vZBFbQqXkcgkKB1PFeeXPhzUZfEcV2LHUIbMNbNZiBrbdZqhG+Niz5UEglvLLblYg9AKzJ/DHiG5bVW/sxoJLzTLyGdI2t0gluGliMRXa29vlEvzSHIz/DnBAPXqKKKACiiigArmr/AP5KToX/AGCdQ/8AR1lXS1zV/wD8lJ0L/sE6h/6OsqAOlooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDI8Ypv8ACWtL62U3/oBrhtAbNtC3rGp/QV33iYbvDeqj1tJf/QDXnnhs50+1PrAn/oIrzcfvE9DBfDIhMptdWldQfLJ59qiv/C3hrVL8399pcEl2TuZ9zKHPqyggN+IrV0+FXvZvMGck8GtJrSPHAxXFByjrFnTXp06tlUin66mTqFzGlr5UaqqABFRRgAdgBS3CGHSoITw56ikvLYC7hVR1bmoPFF4LWKWbGfJiaTH0BNSaqyskdP8AC5MeGZJu095cSD3HmFf/AGWuvrH8H6f/AGX4X0uzJy8cC7z6uRlj+ZNbFe9TXLFI8SpLmk2eT+LUNr46vDjAmjhmH5FT/wCg0zWxJHdWlxCCTjtWx8UrYJf6Tep99xJbN7jG8fyP51UVTdaVFIoy8XNePiY8tWR6+HnelF/Iltbx5UXAbOKg1GC5uImPKxqMkmtaxkjlhVlADd6NRb/RmUZy3FZ9Bp2ZT0yNU0mNV46k1V0Nc+NtFJ7G4P8A5Dx/WtBI/IsEQ9QKo6Ef+K20b/duP/QBV0P4sSav8OR6dRRRXuHjBRRRQAUUUUAFFFFABRRRQAUUUUAFcr4jGoWni7R9UstIvNUt4bG8tpVtZIVZGkktmUkSyICMRP0J7V1VFAHNf8JHqn/Ql+IP+/1h/wDJNH/CR6p/0JfiD/v9Yf8AyTXS0UAc1/wkeqf9CX4g/wC/1h/8k0f8JHqn/Ql+IP8Av9Yf/JNdLRQBzX/CR6p/0JfiD/v9Yf8AyTR/wkeqf9CX4g/7/WH/AMk10tFAHNf8JHqn/Ql+IP8Av9Yf/JNH/CR6p/0JfiD/AL/WH/yTXS0UAc1/wkeqf9CX4g/7/WH/AMk0f8JHqn/Ql+IP+/1h/wDJNdLRQBzX/CR6p/0JfiD/AL/WH/yTVaxfU9U8b6ff3Gg6hplpa6ddwNJdy27bnkktmUKIpXPSJ8k4HSuuooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAz/EQz4f1MetrL/wCgGvPfCw3adZ+hgT/0EV6dcwx3NvLBMu6KVCjrkjIIwRkVn2ug6baRJHb22xEUKo3scADA6muTE0JVWuXodWHrxpJp9TmmtB5m+M7W9anIcJxgtXTjTbQf8sv/AB4/40f2da4/1X/jx/xrnWCn3Rr9bizjDbEzebIeR0rn9ZiS9upbaX/VyxtGfYEYr1E6XZkcw/8Ajx/xqs3h3Smk8w2vz+vmP/jUvA1OjRccZBbplfwLqT6p4Xsppzm6jU28/wD10Q7W/MjP41vVS0vS7PSlnWwh8pZ5TNIN7MC5ABPJOOg6Vdr043SV9zz5NNtrY838c3H2/wAULbA5h0633MP+msp4/JV/8ep2hALAVFdi3h/THuLmdrbM1y/mSsZG+ZsBfXjgDpUkOiafAMRW+3/gbH+tcFXCVKlRzujtp4qEKahZnNi3RW3INp74pzRgsCRkiuoGm2g/5Zf+PH/Gg6baH/ll/wCPH/Gp+pT7oPrUfM5C/wD9UaydAx/wmui/7tx/6AK9Bk0ixkGHgyP99v8AGooNA0y3vYLyK223EG7y38xjt3DB4zjpVU8HONRSbWgSxUHBxs9TUooor0TgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mannikin showing the eight potentially involved lymph node areas used for calculating the Follicular Lymphoma International Prognostic Index (FLIPI). The eight nodal areas include cervical, axillary, epitrochlear, mediastinal, mesenteric, paraaortic, inguinal, and popliteal areas, with the sub-areas as noted in the figure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Celigny, P, Roy, P, Colombat, P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104:1258. Copyright &copy; 2004. American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21959=[""].join("\n");
var outline_f21_28_21959=null;
var title_f21_28_21960="Spontaneous cerebral and cervical artery dissection: Treatment and prognosis";
var content_f21_28_21960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spontaneous cerebral and cervical artery dissection: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/28/21960/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21960/contributors\">",
"     David S Liebeskind, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21960/contributors\">",
"     Jeffrey Saver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/28/21960/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21960/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/28/21960/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21960/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/28/21960/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H28006680\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial dissections are a common cause of stroke in the young, but may occur at any age. Dissection occurs when structural integrity of the arterial wall is compromised, allowing blood to collect between layers as an intramural hematoma.",
"   </p>",
"   <p>",
"    This topic will review the treatment and prognosis of spontaneous cerebral and cervical artery dissection. Other aspects of this disorder are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=see_link\">",
"     \"Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007389\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence suggests that treatment with thrombolytic therapy should not be withheld for eligible patients with very early acute ischemic stroke due to extracranial cervical artery dissection (see",
"    <a class=\"local\" href=\"#H28007403\">",
"     'Thrombolysis'",
"    </a>",
"    below). Beyond the hyperacute period, antithrombotic therapy with either anticoagulation or antiplatelet drugs is accepted treatment for ischemic stroke and TIA caused by extracranial artery dissection, although there is controversy regarding the choice between the two (see",
"    <a class=\"local\" href=\"#H28007410\">",
"     'Antithrombotic therapy'",
"    </a>",
"    below). In addition, there is controversy regarding the use of thrombolytics and antithrombotic agents for ischemic symptoms in patients with either intracranial dissection alone or intracranial extension of extracranial dissection because of the presumed increased risk of subarachnoid hemorrhage.",
"   </p>",
"   <p>",
"    Less often, endovascular methods or surgical repair have been used to treat dissection, mainly for patients who have recurrent ischemia despite antithrombotic therapy (see",
"    <a class=\"local\" href=\"#H28007424\">",
"     'Endovascular and surgical therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Optimal treatment of dissection remains a challenge due to limitations in rapidly establishing a definitive diagnosis, the overall low incidence, low recurrence rate and marked variation in patient characteristics. Most therapeutic studies of dissection have been limited to single center reports rather than multicenter randomized, controlled clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/1\">",
"     1",
"    </a>",
"    ]. A prospective, multicenter randomized controlled trial comparing antiplatelet and anticoagulation therapy in acute (within seven days of onset) carotid and vertebral artery dissection is currently underway [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007396\">",
"    <span class=\"h1\">",
"     ACUTE ISCHEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with cervicocephalic dissection who present with transient ischemic attack or acute ischemic stroke, standard approaches to management should be rigorously followed including blood pressure regulation, fluid administration, control of hyperglycemia and other metabolic derangements, and airway management. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=see_link\">",
"     \"Ischemic stroke in children: Evaluation, initial management, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=see_link\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007403\">",
"    <span class=\"h2\">",
"     Thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major randomized trials of intravenous thrombolysis for acute ischemic stroke did not exclude patients with cervicocephalic arterial dissection. While thrombolysis in the setting of dissection may theoretically cause enlargement of the intramural hematoma, accumulating evidence suggests that the effectiveness and safety of thrombolysis for patients with ischemic stroke related to cervical artery dissection are similar to its effectiveness and safety for patients with ischemic stroke from other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Perhaps the strongest evidence, although indirect, comes from a 2011 meta-analysis of individual patient data from 14 retrospective series and 22 case reports involving 180 patients with cervical artery dissection who were treated with thrombolysis and followed for a median of three months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/5\">",
"     5",
"    </a>",
"    ]. When these patients were compared with matched historic controls from the observational SITS-ISTR registry of patients treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    for acute ischemic stroke, there were no major differences between groups for rates of symptomatic intracranial hemorrhage, mortality, excellent outcome, or favorable outcome.",
"   </p>",
"   <p>",
"    Given these data, we recommend intravenous thrombolysis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    for eligible patients (",
"    <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"     table 1",
"    </a>",
"    ) with acute ischemic stroke, including those with isolated extracranial or intracranial cervical artery dissection, provided that treatment is initiated within 3 hours of clearly defined symptom onset. For patients who cannot be treated in less than 3 hours, we suggest intravenous alteplase therapy, provided that treatment is initiated within 3 to 4.5 hours of clearly defined symptom onset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link\">",
"     \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extension of aortic dissection, however, is a known complication of thrombolysis.",
"   </p>",
"   <p>",
"    Intra-arterial thrombolysis has potential advantages over intravenous thrombolysis for the treatment of ischemia due to dissection, including selective catheterization and delivery of a smaller total dose of lytic agent. It has been used to treat acute ischemic stroke in the setting of dissection in small numbers of patients without an increased complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. Intra-arterial thrombolysis should not preclude treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    for otherwise eligible patients, but is a reasonable treatment option at expert centers for select patients who have contraindications to intravenous thrombolysis. Therefore, for patients who cannot be treated with intravenous thrombolysis within 4.5 hours and have angiographically demonstrated extracranial or intracranial dissection and associated ischemic stroke symptoms but no signs of major early infarction or subarachnoid hemorrhage on a baseline CT or MRI scan, we suggest intra-arterial alteplase therapy, provided that treatment can be started within six hours of clearly defined symptom onset at centers with appropriate expertise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=see_link&amp;anchor=H24#H24\">",
"     \"Reperfusion therapy for acute ischemic stroke\", section on 'Intra-arterial thrombolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007410\">",
"    <span class=\"h1\">",
"     ANTITHROMBOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombotic therapy, with either anticoagulation or antiplatelet drugs, has been used as treatment for ischemic stroke and TIA caused by cervical arterial dissection. In theory, anticoagulation may prevent occlusion of a stenotic vessel and minimize distal embolization. Extension of an intramural hematoma in the presence of anticoagulation is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/5\">",
"     5",
"    </a>",
"    ]. However, no randomized trials have directly compared anticoagulation with antiplatelet therapy for this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/9\">",
"     9",
"    </a>",
"    ]. A 2012 meta-analysis of nonrandomized studies with over 1600 patients with cervical artery dissection reported no significant difference in recurrent stroke risk or mortality comparing anticoagulation with antiplatelets [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, debate regarding optimal antithrombotic strategies in cervicocephalic arterial dissection persists [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some, but not all, experts prefer acute anticoagulation for patients with extracranial dissection who have transient ischemic attack or small to moderate sized infarction, and favor antiplatelet therapy for patients with large infarcts, where the risk of hemorrhagic transformation may be increased. Anticoagulation is generally avoided in the setting of intracranial dissection due to the risk of subarachnoid hemorrhage, although some evidence suggests that anticoagulation can be used safely for some patients who have intracranial dissection without subarachnoid hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early antiplatelet therapy rather than anticoagulation is advocated by some experts for patients with ischemic symptoms due to cervicocephalic dissection. Antiplatelet agents can also be used for patients with contraindications to anticoagulation and for those who do not want anticoagulation.",
"   </p>",
"   <p>",
"    Antiplatelet therapy is favored by some experts for patients with dissection who present with nonischemic symptoms. Most reports have employed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    at various doses on a daily basis, whereas there are no data regarding other antiplatelet agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , or combinations of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007417\">",
"    <span class=\"h2\">",
"     Duration of antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no concrete data regarding optimal duration of antithrombotic therapy. The time course of healing of the vessel wall or resolution of vascular abnormalities may be used to guide duration of initial anticoagulation. Most arterial abnormalities stabilize in appearance or resolve by three months, and vessels that fail to reconstitute a normal lumen by six months are highly unlikely to recover at later time points [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/14\">",
"     14",
"    </a>",
"    ]. After three to six months, repeat imaging is suggested to assess vascular status. Multimodal CT or MRI, ultrasonography, or conventional angiography may be used, although serial noninvasive approaches are favored. Further treatment is tailored to imaging findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007424\">",
"    <span class=\"h2\">",
"     Endovascular and surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular techniques or surgical repair have been used to treat dissection, mainly for patients who have recurrent ischemia despite antithrombotic therapy.",
"   </p>",
"   <p>",
"    Endovascular techniques for the treatment of dissection and dissecting aneurysm include angioplasty, stent placement, embolization with various materials, and combinations of such approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/15\">",
"     15",
"    </a>",
"    ]. Angioplasty and stenting may occlude the false lumen and restore true arterial lumen patency. However, data regarding endovascular treatment of dissection is limited to case reports and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/15-22\">",
"     15-22",
"    </a>",
"    ]. There are no randomized trial data comparing endovascular techniques with medical therapies, and the long-term safety and durability of these methods are unknown.",
"   </p>",
"   <p>",
"    Although unproven, endovascular treatment of intracranial dissection, rather than antithrombotic therapy, may minimize the risk of subarachnoid hemorrhage. The morphology of most dissecting aneurysms limits standard surgical clipping.",
"   </p>",
"   <p>",
"    In isolated cases, accessible lesions may be treated by surgical vessel reconstruction or bypass around a dissecting aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Other surgical revascularization procedures include extracranial-intracranial bypass, endarterectomy, thrombectomy, and proximal vessel ligation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007431\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with ischemic stroke or TIA and extracranial carotid or vertebral arterial dissection, the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    guidelines issued in 2011 conclude that the use of antithrombotic therapy for at least three to six months is reasonable, but that the relative efficacy of antiplatelet versus anticoagulation therapy is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/25\">",
"     25",
"    </a>",
"    ]. Similarly, United Kingdom guidelines published in 2008 from the National Institute for Health and Clinical Excellence recommend treatment with either anticoagulants or antiplatelet agents, preferably as part of a randomized clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/26\">",
"     26",
"    </a>",
"    ]. The 2012 American College of Chest Physician (ACCP) guidelines concluded that the available evidence does not demonstrate a significant difference between antiplatelet therapy and anticoagulation for the acute treatment of patients with stroke secondary to cervical artery dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/27\">",
"     27",
"    </a>",
"    ]. Therefore, the ACCP guidelines for such patients follow the general recommendations for patients with noncardioembolic stroke, meaning",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in the acute phase (within 48 hours of stroke onset) and antiplatelet therapy (eg, aspirin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19271?source=see_link\">",
"     aspirin-extended-release dipyridamole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    ) for secondary prevention of stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with extracranial carotid or vertebral arterial dissection who have definite recurrent ischemic events despite adequate antithrombotic therapy, the 2011",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines conclude that stenting may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/25\">",
"     25",
"    </a>",
"    ]. For patients who fail or are not candidates for endovascular therapy, surgical treatment may be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007438\">",
"    <span class=\"h2\">",
"     Choosing therapy for primary and secondary prevention of ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommendations for the prevention of new and recurrent ischemia in the setting of dissection are based upon currently available evidence, published guidelines, and our clinical experience:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have ischemic neurologic symptoms caused by",
"      <strong>",
"       extracranial",
"      </strong>",
"      dissection, we suggest treatment with anticoagulation, using unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for six months, rather than antiplatelet therapy. However, this approach is controversial, and some experts favor treatment with antiplatelet agents rather than anticoagulation in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute anticoagulation may be achieved with either subcutaneous low-molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      twice daily) or with intravenous unfractionated heparin (dose-adjusted to achieve a goal partial thromboplastin time of 45 to 60 s). Transition to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      can be pursued in the subacute period for clinically stable patients.",
"     </li>",
"     <li>",
"      At three months, as long as symptoms are not recurrent and the arterial lesion is thrombosed or healed, we suggest stopping",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and starting long-term antiplatelet therapy. For patients with persistent vascular luminal stenosis, irregularity, or dissecting aneurysm, we suggest continuing anticoagulation with repeat imaging at regular intervals. We use transcranial Doppler, duplex Doppler, CT angiography, and MR angiography to help us decide the status of the arterial system prior to discontinuing anticoagulation therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"       \"Evaluation of carotid artery stenosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have ischemic neurologic symptoms caused by",
"      <strong>",
"       intracranial",
"      </strong>",
"      dissection, we suggest treatment with antiplatelet therapy rather than anticoagulation.",
"     </li>",
"     <li>",
"      For patients with nonischemic symptoms caused by",
"      <strong>",
"       extracranial",
"      </strong>",
"      cervical dissection, we suggest treatment with antiplatelet therapy for primary prevention of ischemic stroke.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007445\">",
"    <span class=\"h2\">",
"     Management of subarachnoid hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subarachnoid hemorrhage is a rare complication of intracranial dissection. It is managed according to the same principles as subarachnoid hemorrhage caused by rupture of a saccular aneurysm, with the exception that the surgical or endovascular treatment of dissecting aneurysm itself may differ from that of a saccular aneurysm because of morphologic differences between the two types of aneurysms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007452\">",
"    <span class=\"h2\">",
"     Risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no proven methods that reduce the risk of recurrent cervicocephalic arterial dissection. Nevertheless, some experts suggest that patients with dissection should avoid contact sports, chiropractic neck manipulation, and any activity that involves abrupt rotation and flexion-extension of the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In addition, estrogen-containing compounds should be discontinued, as estrogen may induce proliferation of intimal and fibromuscular arterial tissue. All vascular risk factors including hypertension should be addressed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007459\">",
"    <span class=\"h2\">",
"     Management of local symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache and neck pain associated with dissection can usually be managed with simple analgesics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    sodium, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    . There is no specific treatment for other local symptoms of dissection such as Horner syndrome, lower cranial nerve palsy, audible bruit, or tinnitus, but these may improve with time and vessel healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007466\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of cerebral and cervical artery dissection is related primarily to the severity of associated ischemic stroke or subarachnoid hemorrhage. Morbidity and mortality of acute cervicocephalic arterial dissection varies according to the specific arteries involved and location of the lesion. In the CADISP study of 982 patients with extracranial cervical artery dissection, an unfavorable outcome (defined as a modified Rankin Scale score &gt;2) at three months among patients with ischemic stroke was more likely with internal carotid artery dissection compared with vertebral artery dissection (25 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/30\">",
"     30",
"    </a>",
"    ]. This result was largely driven by stroke severity at onset, which was greater by mean National Institutes of Health Stroke Scale (NIHSS) score on admission for patients with internal carotid dissection compared with those who had vertebral dissection (8 versus 3).",
"   </p>",
"   <p>",
"    Only limited systematic data are available regarding long-term outcomes of dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/31\">",
"     31",
"    </a>",
"    ]. Complete or excellent recovery occurs in 70 to 85 percent of patients with extracranial dissection, with major disabling deficits in 10 to 25 percent, and death in 5 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In retrospective observational studies, factors associated with poor functional outcome include a high NIHSS score at onset, arterial occlusion, and older age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Quality of life may be impaired in almost half of long-term survivors after dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007473\">",
"    <span class=\"h2\">",
"     Vessel healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, arteries with stenosis or luminal irregularities caused by spontaneous dissection undergo recanalization and healing in the first months after the initial event.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 61 patients with acute vertebral artery dissection who presented with symptoms vertebrobasilar territory ischemia, complete recanalization of the vertebral artery was observed at six months in 62 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study that followed 76 patients with spontaneous cervical artery dissection involving 105 vessels with a mean follow-up of 58 months, complete recanalization was noted in 51 percent of vessels, nearly all occurring within the first nine months, and hemodynamically significant recanalization in 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, limited data suggest that most dissecting extracranial aneurysms do not resolve with angiographic follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/38\">",
"     38",
"    </a>",
"    ]. Residual headache may indicate persistent vascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007480\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Earlier retrospective studies suggested that rate of recurrent cervicocephalic dissection, at the initial or remote site, was approximately 1 percent annually [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, this low rate is called into question by findings from the large CADISP study that recruited both retrospectively and prospectively and reported a recurrence rate for extracranial cervical dissection &ndash; at only three months &ndash; of 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/30\">",
"     30",
"    </a>",
"    ]. The rate of recurrent ischemic symptoms (stroke and transient ischemic attack) after dissection ranges from 0 to 13 percent in various studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/42\">",
"     42",
"    </a>",
"    ]. It is likely that the actual rate of recurrent ischemic stroke caused by dissection is at the low end of this range. The largest study consisted of 432 surviving patients with carotid or vertebral dissection who were followed for a mean time of 31 months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/40\">",
"     40",
"    </a>",
"    ]. Recurrent ischemic stroke due to initial or recurrent dissection was observed in four patients (0.9 percent), giving an annual incidence of 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/40\">",
"     40",
"    </a>",
"    ]. Transient ischemic attack was observed in eight patients (1.8 percent), for an annual incidence of 0.6 percent.",
"   </p>",
"   <p>",
"    Recurrent dissection may affect several vessels at once, even when preceded by initial dissection isolated to one artery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited, rare patients with familial dissection tend to be young (mean age 36 years) and are probably at high risk for recurrent or multiple dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21960/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28007487\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathophysiology, etiology, clinical features and diagnosis of spontaneous cerebral and cervical artery dissection are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=see_link\">",
"       \"Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The available evidence suggests that treatment with thrombolytic therapy should not be withheld for eligible patients with very early acute ischemic stroke due to extracranial cervical artery dissection. Beyond the hyperacute period, antithrombotic therapy with either anticoagulation or antiplatelet drugs is accepted treatment for ischemic stroke and TIA caused by extracranial artery dissection, although there is controversy regarding the choice between the two (see",
"      <a class=\"local\" href=\"#H28007410\">",
"       'Antithrombotic therapy'",
"      </a>",
"      above). In addition, there is controversy regarding the use of thrombolytics and antithrombotic agents for ischemic symptoms in patients with either intracranial dissection alone or intracranial extension of extracranial dissection because of the presumed increased risk of subarachnoid hemorrhage. Endovascular methods or surgical repair have been used to treat dissection, mainly for patients who have recurrent ischemia despite antithrombotic therapy. (See",
"      <a class=\"local\" href=\"#H28007389\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend intravenous thrombolysis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      for eligible patients (",
"      <a class=\"graphic graphic_table graphicRef71462 \" href=\"UTD.htm?31/40/32397\">",
"       table 1",
"      </a>",
"      ) with acute ischemic stroke, including those with isolated extracranial or intracranial cervical artery dissection, provided that treatment is initiated within 3 hours of clearly defined symptom onset (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients who cannot be treated in less than 3 hours, we suggest intravenous alteplase therapy, provided that treatment is initiated within 3 to 4.5 hours of clearly defined symptom onset (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28007403\">",
"       'Thrombolysis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link\">",
"       \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who cannot be treated with intravenous thrombolysis within 4.5 hours and have angiographically demonstrated extracranial or intracranial dissection and associated ischemic stroke symptoms but no signs of major early infarction or subarachnoid hemorrhage on a baseline CT or MRI scan, we suggest intra-arterial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      therapy, provided that treatment can be started within six hours of clearly defined symptom onset at centers with appropriate expertise (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28007403\">",
"       'Thrombolysis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=see_link\">",
"       \"Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have ischemic neurologic symptoms caused by",
"      <strong>",
"       extracranial",
"      </strong>",
"      dissection who are beyond the hyperacute period or ineligible for thrombolytic therapy, we suggest treatment with anticoagulation, using unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or low molecular weight heparin, followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for six months, rather than antiplatelet therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, this approach is controversial, and some experts favor treatment with antiplatelet agents rather than anticoagulation in this setting. (See",
"      <a class=\"local\" href=\"#H28007410\">",
"       'Antithrombotic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28007438\">",
"       'Choosing therapy for primary and secondary prevention of ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have ischemic neurologic symptoms caused by",
"      <strong>",
"       intracranial",
"      </strong>",
"      dissection, we suggest treatment with antiplatelet therapy rather than anticoagulation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28007438\">",
"       'Choosing therapy for primary and secondary prevention of ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with nonischemic symptoms caused by",
"      <strong>",
"       extracranial",
"      </strong>",
"      cervical dissection, we suggest treatment with antiplatelet therapy for primary prevention of ischemic stroke (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28007438\">",
"       'Choosing therapy for primary and secondary prevention of ischemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endovascular methods or surgical repair have been used to treat dissection, mainly for patients who have recurrent ischemia despite antithrombotic therapy. (See",
"      <a class=\"local\" href=\"#H28007424\">",
"       'Endovascular and surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subarachnoid hemorrhage due to intracranial dissection is managed according to the same principles as subarachnoid hemorrhage caused by rupture of a saccular aneurysm. (See",
"      <a class=\"local\" href=\"#H28007445\">",
"       'Management of subarachnoid hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Headache and neck pain associated with dissection can usually be managed with simple analgesics. (See",
"      <a class=\"local\" href=\"#H28007459\">",
"       'Management of local symptoms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prognosis of cerebral and cervical artery dissection is related primarily to the severity of associated ischemic stroke or subarachnoid hemorrhage. In patients with patients with extracranial dissection, complete or excellent recovery occurs in 70 to 85 percent, while disabling deficits result 10 to 25 percent, and death occurs in 5 to 10 percent. Morbidity and mortality rates may be higher for patients with intracranial dissection. (See",
"      <a class=\"local\" href=\"#H28007466\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, arteries with stenosis or luminal irregularities caused by spontaneous dissection undergo recanalization and healing in the first months after the initial event. In contrast, limited data suggest that most dissecting extracranial aneurysms do not resolve. (See",
"      <a class=\"local\" href=\"#H28007473\">",
"       'Vessel healing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rate of recurrent cervicocephalic dissection is approximately 1 percent annually. The rate of recurrent ischemic symptoms (stroke and transient ischemic attack) after dissection ranges from 0 to 13 percent in various studies. It is likely that the actual rate of recurrent ischemic stroke caused by dissection is at the low end of this range. (See",
"      <a class=\"local\" href=\"#H28007480\">",
"       'Recurrence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/1\">",
"      Menon R, Kerry S, Norris JW, Markus HS. Treatment of cervical artery dissection: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2008; 79:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/2\">",
"      Cervical Artery Dissection in Stroke Study Trial Investigators. Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection in Stroke Study (CADISS). Int J Stroke 2007; 2:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/3\">",
"      Engelter ST, Rutgers MP, Hatz F, et al. Intravenous thrombolysis in stroke attributable to cervical artery dissection. Stroke 2009; 40:3772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/4\">",
"      Georgiadis D, Baumgartner RW. Thrombolysis in cervical artery dissection. Front Neurol Neurosci 2005; 20:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/5\">",
"      Zinkstok SM, Vergouwen MD, Engelter ST, et al. Safety and functional outcome of thrombolysis in dissection-related ischemic stroke: a meta-analysis of individual patient data. Stroke 2011; 42:2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/6\">",
"      Qureshi AI, Chaudhry SA, Hassan AE, et al. Thrombolytic treatment of patients with acute ischemic stroke related to underlying arterial dissection in the United States. Arch Neurol 2011; 68:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/7\">",
"      Engelter ST, Dallongeville J, Kloss M, et al. Thrombolysis in cervical artery dissection--data from the Cervical Artery Dissection and Ischaemic Stroke Patients (CADISP) database. Eur J Neurol 2012; 19:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/8\">",
"      Arnold M, Nedeltchev K, Sturzenegger M, et al. Thrombolysis in patients with acute stroke caused by cervical artery dissection: analysis of 9 patients and review of the literature. Arch Neurol 2002; 59:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/9\">",
"      Engelter ST, Brandt T, Debette S, et al. Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 2007; 38:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/10\">",
"      Kennedy F, Lanfranconi S, Hicks C, et al. Antiplatelets vs anticoagulation for dissection: CADISS nonrandomized arm and meta-analysis. Neurology 2012; 79:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/11\">",
"      Georgiadis D, Arnold M, von Buedingen HC, et al. Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients. Neurology 2009; 72:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/12\">",
"      Kasner SE, Dreier JP. A fresh twist on carotid artery dissections. Neurology 2009; 72:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/13\">",
"      Metso TM, Metso AJ, Helenius J, et al. Prognosis and safety of anticoagulation in intracranial artery dissections in adults. Stroke 2007; 38:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/14\">",
"      Nedeltchev K, Bickel S, Arnold M, et al. R2-recanalization of spontaneous carotid artery dissection. Stroke 2009; 40:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/15\">",
"      Donas KP, Mayer D, Guber I, et al. Endovascular repair of extracranial carotid artery dissection: current status and level of evidence. J Vasc Interv Radiol 2008; 19:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/16\">",
"      Ansari SA, Thompson BG, Gemmete JJ, Gandhi D. Endovascular treatment of distal cervical and intracranial dissections with the neuroform stent. Neurosurgery 2008; 62:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/17\">",
"      Ecker RD, Levy EI, Hopkins LN. Acute neuroform stenting of a symptomatic petrous dissection. J Invasive Cardiol 2007; 19:E137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/18\">",
"      Cohen JE, Leker RR, Gotkine M, et al. Emergent stenting to treat patients with carotid artery dissection: clinically and radiologically directed therapeutic decision making. Stroke 2003; 34:e254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/19\">",
"      Biondi A, Katz JM, Vallabh J, et al. Progressive symptomatic carotid dissection treated with multiple stents. Stroke 2005; 36:e80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/20\">",
"      Kadkhodayan Y, Jeck DT, Moran CJ, et al. Angioplasty and stenting in carotid dissection with or without associated pseudoaneurysm. AJNR Am J Neuroradiol 2005; 26:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/21\">",
"      Edgell RC, Abou-Chebl A, Yadav JS. Endovascular management of spontaneous carotid artery dissection. J Vasc Surg 2005; 42:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/22\">",
"      Kim BM, Shin YS, Kim SH, et al. Incidence and risk factors of recurrence after endovascular treatment of intracranial vertebrobasilar dissecting aneurysms. Stroke 2011; 42:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/23\">",
"      M&uuml;ller BT, Luther B, Hort W, et al. Surgical treatment of 50 carotid dissections: indications and results. J Vasc Surg 2000; 31:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/24\">",
"      Chiche L, Praquin B, Koskas F, Kieffer E. Spontaneous dissection of the extracranial vertebral artery: indications and long-term outcome of surgical treatment. Ann Vasc Surg 2005; 19:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/25\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Stroke: The diagnosis and acute management of stroke and transient ischaemic attacks. Royal College of Physicians, London 2008. file://www.nice.org.uk/CG068 (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/27\">",
"      Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/28\">",
"      Paciaroni M, Bogousslavsky J. Cerebrovascular complications of neck manipulation. Eur Neurol 2009; 61:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/29\">",
"      Reuter U, H&auml;mling M, Kavuk I, et al. Vertebral artery dissections after chiropractic neck manipulation in Germany over three years. J Neurol 2006; 253:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/30\">",
"      Debette S, Grond-Ginsbach C, Bodenant M, et al. Differential features of carotid and vertebral artery dissections: the CADISP study. Neurology 2011; 77:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/31\">",
"      Arauz A, Hoyos L, Espinoza C, et al. Dissection of cervical arteries: Long-term follow-up study of 130 consecutive cases. Cerebrovasc Dis 2006; 22:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/32\">",
"      Arnold M, Bousser MG, Fahrni G, et al. Vertebral artery dissection: presenting findings and predictors of outcome. Stroke 2006; 37:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/33\">",
"      Milhaud D, de Freitas GR, van Melle G, Bogousslavsky J. Occlusion due to carotid artery dissection: a more severe disease than previously suggested. Arch Neurol 2002; 59:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/34\">",
"      Dziewas R, Konrad C, Dr&auml;ger B, et al. Cervical artery dissection--clinical features, risk factors, therapy and outcome in 126 patients. J Neurol 2003; 250:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/35\">",
"      Fischer U, Ledermann I, Nedeltchev K, et al. Quality of life in survivors after cervical artery dissection. J Neurol 2009; 256:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/36\">",
"      Arauz A, M&aacute;rquez JM, Artigas C, et al. Recanalization of vertebral artery dissection. Stroke 2010; 41:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/37\">",
"      Baracchini C, Tonello S, Meneghetti G, Ballotta E. Neurosonographic monitoring of 105 spontaneous cervical artery dissections: a prospective study. Neurology 2010; 75:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/38\">",
"      Guillon B, Brunereau L, Biousse V, et al. Long-term follow-up of aneurysms developed during extracranial internal carotid artery dissection. Neurology 1999; 53:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/39\">",
"      Manabe H, Yonezawa K, Kato T, et al. Incidence of intracranial arterial dissection in non-emergency outpatients complaining of headache: preliminary investigation with MRI/MRA examinations. Acta Neurochir Suppl 2010; 107:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/40\">",
"      Touz&eacute; E, Gauvrit JY, Moulin T, et al. Risk of stroke and recurrent dissection after a cervical artery dissection: a multicenter study. Neurology 2003; 61:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/41\">",
"      Schievink WI, Mokri B, Piepgras DG, Kuiper JD. Recurrent spontaneous arterial dissections: risk in familial versus nonfamilial disease. Stroke 1996; 27:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/42\">",
"      Debette S, Leys D. Cervical-artery dissections: predisposing factors, diagnosis, and outcome. Lancet Neurol 2009; 8:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/43\">",
"      Dittrich R, Nassenstein I, Bachmann R, et al. Polyarterial clustered recurrence of cervical artery dissection seems to be the rule. Neurology 2007; 69:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21960/abstract/44\">",
"      Martin JJ, Hausser I, Lyrer P, et al. Familial cervical artery dissections: clinical, morphologic, and genetic studies. Stroke 2006; 37:2924.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16649 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21960=[""].join("\n");
var outline_f21_28_21960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28007487\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28006680\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28007389\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28007396\">",
"      ACUTE ISCHEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28007403\">",
"      Thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28007410\">",
"      ANTITHROMBOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28007417\">",
"      Duration of antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28007424\">",
"      Endovascular and surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28007431\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28007438\">",
"      Choosing therapy for primary and secondary prevention of ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28007445\">",
"      Management of subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28007452\">",
"      Risk reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28007459\">",
"      Management of local symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28007466\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28007473\">",
"      Vessel healing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28007480\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28007487\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/16649\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/16649|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/40/32397\" title=\"table 1\">",
"      Criteria for treating acute stroke with tPA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10426?source=related_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6570?source=related_link\">",
"      Intravenous fibrinolytic (thrombolytic) therapy in acute ischemic stroke: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=related_link\">",
"      Ischemic stroke in children: Evaluation, initial management, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10730?source=related_link\">",
"      Spontaneous cerebral and cervical artery dissection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_28_21961="Seborrheic dermatitis in adolescents and adults";
var content_f21_28_21961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Seborrheic dermatitis in adolescents and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/28/21961/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21961/contributors\">",
"     Denis Sasseville, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/28/21961/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21961/contributors\">",
"     Joseph Fowler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/28/21961/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21961/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/28/21961/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H34051752\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis is a chronic, relapsing, and usually mild form of dermatitis that occurs in infants and in adults. The severity may vary from minimal, asymptomatic scaliness of the scalp (dandruff) to more widespread involvement. Affected individuals are usually healthy, although seborrheic dermatitis has been associated with human immunodeficiency virus (HIV) infection, Parkinson disease, and use of neuroleptic medications.",
"   </p>",
"   <p>",
"    This topic will discuss the pathogenesis, clinical manifestations, and management of seborrheic dermatitis in adolescents and adults. The infantile form of seborrheic dermatitis and a general overview of dermatitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2278?source=see_link\">",
"     \"Cradle cap and seborrheic dermatitis in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"     \"Overview of dermatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34051759\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis has a biphasic incidence, occurring in infants between the ages of 2 weeks and 12 months, and later, during adolescence and adulthood. The prevalence of clinically significant seborrheic dermatitis is approximately 3 percent, with peak prevalence in the third and fourth decades [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/1\">",
"     1",
"    </a>",
"    ]. The actual prevalence is probably much higher when mild cases are included. Men are affected more frequently than women.",
"   </p>",
"   <p>",
"    The prevalence of seborrheic dermatitis is increased among individuals with HIV in whom it may be a presenting sign. The prevalence has been estimated to be around 35 percent among patients with early HIV infection, and up to 85 percent among patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with parkinsonism frequently present with seborrhea (oily skin) and seborrheic dermatitis, both of which may improve with L-dopa therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations of Parkinson disease\", section on 'Nonmotor symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34051766\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of seborrheic dermatitis is not known. Seborrheic dermatitis is not a disease of the sebaceous glands, nor is the rate of sebum excretion increased in patients with seborrheic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/6\">",
"     6",
"    </a>",
"    ]. Nonetheless, sebaceous glands appear to be necessary for the development of seborrheic dermatitis as indicated by the predilection for body sites with increased numbers of sebaceous glands and larger sebaceous glands (face, scalp, upper trunk, external auditory meatus, and anogenital area). In addition, the infantile form is common early in the first year of life, when transplacental transfer of maternal androgens stimulates the growth of the infant&rsquo;s sebaceous glands.",
"   </p>",
"   <p>",
"    Sebaceous glands may play a permissive role in the pathogenesis of seborrheic dermatitis, possibly by creating a favorable milieu for the growth of fungi of the genus Malassezia. The lipid-dependent Malassezia (formerly known as Pityrosporum ovale) is a saprophyte of normal skin that thrives at the sites of predilection for seborrheic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, there is limited direct evidence that Malassezia is implicated in the etiology of seborrheic dermatitis. Thus far, studies have failed to demonstrate a higher density of Malassezia on the skin of affected individuals or a relationship between the intensity of skin colonization and severity of seborrheic dermatitis, although some specific Malassezia species have been detected more frequently on affected skin than on normal skin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indirect evidence for a role of Malassezia in seborrheic dermatitis derives from the observation that most of the effective therapeutic agents have antifungal activity. However, the non-specific antiinflammatory effect of the azole antifungal agents commonly used for seborrheic dermatitis may also explain their efficacy.",
"   </p>",
"   <p>",
"    Observational studies suggest that in some patients seborrheic dermatitis may result from the host&rsquo;s immune response to Malassezia or to its byproducts (eg, lipases, or free fatty acids) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Other studies, however, were unable to find humoral or cellular immunologic abnormalities in patients with seborrheic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/14\">",
"     14",
"    </a>",
"    ]. The inflammation of seborrheic dermatitis may be irritant rather than immune-mediated, due to Malassezia production of free fatty acids, lipase, and reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reason for the increased susceptibility of patients with HIV infection to seborrheic dermatitis is not known. The relationship between seborrheic dermatitis and neurologic disorders is also poorly understood. Patients with Parkinson disease often have increased sebum production; in these patients seborrhea and seborrheic dermatitis improve with L-dopa therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34051773\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis may first appear soon after puberty or later in life. It is usually characterized by well demarcated erythematous plaques with greasy-looking, yellowish scales distributed on areas rich in sebaceous glands such as the scalp, the external ear, the center of the face, the upper part of the trunk, and the intertriginous areas (",
"    <a class=\"graphic graphic_picture graphicRef56410 graphicRef82073 graphicRef59104 \" href=\"UTD.htm?43/7/44153\">",
"     picture 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498821253\">",
"    <span class=\"h2\">",
"     Scalp",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mildest and most common form of scalp seborrheic dermatitis is dandruff, also known as pityriasis sicca, in which the scalp shows fine, white, diffuse scaliness without underlying erythema (",
"    <a class=\"graphic graphic_picture graphicRef54173 \" href=\"UTD.htm?31/51/32566\">",
"     picture 2",
"    </a>",
"    ). Dandruff may be asymptomatic or accompanied by mild pruritus. More severe forms of scalp seborrheic dermatitis present with visible inflammation, consisting of patchy, orange to salmon-colored plaques covered with yellowish, greasy scales (pityriasis steatoides), mostly over the temporoparietal areas (",
"    <a class=\"graphic graphic_picture graphicRef76985 \" href=\"UTD.htm?8/50/8998\">",
"     picture 1E",
"    </a>",
"    ). Lesions may extend to the post-auricular areas where they often develop fissures, oozing, and crusting, and to the outer canal and concha of the ear, sometimes with marked pruritus and superinfection (otitis externa). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link&amp;anchor=H3#H3\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\", section on 'Pathogenesis and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498821260\">",
"    <span class=\"h2\">",
"     Face",
"    </span>",
"    &nbsp;&mdash;&nbsp;Facial lesions favor the forehead below the hairline, the eyebrows and glabella, and the nasolabial folds. They may extend to the cheeks and malar areas in a butterfly distribution (",
"    <a class=\"graphic graphic_picture graphicRef65167 graphicRef59104 \" href=\"UTD.htm?15/35/15927\">",
"     picture 1C-D",
"    </a>",
"    ). The mustache and beard area are frequently involved in men with facial hair. Shaving helps with treatment and control of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498821267\">",
"    <span class=\"h2\">",
"     Periocular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blepharitis with redness of the free margin of the eyelids and yellow crusting between the eyelashes may be the sole manifestation of seborrheic dermatitis or may accompany its more classic distribution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link&amp;anchor=H8#H8\">",
"     \"Blepharitis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498821274\">",
"    <span class=\"h2\">",
"     Trunk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five patterns of truncal involvement have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moist, erythematous intertrigo of the axillae, infra-mammary folds, umbilicus, and genitocrural area (",
"      <a class=\"graphic graphic_picture graphicRef53407 \" href=\"UTD.htm?25/14/25827\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The &ldquo;petaloid pattern&rdquo;, consisting of polycyclic, finely scaly, thin plaques over the sternum or interscapular area",
"     </li>",
"     <li>",
"      Annular or arcuate, round to oval, slightly scaly plaques on the trunk, sometimes with hypopigmented central clearing, known as &ldquo;seborrheic eczematids&rdquo;",
"     </li>",
"     <li>",
"      The pityriasiform pattern mimicking pityriasis rosea, comprised of 5 to 15 mm oval-shaped, scaly lesions distributed along the skin tension lines",
"     </li>",
"     <li>",
"      The psoriasiform pattern with larger red, rounded plaques, covered with thicker scales",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498821343\">",
"    <span class=\"h2\">",
"     In patients with HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis tends to be more extensive and severe in",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    patients. It sometimes involves unusual sites, such as the extremities, and may be difficult to control [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. Seborrheic dermatitis is frequently observed in patients with CD4 counts &lt;400",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    and is more diffuse and severe in patients with CD4 counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. It may regress with highly active antiretroviral therapy (HAART). However, seborrheic dermatitis also may be a cutaneous manifestation of the immune reconstitution inflammatory syndrome in patients on HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link&amp;anchor=H18#H18\">",
"     \"Immune reconstitution inflammatory syndrome\", section on 'Miscellaneous syndromes possibly associated with IRIS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498821317\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis is a chronic, relapsing condition that may go on for decades. It tends to worsen with stress and during the cold and dry winter months. It tends to improve during the summer months, probably from sun exposure, although it may be precipitated by psoralen and ultraviolet A (PUVA) therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/19\">",
"     19",
"    </a>",
"    ]. The available treatments do not cure seborrheic dermatitis, and must be repeated or continued intermittently to prevent recurrence. (See",
"    <a class=\"local\" href=\"#H27253022\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H710057309\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of seborrheic dermatitis is usually made clinically based on the appearance and location of the lesions. (See",
"    <a class=\"local\" href=\"#H34051773\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Biopsy may be indicated when the diagnosis is uncertain. (See",
"    <a class=\"local\" href=\"#H34051795\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34051788\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although biopsy is not routinely necessary, biopsies of seborrheic dermatitis in HIV-negative patients show focal parakeratosis in the horny layer of the epidermis, mounds of scale-crusts with pyknotic neutrophils on the lips of dilated, sometimes plugged follicular ostia, psoriasiform acanthosis and mild to moderate spongiosis. The dermis harbors a sparse perivascular lymphohistiocytic inflammatory infiltrate. In chronic cases, the histologic picture may be difficult to distinguish from psoriasis, but the presence of even a minimal degree of spongiosis should favor a diagnosis of seborrheic dermatitis.",
"   </p>",
"   <p>",
"    In",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    patients, the histopathologic changes parallel the severity of the disease. Parakeratosis is more widespread and the epidermis shows necrotic keratinocytes. Spongiosis is less prominent; the inflammatory infiltrate is denser and in some areas obliterates the dermoepidermal junction. It contains numerous plasma cells and foci of leukocytoclasis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34051795\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of seborrheic dermatitis includes psoriasis, rosacea, tinea versicolor, pityriasis rosea, tinea corporis, secondary syphilis, systemic lupus erythematosus (SLE), and pemphigus foliaceous. Most of these conditions can be distinguished clinically; syphilis, SLE, and pemphigus foliaceous require laboratory confirmation.",
"   </p>",
"   <p>",
"    Psoriasis is the main condition in the differential diagnosis of seborrheic dermatitis in adolescents and adults. Sometimes the two diseases may coexist, and the term sebopsoriasis has been given to those cases where the distinction cannot be made. Usually, however, psoriatic lesions are sharply demarcated and erythematous and the scales are more abundant and silvery white (",
"    <a class=\"graphic graphic_picture graphicRef74211 \" href=\"UTD.htm?38/13/39135\">",
"     picture 4",
"    </a>",
"    ). In most cases the extensor areas such as the elbows and knees are involved although the lesions can occur in the body folds (inverse psoriasis) (",
"    <a class=\"graphic graphic_picture graphicRef76200 \" href=\"UTD.htm?3/19/3381\">",
"     picture 5",
"    </a>",
"    ). Characteristic nail changes (",
"    <a class=\"graphic graphic_picture graphicRef66374 graphicRef70962 \" href=\"UTD.htm?15/57/16279\">",
"     picture 6A-B",
"    </a>",
"    ), as well as the presence of arthritis or a positive family history may help establish the diagnosis of psoriasis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rosacea is another condition that commonly targets the face, and sometimes coexists with seborrheic dermatitis. A predominance of telangiectasias and papulopustules, and the frequent involvement of the nose, malar, and perioral areas with minimal or no scaliness are typical features of rosacea (",
"    <a class=\"graphic graphic_picture graphicRef77020 graphicRef67890 graphicRef78747 graphicRef59815 graphicRef56083 \" href=\"UTD.htm?39/15/40186\">",
"     picture 7A-E",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=see_link&amp;anchor=H432867#H432867\">",
"     \"Rosacea: Pathogenesis, clinical features, and diagnosis\", section on 'Classification and clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the trunk, petaloid lesions of seborrheic dermatitis may be mistaken for tinea versicolor, which usually lacks erythema (",
"    <a class=\"graphic graphic_picture graphicRef78860 \" href=\"UTD.htm?13/17/13588\">",
"     picture 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3320?source=see_link&amp;anchor=H4#H4\">",
"     \"Tinea versicolor\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pityriasis rosea is distinguished from seborrheic dermatitis by its abrupt onset, presence of a herald patch and resolution within a few weeks (",
"    <a class=\"graphic graphic_picture graphicRef87124 graphicRef87126 \" href=\"UTD.htm?7/13/7384\">",
"     picture 9A-B",
"    </a>",
"    ). The pityriasiform variant of seborrheic dermatitis should be suspected when lesions appear more progressively, persist for more than three months and are accompanied by lesions on areas usually spared by pityriasis rosea (the face and intertriginous areas). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/18999?source=see_link&amp;anchor=H3#H3\">",
"     \"Pityriasis rosea\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Annular or arciform seborrheic dermatitis lesions on the trunk can be confused with tinea corporis (",
"    <a class=\"graphic graphic_picture graphicRef76839 \" href=\"UTD.htm?28/36/29250\">",
"     picture 10",
"    </a>",
"    ); tinea corporis can be ruled out by negative potassium hydroxide (KOH) microscopic examination and negative fungal culture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H23#H23\">",
"     \"Dermatophyte (tinea) infections\", section on 'Tinea corporis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary syphilis, the great imitator, can trigger widespread pityriasiform or psoriasiform eruptions that can be mistaken for seborrheic dermatitis. Additional signs such as palmoplantar and mucosal lesions, or peripheral adenopathy should be looked for, and appropriate serologic testing ordered when indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Secondary syphilis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Seborrheic dermatitis of the face may be mistaken for the butterfly eruption of acute SLE, or the discoid plaques of cutaneous LE (",
"    <a class=\"graphic graphic_picture graphicRef64844 graphicRef75833 \" href=\"UTD.htm?17/33/17945\">",
"     picture 11A-B",
"    </a>",
"    ). The acute eruption of SLE rarely involves the nasolabial sulcus or crosses the bridge of the nose. Discoid lesions exhibit atrophy and sometimes scarring, along with adherent scales that may have &ldquo;carpet tacking&rdquo; on their undersurface (spiny projections that plug dilated follicular openings). Histologic examination and serologic testing for antinuclear autoantibodies should be performed to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H2#H2\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Cutaneous expressions of lupus erythematosus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pemphigus foliaceous is characterized by erythema, scaling, and crusting that first appears on the face and scalp (",
"    <a class=\"graphic graphic_picture graphicRef60530 graphicRef54341 \" href=\"UTD.htm?24/33/25112\">",
"     picture 12A-B",
"    </a>",
"    ) and later involves the chest and back. Histology, direct immunofluorescence, and the measurement of circulating autoantibodies against desmoglein establish the diagnosis. Pemphigus erythematosus of Senear and Usher is a superficial variant of pemphigus foliaceous that is most likely to mimic seborrheic dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link&amp;anchor=H181679733#H181679733\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\", section on 'Pemphigus foliaceus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27253022\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis is a chronic condition. Repeated or long term maintenance treatment is often necessary. The available treatments include topical corticosteroids, topical antifungal agents, and several topical agents with non-specific antimicrobial, antiinflammatory, or keratolytic properties.",
"   </p>",
"   <p>",
"    In randomized trials, topical corticosteroids and topical antifungal agents were effective in treating the acute phase of seborrheic dermatitis, and intermittent use of topical antifungals prevented relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. However in most of the placebo-controlled trials, treatment with placebo (vehicle) was effective in a substantial proportion of patients (usually at least 25 percent). This suggests that frequent shampooing or regular use of emollients may also be beneficial in the management of seborrheic dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1431767\">",
"    <span class=\"h2\">",
"     Seborrheic dermatitis of the scalp",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with seborrheic dermatitis of the scalp (desquamation with inflammation) we suggest treatment with an antifungal shampoo with or without a topical high-potency corticosteroid.",
"   </p>",
"   <p>",
"    Antifungal shampoos include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=see_link\">",
"     selenium sulfide",
"    </a>",
"    2.5%,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2%, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    1% shampoo. The shampoo should be left on for five to ten minutes before rinsing off. The medicated shampoo can be used daily or at least 2 or 3 times per week for several weeks, until remission is achieved. Subsequently, the use of the medicated shampoo once a week may be helpful to prevent relapse. Serious adverse effects have not been reported with antifungal shampoos. Irritation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    burning sensation have been reported in 1 to 3 percent of patients. Some patients complain of dryness of the hair, which can be treated with an over-the-counter conditioner.",
"   </p>",
"   <p>",
"    Inflammation and itching may be controlled with high potency (group three to one (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    )) topical corticosteroid shampoo, lotion, or foam applied once daily for two to four weeks. Several high-potency shampoos are available;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"     fluocinolone",
"    </a>",
"    acetonide 0.01% shampoo is approved by the US Food and Drug Administration for the treatment of seborrheic dermatitis; other high-potency shampoos are approved for treatment of psoriasis and can be used off-label for the treatment of seborrheic dermatitis. Although prolonged cutaneous application of high-potency corticosteroids is associated with cutaneous and systemic side effects, application to the scalp is generally safe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of antifungal shampoos",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    topical corticosteroids for the treatment of seborrheic dermatitis of the scalp is supported by a few randomized trials comparing specific agents with placebo or each other, as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 4-week trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      2% shampoo and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=see_link\">",
"       selenium sulfide",
"      </a>",
"      2.5% shampoo were similarly effective in reducing adherent dandruff, and both were more effective than placebo (mean reduction in dandruff score 73, 67, and 44 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 4-week trial, more patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"       ciclopirox",
"      </a>",
"      1% shampoo twice per week had clinical improvement than those treated with vehicle (26 versus 13 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/24\">",
"       24",
"      </a>",
"      ]. In another 4-week trial, the rates of improvement in patients treated with ciclopirox 1% shampoo twice per week, once per week, and placebo were 58, 45, and 32 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 2-week trial, more patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"       fluocinolone",
"      </a>",
"      acetonide 0.01% shampoo had marked improvement or clearing than those treated with vehicle (84 versus 28 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 4-week trial,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      2% shampoo was slightly more effective than zinc pyrithione 1% shampoo twice per week in improving dandruff severity score (73 versus 67 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440620014\">",
"    <span class=\"h3\">",
"     Dandruff",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dandruff (desquamation without inflammation) is the mildest form of seborrheic dermatitis of the scalp. Limited data from randomized trials suggest that dandruff may be treated with over-the-counter anti-dandruff shampoos containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=see_link\">",
"     selenium sulfide",
"    </a>",
"    2.5% or zinc pyrithione 1 to 2%,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44724?source=see_link\">",
"     coal tar",
"    </a>",
"    , or salicylic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/23,26,27\">",
"     23,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43690674\">",
"    <span class=\"h2\">",
"     Seborrheic dermatitis of the face",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with seborrheic dermatitis of the face, we suggest treatment with a low potency topical corticosteroid cream, a topical antifungal agent, or a combination of the two.",
"   </p>",
"   <p>",
"    Any low potency (group seven or six) topical corticosteroid cream may be used (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). The least potent topical corticosteroid creams should be used because of the potential for adverse effects with prolonged use of higher potency topical corticosteroids on the face. The topical corticosteroid cream is applied to the affected areas once or twice daily only until symptoms subside. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H17#H17\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Cutaneous'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative topical antifungal agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% cream, other azole creams, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    1% cream. Bifonazole is available in Canada and Europe, but not in the United States. Topical antifungal agents are applied to affected areas once or twice daily until symptoms subside.",
"   </p>",
"   <p>",
"    For long term control, we suggest application of a topical antifungal cream to the involved areas once a week; as an alternative,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% shampoo may be used as a facial wash once weekly. Long term (months to years) continuous use of even mild topical corticosteroids can result in permanent telangiectasia and atrophy and should be avoided.",
"   </p>",
"   <p>",
"    Men with seborrheic dermatitis of the face who have mustaches and beards require special consideration. For such patients we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% shampooing of the facial hair daily until remission and then once per week. A low-potency corticosteroid (group seven (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    )) can be added to the initial treatment to control inflammation and itching.",
"   </p>",
"   <p>",
"    The use of topical corticosteroids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antifungals for the treatment of seborrheic dermatitis of the face is supported by a few randomized trials comparing specific agents with placebo or with each other:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial, three weeks of twice daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13828?source=see_link\">",
"       desonide",
"      </a>",
"      0.05% lotion was associated with increased clearing or almost clearing of facial lesions in patients with seborrheic or atopic dermatitis (88 versus 42 percent in the vehicle group); the response rates among the patients with seborrheic dermatitis were not reported separately, but 70 and 80 percent of patients in the desonide and vehicle groups, respectively had seborrheic dermatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial, remission rates were similar among 36 patients with seborrheic dermatitis of the face or trunk who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      2% cream or clobetasone 17-butyrate 0.05% cream (a moderate potency corticosteroid) twice daily for four weeks (approximately 65 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial, more patients treated with four weeks of bifonazole 1% cream had clinical improvement than those treated with placebo (43 versus 23 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Topical calcineurin inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    cream,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ointment), which block inflammation and are not associated with skin atrophy, have also been used for facial seborrheic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/31\">",
"     31",
"    </a>",
"    ]. In randomized trials, pimecrolimus 1% cream was more effective than placebo and similarly effective to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    acetate 1% cream and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% cream [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. However, adverse events (mild skin reaction, burning sensation) were reported more frequently in the pimecrolimus groups. Topical pimecrolimus is not approved for treatment of seborrheic dermatitis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    succinate or gluconate topical preparations are available in Europe, and have been shown to be effective in treating seborrheic dermatitis in areas other than the scalp, probably because of their antiinflammatory properties [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. In a randomized trial, more patients treated with eight weeks of lithium gluconate 8% cream than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% cream had improvement in erythema and desquamation (52 percent versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/38\">",
"     38",
"    </a>",
"    ]. Local irritant reactions have been reported in about 10 percent of patients using topical lithium salts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1666176\">",
"    <span class=\"h2\">",
"     Seborrheic blepharitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of blepharitis, including seborrheic blepharitis, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link&amp;anchor=H21#H21\">",
"     \"Blepharitis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43690682\">",
"    <span class=\"h2\">",
"     Seborrheic dermatitis of the trunk and intertriginous areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with seborrheic dermatitis of the trunk and intertriginous areas, we suggest treatment with topical corticosteroid creams, topical antifungal agents, or a combination of the two. In a randomized trial, remission rates were similar among 36 patients with seborrheic dermatitis of the face or trunk who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% cream or clobetasone 17-butyrate 0.05% cream twice daily for four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any midpotency (group five or four) topical corticosteroid cream may be used (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ). The topical corticosteroid cream is applied to the affected areas once or twice daily only until symptoms subside.",
"   </p>",
"   <p>",
"    Alternative topical antifungal agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% cream, other azole creams, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    cream. Bifonazole is available in Canada and Europe, but not in the United States. Topical antifungal agents are applied to affected areas once or twice daily until symptoms subside. Adverse effects are uncommon with topical antifungal agents.",
"   </p>",
"   <p>",
"    For long term control, we suggest a topical antifungal cream be applied to the involved areas once a week; as an alternative,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% shampoo may be used as body wash once weekly. Emollients can be used liberally. (See",
"    <a class=\"local\" href=\"#H364614144\">",
"     'Prevention of relapse'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1431820\">",
"    <span class=\"h2\">",
"     Seborrheic dermatitis in HIV patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seborrheic dermatitis is more diffuse and severe in HIV positive patients and may require a prolonged course of treatment. There are no studies evaluating the treatment of seborrheic dermatitis in HIV positive patients. Initial management is the same as for patients who are not HIV positive [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In severe cases or in cases that are refractory to topical treatment, a course of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally for one week) may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H710057784\">",
"    <span class=\"h2\">",
"     Severe or refractory seborrheic dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence to guide treatment of severe or refractory seborrheic dermatitis in nonHIV-positive patients. Agents that have been used in observational or small randomized trials include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. Among these, we suggest oral itraconazole. In an observational study, itraconazole (200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally for one week) was associated with improvement in erythema, scaling, and itching [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whenever apparent seborrheic dermatitis does not respond to appropriate therapy, the diagnosis should be reconsidered. (See",
"    <a class=\"local\" href=\"#H34051795\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364614144\">",
"    <span class=\"h1\">",
"     PREVENTION OF RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most patients with seborrheic dermatitis, we suggest intermittent use of topical therapies to prevent relapse.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    2% shampoo and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    1% shampoo, used intermittently, have been shown to be effective in preventing relapses of scalp seborrheic dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a six-month trial in which 312 patients who responded to initial treatment of scalp seborrheic dermatitis were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      2% shampoo once weekly, every two weeks, or placebo, relapses were observed in 19, 31, and 47 percent of the patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a similar study, in which 428 patients were randomly assigned to four months of treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"       ciclopirox",
"      </a>",
"      shampoo once weekly, every two weeks or placebo, the relapse rates were 15, 22, and 35 percent respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21961/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevention of relapse of seborrheic dermatitis at body sites other than the scalp has not been well studied. However, it is common practice to use antifungal cream or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    2% shampoo (as facial or body wash) intermittently to prevent relapse. The risk of side effects with this approach is minimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/5/22610?source=see_link\">",
"       \"Patient information: Seborrheic dermatitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/1/6164?source=see_link\">",
"       \"Patient information: Seborrheic dermatitis (including dandruff and cradle cap) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1666197\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seborrheic dermatitis is a chronic, relapsing and usually mild form of dermatitis of unknown origin occurring in areas rich in sebaceous glands (scalp, face, upper trunk, intertriginous areas); indirect evidence supports a pathogenetic role for the Malassezia yeast. (See",
"      <a class=\"local\" href=\"#H34051766\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mildest and most common form of scalp seborrheic dermatitis is dandruff, a fine, white, diffuse scaliness of the scalp without underlying erythema. Manifestations of severe seborrheic dermatitis of the scalp or other body sites include inflamed, erythematous plaques covered with yellowish, greasy scales (",
"      <a class=\"graphic graphic_picture graphicRef76985 graphicRef59104 \" href=\"UTD.htm?29/29/30168\">",
"       picture 1C, 1E",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H34051773\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of seborrheic dermatitis is usually made clinically based on the appearance and location of the lesions. The differential diagnosis of seborrheic dermatitis includes psoriasis (",
"      <a class=\"graphic graphic_picture graphicRef74211 \" href=\"UTD.htm?38/13/39135\">",
"       picture 4",
"      </a>",
"      ), rosacea (",
"      <a class=\"graphic graphic_picture graphicRef77020 graphicRef67890 graphicRef78747 graphicRef59815 graphicRef56083 \" href=\"UTD.htm?39/15/40186\">",
"       picture 7A-E",
"      </a>",
"      ), tinea versicolor (",
"      <a class=\"graphic graphic_picture graphicRef78860 \" href=\"UTD.htm?13/17/13588\">",
"       picture 8",
"      </a>",
"      ), pityriasis rosea (",
"      <a class=\"graphic graphic_picture graphicRef87126 graphicRef87124 \" href=\"UTD.htm?7/17/7448\">",
"       picture 9A-B",
"      </a>",
"      ), tinea corporis (",
"      <a class=\"graphic graphic_picture graphicRef76839 \" href=\"UTD.htm?28/36/29250\">",
"       picture 10",
"      </a>",
"      ), secondary syphilis, lupus erythematosus (",
"      <a class=\"graphic graphic_picture graphicRef64844 graphicRef75833 \" href=\"UTD.htm?17/33/17945\">",
"       picture 11A-B",
"      </a>",
"      ), and pemphigus foliaceous (",
"      <a class=\"graphic graphic_picture graphicRef60530 graphicRef54341 \" href=\"UTD.htm?24/33/25112\">",
"       picture 12A-B",
"      </a>",
"      ). These conditions can be differentiated clinically",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      through laboratory tests and histology. (See",
"      <a class=\"local\" href=\"#H710057309\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34051795\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several randomized trials indicate that topical corticosteroids and topical antifungal agents are effective for treating seborrheic dermatitis and that intermittent topical antifungals may prevent relapse. However, the high response in the placebo groups suggests that frequent shampooing, or regular use of emollients may also be beneficial. (See",
"      <a class=\"local\" href=\"#H27253022\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with seborrheic dermatitis of the scalp we suggest treatment with antifungal shampoos (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=see_link\">",
"       selenium sulfide",
"      </a>",
"      2.5%,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      2%, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"       ciclopirox",
"      </a>",
"      1%) rather than frequent shampooing with nonmedicated shampoo (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternative medicated shampoos include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44724?source=see_link\">",
"       coal tar",
"      </a>",
"      , salicylic acid, and sulfur, alone or in combination, available over the counter as shampoos or lotions. The medicated shampoo should be used daily or two or three times per week for several weeks, until remission is achieved. (See",
"      <a class=\"local\" href=\"#H1431767\">",
"       'Seborrheic dermatitis of the scalp'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In addition, for patients with itching",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      visible inflammation (patchy, orange to salmon-colored plaques covered with scale), we suggest treatment with a high potency (group three to one) corticosteroid shampoo, lotion, or foam (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The topical corticosteroid should be applied once daily for two to four weeks.",
"      <br/>",
"      <br/>",
"      For long term control of seborrheic dermatitis of the scalp, we suggest ketoconazole 2% shampoo or ciclopirox 1% shampoo once per week (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H364614144\">",
"       'Prevention of relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For initial treatment of patients with seborrheic dermatitis of the face, we suggest treatment with low potency (groups six or seven) topical corticosteroid cream (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      ), or topical antifungal agent (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      2% cream, other azole creams, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"       ciclopirox",
"      </a>",
"      1% cream), or a combination of the two (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The topical therapy is applied to the affected areas once or twice daily only until symptoms subside. (See",
"      <a class=\"local\" href=\"#H43690674\">",
"       'Seborrheic dermatitis of the face'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For men with seborrheic dermatitis of the face who have mustaches and beards, we suggest ketoconazole 2% shampooing of the facial hair (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The shampoo is used daily until remission and then once per week. A low-potency corticosteroid (group seven (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )) can be added to the initial treatment to control inflammation and itching.",
"      <br/>",
"      <br/>",
"      For long term control of facial seborrheic dermatitis, we suggest ketoconazole 2% cream or shampoo, other azole cream, or ciclopirox 1% cream once per week (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H364614144\">",
"       'Prevention of relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with seborrheic dermatitis of the trunk and intertriginous areas, we suggest treatment with mid-potency (groups five or four) topical corticosteroid cream (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      ) or topical antifungal agents, or a combination of the two (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The topical therapy is applied to the affected areas once or twice daily only until symptoms subside.",
"      <br/>",
"      <br/>",
"      For long term control of seborrheic dermatitis of the trunk and intertriginous areas, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      2% cream or shampoo, other azole cream, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"       ciclopirox",
"      </a>",
"      1% cream once per week (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H43690682\">",
"       'Seborrheic dermatitis of the trunk and intertriginous areas'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H364614144\">",
"       'Prevention of relapse'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Johnson MLT. Skin Conditions and Related Need for Medical Care among Persons 1&ndash;74 Years, United States, 1971&ndash;1974. Series 11, Data from the National Health Survey November, No. 212, DHEW Pub No. (PHS) 79&ndash;1660. U.S. Department of Health, Education, and Welfare, Public Health Service, National Center for Health, Hyattsville, MD 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/2\">",
"      Berger RS, Stoner MF, Hobbs ER, et al. Cutaneous manifestations of early human immunodeficiency virus exposure. J Am Acad Dermatol 1988; 19:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/3\">",
"      Soeprono FF, Schinella RA, Cockerell CJ, Comite SL. Seborrheic-like dermatitis of acquired immunodeficiency syndrome. A clinicopathologic study. J Am Acad Dermatol 1986; 14:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/4\">",
"      Burton JL, Cartlidge M, Shuster S. Effect of L-dopa on the seborrhoea of Parkinsonism. Br J Dermatol 1973; 88:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/5\">",
"      Kohn SR, Pochi PE, Strauss JS, et al. Sebaceous gland secretion in Parkinson's disease during L-dopa treatment. J Invest Dermatol 1973; 60:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/6\">",
"      Burton JL, Pye RJ. Seborrhoea is not a feature of seborrhoeic dermatitis. Br Med J (Clin Res Ed) 1983; 286:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/7\">",
"      McGinley KJ, Leyden JJ, Marples RR, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol 1975; 64:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/8\">",
"      Heng MC, Henderson CL, Barker DC, Haberfelde G. Correlation of Pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol 1990; 23:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/9\">",
"      Gupta AK, Kohli Y, Summerbell RC, Faergemann J. Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol 2001; 39:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/10\">",
"      Pech&egrave;re M, Krischer J, Remondat C, et al. Malassezia spp carriage in patients with seborrheic dermatitis. J Dermatol 1999; 26:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/11\">",
"      Sandstr&ouml;m Falk MH, Tengvall Linder M, Johansson C, et al. The prevalence of Malassezia yeasts in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls. Acta Derm Venereol 2005; 85:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/12\">",
"      Faergemann J, Bergbrant IM, Dohs&eacute; M, et al. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001; 144:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/13\">",
"      Riciputo RM, Oliveri S, Micali G, Sapuppo A. Phospholipase activity in Malassezia furfur pathogenic strains. Mycoses 1996; 39:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/14\">",
"      Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998; 139:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/15\">",
"      Mathes BM, Douglass MC. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 1985; 13:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/16\">",
"      Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med 2009; 360:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/17\">",
"      Mu&ntilde;oz-P&eacute;rez MA, Rodriguez-Pichardo A, Camacho F, Colmenero MA. Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse. Br J Dermatol 1998; 139:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/18\">",
"      Osei-Sekyere B, Karstaedt AS. Immune reconstitution inflammatory syndrome involving the skin. Clin Exp Dermatol 2010; 35:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/19\">",
"      Tegner E. Seborrhoeic dermatitis of the face induced by PUVA treatment. Acta Derm Venereol 1983; 63:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/20\">",
"      Reygagne P, Poncet M, Sidou F, Soto P. Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: results of a pilot study. Cutis 2007; 79:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/21\">",
"      Shuster S, Meynadier J, Kerl H, Nolting S. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol 2005; 141:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/22\">",
"      Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol 1995; 132:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/23\">",
"      Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol 1993; 29:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/24\">",
"      Lebwohl M, Plott T. Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol 2004; 43 Suppl 1:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/25\">",
"      Ramirez RG, Dorton D. Double-blind placebo-controlled multicentrestudy of fluocinolone acetonide shampoo (FS shampoo) in scalp seborrheic dermatitis. J Dermatol Treat 1993; 3:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/26\">",
"      Pi&eacute;rard-Franchimont C, Goffin V, Decroix J, Pi&eacute;rard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol 2002; 15:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/27\">",
"      Pi&eacute;rard-Franchimont C, Pi&eacute;rard GE, Vroome V, et al. Comparative anti-dandruff efficacy between a tar and a non-tar shampoo. Dermatology 2000; 200:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/28\">",
"      Freeman S, Howard A, Foley P, et al. Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis. Australas J Dermatol 2002; 43:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/29\">",
"      Pari T, Pulimood S, Jacob M, et al. Randomised double blind controlled trial of 2% ketoconazole cream versus 0.05% clobetasol 17-butyrate cream in seborrhoeic dermatitis. J Eur Acad Dermatol Venereol 1998; 10:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/30\">",
"      Zienicke H, Korting HC, Braun-Falco O, et al. Comparative efficacy and safety of bifonazole 1% cream and the corresponding base preparation in the treatment of seborrhoeic dermatitis. Mycoses 1993; 36:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/31\">",
"      Cook BA, Warshaw EM. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol 2009; 10:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/32\">",
"      Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol 2007; 57:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/33\">",
"      Firooz A, Solhpour A, Gorouhi F, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006; 142:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/34\">",
"      Koc E, Arca E, Kose O, Akar A. An open, randomized, prospective, comparative study of topical pimecrolimus 1% cream and topical ketoconazole 2% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat 2009; 20:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/35\">",
"      Ballanger F, Tenaud I, Volteau C, et al. Anti-inflammatory effects of lithium gluconate on keratinocytes: a possible explanation for efficiency in seborrhoeic dermatitis. Arch Dermatol Res 2008; 300:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/36\">",
"      Dreno B, Moyse D. Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomised, double-blind study versus placebo. Eur J Dermatol 2002; 12:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/37\">",
"      A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis. Efalith Multicenter Trial Group. J Am Acad Dermatol 1992; 26:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/38\">",
"      Dreno B, Chosidow O, Revuz J, et al. Lithium gluconate 8% vs ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study. Br J Dermatol 2003; 148:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/39\">",
"      Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol 2004; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/40\">",
"      Osborne GE, Taylor C, Fuller LC. The management of HIV-related skin disease. Part II: neoplasms and inflammatory disorders. Int J STD AIDS 2003; 14:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/41\">",
"      Shemer A, Kaplan B, Nathansohn N, et al. Treatment of moderate to severe facial seborrheic dermatitis with itraconazole: an open non-comparative study. Isr Med Assoc J 2008; 10:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/42\">",
"      Scaparro E, Quadri G, Virno G, et al. Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol 2001; 144:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/43\">",
"      Vena GA, Micali G, Santoianni P, et al. Oral terbinafine in the treatment of multi-site seborrhoic dermatitis: a multicenter, double-blind placebo-controlled study. Int J Immunopathol Pharmacol 2005; 18:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21961/abstract/44\">",
"      Ford GP, Farr PM, Ive FA, Shuster S. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984; 111:603.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13669 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21961=[""].join("\n");
var outline_f21_28_21961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1666197\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34051752\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34051759\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34051766\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34051773\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H498821253\">",
"      Scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H498821260\">",
"      Face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H498821267\">",
"      Periocular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H498821274\">",
"      Trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H498821343\">",
"      In patients with HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H498821317\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H710057309\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34051788\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34051795\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27253022\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1431767\">",
"      Seborrheic dermatitis of the scalp",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H440620014\">",
"      - Dandruff",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43690674\">",
"      Seborrheic dermatitis of the face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1666176\">",
"      Seborrheic blepharitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43690682\">",
"      Seborrheic dermatitis of the trunk and intertriginous areas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1431820\">",
"      Seborrheic dermatitis in HIV patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H710057784\">",
"      Severe or refractory seborrheic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H364614144\">",
"      PREVENTION OF RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1666197\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13669\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13669|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/58/34721\" title=\"picture 1A\">",
"      Seborrheic dermatitis face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/14/3301\" title=\"picture 1B\">",
"      Seborrheic dermatitis ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/42/28320\" title=\"picture 1C\">",
"      Seborrheic dermatitis face 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/31/20979\" title=\"picture 1D\">",
"      Seborrheic dermatitis face 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/50/8998\" title=\"picture 1E\">",
"      Seborrheic dermatitis scalp 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/51/32566\" title=\"picture 2\">",
"      Seborrheic dermatitis scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/14/25827\" title=\"picture 3\">",
"      Seborrheic dermatitis axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/13/39135\" title=\"picture 4\">",
"      Plaque type psoriasis PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/19/3381\" title=\"picture 5\">",
"      Inverse psoriasis groin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/51/33585\" title=\"picture 6A\">",
"      Nail psoriasis oil drop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/7/15474\" title=\"picture 6B\">",
"      Nail psoriasis pits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/49/37649\" title=\"picture 7A\">",
"      Rosacea erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/52/41794\" title=\"picture 7B\">",
"      Rosacea papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/54/7011\" title=\"picture 7C\">",
"      Rosacea papules and pustules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/3/15410\" title=\"picture 7D\">",
"      Rosacea papulopustular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/61/32722\" title=\"picture 7E\">",
"      Rosacea erythema cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/17/13588\" title=\"picture 8\">",
"      Tinea versicolor chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/18/8484\" title=\"picture 9A\">",
"      Pityriasis rosea on abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/61/35793\" title=\"picture 9B\">",
"      Pityriasis rosea with herald patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/36/29250\" title=\"picture 10\">",
"      Tinea corporis 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/56/16261\" title=\"picture 11A\">",
"      Discoid lupus - right cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/11/8372\" title=\"picture 11B\">",
"      Discoid lupus - left ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/2/11300\" title=\"picture 12A\">",
"      Pemphigus foliaceus scalp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/5/35922\" title=\"picture 12B\">",
"      Pemphigus foliaceus face",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13669|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2278?source=related_link\">",
"      Cradle cap and seborrheic dermatitis in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=related_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/5/22610?source=related_link\">",
"      Patient information: Seborrheic dermatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/1/6164?source=related_link\">",
"      Patient information: Seborrheic dermatitis (including dandruff and cradle cap) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/18999?source=related_link\">",
"      Pityriasis rosea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36584?source=related_link\">",
"      Rosacea: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3320?source=related_link\">",
"      Tinea versicolor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_28_21962="Thymic neuroendocrine (carcinoid) tumors";
var content_f21_28_21962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thymic neuroendocrine (carcinoid) tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/28/21962/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21962/contributors\">",
"     Jonathan R Strosberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21962/contributors\">",
"     Mark F Berry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21962/contributors\">",
"     Henry D Tazelaar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/28/21962/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21962/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21962/contributors\">",
"     Sally E Carty, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21962/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/28/21962/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/28/21962/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/28/21962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H703971452\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymic neuroendocrine tumors (NETs), otherwise known as thymic carcinoid tumors, are exceedingly uncommon primary thymic neoplasms with neuroendocrine differentiation that generally present as a mass within the anterior mediastinum. This topic review will cover the epidemiology, pathology, classification, clinical presentation, staging, and treatment of neuroendocrine tumors arising in the thymus. Thymomas and thymic carcinomas are addressed elsewhere, as is the diagnostic evaluation of patients with a mediastinal mass, and the differential diagnosis of an anterior mediastinal mass lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=see_link\">",
"     \"Clinical presentation and management of thymoma and thymic carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=see_link\">",
"     \"Anterior mediastinal mass lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2663177\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thymus is an anterior mediastinal organ that weighs 12 to 15 grams at birth, reaches its maximum weight of 40 grams around puberty, and then involutes and persists in an atrophic state into old age. The gland is composed of a central medulla and an outer cortex, surrounded by an outer capsule. The thymus consists primarily of epithelial cells, keratinized epithelial cells (Hassall's corpuscles), myoid cells, thymic lymphocytes (\"thymocytes\"), and B-lymphocytes, which may rarely form germinal centers. The thymus is primarily involved in the processing and maturation of lymphocytes, which become T-lymphocytes upon release into the circulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link&amp;anchor=H1231136#H1231136\">",
"     \"Normal B and T lymphocyte development\", section on 'T cell development'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thymic neoplasms typically present as a mass in the anterior mediastinal compartment (",
"    <a class=\"graphic graphic_figure graphicRef56637 \" href=\"UTD.htm?10/31/10743\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75493 \" href=\"UTD.htm?34/28/35265\">",
"     image 1",
"    </a>",
"    ). Thymectomy and resection of anterior mediastinal masses can be achieved via several different techniques, which are generally chosen based on thymus size and location. Minimally invasive approaches may be appropriate for masses less than 4 to 5 cm in size, and can be performed through the neck (transcervical thymectomy) or through the chest (video-assisted thoracoscopic surgery (VATS) or robotic thymectomy). Larger resections require a median sternotomy, possibly with thoracotomy extension into either or both sides of the chest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of mediastinal masses\", section on 'Mediastinal anatomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=see_link\">",
"     \"Anterior mediastinal mass lesions\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4769298\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymic malignancies as a group are relatively rare (0.2 to 1.5 percent of all malignancies, 0.13 cases per 100,000 population in the United States [US]), but they are among the most common mediastinal primary tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of the primary thymic malignancies, NETs are the least common, accounting for 2 to 5 percent of thymic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A thymic primary site accounts for approximately 0.4 percent of all carcinoid tumors; this corresponds to an estimated annual incidence in the US of approximately 0.2 per million [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link\">",
"     \"Pathology of mediastinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Almost all cases have been reported in adults, with a median age of about 54 years and a strong male preponderance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/4,5,7-11\">",
"     4,5,7-11",
"    </a>",
"    ]. The largest reported series of thymic NETs consists of 160 patients who were reported to the Surveillance, Epidemiology and End Results (SEER) database over a 33-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/5\">",
"     5",
"    </a>",
"    ]. The median age at presentation was 57, and the male to female ratio was 3:1. Disease was confined to the thymus, locally invasive (or involving regional lymph nodes), or distantly metastatic in 27, 36, and 28 percent of cases, respectively. Histologically, tumors were classified as well-differentiated, moderately-differentiated, or",
"    <span class=\"nowrap\">",
"     poorly-differentiated/anaplastic",
"    </span>",
"    in 58, 10, and 12 percent of cases, respectively.",
"   </p>",
"   <p>",
"    Up to 25 percent of thymic NETs arise in patients with multiple endocrine neoplasia type 1 (MEN1), a genetic disorder that predisposes to the development of multiple endocrine and non-endocrine proliferations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Among MEN1 patients, thymic NETs develop in approximately 3 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], although the prevalence is probably underestimated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/15\">",
"     15",
"    </a>",
"    ]. Thymic carcinoids appear to be a relatively late manifestation of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link&amp;anchor=H12#H12\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'Carcinoid tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vast majority of reported cases of MEN1-associated thymic NETs have occurred in men (a surprising fact given the autosomal dominant nature of the inheritance pattern), and virtually all were heavy smokers, suggesting that tobacco exposure may represent a risk factor. The association between cigarette smoke and sporadic thymic carcinoids is unclear. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4769305\">",
"    <span class=\"h2\">",
"     Screening in MEN1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymic NETs, while rare, represent a neoplasm with greater malignant potential than other MEN1-associated tumors, and therefore are an important cause of morbidity and mortality in MEN1 kindreds. Some experts have recommended that male MEN1 patients over the age of 25 undergo screening with annual chest x-ray and chest CT every three years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/12\">",
"     12",
"    </a>",
"    ], but there is no consensus on this issue. Others recommend annual chest CT in all patients with MEN1 who are over the age of 25, particularly men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/13\">",
"     13",
"    </a>",
"    ]. The benefits of screening are debated, given that no study has shown that early diagnosis through screening improves prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link&amp;anchor=H14907078#H14907078\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'Screening for MEN1-associated tumors'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H37710672\">",
"     'Prognosis and management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Prophylactic thymectomy is generally recommended during parathyroidectomy for patients with MEN1 who have primary hyperparathyroidism, although its benefits are also debated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/12,16,17\">",
"     12,16,17",
"    </a>",
"    ]. Prophylactic thymectomy may not prevent the development of thymic carcinoids, as the occurrence of thymic carcinoid in a patient with MEN1 despite a prophylactic transcervical thymectomy has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/13,18\">",
"     13,18",
"    </a>",
"    ]. If prophylactic thymectomy is considered, it is imperative that complete resection of all anterior mediastinal tissue that can potentially contain thymic tissue is performed.",
"    <br/>",
"    <br/>",
"    Furthermore, its benefit in improving prognosis is unproven. Nevertheless, routine cervical thymectomy does not increase morbidity, and there is potential benefit of preventing at least some thymic carcinoids, so it is generally favored. Other minimally invasive approaches to achieve thymectomy may allow more complete thymic tissue resection, and represent options for prophylactic thymectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=see_link&amp;anchor=H6#H6\">",
"     \"Multiple endocrine neoplasia type 1: Treatment\", section on 'Surgical approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703971797\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until 1972, all epithelial tumors of the thymus were referred to as \"epithelial thymomas\". In 1972, Rosai and Higa reported eight cases of neuroendocrine tumors of the thymus and coined the term \"thymic carcinoid\" [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/7\">",
"     7",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link&amp;anchor=H11#H11\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'Other tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thymic NETs were previously called typical thymic carcinoid, atypical thymic carcinoid, and thymic small cell carcinoma. These tumors should all be regarded as neuroendocrine tumors (NETs), with a spectrum of differentiation which predicts biologic behavior.",
"   </p>",
"   <p>",
"    The 2004 World Health Organization classification for thymic NETs is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef53024 \" href=\"UTD.htm?34/28/35277\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/19\">",
"     19",
"    </a>",
"    ]. NETs arising in the thymus are broadly categorized as well-differentiated NETs or poorly-differentiated carcinomas (small cell and large cell variants). Well-differentiated tumors are further divided into two categories based upon the presence or absence of necrosis and the proliferative rate into typical carcinoid and atypical carcinoid (corresponding roughly to &ldquo;low-grade&rdquo; and &ldquo;intermediate&ndash;grade&rdquo; NETs of the digestive tract). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H2474956#H2474956\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on '2010 WHO classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histologic diagnosis of a well-differentiated thymic NET is based upon recognition of neuroendocrine features such as organoid nests, trabeculae, rosettes, or palisading and homogeneous cytologic features (",
"    <a class=\"graphic graphic_picture graphicRef59363 graphicRef61672 \" href=\"UTD.htm?41/23/42360\">",
"     picture 1A-B",
"    </a>",
"    ). The cells are relatively uniform, and they have round to oval nuclei, coarsely stippled chromatin, and finely granular cytoplasm. The cells produce abundant neurosecretory granules, as reflected in the strong and diffuse immunohistochemical expression of neuroendocrine markers such as synaptophysin and chromogranin. As with other well-differentiated NETs, there are no firmly established histologic characteristics (besides histologic grade) that predict overtly aggressive behavior. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The criteria used to separate typical from atypical carcinoid (and well-differentiated NETs from poorly-differentiated neuroendocrine carcinomas) are the same as those applied in the classification of pulmonary NETs. However, the prognostic value of this classification for thymic lesions has not been proven, but does provide for more consistent classification [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/3\">",
"     3",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H20#H20\">",
"     \"Pathology of lung malignancies\", section on 'Non-small cell neuroendocrine tumors'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typical carcinoids show no necrosis and less than 2 mitoses per 2 mm",
"      <sup>",
"       2",
"      </sup>",
"      while atypical carcinoids have areas of necrosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      2 to 10 mitoses per 2 mm",
"      <sup>",
"       2",
"      </sup>",
"      . Among reported cases of well-differentiated thymic NETs, almost all are classified as atypical carcinoids [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large cell neuroendocrine carcinomas (LCNEC) are composed of large atypical cells with extensive areas of necrosis, often located centrally within tumor cell nests [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/20\">",
"       20",
"      </a>",
"      ]. They show cytologic features of a non-small cell carcinoma, with coarse chromatin and prominent nucleoli in the majority of cells, with more than 10 mitoses per 2 mm",
"      <sup>",
"       2",
"      </sup>",
"      .",
"      <sup>",
"      </sup>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H20#H20\">",
"       \"Pathology of lung malignancies\", section on 'Non-small cell neuroendocrine tumors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small cell neuroendocrine carcinomas have a high mitotic rate, but cytologic features of a small cell carcinoma. Small cell neuroendocrine carcinoma rarely occurs as a primary thymic neoplasm. It is a high-grade tumor and is similar morphologically to its counterpart in the lung, small cell lung cancer. Immunohistochemical staining for keratin and for neuroendocrine markers such as chromogranin, CD56, or synaptophysin is usually positive, and dense core granules can be demonstrated by electron microscopy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H13#H13\">",
"       \"Pathology of lung malignancies\", section on 'Small cell carcinoma'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For both LCNEC and small cell carcinoma, mitoses usually average 60 to 70 per 2 mm",
"      <sup>",
"       2",
"      </sup>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several histologic variants of well-differentiated thymic NETs. While their clinical behavior is similar to that of other thymic carcinoids, their unusual morphology may present diagnostic problems:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spindle cell pattern of thymic NET can be mistaken for spindle cell thymoma (",
"      <a class=\"graphic graphic_picture graphicRef54346 \" href=\"UTD.htm?6/34/6692\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/21\">",
"       21",
"      </a>",
"      ]. The distinction can be readily established utilizing neuroendocrine immunohistochemical markers.",
"     </li>",
"     <li>",
"      Pigmented thymic NETs contain intracytoplasmic melanin and should be distinguished from a melanoma. Positive staining for neuroendocrine markers and negative studies for S-100 protein and HMB-45 exclude melanoma from consideration.",
"     </li>",
"     <li>",
"      Thymic NET with amyloid is a spindle cell neoplasm with amyloid stroma and positivity for calcitonin which is thought to derive from extrathyroid C cells [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703971811\">",
"    <span class=\"h2\">",
"     Histologic differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of a primary NET of the thymus includes multiple non-neoplastic and neoplastic lesions within the thymus gland, or extrathymic lesions within the anterior mediastinum. Histologically, a thymic NET must be distinguished from thymoma and thymic carcinoma, paraganglioma, lymphoma, germ cell tumor, parathyroid tumors, and metastasis from another primary site (",
"    <a class=\"graphic graphic_figure graphicRef56637 \" href=\"UTD.htm?10/31/10743\">",
"     figure 1",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H30334400\">",
"     'Differential diagnosis'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metastasis from a NET at another site must be excluded to make the diagnosis of a primary thymic NET. (See",
"      <a class=\"local\" href=\"#H6761729\">",
"       'Evaluation and staging'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=see_link&amp;anchor=H7120407#H7120407\">",
"       \"Neuroendocrine cancer of unknown primary site\", section on 'Evaluation and management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The morphology of thymoma can mimic a NET if there are features such as peripheral palisading and rosettes. However, thymomas commonly have features such as fibrous trabeculae, perivascular spaces, and a dual population of thymic epithelial cells and lymphocytes that are not present in NETs.",
"      <br/>",
"      <br/>",
"      Leu-7, a marker often used to detect neuroendocrine differentiation, is positive in the epithelial cells of thymoma. However, while neuroendocrine markers can be present in thymomas and thymic carcinomas, in contrast to NETs, they usually lack neuroendocrine morphology and show more focal staining of neuroendocrine markers [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link&amp;anchor=H3#H3\">",
"       \"Pathology of mediastinal tumors\", section on 'Thymoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paraganglioma is an unusual tumor in the mediastinum that can be misdiagnosed as a NET. Histologically, paraganglioma demonstrates an organoid nesting pattern (zellballen) with prominent vascularity and variation in cellular and nuclear size. Immunohistochemical staining for neuroendocrine markers is typically positive. Positive immunostaining for keratin favors carcinoid and excludes paraganglioma [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=see_link\">",
"       \"Paragangliomas of the head and neck\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Parathyroid adenomas and adenocarcinomas may be confused with a carcinoid tumor. Ectopic parathyroid glands may be found within the thymus, due to the common origin of the thymus and the inferior parathyroid glands from the third branchial pouch. Histologically, parathyroid adenomas are composed of sheets, nests, trabeculae, and tubules made of chief cells, water-clear cells, and oncocytic cells [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/24\">",
"       24",
"      </a>",
"      ], the latter of which can be present in some carcinoid tumors. Neuroendocrine markers are positive in both carcinoid and parathyroid lesions. However, parathyroid hormone shows positive staining only in the latter. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link\">",
"       \"Clinical manifestations of primary hyperparathyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=see_link\">",
"       \"Parathyroid carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703971818\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymic tumors typically present as a mass in the anterior mediastinal compartment; they rarely arise in the middle or posterior mediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/4\">",
"     4",
"    </a>",
"    ]. The anterior compartment (also referred to as the anterosuperior compartment or retrosternal space) is anterior to the pericardium and includes the thymus, the extrapericardial aorta and its branches, the great veins, and lymphatic tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of mediastinal masses\", section on 'Mediastinal anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thymic NETs can be aggressive neoplasms with a tendency to invade adjacent structures (mediastinal fatty tissue, lung, pericardium, great vessels). Many are locally invasive at the time of diagnosis, and mediastinal lymph node metastases are present in approximately 50 percent of patients at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/8,25\">",
"     8,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thymic NETs can vary considerably in size [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. In published reports to date, most patients present with a large locally advanced tumor and are symptomatic from local neoplastic mass effects. Symptoms vary according to disease extent, ranging from cough, dyspnea and chest pain to superior vena cava (SVC) syndrome (in approximately 20 percent) and hoarseness from invasion of the recurrent laryngeal nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/8,27,28\">",
"     8,27,28",
"    </a>",
"    ]. About one-third of thymic NETs are asymptomatic and incidentally discovered on a radiographic study done for an unrelated cause [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/4\">",
"     4",
"    </a>",
"    ] or for MEN1 surveillance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link&amp;anchor=H7#H7\">",
"     \"Malignancy-related superior vena cava syndrome\", section on 'Other'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link&amp;anchor=H14907078#H14907078\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'Screening for MEN1-associated tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metastatic spread occurs by the hematogenous and lymphatic routes. Between 20 and 40 percent have distant metastases at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/4,9,12\">",
"     4,9,12",
"    </a>",
"    ]. Common sites of distant metastases include lung and pleura, bone, liver, pancreas, and chest wall [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/4,27,29\">",
"     4,27,29",
"    </a>",
"    ]. Brain metastases have been described in several cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4143779\">",
"    <span class=\"h2\">",
"     Paraneoplastic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid syndrome has only rarely been reported in association with a thymic carcinoid [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In older series, a clinically apparent endocrinopathy has developed in up to one-half of cases of patients with thymic NET [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The most common is Cushing&rsquo;s syndrome due to ectopic production of ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/33\">",
"     33",
"    </a>",
"    ]. The diagnosis of a carcinoid-related Cushing&rsquo;s syndrome may be difficult because the production of ACTH by bronchial carcinoids can be suppressed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , unlike other tumors that produce ectopic ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=see_link\">",
"     \"Establishing the cause of Cushing's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=see_link&amp;anchor=H4#H4\">",
"     \"Dexamethasone suppression tests\", section on 'Low-dose dexamethasone suppression tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acromegaly (due to ectopic production of growth hormone releasing hormone), hyponatremia (due to the syndrome of inappropriate antidiuretic hormone (SIADH) or production of atrial natriuretic peptide) are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Paraneoplastic endocrinopathy is almost exclusively seen in sporadic cases. In MEN1-associated thymic NETs, acromegaly has been rarely reported [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/37\">",
"     37",
"    </a>",
"    ], but ectopic ACTH production has not [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnosis of acromegaly\", section on 'Other causes of acromegaly'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to endocrinopathies, other less commonly reported paraneoplastic conditions associated with these tumors are polyarthropathy, proximal myopathy, peripheral neuropathy, hypertrophic osteoarthropathy, and Lambert-Eaton syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/9,38\">",
"     9,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30334400\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most thymic NETs present as a mass in the anterior mediastinal compartment. The differential diagnosis includes other masses that arise in this compartment including mediastinal cysts, thyroid tissue, parathyroid tissue, and a variety of neoplasms, both benign or malignant, that can arise in the thymus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/39\">",
"     39",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=see_link\">",
"     \"Anterior mediastinal mass lesions\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H703971818\">",
"     'Clinical presentation'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thymic cysts may be congenital or acquired, and may be associated with a thymic malignancy. Thymic cysts can generally be observed unless the diagnosis is not clear, they are enlarging, or they are causing associated symptoms.",
"     </li>",
"     <li>",
"      Thymolipoma is a benign neoplasm comprised of thymic epithelium and abundant adipose tissue.",
"     </li>",
"     <li>",
"      True thymic hyperplasia and thymic lymphoid hyperplasia (generally defined by the presence of large numbers of lymphoid follicles with germinal centers) may enlarge the thymus, and simulate a neoplasm.",
"     </li>",
"     <li>",
"      Thymoma and thymic carcinoma are epithelial malignancies with distinct clinicopathologic features. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=see_link\">",
"       \"Clinical presentation and management of thymoma and thymic carcinoma\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Thymic neuroendocrine tumors (thymic carcinoid) are rare epithelial neoplasms with neuroendocrine differentiation. They account for only about 5 percent of all thymic lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/24\">",
"       24",
"      </a>",
"      ]. Up to 25 percent are found in patients with multiple endocrine neoplasia type 1 (MEN1) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link\">",
"       \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Lymphomas may primarily or secondarily involve the thymus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mediastinal germ cell tumors may arise primarily within the thymus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=see_link\">",
"       \"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6761729\">",
"    <span class=\"h1\">",
"     EVALUATION AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of the initial evaluation for patients with an anterior mediastinal mass is to characterize the nature of the mass and extent of the disease. The noninvasive evaluation of a newly diagnosed mediastinal mass is discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    ). The following issues are germane to the diagnosis of a thymic NET:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851153\">",
"    <span class=\"h2\">",
"     Cross sectional imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-sectional imaging is indicated whenever a mediastinal mass is detected on a chest radiograph. A chest computed tomography (CT) scan, preferably with intravenous water-soluble contrast material, refines lesion localization, allows further characterization of the morphologic features of the mass, and allows the evaluation of adjacent thoracic structures for evidence of local invasion or regional metastases. In some cases, the findings are sufficiently characteristic for specific histologies (eg, a teratoma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=see_link&amp;anchor=H10#H10\">",
"     \"Anterior mediastinal mass lesions\", section on 'Clinical findings'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    A thymic NET typically manifests as a large, lobulated, usually invasive, anterior mediastinal mass with heterogeneous enhancement that may exhibit areas of hemorrhage and necrosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75493 \" href=\"UTD.htm?34/28/35265\">",
"     image 1",
"    </a>",
"    ). Punctate and dystrophic calcifications may also be seen. There are no pathognomonic findings, and it may be difficult to distinguish a thymic NET from other thymic malignancies or from nonthymic malignancies such as lymphoma or metastatic disease on the basis of radiographic imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In general, the presence of extensive mediastinal lymphadenopathy in association with a dominant mediastinal mass suggests a thymic carcinoma or NET (or lymphoma or metastatic disease) rather than a thymoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=see_link&amp;anchor=H3#H3\">",
"     \"Anterior mediastinal mass lesions\", section on 'Clinical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    In general, CT is the imaging procedure of choice for anterior mediastinal masses. However, MRI, in particular, a cardiac MRI, can be very helpful in assessing invasion of the pericardium, proximal great vessels, or heart structures in cases of large masses that are causing at least displacement of these structures due to mass effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of mediastinal masses\", section on 'Computed tomography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of mediastinal masses\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851421\">",
"    <span class=\"h2\">",
"     Somatostatin receptor scintigraphy and other imaging methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin receptors are overexpressed in NETs (including thymic primaries) and in malignant thymic epithelial tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/42\">",
"     42",
"    </a>",
"    ]. Somatostatin receptor scintigraphy (SRS) using radiolabeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (OctreoScan) can be used to identify these tumors, distinguish them from other malignancies arising in the anterior mediastinal compartment, and to exclude a primary NET in another site that may have metastasized to the thymus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link&amp;anchor=H31868296#H31868296\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Somatostatin-receptor scintigraphy (OctreoScan)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there are several caveats to the use of SRS in patients with thymic neoplasms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive SRS cannot differentiate between thymoma, thymic carcinoma, and thymic NET.",
"     </li>",
"     <li>",
"      Not all thymic NETs express somatostatin receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/13,29,42\">",
"       13,29,42",
"      </a>",
"      ]. Thus, if the SRS is negative, this does not exclude the diagnosis of a thymic NET.",
"     </li>",
"     <li>",
"      SRS may not be more sensitive than CT or MRI for detecting distant metastases from thymic carcinoids. At least one report documents two cases of bone metastases from a thymic carcinoid that were SRS-negative, but seen on MRI and CT [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/13\">",
"       13",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another imaging study that may be useful for localizing a NET (including one arising in the thymus) and assessing disease extent is integrated FDG ((18-F)-fluorodeoxyglucose) positron emission tomography (PET) with integrated CT [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of mediastinal masses\", section on 'Radionuclide scanning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common sites of distant metastases include lung and pleura, bone, liver, pancreas, and chest wall. (See",
"    <a class=\"local\" href=\"#H703971818\">",
"     'Clinical presentation'",
"    </a>",
"    above.).",
"   </p>",
"   <p>",
"    There are no widely accepted guidelines for pretreatment radiographic staging evaluation for a suspected thymic NET, and no consensus on this issue. Although some have suggested that all patients undergo MRI of the spine to assess for bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/13\">",
"     13",
"    </a>",
"    ], in our view, this approach is not justified. The staging evaluation should ideally be guided by symptoms. If there is a high index of suspicion for bone metastases, we would pursue a PET or bone scan rather than spine MRI. For asymptomatic patients, a standard CT of the thorax and abdomen should detect bone metastases, if they are present. However, at some institutions, PET scanning is routinely performed prior to resection in patients who appear to have potentially resectable disease to identify otherwise radiographically occult disease that would preclude attempted resection. &nbsp;",
"   </p>",
"   <p>",
"    Brain metastases are reported, although rare. A low index of suspicion for brain metastases is warranted. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851160\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of thymic NETs do not produce bioactive amines (nonfunctioning). Thus, collection of urine for 5-HIAA testing is generally not helpful in the diagnostic evaluation for a thymic NET. Serum levels of chromogranin A (CGA) may be elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/13\">",
"     13",
"    </a>",
"    ], but CGA cannot be recommended as a diagnostic marker for a NET because it can be elevated in number of unrelated conditions. CGA can be useful to follow disease activity in those with advanced or metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical characteristics of carcinoid tumors\", section on 'Foregut tumors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H9#H9\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Urinary 5-HIAA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H10#H10\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Chromogranin A'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Given the high incidence of Cushing&rsquo;s syndrome, patients with non-MEN1-associated thymic NETs should undergo measurement of cortisol levels in the serum or in a 24-hour urine collection. (See",
"    <a class=\"local\" href=\"#H4143779\">",
"     'Paraneoplastic conditions'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link&amp;anchor=H7#H7\">",
"     \"Establishing the diagnosis of Cushing's syndrome\", section on 'Daily urinary cortisol excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851428\">",
"    <span class=\"h2\">",
"     Need for biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, among patients with a mediastinal mass, the CT appearance forms the basis for deciding whether to proceed directly with resection or obtain a tissue diagnosis preoperatively. Among patients with an anterior mediastinal mass, exclusion of lymphoma and a mediastinal germ cell tumor is important since these two conditions would be treated medically rather than surgically. A small, seemingly encapsulated mass should ideally be resected along with the thymus gland, to establish the diagnosis and effect therapy, whereas a larger mass with indistinct margins should be biopsied before proceeding with resection to establish the diagnosis, and provide for decision-making about neoadjuvant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H851934\">",
"     'Neoadjuvant therapy for locally advanced disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical presentation and management of thymoma and thymic carcinoma\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a biopsy is indicated, the diagnostic procedure of choice is CT-guided core needle biopsy.",
"   </p>",
"   <p>",
"    Although CT-guided fine needle aspiration (FNA) biopsy via a parasternal approach can allow preoperative identification of a thymic NET [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/28,51-53\">",
"     28,51-53",
"    </a>",
"    ], it may not be possible to secure a definitive diagnosis, particularly if the differential is between lymphoma and a thymic neoplasm. There may not be sufficient tumor cells in the cell block to perform immunohistochemistry for neuroendocrine markers or flow cytometry. Furthermore, it may not be possible to distinguish between a moderately-differentiated and poorly-differentiated thymic NET by cytologic study since two of the most important morphologic criteria for the distinction (mitotic counts and necrosis) are not measurable in FNA material [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/53\">",
"     53",
"    </a>",
"    ]. Endoscopic or transbronchial ultrasound-guided FNA may be valuable in select cases, for example when metastatic cancer to mediastinal lymph nodes is suspected (",
"    <a class=\"graphic graphic_figure graphicRef63771 \" href=\"UTD.htm?0/10/167\">",
"     figure 2",
"    </a>",
"    ). Cervical mediastinoscopy is another excellent approach to biopsying mediastinal lymph nodes not accessible by less invasive endoscopic techniques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link&amp;anchor=H344103788#H344103788\">",
"     \"Evaluation of mediastinal masses\", section on 'Ultrasound'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=see_link&amp;anchor=H9#H9\">",
"     \"Endobronchial ultrasound: Indications, advantages, and complications\", section on 'Mediastinal lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If this procedure does not establish a diagnosis, then a surgical biopsy may be indicated. The approach depends upon the location of the tumor and the expertise of the surgeon. If the mass abuts the anterior chest wall then a direct cutdown, an anterior mediastinotomy (Chamberlain procedure), may be the simplest approach. In cases where the mass protrudes into either side of the chest, the lesion can be approached with a video-assisted thoracoscopic (VATS) approach. VATS can often be performed with a single one centimeter incision that both provides access to the mass for a biopsy and also allows",
"    <span class=\"nowrap\">",
"     inspection/biopsy",
"    </span>",
"    of the pleural space. This approach may be ideal if there is suspicion of lung metastases that have defied other diagnostic attempts. A disadvantage to a VATS approach is that a postoperative chest tube and at least a one night hospital admission may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23027665\">",
"    <span class=\"h2\">",
"     Staging classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;A formal staging classification for thymic NETs has not been developed, and therefore the terms &ldquo;local&rdquo;, &ldquo;locally advanced&rdquo; (or locoregional), and &ldquo;metastatic&rdquo; are commonly used [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/5\">",
"     5",
"    </a>",
"    ]. However, many authors use the Masaoka staging classification, as is used for thymic epithelial tumors (",
"    <a class=\"graphic graphic_table graphicRef79311 \" href=\"UTD.htm?19/13/19677\">",
"     table 2",
"    </a>",
"    ), for thymic NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/29,33\">",
"     29,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37710672\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because most thymic NETs represent atypical carcinoids or higher grade tumors, they are generally characterized by aggressive behavior, a tendency to recur locally and metastasize, resistance to therapy, and a prognosis that is generally inferior to other NETs of similar stage and grade arising elsewhere in the body, particularly in the lung (in which ordinary non atypical carcinoids predominate). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 14 cases with long-term follow-up, all patients died within 109 months as a result of local progression (five cases), local relapse (three cases), or distant metastases (eight cases) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/8\">",
"       8",
"      </a>",
"      ]. Only three of the 14 had complete resection, two of whom also had postoperative RT.",
"     </li>",
"     <li>",
"      In the largest North American series of 80 cases of thymic NET, overall 5- and 10-year survival rates were 28 and 10 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/27\">",
"       27",
"      </a>",
"      ]. In a group of 50 with long-term clinical follow-up, disease-free survival correlated with tumor grade. Low-grade tumors had a 5- and 10-year disease-free survival of 50 and 9 percent, intermediate-grade tumors had a disease-free survival of 20 percent at five years and none were disease-free at ten years; none of the patients with high-grade tumors were disease-free at 5 years.",
"     </li>",
"     <li>",
"      Prognosis is related to disease stage. In a SEER database review of 160 cases of thymic NET, the median survival for patients with localized, regional, and distant metastases were 110, 59, and 35 months, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/5\">",
"       5",
"      </a>",
"      ]. 1, 3, and 5-year survival rates stratified according to disease stage are depicted in the table (",
"      <a class=\"graphic graphic_table graphicRef53758 \" href=\"UTD.htm?30/29/31195\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not all series report such adverse prognosis. In one report of 12 patients with thymic atypical carcinoid, recurrence occurred in only two of the resected patients, and five-year survival was 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/3\">",
"     3",
"    </a>",
"    ]. The reason for this favorable outcome is not clear, but the follow-up duration was relative short in this series (more than five years in only three of the surviving patients), and all but one of the thymic NETs was diploid rather than aneuploid (with aneuploidy being reported as a poor prognostic feature, at least in bronchial carcinoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/54\">",
"     54",
"    </a>",
"    ]). Nevertheless, the majority of reported series indicate a relatively poor prognosis for thymic NETs, even if well-differentiated. &nbsp;",
"   </p>",
"   <p>",
"    Some reports indicate a somewhat more favorable prognosis for patients with thymic NETs that are not accompanied by an endocrinopathy as compared to those associated with Cushing syndrome or MEN1 (70 versus 35 percent survival at five years in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/55\">",
"     55",
"    </a>",
"    ]. However, this has not been a consistent finding in the more recent literature.",
"   </p>",
"   <p>",
"    Poor prognosis is related, at least in part, to late tumor detection. A high degree of suspicion in families with MEN1, and earlier detection of thymic NETs may improve outcomes, although this has not yet been borne out in clinical studies. As an example, in one report, 85 patients with MEN1 were prospectively evaluated over a mean of eight years with CT, MRI, chest x-ray and SRS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/13\">",
"     13",
"    </a>",
"    ]. Seven patients were diagnosed with a thymic NET, and all underwent resection. Despite the presumably early diagnosis, all patients followed for longer than one year recurred. With the exception of male gender, no clinical, laboratory, or other feature of the MEN1 patients distinguished those who developed a NET from those who did not. The issue of screening for thymic carcinoids in patients with MEN1 is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link&amp;anchor=H14907078#H14907078\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'Screening for MEN1-associated tumors'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In other patients, the natural history can often be prolonged, with a tendency to recur and metastasize over many years (as many as 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/56\">",
"     56",
"    </a>",
"    ]) after the initial operation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/9,57,58\">",
"     9,57,58",
"    </a>",
"    ]. Thus, posttreatment surveillance should be extended beyond five years (see",
"    <a class=\"local\" href=\"#H852081\">",
"     'Posttreatment surveillance'",
"    </a>",
"    below). &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851564\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the rarity of these tumors, data to guide optimal treatment are necessarily limited by the small size of most reports and case series, and the lack of prospective trials. Surgery is the mainstay of therapy for resectable cases, whereas adjuvant or neoadjuvant radiation therapy plays a role in subtotally resected or unresectable cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851915\">",
"    <span class=\"h3\">",
"     Resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thymus receives its arterial blood supply from poorly defined branches of the internal mammary, superior thyroid, and inferior thyroid arteries. Venous drainage is via better defined branches of the innominate vein. Anatomically, the thymus is located in both the cervical region and in the mediastinum, consisting of bilateral cervical horns and extending into the chest down to the diaphragm anterior to the pericardium. Complete surgical resection of all thymic tissue is generally felt to require resection of all mediastinal tissue anterior to pericardium from the cervical horns in the neck down to the diaphragm, and laterally to each phrenic nerve.",
"   </p>",
"   <p>",
"    Completeness of resection is a strong prognostic factor for overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/5,8,25,28,29,33\">",
"     5,8,25,28,29,33",
"    </a>",
"    ]. Whenever possible, complete surgical resection (of the primary tumor and regional nodes) is the treatment of choice. Unfortunately, microscopically complete resections are uncommonly achieved with tumors that invade contiguous mediastinal structures such as major blood vessels, pericardium, or phrenic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/33\">",
"     33",
"    </a>",
"    ]. Furthermore, even after complete surgical resection, there is a high rate of local recurrence.",
"   </p>",
"   <p>",
"    In general, these tumors are diagnosed at a size that is not amenable to minimally invasive techniques. Most approaches to resection require at least a median sternotomy. Tumors that extend into one side of the chest may require a hemi-clamshell incision, while tumors that extend into both sides of the chest may require a thoracosternotomy (clamshell incision). In some cases, the use of cardiopulmonary bypass available may facilitate safe exploration and resection in cases where cardiac or great vessel invasion cannot be ruled out before surgery. (See",
"    <a class=\"local\" href=\"#H37710672\">",
"     'Prognosis and management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is unclear whether surgical debulking of large tumors without curative intent confers any survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/59\">",
"     59",
"    </a>",
"    ]. However, palliative surgical resection or debulking of a large primary tumor causing compression symptoms may provide benefits in terms of symptom control [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/4\">",
"     4",
"    </a>",
"    ]. Proceeding with a major operation with palliative intent should only be undertaken in highly selected cases, and ideally the decision made in with multidisciplinary team input. Palliative resection could also be considered if a hormonal secretory condition such as Cushing&rsquo;s or carcinoid syndrome is debilitating. Patients with refractory Cushing&rsquo;s disease may need end-organ ablation (ie, bilateral adrenalectomy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the treatment of Cushing's syndrome\", section on 'Cushing's disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with SVC syndrome may also benefit from endovascular stent placement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link&amp;anchor=H25#H25\">",
"     \"Malignancy-related superior vena cava syndrome\", section on 'Endovascular stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrent local disease should also be addressed surgically, when possible [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/4,10,26\">",
"     4,10,26",
"    </a>",
"    ]. Survivals as long as 12 to 15 years have been reported with aggressive surgical resection of both locally recurrent and distant metastatic lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851809\">",
"    <span class=\"h3\">",
"     Role of RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence supporting benefit for adjuvant or definitive RT is extremely limited. While there are series and case reports suggesting that the addition of local RT improves local control following complete resection, there is no evidence that this confers a survival benefit. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 12 patients undergoing resection for a thymic carcinoid, nine had a complete resection, three of whom received adjuvant RT with no recurrence documented [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/29\">",
"       29",
"      </a>",
"      ]. In contrast, four of the six who did not receive adjuvant RT recurred locally. Distant metastases developed in nine patients, and only two of the entire cohort were alive and disease-free at 67 and 81 months, only one of whom had received adjuvant RT.",
"     </li>",
"     <li>",
"      Evidence of improved local control has been seen in other series as well, including patients with incompletely resected tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/10,25,28,60\">",
"       10,25,28,60",
"      </a>",
"      ]. However, as in the prior series, although local control appeared to be improved by RT, distant metastases developed in ten of the 13 completely resected patients, and only one remained tumor-free and alive beyond five years.",
"     </li>",
"     <li>",
"      In an analysis of 160 cases in the SEER registry, patients receiving adjuvant or definitive radiation experienced poorer outcomes than those who did not, and in multivariate analysis, there was no survival benefit for RT delivered as part of primary therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/5\">",
"       5",
"      </a>",
"      ]. However, due the non-randomized nature of this analysis, it is difficult to draw definitive conclusions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these data, maximal resection followed by local RT for control of residual disease would seem to be a reasonable local management strategy for well-differentiated tumors. For poorly-differentiated neuroendocrine carcinomas, even those that are completely resected, we suggest postoperative chemoradiotherapy with a",
"    <span class=\"nowrap\">",
"     platinum/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"      etoposide",
"     </a>",
"    </span>",
"    based chemoradiation, as is typically used for small cell lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link&amp;anchor=H9#H9\">",
"     \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\", section on 'Integration with chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN guidelines",
"    </a>",
"    suggest RT in patients with an incomplete resection, with or without chemotherapy (concurrent use of radiosensitizing doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    being considered appropriate for patients with moderately differentiated or atypical tumors).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851934\">",
"    <span class=\"h3\">",
"     Neoadjuvant therapy for locally advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with locally advanced disease, there has been interest in neoadjuvant therapy using chemotherapy or a combination of chemotherapy and radiotherapy to increase resectability. The feasibility of such an approach has been shown [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], but whether this improves outcomes over maximum resection followed by adjuvant RT is unknown. In a single case report, a 39-year old man with locally advanced atypical thymic carcinoid was treated with four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , followed by RT (42 Gy), in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/61\">",
"     61",
"    </a>",
"    ]. A moderate antitumor response was achieved, and following an extensive but potentially curative surgical procedure, he remained disease-free, albeit with relatively short follow-up (18 months). In another report, three cycles of neoadjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and etoposide did not produce any objective response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single case report documents an objective partial response to a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    that allowed for subsequent resection with negative margins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/62\">",
"     62",
"    </a>",
"    ], but long-term outcomes were not reported",
"   </p>",
"   <p>",
"    Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    on treatment of thymic NETs do not address the utility of neoadjuvant therapy. However, the strategy of using preoperative chemotherapy for large, locally advanced or borderline resectable tumors makes sense for several reasons. Patients are more likely to tolerate the full desired chemotherapy or chemoradiotherapy regimen before undergoing a large surgical procedure as opposed to afterwards. Patients are also more likely to receive their desired therapy over a shorter time period. Starting with chemotherapy and then restaging prior to surgery may allow identification of patients with distant and likely incurable disease prior to surgery, thereby saving those patients from a potentially morbid procedure that may not provide long-term benefit. In general, surgery should be undertaken four to six weeks after completion of induction therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H851848\">",
"    <span class=\"h3\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few reported cases of objective radiographic response to systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/61\">",
"     61",
"    </a>",
"    ], and it is unclear whether somatostatin analogs exert any stabilizing effect on tumor growth [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/14\">",
"     14",
"    </a>",
"    ], as they do with some gastroenteropancreatic NETs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948921#H190948921\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Somatostatin analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One retrospective analysis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    for advanced NETs included seven patients with thymic carcinoid, among whom five patients (71 percent) experienced stable disease as their best response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/64\">",
"     64",
"    </a>",
"    ]. In our practice, we have seen one objective radiographic response among two thymic NET patients treated with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and temozolomide.",
"   </p>",
"   <p>",
"    Some patients respond to platinum-based chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/65\">",
"     65",
"    </a>",
"    ]. In particular, poorly differentiated thymic neuroendocrine carcinomas should be treated with platinum-based regimens such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , as per treatment guidelines for poorly differentiated NETs at other sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949019#H190949019\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Poorly differentiated tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Where available, and for patients whose tumors have a high expression of somatostatin receptors (as determined by somatostatin receptor scintigraphy [Octreoscan]), systemic therapy using peptide receptor radioligands is an option for disease control, although the data on thymic carcinoids is limited by few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/66\">",
"     66",
"    </a>",
"    ]. The most frequently used radionuclides for targeted radiotherapy are yttrium (90Y) and lutetium (177Lu). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949126#H190949126\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Radiolabeled somatostatin analogs'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H852081\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no evidence-based guidelines for posttreatment surveillance. Consensus-based guidelines are available from two groups, the European Society of Medical Oncology (ESMO), and NCCN:",
"   </p>",
"   <p>",
"    ESMO recommends that patients with typical and atypical carcinoid undergo at least annual evaluation for up to ten years, given the potentially long delay between primary treatment and the development of metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/67\">",
"     67",
"    </a>",
"    ]. After primary surgery, they recommend assay of biochemical markers such as chromogranin A every 3 to 6 months, and cross sectional imaging (CT or MRI) once yearly. Metastatic or recurrent disease should be followed more often, with imaging evaluation every 6 months.",
"   </p>",
"   <p>",
"    NCCN guidelines recommend history and physical examination with cross sectional imaging of the chest between 3 and 12 months postresection, with &ldquo;consideration&rdquo; of serum CGA [",
"    <a class=\"abstract\" href=\"UTD.htm?21/28/21962/abstract/68\">",
"     68",
"    </a>",
"    ]. After one year postresection, they recommend assessment every 6 to 12 months with history and physical examination, &ldquo;consideration&rdquo; of serum CGA assay, and imaging studies as clinically indicated.",
"   </p>",
"   <p>",
"    Because histology cannot reliably predict NET prognosis, after resection, long-term surveillance (up to ten years) is required (by imaging and, if applicable, tumor markers).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6761221\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thymic neuroendocrine tumors (NETs) are exceedingly uncommon primary thymic neoplasms with neuroendocrine differentiation that generally present as a mass within the anterior mediastinum. Even if well differentiated histologically, thymic NETs are characterized by relatively aggressive clinical behavior and a high propensity for locoregional invasion, local recurrence, and distant metastases.",
"      <sup>",
"      </sup>",
"      (See",
"      <a class=\"local\" href=\"#H703971797\">",
"       'Pathology and classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H37710672\">",
"       'Prognosis and management'",
"      </a>",
"      above.)",
"      <sup>",
"      </sup>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thymic NETs may manifest in one of four ways: asymptomatically, as an incidental finding on radiographic imaging; with symptoms related to an associated endocrinopathy, of which Cushing&rsquo;s syndrome is the most common; or with symptoms and signs related to distant metastases. (See",
"      <a class=\"local\" href=\"#H703971818\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Males are affected more often than females. Approximately 25 percent of thymic NETs occur in patients with multiple endocrine neoplasia type 1 (MEN1). Among patients with MEN1, thymic NETs arise primarily in male smokers. (See",
"      <a class=\"local\" href=\"#H4769298\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Issues related to screening of patients with MEN1 for thymic NETs and prophylactic thymectomy are addressed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link&amp;anchor=H14907078#H14907078\">",
"       \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\", section on 'Screening for MEN1-associated tumors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=see_link&amp;anchor=H6#H6\">",
"       \"Multiple endocrine neoplasia type 1: Treatment\", section on 'Surgical approach'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The appearance of an anterior mediastinal mass on cross sectional imaging forms the basis for deciding whether to proceed directly with resection or obtain a tissue diagnosis preoperatively. Exclusion of lymphoma and germ cell tumor is important since these two conditions may be treated medically rather than surgically. For small, seemingly encapsulated masses where surgical resection appears feasible, thymectomy should be performed, with en bloc resection of adjacent tissues based on local stage of disease. (See",
"      <a class=\"local\" href=\"#H851915\">",
"       'Resection'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For a larger mass with indistinct margins we prefer a biopsy before proceeding with resection to establish the diagnosis, and provide for decision-making about neoadjuvant therapy. (See",
"      <a class=\"local\" href=\"#H851428\">",
"       'Need for biopsy'",
"      </a>",
"      above.) If the diagnosis of thymic carcinoid is established, we suggest maximal surgical resection, if feasible (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Given the high incidence of Cushing&rsquo;s syndrome, patients with non-MEN1-associated thymic NETs should be evaluated by measurement of cortisol levels in the serum or in a 24-hour urine collection. (See",
"      <a class=\"local\" href=\"#H4143779\">",
"       'Paraneoplastic conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of surgery plus RT offers a reasonable probability of local control, but these patients are at high risk for distant metastases even after a complete (R0) resection. Although the benefit seems limited to enhanced local control we suggest adding postoperative radiation therapy for patients with positive margins or gross residual disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For poorly-differentiated neuroendocrine carcinomas, we suggest postoperative chemoradiotherapy with a",
"      <span class=\"nowrap\">",
"       platinum/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"        etoposide",
"       </a>",
"      </span>",
"      based chemoradiation, as is typically used for small cell lung cancer, rather than radiotherapy alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H851809\">",
"       'Role of RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no known effective systemic therapy for patients with",
"      <span class=\"nowrap\">",
"       advanced/metastatic",
"      </span>",
"      disease. We encourage eligible patients to enroll on clinical trials, where available. If protocol participation is not possible or desired,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      based chemotherapy is a reasonable choice based upon extremely limited data. (See",
"      <a class=\"local\" href=\"#H851848\">",
"       'Systemic therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Poorly differentiated neuroendocrine carcinomas should be treated similarly to small cell carcinoma of the lung, with combined platinum plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=see_link\">",
"       \"Treatment of refractory and relapsed small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The optimal posttreatment surveillance strategy is not established. Because histology cannot reliably predict NET prognosis after resection, long-term surveillance (up to 10 years) is recommended with scans at least annually. Patients with aggressive histological features (atypical or poorly differentiated) should be monitored more frequently. (See",
"      <a class=\"local\" href=\"#H852081\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/1\">",
"      Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010; 5:S260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/2\">",
"      Strollo DC, Rosado de Christenson ML, Jett JR. Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum. Chest 1997; 112:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/3\">",
"      Goto K, Kodama T, Matsuno Y, et al. Clinicopathologic and DNA cytometric analysis of carcinoid tumors of the thymus. Mod Pathol 2001; 14:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/4\">",
"      Chaer R, Massad MG, Evans A, et al. Primary neuroendocrine tumors of the thymus. Ann Thorac Surg 2002; 74:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/5\">",
"      Gaur P, Leary C, Yao JC. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg 2010; 251:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/6\">",
"      Yao JC, Hassan M, Phan A, et al. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/7\">",
"      Rosai J, Higa E. Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor. Clinicopathologic study of 8 cases. Cancer 1972; 29:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/8\">",
"      de Montpr&eacute;ville VT, Macchiarini P, Dulmet E. Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases. J Thorac Cardiovasc Surg 1996; 111:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/9\">",
"      Wick MR, Scheithauer BW. Thymic carcinoid. A histologic, immunohistochemical, and ultrastructural study of 12 cases. Cancer 1984; 53:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/10\">",
"      Economopoulos GC, Lewis JW Jr, Lee MW, Silverman NA. Carcinoid tumors of the thymus. Ann Thorac Surg 1990; 50:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/11\">",
"      Valli M, Fabris GA, Dewar A, et al. Atypical carcinoid tumour of the thymus: a study of eight cases. Histopathology 1994; 24:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/12\">",
"      Teh BT, McArdle J, Chan SP, et al. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine (Baltimore) 1997; 76:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/13\">",
"      Gibril F, Chen YJ, Schrump DS, et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003; 88:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/14\">",
"      Ferolla P, Falchetti A, Filosso P, et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab 2005; 90:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/15\">",
"      Ferolla P, Urbani M, Ascani S, et al. [Prevalence of the neuroendocrine phenotype in thymus neoplasms]. Chir Ital 2002; 54:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/16\">",
"      Duh QY, Hybarger CP, Geist R, et al. Carcinoids associated with multiple endocrine neoplasia syndromes. Am J Surg 1987; 154:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/17\">",
"      Powell AC, Alexander HR, Pingpank JF, et al. The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. Surgery 2008; 144:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/18\">",
"      Burgess JR, Giles N, Shepherd JJ. Malignant thymic carcinoid is not prevented by transcervical thymectomy in multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2001; 55:689.",
"     </a>",
"    </li>",
"    <li>",
"     Marx A, Shimosato Y, Kuo TT, et al. Thymic neuroendocrine tumours. In: Pathology &amp; genetics: Tumours of the lung, pleura, thymus and heart, Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds), IARC Press, Lyon, France 2004.",
"    </li>",
"    <li>",
"     Rosai J. Histological Typing of Tumours of the Thymus, 2nd, Springer, Berlin 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/21\">",
"      Moran CA, Suster S. Spindle-cell neuroendocrine carcinomas of the thymus (spindle-cell thymic carcinoid): a clinicopathologic and immunohistochemical study of seven cases. Mod Pathol 1999; 12:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/22\">",
"      Hishima T, Fukayama M, Hayashi Y, et al. Neuroendocrine differentiation in thymic epithelial tumors with special reference to thymic carcinoma and atypical thymoma. Hum Pathol 1998; 29:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/23\">",
"      Moran CA, Suster S, Fishback N, Koss MN. Mediastinal paragangliomas. A clinicopathologic and immunohistochemical study of 16 cases. Cancer 1993; 72:2358.",
"     </a>",
"    </li>",
"    <li>",
"     Shimosato Y, Mukai K. Tumors of the Mediastinum, 3rd, Armed Forces Institute of Pathology, Washington, DC 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/25\">",
"      Fukai I, Masaoka A, Fujii Y, et al. Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study in 15 patients. Ann Thorac Surg 1999; 67:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/26\">",
"      Wick MR, Carney JA, Bernatz PE, Brown LR. Primary mediastinal carcinoid tumors. Am J Surg Pathol 1982; 6:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/27\">",
"      Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. Am J Clin Pathol 2000; 114:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/28\">",
"      Wang DY, Chang DB, Kuo SH, et al. Carcinoid tumours of the thymus. Thorax 1994; 49:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/29\">",
"      Tiffet O, Nicholson AG, Ladas G, et al. A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus. Chest 2003; 124:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/30\">",
"      Soga J, Yakuwa Y, Osaka M. Evaluation of 342 cases of mediastinal/thymic carcinoids collected from literature: a comparative study between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg 1999; 5:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/31\">",
"      Wick MR, Rosai J. Neuroendocrine neoplasms of the thymus. Pathol Res Pract 1988; 183:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/32\">",
"      de Perrot M, Spiliopoulos A, Fischer S, et al. Neuroendocrine carcinoma (carcinoid) of the thymus associated with Cushing's syndrome. Ann Thorac Surg 2002; 73:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/33\">",
"      Gal AA, Kornstein MJ, Cohen C, et al. Neuroendocrine tumors of the thymus: a clinicopathological and prognostic study. Ann Thorac Surg 2001; 72:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/34\">",
"      Malchoff CD, Orth DN, Abboud C, et al. Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Am J Med 1988; 84:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/35\">",
"      Jansson JO, Svensson J, Bengtsson BA, et al. Acromegaly and Cushing's syndrome due to ectopic production of GHRH and ACTH by a thymic carcinoid tumour: in vitro responses to GHRH and GHRP-6. Clin Endocrinol (Oxf) 1998; 48:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/36\">",
"      Okada S, Ohshima K, Mori M. The Cushing syndrome induced by atrial natriuretic peptide-producing thymic carcinoid. Ann Intern Med 1994; 121:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/37\">",
"      Boix E, Pic&oacute; A, Pinedo R, et al. Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour. Clin Endocrinol (Oxf) 2002; 57:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/38\">",
"      Lowenthal RM, Gumpel JM, Kreel L, et al. Carcinoid tumour of the thymus with systemic manifestations: a radiological and pathological study. Thorax 1974; 29:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/39\">",
"      Strollo DC, Rosado-de-Christenson ML. Tumors of the thymus. J Thorac Imaging 1999; 14:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/40\">",
"      Ferrozzi F, Ganzetti A, Mugnoli E, et al. [Thymic carcinoid: CT and MR findings]. Radiol Med 1997; 94:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/41\">",
"      Adolph JM, Kimmig BN, Georgi P, zum Winkel K. Carcinoid tumors: CT and I-131 meta-iodo-benzylguanidine scintigraphy. Radiology 1987; 164:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/42\">",
"      Guidoccio F, Grosso M, Maccauro M, et al. Current role of 111In-DTPA-octreotide scintigraphy in diagnosis of thymic masses. Tumori 2011; 97:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/43\">",
"      Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/44\">",
"      Lastoria S, Vergara E, Palmieri G, et al. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy. J Nucl Med 1998; 39:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/45\">",
"      Nilsson O, K&ouml;lby L, W&auml;ngberg B, et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998; 77:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/46\">",
"      Silva F, V&aacute;zquez-Sell&eacute;s J, Aguil&ouml; F, et al. Recurrent ectopic adrenocorticotropic hormone producing thymic carcinoid detected with octreotide imaging. Clin Nucl Med 1999; 24:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/47\">",
"      Whitaker D, Dussek J. PET scanning in thymic neuroendocrine tumors. Chest 2004; 125:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/48\">",
"      Groves AM, Mohan HK, Wegner EA, et al. Positron emission tomography with FDG to show thymic carcinoid. AJR Am J Roentgenol 2004; 182:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/49\">",
"      Fujishita T, Kishida M, Taki H, et al. Detection of primary and metastatic lesions by [18F]fluoro-2-deoxy-D-glucose PET in a patient with thymic carcinoid. Respirology 2007; 12:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/50\">",
"      Kaiser LR. Surgical treatment of thymic epithelial neoplasms. Hematol Oncol Clin North Am 2008; 22:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/51\">",
"      Shabb NS, Fahl M, Shabb B, et al. Fine-needle aspiration of the mediastinum: a clinical, radiologic, cytologic, and histologic study of 42 cases. Diagn Cytopathol 1998; 19:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/52\">",
"      Zakowski MF, Huang J, Bramlage MP. The role of fine needle aspiration cytology in the diagnosis and management of thymic neoplasia. J Thorac Oncol 2010; 5:S281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/53\">",
"      Wakely PE Jr. Fine needle aspiration in the diagnosis of thymic epithelial neoplasms. Hematol Oncol Clin North Am 2008; 22:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/54\">",
"      Jones DJ, Hasleton PS, Moore M. DNA ploidy in bronchopulmonary carcinoid tumours. Thorax 1988; 43:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/55\">",
"      Wick MR, Scott RE, Li CY, Carney JA. Carcinoid tumor of the thymus: a clinicopathologic report of seven cases with a review of the literature. Mayo Clin Proc 1980; 55:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/56\">",
"      Hayashi R, Hanyu N, Moriyama S. Efficacy of steroid therapy on liver metastasis of thymic carcinoid. Intern Med 1994; 33:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/57\">",
"      Sugiura H, Morikawa T, Itoh K, et al. Thymic neuroendocrine carcinoma: a clinicopathologic study in four patients. Ann Thorac Cardiovasc Surg 2000; 6:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/58\">",
"      Tsuchida M, Yamato Y, Hashimoto T, et al. Recurrent thymic carcinoid tumor in the pleural cavity. 2 cases of long-term survivors. Jpn J Thorac Cardiovasc Surg 2001; 49:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/59\">",
"      Asbun HJ, Calabria RP, Calmes S, et al. Thymic carcinoid. Am Surg 1991; 57:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/60\">",
"      Lin FC, Lin CM, Hsieh CC, et al. Atypical thymic carcinoid and malignant somatostatinoma in type I multiple endocrine neoplasia syndrome: case report. Am J Clin Oncol 2003; 26:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/61\">",
"      Filosso PL, Actis Dato GM, Ruffini E, et al. Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): report of a successful case and review of the literature. J Thorac Cardiovasc Surg 2004; 127:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/62\">",
"      Dham A, Truskinovsky AM, Dudek AZ. Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report. J Thorac Oncol 2008; 3:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/63\">",
"      Spaggiari L, Pastorino U. Double transmanubrial approach and sternotomy for resection of a giant thymic carcinoid tumor. Ann Thorac Surg 2001; 72:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/64\">",
"      Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13:2986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/65\">",
"      Takahashi T, Hatao K, Yamashita Y, Tanizawa Y. Ectopic ACTH syndrome due to thymic atypical carcinoid treated with combination chemotherapy of cisplatin and etoposide. Intern Med 2003; 42:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/66\">",
"      van Essen M, Krenning EP, Bakker WH, et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging 2007; 34:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/28/21962/abstract/67\">",
"      Oberg K, Jelic S, ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 Suppl 2:ii102.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network guidelines available online at www.nccn.org (Accessed on December 12, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16667 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.244-E0F60D9195-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21962=[""].join("\n");
var outline_f21_28_21962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6761221\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H703971452\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2663177\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4769298\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4769305\">",
"      Screening in MEN1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H703971797\">",
"      PATHOLOGY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H703971811\">",
"      Histologic differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H703971818\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4143779\">",
"      Paraneoplastic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30334400\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6761729\">",
"      EVALUATION AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H851153\">",
"      Cross sectional imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H851421\">",
"      Somatostatin receptor scintigraphy and other imaging methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H851160\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H851428\">",
"      Need for biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23027665\">",
"      Staging classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37710672\">",
"      PROGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H851564\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H851915\">",
"      - Resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H851809\">",
"      - Role of RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H851934\">",
"      - Neoadjuvant therapy for locally advanced disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H851848\">",
"      - Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H852081\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6761221\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16667\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16667|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/28/35265\" title=\"diagnostic image 1\">",
"      CT of a thymic carcinoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16667|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/31/10743\" title=\"figure 1\">",
"      Mediastinal mass compartment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/10/167\" title=\"figure 2\">",
"      Mediastinal LN approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16667|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/12/15557\" title=\"picture 1A\">",
"      Thymic carcinoid high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/2/32802\" title=\"picture 1B\">",
"      Mitosis in thymic carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/34/6692\" title=\"picture 2\">",
"      Spindle cell thymic carcinoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16667|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/28/35277\" title=\"table 1\">",
"      WHO tumors of the thymus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/13/19677\" title=\"table 2\">",
"      Staging of thymic tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/29/31195\" title=\"table 3\">",
"      Survival according to stage for thymic carcinoids in the SEER da",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32392?source=related_link\">",
"      Anterior mediastinal mass lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=related_link\">",
"      Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8474?source=related_link\">",
"      Clinical presentation and management of thymoma and thymic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/41/37528?source=related_link\">",
"      Dexamethasone suppression tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43076?source=related_link\">",
"      Diagnosis of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19976?source=related_link\">",
"      Endobronchial ultrasound: Indications, advantages, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31225?source=related_link\">",
"      Establishing the cause of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10058?source=related_link\">",
"      Extragonadal germ cell tumors involving the mediastinum and retroperitoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=related_link\">",
"      Neuroendocrine cancer of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1016?source=related_link\">",
"      Overview of the treatment of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21720?source=related_link\">",
"      Paragangliomas of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=related_link\">",
"      Parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=related_link\">",
"      Pathology of mediastinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=related_link\">",
"      Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4183?source=related_link\">",
"      Treatment of refractory and relapsed small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_28_21963="Differential diagnosis of papilledema";
var content_f21_28_21963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F54401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F54401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of papilledema",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Bilateral disc abnormalities*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased intracranial pressure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pseudopapilledema",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignant hypertension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diabetic papillopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Others (hyperviscosity, toxins)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Unilateral disc abnormalities*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anterior ischemic optic neuropathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Papillitis, neuroretinitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sarcoidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Central retinal vein occlusion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Papillophlebitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leber's hereditary optic neuropathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Other causes (low intraocular pressure, ocular injury, radiation)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * There is some overlap between the two categories, entities are classified here as to whether they are more usually bilateral versus unilateral.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21963=[""].join("\n");
var outline_f21_28_21963=null;
var title_f21_28_21964="Major functions of nephron segments";
var content_f21_28_21964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major functions of nephron segments",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nephron segment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major functions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glomerulus",
"       </td>",
"       <td>",
"        Forms an ultrafiltrate of plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proximal tubule",
"       </td>",
"       <td>",
"        <p>",
"         Reabsorbs isosmotically 60 to 65 percent of the filtered NaCl and H2O",
"        </p>",
"        <p>",
"         Reabsorbs 90 percent of the filtered HCO3-",
"        </p>",
"        <p>",
"         Major site of ammonia production in the nephron",
"        </p>",
"        <p>",
"         Reabsorbs almost all of filtered glucose and amino acids",
"        </p>",
"        <p>",
"         Reabsorbs K+, phosphate, calcium, magnesium, urea, and uric acid",
"        </p>",
"        <p>",
"         Secretes organic anions (such as urate) and cations (such as creatine); this pathway is also used for excretion of protein-bound drugs and toxins",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loop of Henle",
"       </td>",
"       <td>",
"        <p>",
"         Reabsorbs 25 to 35 percent of filtered NaCl",
"        </p>",
"        <p>",
"         Countercurrent multiplier as NaCl reabsorbed in excess of water",
"        </p>",
"        <p>",
"         Major site of active regulation of magnesium excretion",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal tubule",
"       </td>",
"       <td>",
"        <p>",
"         Reabsorbs about 5 percent of filtered NaCl but almost no water",
"        </p>",
"        <p>",
"         Major site, with connecting segment, of active regulation of calcium excretion",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Connecting segment and cortical collecting tubule",
"       </td>",
"       <td>",
"        <p>",
"         Principal cells reabsorb Na+ and Cl- and secrete K+ under the influence of aldosterone",
"        </p>",
"        <p>",
"         Intercalated cells secrete H+, reabsorb K+, and, in metabolic alkalosis, secrete HCO3-",
"        </p>",
"        <p>",
"         Reabsorb water in the presence of antidiuretic hormone",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medullary collecting tubule",
"       </td>",
"       <td>",
"        <p>",
"         Site of final modification of the urine",
"        </p>",
"        <p>",
"         Reabsorb NaCl, the concentration of which can be reduced to less than 1 meq/L",
"        </p>",
"        <p>",
"         Reabsorb water and urea relative to the amount of antidiuretic hormone present, allowing a concentrated or dilute urine to be excreted",
"        </p>",
"        <p>",
"         Secrete H+ and NH3; urine pH can be reduced to as low as 4.5 to 5.0",
"        </p>",
"        <p>",
"         Can contribute to potassium balance by reabsorption or secretion of K+",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Contribution of the different nephron segments to solute and water homeostasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21964=[""].join("\n");
var outline_f21_28_21964=null;
var title_f21_28_21965="Survival cardiac amyloid";
var content_f21_28_21965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Better outcome with familial amyloid cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 36 patients with amyloid cardiomyopathy, the 24 with familial amyloidosis have a better survival free of death or the need for cardiac transplantation than those with primary (AL) amyloidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Dubrey SW, Cha K, Skinner M, et al. Heart 1997; 78:74.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21965=[""].join("\n");
var outline_f21_28_21965=null;
var title_f21_28_21966="Ipratropium vs metaproterenol";
var content_f21_28_21966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Effect of ipratropium bromide versus metaproterenol in patients with COPD without asthma or atopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 302px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean percentage changes in FEV",
"    <sub>",
"     1",
"    </sub>",
"    at serial times after inhalation of ipratropium bromide (40 mcg) or metaproterenol (1500 mcg) on day 90 of the 90 day trial period of daily drug administration. Ipratropium was more potent at the peak of its effect and was longer acting than the adrenergic agent. Similar results were demonstrated on days 1 and 45 (not shown).",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second.",
"     <br>",
"      * p&le;0.05.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       p&le;0.01.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Tashkin DP, Ashutosh K, Bleecker ER, et al. Am J Med 1986; 81(Suppl A):81.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21966=[""].join("\n");
var outline_f21_28_21966=null;
var title_f21_28_21967="Palpation radial styloid";
var content_f21_28_21967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the radial styloid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The wrist is placed in a neutral position with the radial side up. The most distal portion of the radial styloid is identified, marked, and palpated for local tenderness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_28_21967=[""].join("\n");
var outline_f21_28_21967=null;
